0001144204-13-055158.txt : 20131015 0001144204-13-055158.hdr.sgml : 20131014 20131015132311 ACCESSION NUMBER: 0001144204-13-055158 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20130831 FILED AS OF DATE: 20131015 DATE AS OF CHANGE: 20131015 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MultiCell Technologies, Inc. CENTRAL INDEX KEY: 0000811779 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 521412493 STATE OF INCORPORATION: DE FISCAL YEAR END: 1130 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-10221 FILM NUMBER: 131151375 BUSINESS ADDRESS: STREET 1: 68 CUMBERLAND STREET, SUITE 301 CITY: WOONSOCKET STATE: RI ZIP: 02865 BUSINESS PHONE: (401)762-0045 MAIL ADDRESS: STREET 1: 68 CUMBERLAND STREET, SUITE 301 CITY: WOONSOCKET STATE: RI ZIP: 02865 FORMER COMPANY: FORMER CONFORMED NAME: Multicell Technologies Inc. DATE OF NAME CHANGE: 20040615 FORMER COMPANY: FORMER CONFORMED NAME: EXTEN INDUSTRIES INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: EXTEN VENTURES INC DATE OF NAME CHANGE: 19910923 10-Q 1 v355911_10q.htm QUARTERLY REPORT

U. S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended August 31, 2013.

Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

Commission File Number

001-10221

MultiCell Technologies, Inc.

(Exact name of registrant as specified in its charter)

DELAWARE

52-1412493

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification No.)

68 Cumberland Street, Suite 301

Woonsocket, RI 02895

(Address of principal executive offices)

401-762-0045

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer ¨
Non-accelerated filer	¨ (Do not check if a smaller reporting company)	Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: As of October 8, 2013, the issuer had 2,513,461,835 shares of Common Stock, $.01 par value, outstanding.

TABLE OF CONTENTS

PART I FINANCIAL INFORMATION

Item 1. Financial Statements

Condensed Consolidated Balance Sheets (unaudited) as of August 31, 2013 and November 30, 2012	3

Condensed Consolidated Statements of Operations (unaudited) for the Three and Nine Months Ended August 31, 2013 and 2012	4

Condensed Consolidated Statements of Equity (Deficiency) (unaudited) for the Nine Months Ended August 31, 2012 and 2013	5

Condensed Consolidated Statements of Cash Flows (unaudited) for the Nine Months Ended August 31, 2013 and 2012	6

Notes to Condensed Consolidated Financial Statements (unaudited)	7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	17

Item 3. Quantitative And Qualitative Disclosures About Market Risk	23

Item 4. Controls and Procedures	23

PART II OTHER INFORMATION

Item 1. Legal Proceedings	25

Item 1A. Risk Factors	25

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	25

Item 3. Defaults Upon Senior Securities	25

Item 4. Mine Safety Disclosures	25

Item 5. Other Information	26

Item 6. Exhibits	26

SIGNATURES	27

PART I FINANCIAL INFORMATION

Item 1: Financial Statements

MULTICELL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

	August 31,			November 30,
	2013			2012
ASSETS

Current assets
Cash and cash equivalents	$	178,121		$	199,472
Receivable from warrant holder		130,800			-
Other current assets		14,617			11,293
Total current assets		323,538			210,765

Property and equipment, net of accumulated depreciation of $40,561		-			-

Other assets		280			280

Total assets	$	323,818		$	211,045

LIABILITIES AND EQUITY (DEFICIENCY)

Current liabilities
Accounts payable and accrued expenses	$	1,085,649		$	1,106,177
Payable to related party		50,000			50,000
Advance from warrant holder		-			50,000
Convertible debentures		46,596			-
Current portion of deferred revenue		49,318			49,318
Total current liabilities		1,231,563			1,255,495

Non-current liabilities
Convertible debentures		-			56,026
Deferred revenue, net of current portion		461,753			498,741
Derivative liability related to Series B convertible preferred stock		30,587			19,245
Total non-current liabilities		492,340			574,012

Total liabilities		1,723,903			1,829,507

Commitments and contingencies		-			-

Equity (Deficiency)
MultiCell Technologies, Inc. equity (deficiency)
Undesignated preferred stock, $0.01 par value; 963,000 shares authorized; zero shares issued and outstanding		-			-
Series B convertible preferred stock, 17,000 shares designated; 3,448 shares issued and outstanding: liquidation value of $470,316		461,835			461,835
Series I convertible preferred stock, 20,000 shares designated; zero shares issued and outstanding		-			-
Common stock, $0.01 par value; 3,000,000,000 shares authorized; 2,391,239,613 and 1,349,803,029 shares issued and outstanding at August 31, 2013 and November 30, 2012, respectively		23,912,396			13,498,030
Additional paid-in capital		18,554,395			27,755,595
Accumulated deficit		(43,158,172	)		(42,254,594	)
Total MultiCell Technologies, Inc. stockholders' equity (deficiency)		(229,546	)		(539,134	)
Noncontrolling interests		(1,170,539	)		(1,079,328	)
Total equity (deficiency)		(1,400,085	)		(1,618,462	)

Total liabilities and equity (deficiency)	$	323,818		$	211,045

See accompanying notes to condensed consolidated financial statements.

MULTICELL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	For the Three Months Ended						For the Nine Months Ended
	August 31,			August 31,			August 31,			August 31,
	2013			2012			2013			2012

Revenue	$	12,329		$	12,329		$	36,988		$	36,988

Operating expenses
Selling, general and administrative		207,753			231,953			626,092			649,454
Research and development		95,418			53,694			216,590			276,324
Stock-based compensation		52,945			105,446			175,866			226,162

Total operating expenses		356,116			391,093			1,018,548			1,151,940

Loss from operations		(343,787	)		(378,764	)		(981,560	)		(1,114,952	)

Other income (expense)
Interest expense		(707	)		(762	)		(2,058	)		(7,424	)
Change in fair value of derivative liability		(902	)		60,562			(11,342	)		104,526
Gain on disposition of equipment		-			1,500			-			1,500
Interest income		36			106			171			593

Total other income (expense)		(1,573	)		61,406			(13,229	)		99,195

Net loss		(345,360	)		(317,358	)		(994,789	)		(1,015,757	)

Less net loss attributable to the noncontrolling interests		(42,264	)		(22,771	)		(91,211	)		(71,841	)

Net loss attributable to MultiCell Technologies, Inc.	$	(303,096	)	$	(294,587	)	$	(903,578	)	$	(943,916	)

Basic and Diluted Loss Per Common Share	$	(0.00014	)	$	(0.00028	)	$	(0.00052	)	$	(0.00099	)

Basic and Diluted Weighted-Average Common Shares Outstanding		2,105,332,608			1,065,058,664			1,730,465,999			957,413,780

See accompanying notes to condensed consolidated financial statements.

MULTICELL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (DEFICIENCY)

For the Nine Months Ended August 31, 2012 and 2013

(Unaudited)

	Preferred Stock												Additional									Total
	Series B				Series I				Common Stock				Paid in			Accumulated			Noncontrolling			Equity
	Shares		Amount		Shares		Amount		Shares		Par Value		Capital			Deficit			Interests			(Deficiency)

Balance at November 30, 2011		11,339	$	1,349,844		5,734	$	573,400		823,385,986	$	8,233,860	$	30,064,619		$	(40,998,344	)	$	(976,978	)	$	(1,753,599	)

Issuance of common stock for conversion of 4.75% debentures		-		-		-		-		323,936,571		3,239,366		(3,232,076	)		-			-			7,290

Issuance of common stock for exercise of warrants		-		-		-		-		729,000		7,290		787,320			-			-			794,610

Stock-based compensation		-		-		-		-		-		-		226,162			-			-			226,162

Net loss		-		-		-		-		-		-		-			(943,916	)		(71,841	)		(1,015,757	)

Balance at August 31, 2012		11,339	$	1,349,844		5,734	$	573,400		1,148,051,557	$	11,480,516	$	27,846,025		$	(41,942,260	)	$	(1,048,819	)	$	(1,741,294	)

Balance at November 30, 2012		3,448	$	461,835		-	$	-		1,349,803,029	$	13,498,030	$	27,755,595		$	(42,254,594	)	$	(1,079,328	)	$	(1,618,462	)

Issuance of common stock for conversion of 4.75% debentures		-		-		-		-		1,040,493,584		10,404,936		(10,395,506	)		-			-			9,430

Issuance of common stock for exercise of warrants		-		-		-		-		943,000		9,430		1,018,440			-			-			1,027,870

Stock-based compensation		-		-		-		-		-		-		175,866			-			-			175,866

Net loss		-		-		-		-		-		-		-			(903,578	)		(91,211	)		(994,789	)

Balance at August 31, 2013		3,448	$	461,835		-	$	-		2,391,239,613	$	23,912,396	$	18,554,395		$	(43,158,172	)	$	(1,170,539	)	$	(1,400,085	)

See accompanying notes to condensed consolidated financial statements.

MULTICELL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For the Nine Months Ended
	August 31,			August 31,
	2013			2012
Cash flows from operating activities
Net loss	$	(994,789	)	$	(1,015,757	)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation		175,866			226,162
Gain from disposition of equipment		-			(1,500	)
Interest expense from amortization of discount on convertible debentures		-			5,000
Change in fair value of derivative liability		11,342			(104,526	)
Changes in assets and liabilities
Grant receivable		-			303,102
Other current assets		(3,324	)		305
Accounts payable and accrued liabilities		(20,528	)		28,864
Deferred revenue		(36,988	)		(36,988	)
Net cash used in operating activities		(868,421	)		(595,338	)

Cash flows from investing activities
Proceeds from disposition of equipment		-			1,500
Net cash provided by investing activities		-			1,500

Cash flows from financing activities
Proceeds from the exercise of stock warrants		1,027,870			794,610
Change in receivable or advance from warrant holder		(180,800	)		(301,930	)
Net cash provided by financing activities		847,070			492,680
Net decrease in cash and cash equivalents		(21,351	)		(101,158	)
Cash and cash equivalents at beginning of period		199,472			405,327
Cash and cash equivalents at end of period	$	178,121		$	304,169

Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	$	2,142		$	2,502
Noncash Investing and Financing Activities:
Issuance of common stock for conversion of 4.75% debentures		9,430			7,290

See accompanying notes to condensed consolidated financial statements.

MULTICELL TECHNOLOGIES, INC. and SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 1. ORGANIZATION AND NATURE OF OPERATIONS, BASIS OF PRESENTATION, AND RECLASSIFICATIONS

ORGANIZATION AND NATURE OF OPERATIONS

MultiCell Technologies, Inc. (“MultiCell”), has two subsidiaries, Xenogenics Corporation (“Xenogenics”) and MultiCell Immunotherapeutics, Inc. (“MCTI”). MultiCell holds 95.3% of the outstanding shares (on an as-if-converted to common stock basis) of Xenogenics. MultiCell holds approximately 67% of the outstanding shares (on an as-if-converted to common stock basis) of MCTI. As used herein, the “Company” refers to MultiCell, together with Xenogenics and MCTI.

The Company’s therapeutic development platform includes several patented techniques used to: (i) isolate, characterize and differentiate stem cells from human liver; (ii) control the immune response at transcriptional and translational levels through double-stranded RNA (dsRNA)-sensing molecules such as the Toll-like Receptors (TLRs), RIG-I-like receptor (RLR), and Melanoma Differentiation-Associated protein 5 (MDA-5) signaling; (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology; and (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway. The Company’s medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent™, for interventional cardiology and peripheral vessel applications.

BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements and related notes of MultiCell and its subsidiaries have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial statements. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. In the opinion of management, all adjustments consisting of normal recurring adjustments considered necessary for a fair presentation have been included. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended November 30, 2012, previously filed with the SEC. The results of operations for the three-month and nine-month periods ended August 31, 2013, are not necessarily indicative of the operating results for the fiscal year ending November 30, 2013. The condensed consolidated balance sheet as of November 30, 2012, has been derived from the Company’s audited consolidated financial statements.

RECLASSIFICATIONS

Certain amounts of operating expenses from the condensed consolidated statement of operations for the three months and the nine months ended August 31, 2012, have been reclassified in the current presentation to conform to the presentation of operating expenses for the three months and nine months ended August 31, 2013. These reclassifications had no effect on the total amount of operating expenses, on the amount of net loss, or on the basic and diluted loss per common share for the three months and the nine months ended August 31, 2012.

MULTICELL TECHNOLOGIES, INC. and SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 2. GOING CONCERN

These condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As of August 31, 2013, the Company has operating and liquidity concerns and, as a result of recurring losses, has incurred an accumulated deficit of $43,158,172. The Company will have to raise additional capital in order to initiate Phase IIb clinical trials for MCT-125, its therapeutic product for the treatment of fatigue in multiple sclerosis patients, conduct further research on MCT-465 and MCT-485 for the treatment of primary liver cancer, and initiate clinical trials for Xenogenic’s bioabsorbable, drug eluting stent, the Ideal BioStent™. The Company’s management is evaluating several sources of financing for the Company’s clinical trial program. Additionally, with its strategic shift in focus to therapeutic programs and technologies, management expects the Company’s future cash requirements to increase significantly as it advances the Company’s therapeutic programs into clinical trials. Until the Company is successful in raising additional funds, it may have to prioritize its therapeutic programs and delays may be necessary in some of the Company’s development programs.

Since March 2008, the Company has operated on working capital provided by La Jolla Cove Investors, Inc. (“LJCI”). As further described in Note 3 to these condensed consolidated financial statements, under the terms of the LJCI Agreement (as defined below), LJCI can convert a portion of the convertible debenture by simultaneously exercising a warrant at $1.09 per share. As of August 31, 2013, there are 4,659,629 shares remaining on the stock purchase warrant and a balance of $46,596 remaining on the convertible debenture. Should LJCI continue to exercise all of its remaining warrants, approximately $5.1 million of cash would be provided to the Company. The LJCI Agreement limits LJCI’s investment to an aggregate ownership that does not exceed 9.99% of the outstanding shares of the Company. The Company expects that LJCI will continue to exercise the warrants and convert the debenture through February 28, 2014, the date that the debenture is due and the warrants expire, subject to the limitations of the LCJI Agreement and the availability of authorized common stock of the Company.

These factors, among others, create an uncertainty about the Company’s ability to continue as a going concern. There can be no assurance that LJCI will continue to exercise its warrant to purchase the Company’s common stock, or that the Company will be able to successfully acquire the necessary capital to continue its on-going research efforts and bring its products to the commercial market. Management’s plans to acquire future funding include the potential sale of shares of the Company’s common and/or preferred stock, the sale of warrants, and continued sales of the Company’s proprietary media, immortalized cells and primary cells to the pharmaceutical industry. Additionally, the Company continues to pursue research projects, government grants and capital investment. The accompanying condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

NOTE 3. CONVERTIBLE DEBENTURES

MultiCell entered into a Securities Purchase Agreement with LJCI on February 28, 2007 (the “LJCI Agreement”), pursuant to which MultiCell agreed to sell a convertible debenture to LJCI in the principal amount of $100,000 and originally scheduled to mature on February 28, 2012 (the “Debenture”). On August 16, 2011, MultiCell and LJCI amended the Debenture to extend the maturity date to February 28, 2014. The Debenture accrues interest at 4.75% per year, payable in cash or common stock at the option of LJCI. In connection with the Debenture, MultiCell issued LJCI a warrant to purchase up to 10 million shares of the Company’s common stock (the “LJCI Warrant”) at an exercise price of $1.09 per share, exercisable over the next five years according to a schedule described in a letter agreement dated February 28, 2007. On August 16, 2011, MultiCell and LJCI amended the LJCI Warrant to extend the expiration date to February 28, 2014. Pursuant to the terms of the LJCI Warrant, upon the conversion of any portion of the principal amount of the Debenture, LJCI is required to simultaneously exercise and purchase that same percentage of the warrant shares equal to the percentage of the dollar amount of the Debenture being converted. Therefore, as an example, for each $1,000 of the principal converted, LJCI would be required to simultaneously purchase 100,000 shares under the LJCI Warrant at $1.09 per share.

MULTICELL TECHNOLOGIES, INC. and SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The Debenture is convertible at the option of LJCI at any time up to maturity into the number of shares determined by the dollar amount of the Debenture being converted multiplied by 110, minus the product of the Conversion Price (as defined below) multiplied by 100 times the dollar amount of the Debenture being converted, with the entire result divided by the Conversion Price. The “Conversion Price” is equal to the lesser of $1.00 or 80% of the average of the three lowest volume-weighted average prices during the twenty trading days prior to the election to convert. LJCI converted $9,430 and $7,290 of the Debenture into 1,040,493,584 and 323,936,571 shares, respectively, of the Company’s common stock during the nine months ended August 31, 2013 and 2012, respectively. Simultaneously with these conversions, LJCI exercised warrants to purchase 943,000 shares and 729,000 shares of the Company’s common stock during the nine months ended August 31, 2013 and 2012, respectively. Proceeds from the exercise of the warrants were $1,027,870 and $794,610 for the nine months ended August 31, 2013 and 2012, respectively. At times, LJCI makes advances to MultiCell prior to the exercise of warrants. At August 31, 2013 and November 30, 2012, LJCI had advanced $0 and $50,000, respectively, to MultiCell in advance of LJCI’s exercise of warrants. At August 31, 2013 MultiCell had a receivable from LJCI of $130,800 for proceeds from LJCI’s exercise of warrants in excess of advances previously received. This receivable was collected on September 5, 2013.

As of August 31, 2013, the remainder of the Debenture in the amount of $46,596 could have been converted by LJCI into approximately 5.8 billion shares of the Company’s common stock, which would require LJCI to simultaneously exercise and purchase all of the remaining 4,659,629 shares of the Company’s common stock under the LJCI Warrant at $1.09 per share. As of November 30, 2012, the balance of the Debenture was $56,026. For the Debenture, upon receipt of a conversion notice from the holder, MultiCell may elect to immediately redeem that portion of the Debenture that the holder elected to convert in such conversion notice, plus accrued and unpaid interest. MultiCell, at its sole discretion, has the right, without limitation or penalty, to redeem the outstanding principal amount of the Debenture not yet converted by the holder into common stock, plus accrued and unpaid interest thereon.

NOTE 4. SERIES B CONVERTIBLE PREFERRED STOCK

The Series B shares are convertible at any time into shares of the Company’s common stock at a conversion price determined by dividing the purchase price per share of $100 by the conversion price. The conversion price was originally $0.32 per share. Upon the occurrence of an event of default (as defined in the applicable Series B convertible preferred stock purchase agreement), the conversion price of the Series B shares shall be reduced to 85% of the then-applicable conversion price of such shares. The conversion price is subject to equitable adjustment in the event of any stock splits, stock dividends, recapitalizations and the like. In addition, the conversion price is subject to weighted average anti-dilution adjustments in the event the Company sells common stock or other securities convertible into or exercisable for common stock at a per share price, exercise price or conversion price lower than the conversion price then in effect in any transaction (other than in connection with an acquisition of the securities, assets or business of another company, a joint venture and/or the issuance of employee stock options). As a result of the Company issuing shares of its common stock upon conversion of convertible debentures and upon the exercise of warrants both at prices lower than the conversion price of the Series B convertible preferred stock, and due to the Company not paying the Series B dividends on a monthly basis (as discussed below), the conversion price of the Series B convertible preferred stock has been reduced to $0.0124 per share as of August 31, 2013 and to $0.0215 per share as of November 30, 2012. Pursuant to the applicable Series B convertible preferred stock purchase agreement, each investor may only convert that number of shares of Series B convertible preferred stock into that number of shares of the Company’s common stock that does not exceed 9.99% of the outstanding shares of common stock of the Company on the date of conversion.

MULTICELL TECHNOLOGIES, INC. and SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Commencing on the date of issuance of the Series B convertible preferred stock until the date a registration statement registering the shares of the Company’s common stock underlying the preferred stock and warrants issued is declared effective by the SEC, the Company was required to pay on each outstanding share of Series B convertible preferred stock a preferential cumulative dividend at an annual rate equal to the product of multiplying $100 per share by the higher of (i) the Wall Street Journal Prime Rate plus 1%, or (ii) 9%. In no event was the dividend rate to be greater than 12% per annum. The dividend was payable monthly in arrears in cash on the last day of each month based on the number of shares of Series B convertible preferred stock outstanding as of the first day of that month. In the event the Company did not pay the Series B convertible preferred dividends when due, the conversion price of the Series B preferred shares was reduced to 85% of the otherwise applicable conversion price. The Company did not pay the required monthly Series B preferred dividends beginning on November 30, 2006, which, in part, caused the conversion price to be reduced. Subsequent to November 30, 2010, the Company received an opinion of outside counsel providing for the removal of the restrictive legend on the Series B convertible preferred stock, which in turn terminated the requirement to accrue the related dividends. Accordingly, no dividends have been accrued since November 30, 2010. Total accrued but unpaid preferred dividends recorded in the accompanying condensed consolidated balance sheets as of August 31, 2013, and as of November 30, 2012, are $290,724 of which $125,516 are recorded in permanent equity with the Series B convertible preferred stock, and $165,208 are recorded as a current liability in accounts payable and accrued expenses.

The conversion feature which gives the holders of the Series B convertible preferred stock the right to acquire shares of the Company’s common stock is an embedded derivative. As of August 31, 2013 and November 30, 2012, there were 3,448 shares of Series B convertible preferred stock that were convertible into 27,806,452 and 16,037,209 shares of common stock of the Company, respectively. The fair value of the conversion feature was estimated at $30,587 ($0.0011 per share of common stock) and $19,245 ($0.0012 per share of common stock) at August 31, 2013 and November 30, 2012, respectively, and has been estimated using the Black-Scholes option-pricing model using the following assumptions:

	August 31, 2013			May 31, 2013			February 28, 2013			November 30, 2012

Fair value of common stock	$	0.0012		$	0.0014		$	0.0038		$	0.0013
Conversion price of preferred stock	$	0.0124		$	0.0151		$	0.0190		$	0.0215
Risk free interest rate		2.78	%		2.16	%		1.89	%		1.62	%
Expected life		10 Years			10 Years			10 Years			10 Years
Dividend yield		-			-			-			-
Volatility		148	%		148	%		147	%		141	%

The fair value of the conversion feature increased by $902 and by $11,342 during the three months and the nine months ended August 31, 2013, respectively, which has been recorded as a loss from the change in the fair value of the derivative liability. The fair value of the conversion feature decreased by $60,562 and by $104,526 during the three months and nine months ended August 31, 2012, respectively, which has been recorded as a gain from the change in the fair value of the derivative liability.

In the event of any dissolution or winding up of the Company, whether voluntary or involuntary, holders of each outstanding share of Series B convertible preferred stock shall be entitled to be paid first in priority out of the assets of the Company available for distribution to stockholders, an amount equal to $100 per share of Series B convertible preferred stock held plus any declared but unpaid dividends. After such payment has been made in full, such holders of Series B convertible preferred stock shall be entitled to no further participation in the distribution of the assets of the Company.

MULTICELL TECHNOLOGIES, INC. and SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 5. SERIES I CONVERTIBLE PREFERRED STOCK

The Company’s Board of Directors has the authority, without further action by the stockholders, to issue up to 1,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions of these shares of preferred stock. The Board of Directors originally designated 20,000 shares as Series I convertible preferred stock. On July 13, 2004, the Company completed a private placement of Series I convertible preferred stock and a total of 20,000 shares were originally sold to accredited investors. As of August 31, 2013 and November 30, 2012, all of the shares of Series I convertible preferred stock have been converted into shares of the common stock of the Company and no shares of the Company’s Series I convertible preferred stock are outstanding.

NOTE 6. LICENSE AGREEMENTS AND DEFERRED REVENUE

On October 9, 2007, MultiCell executed an exclusive license and purchase agreement (the “Agreement”) with Corning Incorporated (“Corning”) of Corning, New York. Under the terms of the Agreement, Corning has the right to develop, use, manufacture, and sell MultiCell’s Fa2N-4 cell lines and related cell culture media for use as a drug discovery assay tool, including biomarker identification for the development of drug development assay tools, and for the performance of absorption, distribution, metabolism, elimination and toxicity assays (ADME/Tox assays). MultiCell retained and will continue to support its existing licensee, Pfizer, Inc. (“Pfizer”). MultiCell retains the right to use the Fa2N-4 cells for use in applications not related to drug discovery or ADME/Tox assays. MultiCell also retains rights to use the Fa2N-4 cell lines and other cell lines to further develop its Sybiol® liver assist device, to identify drug targets and for other applications related to the Company’s internal drug development programs. Corning paid MultiCell $750,000 in consideration for the license granted. The Company is recognizing the income ratably over a 17 year period. The Company recognized $11,029 and $33,088, respectively, in income for each of the three months and nine months ended August 31, 2013 and 2012. The balance of deferred revenue from this license is $488,971 at August 31, 2013 and will be amortized into revenue through October 2024.

The Company has another license agreement with Pfizer, for which revenue is being deferred. The Company recognized revenue from the agreement with Pfizer in the amount of $1,300 and $3,900 for the three months and the nine months ended each of August 31, 2013 and 2012, respectively. The balance of deferred revenue from the agreement with Pfizer is $22,100 at August 31, 2013, which will be amortized into revenue through January 2018.

NOTE 7. STOCK COMPENSATION PLANS

On July 11, 2011, at the Company’s Annual Meeting of Stockholders, the stockholders approved an amendment to increase the number of shares reserved under the 2004 Equity Incentive Plan (the “2004 Plan”) to a total of 70,974,213 shares. Additionally, an annual increase in the number of shares reserved under the plan was approved and certain prior increases in the number of shares reserved for issuance under the plan were ratified. Furthermore, on each of December 1, 2011 and on December 1, 2012, the number of shares reserved under the 2004 Plan was increased by an additional 1,500,000 shares pursuant to the provisions of the 2004 Plan. The purpose of the 2004 Plan is to provide a means by which eligible recipients of stock awards may be given the opportunity to benefit from increases in the value of the Company’s common stock through granting of incentive stock options (ISO), non-statutory stock options, stock purchase awards, stock bonus awards, stock appreciation rights, stock unit awards and other stock awards. As amended, there are 22,074,710 shares of common stock available for future awards under the 2004 Plan at August 31, 2013.

MULTICELL TECHNOLOGIES, INC. and SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

GAAP treatment for stock options requires the recognition of the cost of employee services received in exchange for an award of equity instruments in the financial statements, which is measured based on the grant date fair value of the award, and requires the stock option compensation expense to be recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period), net of estimated forfeitures. The estimation of forfeitures requires significant judgment, and to the extent actual results or updated estimates differ from the current estimates, such resulting adjustment will be recorded in the period estimates are revised. No income tax benefit has been recognized for stock-based compensation arrangements and no compensation cost has been capitalized in the consolidated balance sheets.

A summary of the status of stock options granted by MultiCell at August 31, 2013, and changes during the nine months then ended is presented in the following table:

						Weighted
				Weighted		Average
	Shares			Average		Remaining	Aggregate
	Under			Exercise		Contractual	Intrinsic
	Option			Price		Life	Value

Outstanding at November 30, 2012		26,068,947		$	0.0084	3.1 years	$	-
Granted		30,000,000			0.0011
Exercised		-			-
Expired or forfeited		(5,669,444	)		0.0090

Outstanding at August 31, 2013		50,399,503		$	0.0040	3.9 years	$	3,000

Exercisable at August 31, 2013		19,017,559		$	0.0086	2.2 years	$	-

On August 16, 2013, the MultiCell Board of Directors granted an option to each of the five members of its Board of Directors to purchase 5,000,000 shares of the Company’s common stock at $0.0011 per share. The options vest quarterly over one year, subject to continuing service as a director on each such vesting date, and expire five years after grant. Additionally, the Board of Directors granted an option to an employee to purchase 5,000,000 shares of common stock at $0.0011 per share. This option vests monthly over three years, subject to continuing service as an employee on each such vesting date, and expires five years after grant. On June 1, 2012, the MultiCell Board of Directors granted an option to each of the five members of its Board of Directors to purchase 1,000,000 shares of the Company’s common stock at $0.0032 per share, the closing price of the Company’s common stock on the date of grant. The options vest quarterly over one year, subject to continuing service as a director on each such vesting date, and expire five years after grant. Additionally, the Board of Directors granted an option to an employee to purchase 1,000,000 shares of common stock at $0.0032 per share. This option vests monthly over three years, subject to continuing service as an employee on each such vesting date, and expires five years after grant. The fair value of stock option grants is estimated on the date of grant using the Black-Scholes option pricing model. The weighted-average fair value of stock options granted during the nine months ended August 31, 2013 was $0.0011 per share. The weighted-average assumptions used for options granted during the nine months ended August 31, 2013 were risk-free interest rate of 1.60%, volatility of 175%, expected life of 5.0 years, and dividend yield of zero. The weighted-average fair value of stock options granted during the nine months ended August 31, 2012 was $0.0030 per share. The weighted-average assumptions used for options granted during the nine months ended August 31, 2012 were risk-free interest rate of 0.62%, volatility of 170%, expected life of 5.0 years, and dividend yield of zero. The assumptions employed in the Black-Scholes option pricing model include the following: (i) the expected life of stock options represents the period of time that the stock options granted are expected to be outstanding prior to exercise; (ii) the expected volatility is based on the historical price volatility of the Company’s common stock; (iii) the risk-free interest rate represents the U.S. Treasury Department’s constant maturities rate for the expected life of the related stock options; and (iv) the dividend yield represents anticipated cash dividends to be paid over the expected life of the stock options.

For the three months ended August 31, 2013 and 2012, MultiCell reported stock-based compensation expense for services related to stock options of $1,893 and $9,521, respectively. For the nine months ended August 31, 2013 and 2012, MultiCell reported stock-based compensation expense for services related to stock options of $10,705 and $32,759, respectively. As of August 31, 2013, there is approximately $35,000 of unrecognized compensation cost related to stock-based payments that will be recognized over a weighted average period of approximately 1.4 years. The intrinsic values at August 31, 2013 are based on a closing price of $0.0012.

MULTICELL TECHNOLOGIES, INC. and SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

In October 2010, Xenogenics adopted the 2010 Stock Incentive Plan (the “2010 Plan”) which authorized the granting of stock awards to Xenogenics’ employees, directors, and consultants. As originally adopted, the 2010 Plan provided that the number of shares of Xenogenics’ common stock that could be issued pursuant to stock awards could not exceed 5,000,000 shares of common stock. On February 3, 2011, the 2010 Plan was amended such that the number of shares of Xenogenics’ common stock that could be issued pursuant to stock awards could not exceed 8,000,000 shares of common stock. The purpose of the 2010 Plan is to provide a means by which eligible recipients of stock awards may be given the opportunity to benefit from increases in the value of Xenogenics’ common stock through granting of incentive stock options (“ISO”), non-statutory stock options, stock bonus awards, stock appreciation rights, and rights to acquire restricted stock. ISO’s may be granted only to employees. The exercise price of each ISO granted under the plan must equal 100% of the market price of Xenogenics’ stock on the date of the grant. A 10% stockholder shall not be granted an ISO unless the exercise price of such option is at least 110% of the fair market value of Xenogenics’ common stock on the date of the grants and the option is not exercisable after the expiration of five years from the date of the grant. The Board of Directors of Xenogenics, in its discretion, shall determine the exercise price of each nonstatutory stock option. An option’s maximum term is 10 years.

In November 2010, Xenogenics granted an option to a prospective executive officer to purchase an aggregate of 2,500,000 shares of its common stock, exercisable at $0.246 per share of common stock and having an expiration date in November 2015. The option to acquire 500,000 of the shares vested on the grant date and the remaining 2,000,000 shares vest in the future upon the achievement of specified milestones. The fair value of these options was estimated to be $576,250, or $0.2305 per share, as estimated using the Black-Scholes option-pricing model, using a risk-free interest rate of 1.23%, volatility of 165%, expected life of five years, and dividend yield of zero.

In March 2011, Xenogenics granted options to other prospective officers and to the members of its scientific advisory board to purchase an aggregate of 3,000,000 shares of its common stock, exercisable at $0.246 per share of common stock and having a term of approximately five years. 50% of the options vested immediately and the remaining 50% were to vest upon the closing of a Qualified Financing by December 31, 2011. A “Qualified Financing” meant a single sale, or a related series of sales, by Xenogenics of its common stock (or common stock equivalents) in which the aggregate gross proceeds (before costs and commissions) received by Xenogenics was equal to or exceed $5,000,000. The fair value of these options was estimated to be $692,700, or $0.2309 per share, as estimated using the Black-Scholes option-pricing model, using a risk-free interest rate of 2.20%, volatility of 165%, expected lives of five years, and dividend yield of zero. A Qualified Financing was not closed by December 31, 2011, and accordingly, options to acquire 1,500,000 shares of Xenogenics common stock were forfeited. As described in the following paragraph, Xenogenics granted replacement options to four of five of these individuals whose options expired on December 31, 2011. The replacement of the options to the four individuals was treated as a modification under GAAP. The forfeiture of the option to the fifth individual resulted in the reversal of $57,725 of previously-recognized stock-based compensation expense in the three months ended February 29, 2012.

On February 28, 2012, Xenogenics granted replacement options to four of five of those individuals whose options expired on December 31, 2011, as described in the previous paragraph. The replacement options to purchase 1,250,000 shares of Xenogenics’ common stock are exercisable at $0.253 per share and vest monthly over one year. These replacement options have a term of five years, provided a Qualified Financing has closed by February 28, 2013. No Qualified Financing closed by February 28, 2013. Consequently, these replacement options expired on February 28, 2013. The fair value of these options was estimated to be $298,500, or $0.2338 per share, as estimated using the Black-Scholes option-pricing model, using a risk-free interest rate of 0.84%, volatility of 170%, expected lives of five years, and dividend yield of zero.

MULTICELL TECHNOLOGIES, INC. and SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

On July 28, 2013, Xenogenics granted an option to a consultant to purchase 500,000 shares of Xenogenics’ common stock at $0.246 per share. The option vests in equal increments of 125,000 on each of July 28, 2013, October 1, 2013, January 1, 2014, and April 1, 2014, subject to continuing service to Xenogenics on each such vesting date, and expires five years after grant. The fair value of these options was estimated to be $117,000, or $0.234 per share, as estimated using the Black-Scholes option-pricing model, using a risk-free interest rate of 1.37%, volatility of 175%, expected lives of five years, and dividend yield of zero.

For the three months and nine months ended August 31 2013, Xenogenics reported stock-based compensation of $51,052 and $165,161, respectively. For the three months ended August 31, 2012, Xenogenics reported stock-based compensation expense for options of $95,925. For the nine months ended August 31, 2012, Xenogenics reported stock-based compensation expense for options of $251,128, less the reversal of previously recognized stock-based compensation in the amount of $57,725, for net stock-based compensation of $193,403. As of August 31, 2013, there is approximately $83,000 of unrecognized compensation cost related to stock-based payments that will be recognized over a weighted average period of approximately 0.5 years.

NOTE 8. STOCK WARRANTS

Since the Company’s inception, it has financed its operations primarily through the issuance of debt or equity instruments, which have often included the issuance of warrants to purchase shares of the Company’s common stock.

As further described in Note 3 to these condensed consolidated financial statements, MultiCell entered into the LJCI Agreement pursuant to which MultiCell agreed to sell the Debenture in the principal amount of $100,000. In connection with the Debenture, MultiCell issued LJCI a warrant to purchase up to 10 million shares of the Company’s common stock at an exercise price of $1.09 per share, exercisable over the next five years according to a schedule described in a letter agreement dated February 28, 2007. Pursuant to the terms of the LJCI Warrant, upon the conversion of any portion of the principal amount of the Debenture, LJCI is required to simultaneously exercise and purchase that same percentage of the warrant shares equal to the percentage of the dollar amount of the Debenture being converted. Therefore, as an example, for each $1,000 of the principal of the Debenture converted, LJCI would be required to simultaneously purchase 100,000 shares under the warrant at $1.09 per share. During the nine months ended August 31, 2013, LJCI exercised warrants to purchase 943,000 shares of the Company’s common stock, resulting in proceeds to the Company of $1,027,870. During the nine months ended August 31, 2012, LJCI exercised warrants to purchase 729,000 shares of the Company’s common stock, resulting in proceeds to the Company of $794,610.

A summary of the status of warrants at August 31, 2013, and changes during the nine months then ended is presented in the following table:

						Weighted
				Weighted		Average
	Shares			Average		Remaining	Aggregate
	Under			Exercise		Contractual	Intrinsic
	Warrants			Price		Life	Value

Outstanding at November 30, 2012		9,277,030		$	0.7535	2.2 years	$	-
Issued		-			-
Exercised		(943,000	)		1.0900
Expired		(360,000	)		0.5000

Outstanding at August 31, 2013		7,974,030		$	0.7251	1.7 years	$	-

MULTICELL TECHNOLOGIES, INC. and SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 9. LOSS PER SHARE

Basic loss per share is computed on the basis of the weighted-average number of shares of the Company’s common stock outstanding during the period. Diluted loss per share is computed on the basis of the weighted-average number of shares of the Company’s common stock and all dilutive potentially issuable shares of the Company’s common stock outstanding during the year. Shares of the Company’s common stock issuable upon conversion of debt and preferred stock, or exercise of stock options and stock warrants have not been included in the loss per share for the three months and the nine months ended August 31, 2013 or 2012, as they are anti-dilutive.

The potential shares of the Company’s common stock issuable upon exercise of options or warrants, or upon conversion of other convertible securities issued by the Company, as of August 31, 2013 and 2012, are as follows:

	2013		2012

Warrants		7,974,030		9,963,030
Stock options		50,399,503		24,168,947
Series B Convertible Preferred Stock		27,806,452		47,049,793
Series I Convertible Preferred Stock		-		2,293,600
LJCI Debenture		5,819,876,621		6,055,511,583

		5,906,056,606		6,138,986,953

MultiCell does not currently have sufficient authorized shares of its common stock to meet the commitments entered into under the Debenture and the related LJCI Warrants. As further discussed in Note 3, upon the conversion of any portion of the remaining $46,596 principal amount of the Debenture, LJCI is required to simultaneously exercise and purchase that same percentage of the remaining 4,659,629 warrant shares equal to the percentage of the dollar amount of the Debenture being converted. The agreement limits LJCI’s investment to an aggregate common stock ownership that does not exceed 9.99% of the outstanding shares of common stock of the Company. Furthermore, MultiCell has the right to redeem that portion of the Debenture that the holder may elect to convert and also has the right to redeem the outstanding principal amount of the Debenture not yet converted by the holder into common stock, plus accrued and unpaid interest thereon.

NOTE 10. FAIR VALUE MEASUREMENTS

For assets and liabilities measured at fair value, the Company uses the following hierarchy of inputs:

	•		Level one — Quoted market prices in active markets for identical assets or liabilities;

	•		Level two — Inputs other than level one inputs that are either directly or indirectly observable; and

	•		Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the Company and reflect those assumptions that a market participant would use.

Liabilities measured at fair value on a recurring basis at August 31, 2013 and November 30, 2012, are summarized as follows:

	August 31, 2013								November 30, 2012
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total

Derivative liability	$	-	$	30,587	$	-	$	30,587	$	-	$	19,245	$	-	$	19,245

MULTICELL TECHNOLOGIES, INC. and SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

As further described in Note 4, the fair value of the derivative liability is determined using the Black-Scholes pricing model.

NOTE 11. SUBSEQUENT EVENTS

Stock Issued for Conversion of Debenture and Exercise of Warrants

As more fully discussed in Note 3 to these consolidated financial statements, MultiCell sold the Debenture to LJCI and issued LJCI a stock warrant in connection with the Debenture. During the period subsequent to August 31, 2013 through the date of issuance of the condensed consolidated financial statements, LJCI converted $1,000 of the Debenture into 122,122,222 shares of the Company’s common stock. Simultaneously with the conversions of the Debenture, LJCI was required to exercise warrants to purchase 100,000 shares of the Company’s common stock at $1.09 per share. The total proceeds from the exercise of the warrants were $109,000.

Sponsored Research Agreement

On September 27, 2013, MultiCell entered into a new sponsored research agreement with Anand Ghanekar, M.D., Ph.D, of the University Health Network’s Toronto General Hospital expanding the scope of the current research project with the University Health Network (“UHN”) to evaluate MCT-485 in animal models for the treatment of primary liver cancer (the “Ghanekar Agreement”). On July 5, 2011, the Company had previously entered into a sponsored research agreement with UHN pursuant to which UHN evaluated the Company’s product candidates, MCT-465 and MCT-485, in in vitro models for the treatment of primary liver cancer (the “UHN Agreement”). The mechanism of action of MCT-465 and MCT-485 and their potential selective effect on liver cancer stem cells were also evaluated. Under the terms of each of the Ghanekar Agreement and the UHN Agreement, the Company retains exclusive access to the research findings and intellectual property resulting from the research activities preformed by each of Dr. Ghanekar and UHN, respectively.

Ideal BioStent™ — Amendment of Foreclosure Sale Agreement

On September 30, 2010, Xenogenics entered into a Foreclosure Sale Agreement (“Foreclosure Sale Agreement”). Pursuant to the Foreclosure Sale Agreement, Xenogenics acquired all of the sellers’ interests in certain bioabsorbable stent assets (known as “Ideal BioStent™”) and related technologies. Under the Foreclosure Sale Agreement, Xenogenics is also required to make cash payments totaling $4.3 million to the sellers based on the achievement of certain milestones at certain dates. None of these milestones were achieved as of September 30, 2013. Xenogenics’ obligations under the Foreclosure Sale Agreement had been previously extended pursuant to Amendments No. 1 and No. 2, dated September 30, 2011 and October 23, 2012, respectively. On October 11, 2013, Xenogenics entered into Amendment No. 3 to the Foreclosure Sale Agreement which further extended the deadlines for the achievement of these milestones under the Foreclosure Sale Agreement by an additional twelve months. Xenogenics is required to use good faith reasonable efforts to achieve these milestones. Failure to achieve any of these milestones could result in all milestone payments, totaling $4.3 million, becoming immediately due and payable.

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This document contains forward-looking statements that are based upon current expectations within the meaning of the Private Securities Litigation Reform Act of 1995. It is our intent that such statements be protected by the safe harbor created thereby. This discussion and analysis should be read in conjunction with our financial statements and accompanying notes included elsewhere in this report. Operating results are not necessarily indicative of results that may occur in future periods.

Forward-looking statements involve risks and uncertainties and our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Examples of such forward-looking statements include, but are not limited to, statements about or relating to: our plans to pursue research and development of therapeutics in addition to continuing to advance our cellular systems business, our plans to become an integrated biopharmaceutical company, our use of proprietary cell-based systems and immune system modulation technologies to discover, develop and commercialize new therapeutics, our plans to continue to operate our business and minimize expenses, our expectations regarding future cash expenditures increasing significantly, our intent to gradually add scientific and support personnel, the expansion of our product offerings, additional revenues and profits, our ability to complete strategic mergers and acquisitions of product candidates, plans to increase further our operating expenses and administrative resources, future potential direct product sales, the sale of additional equity securities, debt financing and/or the sale or licensing of our technologies.

Such forward-looking statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, obtaining regulatory approval, and undertaking production and marketing of our drug candidates; difficulties or delays in patient enrollment for our clinical trials; unexpected adverse side effects or inadequate therapeutic efficacy of our drug candidates that could slow or prevent product approval (including the risk that current and past results of clinical trials or preclinical studies are not indicative of future results of clinical trials); activities and decisions of, and market conditions affecting, current and future strategic partners; pricing pressures; accurately forecasting operating and clinical trial costs; uncertainties of litigation and other business conditions; our ability to obtain additional financing if necessary; changing standards of care and the introduction of products by competitors or alternative therapies for the treatment of indications we target; the uncertainty of protection for our intellectual property or trade secrets, through patents or otherwise; and potential infringement of the intellectual property rights or trade secrets of third parties. In addition such statements are subject to the risks and uncertainties discussed under the “Risk Factors” section included in our Annual Report filed on Form 10-K for the year ended November 30, 2012.

Overview

MultiCell is a biopharmaceutical company developing novel therapeutics and discovery tools to address unmet medical needs for the treatment of neurological disorders, hepatic disease, cancer and interventional cardiology and peripheral vessel applications. Historically, we have specialized in developing primary liver cell immortalization technologies to produce cell-based assay systems for use in drug discovery. We seek to become an integrated biopharmaceutical company that will use our immune system modulation technologies to discover, develop and commercialize new therapeutics ourself and with strategic partners.

On October 9, 2007, MultiCell executed an exclusive license and purchase agreement with Corning of Corning, New York. Under the terms of such agreement, Corning has the right to develop, use, manufacture and sell MultiCell’s Fa2N-4 cell lines and related cell culture media for use as a drug discovery assay tool, including biomarker identification for the development of drug development assay tools, and for the performance of absorption, distribution, metabolism, elimination and toxicity assays (ADME/Tox assays). Corning paid MultiCell a non-refundable license fee, purchased certain inventory and equipment related to MultiCell’s Fa2N-4 cell line business, hired certain MultiCell scientific personnel, and paid for access to MultiCell’s laboratories during the transfer of the Fa2N-4 cell lines to Corning. MultiCell retained and continues to support all of its existing licensees. MultiCell retained the right to use the Fa2N-4 cells for use in applications not related to drug discovery or ADME/Tox assays. MultiCell also retained rights to use the Fa2N-4 cell lines and other cell lines to further develop its Sybiol® liver assist device, to identify drug targets and for other applications related to the Company’s internal drug development programs.

Our therapeutic development platform includes several patented techniques used to: (i) isolate, characterize and differentiate stem cells from human liver; (ii) control the immune response at transcriptional and translational levels through double-stranded RNA (“dsRNA”)-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and Melanoma Differentiation-Associated protein 5 (“MDA-5”) signaling; (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology; (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway. Our medical device development platform is based on the design of next-generation bioabsorbable stents, the Ideal BioStent™, for interventional cardiology and peripheral vessel applications.

On July 5, 2011, MultiCell entered into a sponsored research agreement with the University Health Network, or UHN, a not-for-profit corporation incorporated under the laws of Canada. Under this agreement UHN will evaluate the Company’s product candidates, MCT-465 and MCT-485, in its in vitro models for the treatment of primary liver cancer. The mechanism of action of MCT-465 and MCT-485 and their potential selective effect on liver cancer stem cells will also be evaluated. Under the terms of this agreement, we will retain exclusive access to the research findings and intellectual property resulting from the research activities preformed by UHN. On September 27, 2013, MultiCell entered into a new sponsored research agreement with Anand Ghanekar, M.D., Ph.D, of UHN’s Toronto General Hospital expanding the scope of the current research project with UHN to evaluate MCT-485 in animal models for the treatment of primary liver cancer (the “Ghanekar Agreement”). Under the terms of each of the Ghanekar Agreement, the Company retains exclusive access to the research findings and intellectual property resulting from the research activities preformed by of Dr. Ghanekar.

In December 2005, MultiCell exclusively licensed LAX-202 from Amarin Neuroscience Limited (“Amarin”) for the treatment of fatigue in patients suffering from multiple sclerosis (“MS”). MultiCell renamed LAX-202 to MCT-125, and intends to further evaluate MCT-125 in a pivotal Phase IIb/III clinical trial. In a 138 patient, multi-center, double-blind placebo controlled Phase II clinical trial conducted in the United Kingdom by Amarin, LAX-202 demonstrated efficacy in significantly reducing the levels of fatigue in MS patients enrolled in the study. LAX-202 proved to be effective within 4 weeks of the first daily oral dosing, and showed efficacy in MS patients who were moderately as well as severely affected. LAX-202 demonstrated efficacy in all MS patient sub-populations including relapsing-remitting, secondary progressive and primary progressive. Patients enrolled in the Phase II trial conducted by Amarin also reported few if any side effects following daily oral dosing of LAX-202. MultiCell intends to proceed with the anticipated pivotal Phase IIb/III trial of MCT-125 using the data generated by Amarin for LAX-202 following discussions with the regulatory authorities.

On September 30, 2010, Xenogenics entered into a Foreclosure Sale Agreement (the “Foreclosure Sale Agreement”) with Venture Lending & Leasing IV, Inc., Venture Lending & Leasing V, Inc. and Silicon Valley Bank (collectively, the “Sellers”). Pursuant to the Foreclosure Sale Agreement, as amended on September 30, 2011, and on October 23, 2012, Xenogenics acquired all of the Sellers’ interests in certain bioabsorbable stent assets (known as “Ideal BioStent™”) and related technologies. Under the Foreclosure Sale Agreement, Xenogenics is also required to make cash payments totaling $4.3 million to the sellers based on the achievement of certain milestones at certain dates. None of these milestones were achieved as of September 30, 2013. Xenogenics’ obligations under the Foreclosure Sale Agreement had been previously extended pursuant to Amendments No. 1 and No. 2, dated September 30, 2011 and October 23, 2012, respectively. On October 11, 2013, Xenogenics entered into Amendment No. 3 to the Foreclosure Sale Agreement which further extended the deadlines for the achievement of the milestones under the Foreclosure Sale Agreement by an additional twelve months. Xenogenics is required to use good faith reasonable efforts to achieve these milestones. Failure to achieve any of these milestones could result in all milestone payments, totaling $4.3 million, becoming immediately due and payable.

Effective September 30, 2010, Xenogenics entered into a license agreement (the “Rutgers License Agreement”) with Rutgers, The State University of New Jersey (“Rutgers”). Pursuant to the Rutgers License Agreement, Rutgers granted Xenogenics a worldwide exclusive license to exploit and commercialize certain patents and other intellectual property rights, as further described in the Rutgers License Agreement, relating to bioabsorbable stents for interventional cardiology and peripheral vascular applications.

Results of Operations

The following discussion is included to describe our consolidated financial position and results of operations. The condensed consolidated financial statements and notes thereto contain detailed information that should be referred to in conjunction with this discussion.

Three Months Ended August 31, 2013 Compared to the Three Months Ended August 31, 2012

Revenue. Total revenue for the three months ended August 31, 2013 and 2012 was $12,329. All of the revenue for the three months ended August 31, 2013 and 2012 is from the amortization of deferred revenue under license agreements with Corning and Pfizer.

Operating Expenses. Total operating expenses for the three months ended August 31, 2013 were $356,116, compared to operating expenses for the three months ended August 31, 2012 of $391,093, representing a decrease of $34,977. This decrease was due to a decrease of $52,501 in the amount of stock-based compensation, a decrease in shareholder meeting expense of $27,406, offset by increases of $37,727 in fees paid for consulting and contract services and $7,203 in all other operating expenses.

A significant portion of the decrease in stock-based compensation relates to the options granted by our subsidiary, Xenogenics. As more fully discussed in Note 7 to the accompanying condensed consolidated financial statements, Xenogenics granted options to certain prospective officers, to the members of its scientific advisory board, and to an outside consultant between November 2010 and July 2013. During the three months ended August 31, 2013, stock-based compensation included $51,052 related to these options. During the three months ended August 31, 2012, stock-based compensation included $95,925 related to these options. The decrease between the two periods relates to the vesting patterns of the options granted and the number of options that are vested in each period.

The decrease in shareholder meeting expense relates to the timing of the 2012 meeting (August 2012) compared to the anticipated timing of the 2013 meeting (November 2013). We will incur additional shareholder meeting expense during the quarter ending November 30, 2013.

The increase in consulting and contract services is primarily related to costs of $16,000 under a materials development agreement and increased payments to a consultant that is working on clinical trial development for MCT-125 in Europe.

Other income/(expense). Other income (expense) amounted to net expense of $1,573 for the three months ended August 31, 2013 as compared to net income of $61,406 for the three months ended August 31, 2012. Other income (expense) for the three months ended August 31, 2013 consists of (i) interest expense of $707, (ii) a loss from the change in fair value of derivative liability of $902, and (iii) interest income of $36. Other income (expense) for the three months ended August 31, 2012 was composed of (i) interest expense of $762, (ii) a gain from the change in fair value of derivative liability of $60,562, (iii) a gain from the disposition of equipment of $1,500, and (iv) interest income of $106.

Interest expense for the three months ended August 31, 2013 and 2012 principally includes interest on the 4.75% debenture.

The change in fair value of derivative liability is related to the embedded conversion feature in the Series B convertible preferred stock. The valuation of the derivative liability is dependent upon a number of factors beyond our control. As such, the amount of other income or expense that we report related to the change in the fair value of the derivative liability is somewhat unpredictable, but may be significant, and will continue to be reported until the holders of the Series B convertible preferred stock have converted their shares into shares of our common stock.

Net Loss. Net loss for the three months ended August 31, 2013 was $345,360, as compared to a net loss of $317,358 for the same period in the prior fiscal year, representing an increase in the net loss of $28,002. The reasons for this increase in net loss in the current period are due to the reasons described above in detail.

Nine Months Ended August 31, 2013 Compared to the Nine Months Ended August 31, 2012

Revenue. Total revenue for the nine months ended August 31, 2013 and 2012 was $36,988. All of the revenue for the nine months ended August 31, 2013 and 2012 is from the amortization of deferred revenue under license agreements with Corning and Pfizer.

Operating Expenses. Total operating expenses for the nine months ended August 31, 2013 were $1,018,548, compared to operating expenses for the nine months ended August 31, 2012 of $1,151,940, representing a decrease of $133,392. This decrease was due to a decrease of $50,296 in the amount of stock-based compensation, a decrease in shareholder meeting expense of $27,349, a decrease of $101,180 in legal and accounting fees, offset by increases of $43,160 in fees paid for consulting and contract services and $2,273 in all other operating expenses.

As described in more detail above, a significant portion of the decrease in stock-based compensation relates to the options granted by our subsidiary, Xenogenics and the decrease between the two periods relates to the vesting patterns of the options granted and the number of options that are vested in each period.

The decrease in legal and accounting expense relates principally to a reduction in patent-related legal costs incurred primarily by our subsidiary Xenogenics related to Ideal BioStent™ as a result of less patent-related legal work related to the stent during the nine months ended August 31, 2013.

Other income/(expense). Other income (expense) amounted to net expense of $13,229 for the nine months ended August 31, 2013 as compared to net income of $99,195 for the nine months ended August 31, 2012. Other income (expense) for the nine months ended August 31, 2013 consists of (i) interest expense of $2,058, (ii) a loss from the change in fair value of derivative liability of $11,342, and (iii) interest income of $171. Other income (expense) for the nine months ended August 31, 2012 was composed of (i) interest expense of $7,424, (ii) a gain from the change in fair value of derivative liability of $104,526, (iii) a gain from the disposition of equipment of $1,500, and (iv) interest income of $593.

Interest expense principally includes interest on the 4.75% debentures, including amortization of discount in the amount of $5,000 through February 28, 2012, the end of the original term of the debentures.

Net Loss. Net loss for the nine months ended August 31, 2013 was $994,789, as compared to a net loss of $1,015,757 for the same period in the prior fiscal year, representing a decrease in the net loss of $20,968. The reasons for this increase in net loss in the current period are due to the reasons described above in detail.

Liquidity and Capital Resources

Since our inception, we have financed our operations primarily through the issuance of debt or equity instruments. The following is a summary of our key liquidity measures at August 31, 2013 and 2012:

	August 31, 2013			August 31, 2012

Cash and cash equivalents	$	178,121		$	304,169

Current assets	$	323,538		$	314,462
Current liabilities		(1,231,563	)		(1,432,604	)

Working capital deficiency	$	(908,025	)	$	(1,118,142	)

We will have to raise additional capital in order to initiate Phase IIb clinical trials for MCT-125, our therapeutic product for the treatment of fatigue in MS patients. Our management is evaluating several sources of financing for our clinical trial program. Additionally, with our strategic shift in focus to therapeutic programs and technologies, we expect our future cash requirements to increase significantly as we advance our therapeutic programs into clinical trials. Until we are successful in raising additional funds, we may have to prioritize our therapeutic programs and delays may be necessary in some of our development programs.

Commencing in March 2008, we have operated on working capital provided by LJCI, in connection with its exercise of warrants issued to it by MultiCell (which LJCI must exercise whenever it converts amounts owed under the Debenture it holds), all as discussed in more detail below. The warrants are exercisable at $1.09 per share. As of August 31, 2013, there were 4,659,629 shares remaining on the LJCI Warrant. Should LJCI continue to exercise all of its remaining warrants, approximately $5.1 million of cash would be provided to us. However, the LJCI Agreement limits LJCI’s stock ownership in our common stock to 9.99% of the outstanding shares of our common stock. In August 2011, the Debenture and the warrant agreement were amended to extend the maturity date of the Debenture and the expiration date of the warrants to February 28, 2014. We expect that LJCI will continue to exercise the warrants and convert the Debenture through February 28, 2014, subject to the limitations of the LJCI Agreement and the availability of our authorized common stock. We are also investigating the possible sale or license of certain assets that we did not already license to Corning in October 2007. We are presently pursuing discussions with companies operating in the stem cell research market and the general life science research market.

On July 14, 2006, we completed a private placement of Series B convertible preferred stock. A total of 17,000 shares of Series B convertible preferred stock were sold to accredited investors at a price of $100 per share. Originally, the Series B shares were convertible at any time into shares of our common stock at a conversion price determined by dividing the purchase price per share of $100 by $0.32 per share (the “Series B Conversion Price”). The Series B Conversion Price was reduced to 85% of the then applicable Series B Conversion Price as a result of an event of default in the payment of preferred dividends. The Series B Conversion Price is also subject to equitable adjustment in the event of any stock splits, stock dividends, recapitalizations and the like. In addition, the Series B Conversion Price is subject to weighted average anti-dilution adjustments in the event that we sell shares of our common stock or other securities convertible into or exercisable for shares of our common stock at a per share price, exercise price or conversion price lower than the Series B Conversion Price then in effect in any transaction (other than in connection with an acquisition of the securities, assets or business of another company, a joint venture and/or the issuance of employee stock options). As a result of these adjustments, the Series B Conversion Price has been reduced to $0.0124 per share as of August 31, 2013. Pursuant to the applicable Series B convertible preferred stock purchase agreement, each investor may only convert that number of shares of Series B convertible preferred stock into that number of shares of our common stock that does not exceed 9.99% of the outstanding shares of our common stock on the date of conversion. The Series B convertible preferred stock does not have voting rights. Commencing on the date of issuance of the Series B convertible preferred stock until the date a registration statement registering the common shares underlying the preferred stock and warrants issued was declared effective by the SEC, we paid on each outstanding share of Series B convertible preferred stock a preferential cumulative dividend at an annual rate equal to the product of multiplying $100 per share by the higher of (a) the Wall Street Journal Prime Rate plus 1%, or (b) 9%. In no event was the dividend rate greater than 12% per annum. Subsequent to November 30, 2010, we received an opinion of outside counsel providing for the removal of the restrictive legend on the Series B convertible preferred stock, which in turn terminated the requirement to accrue the related dividends. As of August 31, 2013, there are 3,448 shares of Series B convertible preferred stock outstanding.

In the event of any dissolution or winding up of our company, whether voluntary or involuntary, holders of each outstanding share of Series B convertible preferred stock shall be entitled to be paid first in priority out of our assets available for distribution to stockholders, an amount equal to $100 per share of Series B convertible preferred stock held plus any declared but unpaid dividends. After such payment has been made in full, such holders of Series B convertible preferred stock shall be entitled to no further participation in the distribution of our assets.

We entered into the LJCI Agreement pursuant to which we agreed to sell convertible debentures in the principal amount of $100,000 and originally scheduled to mature on February 28, 2012. In addition, we issued to LJCI a warrant to purchase up to 10 million shares of our common stock at an exercise price of $1.09 per share, exercisable over the next five years according to a schedule described in a letter agreement dated February 28, 2007. In August 2011, we and LJCI amended the Debenture and the warrant agreement to extend the maturity date of the Debenture and the expiration date of the warrants to February 28, 2014.

The Debenture is convertible at the option of LJCI at any time up to maturity at a conversion price equal to the lesser of the fixed conversion price of $1.00, or 80% of the average of the lowest three daily volume weighted average trading prices per share of our common stock during the twenty trading days immediately preceding the conversion date. The Debenture accrues interest at 4.75% per year payable in cash or our common stock. Through August 31, 2013, interest is being paid in cash. If paid in stock, the stock will be valued at the rate equal to the conversion price of the Debenture in effect at the time of payment.

For the Debenture, upon receipt of a conversion notice from the holder, we may elect to immediately redeem that portion of the Debenture that the holder elected to convert in such conversion notice, plus accrued and unpaid interest. After February 28, 2008, we, at our sole discretion, have the right, without limitation or penalty, to redeem the outstanding principal amount of the Debenture not yet converted by holder into shares of our common stock, plus accrued and unpaid interest thereon.

Cash provided by (used in) operating, investing and financing activities for the nine month periods ended August 31, 2013 and 2012 is as follows:

	August 31, 2013			August 31, 2012

Operating activities	$	(868,421	)	$	(595,338	)
Investing activities		-			1,500
Financing activities		847,070			492,680

Net decrease in cash and cash equivalents	$	(21,351	)	$	(101,158	)

Operating Activities

For the nine months ended August 31, 2013, the differences between our net loss and net cash used in operating activities are due to non-cash charges totaling $187,208 included in our net loss for stock-based compensation and change in fair value of derivative liability, less changes in non-cash working capital totaling $60,840. For the nine months ended August 31, 2012, the differences between our net loss and net cash provided by operating activities are due to net non-cash charges and credits totaling $125,136 included in our net loss for stock-based compensation, interest, gain on disposition of equipment, and change in fair value of derivative liability, plus changes in non-cash working capital totaling $295,283 (principally the collection of the grant receivable of $303,102).

Investing Activities

We had no cash flows from investing activities during the nine months ended August 31, 2013. During the nine months ended August 31, 2012, we sold surplus equipment for $1,500.

Financing Activities

During the nine months ended August 31, 2013 and 2012, cash flows from financing activities are related to LJCI’s payments to us of $847,070 and $492,680, respectively, which are applied towards the exercise of common stock warrants.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable to a “smaller reporting company” as defined in Item 10(f)(1) of SEC Regulation S-K.

Item 4. CONTROLS AND PROCEDURES

We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable assurance of achieving the desired control objectives, and we necessarily are required to apply our judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures.

Our management, including our principal executive officer and principal financial officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of August 31, 2013, and concluded that the disclosure controls and procedures were not effective, because certain deficiencies involving internal controls constituted material weaknesses as discussed below. The material weaknesses identified did not result in the restatement of any previously reported financial statements or any other related financial disclosure, nor does management believe that it had any effect on the accuracy of our financial statements for the current reporting period.

Based on its evaluation, our management concluded that there is a material weakness in our internal control over financial reporting. A material weakness is a deficiency, or a combination of control deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. As of August 31, 2013, the following material weaknesses existed:

Entity-Level Controls: We did not maintain effective entity-level controls as defined by the framework issued by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control –Integrated Framework. Specifically, we did not effectively segregate certain accounting duties due to the small size of our accounting staff, and maintain a sufficient number of adequately trained personnel necessary to anticipate and identify risks critical to financial reporting.

Information Technology: We did not maintain effective controls over the segregation of duties and access to financial reporting systems. Specifically, key financial reporting systems were not appropriately configured to ensure that certain transactions were properly processed with segregated duties among personnel and to ensure that unauthorized individuals did not have access to add or change key financial data.

Due to this material weakness, management has concluded that our internal control over financial reporting was not effective as of August 31, 2013.

In order to mitigate these material weaknesses to the fullest extent possible, all financial reports are reviewed by the Chief Financial Officer, who has limited system access. In addition, regular meetings are held with our Board of Directors and the Audit Committee. If at any time we determine a new control can be implemented to mitigate these risks at a reasonable cost, it is implemented as soon as possible.

There were no changes in our internal control over financial reporting that occurred during the quarter ended August 31, 2013, that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1: LEGAL PROCEEDINGS

None.

Item 1A: RISK FACTORS

Not required for “smaller reporting companies.”

Item 2: UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Stock Issuances

On June 17, 2013, we issued 69,609,667 shares of our common stock to LJCI pursuant to its conversion of $570 of the Debenture. We also issued 57,000 shares of our common stock to LJCI pursuant to its exercise of warrants. Proceeds from the exercise were $62,130, or $1.09 per share. The securities were issued in a transaction pursuant to Regulation D under the Securities Act of 1933, as amended.

On June 28, 2013, we issued 79,379,444 shares of our common stock to LJCI pursuant to its conversion of $650 of the Debenture. We also issued 65,000 shares of our common stock to LJCI pursuant to its exercise of warrants. Proceeds from the exercise were $70,850, or $1.09 per share. The securities were issued in a transaction pursuant to Regulation D under the Securities Act of 1933, as amended.

On July 23, 2013, we issued 61,061,111 shares of our common stock to LJCI pursuant to its conversion of $500 of the Debenture. We also issued 50,000 shares of our common stock to LJCI pursuant to its exercise of warrants. Proceeds from the exercise were $54,500, or $1.09 per share. The securities were issued in a transaction pursuant to Regulation D under the Securities Act of 1933, as amended.

On August 13, 2013, we issued 89,149,222 shares of our common stock to LJCI pursuant to its conversion of $730 of the Debenture. We also issued 73,000 shares of our common stock to LJCI pursuant to its exercise of warrants. Proceeds from the exercise were $79,570, or $1.09 per share. The securities were issued in a transaction pursuant to Regulation D under the Securities Act of 1933, as amended.

On August 18, 2013, we issued 146,546,667 shares of our common stock to LJCI pursuant to its conversion of $1,200 of the Debenture. We also issued 120,000 shares of our common stock to LJCI pursuant to its exercise of warrants. Proceeds from the exercise were $130,800, or $1.09 per share. The securities were issued in a transaction pursuant to Regulation D under the Securities Act of 1933, as amended.

Item 3: DEFAULTS UPON SENIOR SECURITIES

None.

Item 4: MINE SAFETY DISCLOSURES

Not applicable.

Item 5: OTHER INFORMATION

None.

Item 6: EXHIBITS:

Exhibit Number		Exhibit Description

3.1 (1)		Certificate of Incorporation, as filed on April 28, 1970.
3.2 (1)		Certificate of Amendment, as filed on October 27, 1986.
3.3 (1)		Certificate of Amendment, as filed on August 24, 1989.
3.4 (1)		Certificate of Amendment, as filed on July 31, 1991.
3.5 (1)		Certificate of Amendment, as filed on August 14, 1991.
3.6 (1)		Certificate of Amendment, as filed on June 13, 2000.
3.7 (2)		Certificate of Amendment, as filed May 18, 2005.
3.8 (3)		Certificate of Correction, as filed June 2, 2005.
3.9 (4)		Certificate of Amendment, as filed September 1, 2010.
3.10 (5)		Certificate of Amendment, as filed July 13, 2011.
3.11 (6)		Certificate of Amendment, as filed August 29, 2012.
3.12 (7)		Certificate of Incorporation, as amended as of February 28, 2013.
3.13 (1)		Bylaws, as amended May 18, 2005.
3.14 (1)		Specimen Stock Certificate.
4.1 (8)		Certificate of Designations of Preferences and Rights of Series I Convertible Preferred Stock, as filed on July 13, 2004.
4.2 (9)		Certificate of Designation of Series B Convertible Preferred Stock, as filed July 14, 2006.
4.3 (10)		Securities Purchase Agreement, between Multicell Technologies, Inc. and La Jolla Cove Investors, Inc., dated February 28, 2007.
4.4 (10)		4 ¾ % Convertible Debenture for $100,000 issued by Multicell Technologies, Inc. to La Jolla Cove Investors, Inc., dated February 28, 2007.
4.5 (10)		Warrant to Purchase Common Stock dated February 28, 2007.
4.6 (10)		Letter, dated February 28, 2007, to Multicell Technologies, Inc. from La Jolla Cove Investors, Inc.
4.7 (11)		Form of Warrant to Purchase Common Stock (Cashless Exercise), dated July 14, 2006, issued by Multicell Technologies, Inc. to Monarch Pointe Fund, Ltd., Mercator Momentum Fund III, L.P., Asset Managers International Ltd. and Pentagon Special Purpose Fund Ltd.
4.8 (11)		Form of Warrant to Purchase Common Stock (Cash Exercise), dated July 14, 2006, issued by Multicell Technologies, Inc. to Monarch Pointe Fund, Ltd., Mercator Momentum Fund III, L.P., Asset Managers International Ltd. and Pentagon Special Purpose Fund Ltd.
4.9 (11)		Form of Shares of Series B Convertible Preferred Stock and Common Stock Warrants Subscription Agreement, dated July 14, 2006, by and between Multicell Technologies, Inc. and Monarch Pointe Fund, Ltd., Mercator Momentum Fund III, L.P., Asset Managers International Ltd. and Pentagon Special Purpose Fund Ltd.
10.1		Amendment No. 3 to Foreclosure Sale Agreement, dated as of September 30, 2010, by and among Venture Lending & Leasing IV, Inc., Venture Lending & Leasing V, Inc. Silicon Valley Bank, and Xenogenics Corporation, dated as of October 11, 2013. *
31.1		Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 302. *
32.1		Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350. *
101 INS		XBRL Instance Document**
101 SCH		XBRL Schema Document**
101 CAL		XBRL Calculation Linkbase Document**
101 LAB		XBRL Labels Linkbase Document**
101 PRE		XBRL Presentation Linkbase Document**
101 DEF		XBRL Definition Linkbase Document**

* Filed herewith

** The XBRL related information in Exhibit 101 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section and shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

(1) Incorporated by reference from an exhibit to our Post-Effective Amendment No. 1 to our Registration Statement on Form SB-2 filed on May 6, 2005.

(2) Incorporated by reference from an exhibit to our Current Report on Form 8-K filed on May 18, 2005.

(3) Incorporated by reference from an exhibit to our Post-Effective Amendment No. 2 to our Registration Statement on Form SB-2 filed on September 27, 2005.

(4) Incorporated by reference from an exhibit to our Current Report on Form 8-K filed on September 1, 2010.

(5) Incorporated by reference from an exhibit to our Current Report on Form 8-K filed on July 13, 2011.

(6) Incorporated by reference from an exhibit to our Quarterly Report on Form 10-Q filed on October 15, 2012.

(7) Incorporated by reference from an exhibit to our Annual Report on Form 10-K filed on February 28, 2013.

(8) Incorporated by reference from an exhibit to our Form SB-2 Registration Statement filed on August 12, 2004.

(9) Incorporated by reference from an exhibit to our Current Report on Form 8-K filed on July 19, 2006.

(10) Incorporated by reference from an exhibit to our Current Report on Form 8-K/A filed on March 7, 2007.

(11) Incorporated by reference from an exhibit to our Current Report on Form 8-K filed on July 20, 2006.

* * *

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	MULTICELL TECHNOLOGIES, INC.

October 15, 2013	By:	/s/ W. Gerald Newmin

		W. Gerald Newmin
		(Chief Executive Officer and Chief Financial Officer)

EX-10.1 2 v355911_ex10-1.htm EXHIBIT 10.1

EXHIBIT 10.1

AMENDMENT NO. 3 TO FORECLOSURE SALE AGREEMENT

This Amendment No. III to the FORECLOSURE SALE AGREEMENT (this “Amendment No. 3”) is entered into as of October 11, 2013 by and among Venture Lending & Leasing IV, Inc. (“VLL4”), Venture Lending & Leasing V, Inc. (“VLL5”), Silicon Valley Bank (“SVB”) and Xenogenics Corporation, a Nevada corporation (“Purchaser”). VLL4, VLL5 and SVB are sometimes referred to hereinafter collectively, as “Sellers” and individually as a “Seller” and VLL5, in its capacity as collateral agent for the Sellers under the Loan Agreement (as defined in the Agreement, as defined below) is sometimes referred to herein as “Agent.”

RECITALS

WHEREAS, the Sellers entered into a FORECLOSURE SALE AGREEMENT dated September 30, 2010 with Purchaser (the “Agreement”);

WHEREAS, the Sellers entered into AMENDMENT NO. 1 (attached hereto as Exhibit A and hereinafter referred to as Amendment No. 1) dated September 30, 2011 with Purchaser modifying certain terms and conditions of the Agreement;

WHEREAS, the Sellers entered into AMENDMENT NO. 2 (attached hereto as Exhibit B and hereinafter referred to as Amendment No. 2) dated October 9, 2012 with Purchaser modifying certain terms and conditions of the Agreement;

WHEREAS, the Purchaser and Sellers now desire to amend the terms of the Agreement as set forth below; and

WHEREAS, pursuant to Section 14(f) of the Agreement, any provision of the Agreement may be amended by written agreement signed by Purchaser and Sellers.

NOW, THEREFORE, in consideration of these premises and the mutual covenants, terms and conditions set forth herein, all of the parties hereto mutually agree as follows:

AMENDMENT

1. Amendment to Section 12 development milestones. The first paragraph of Section 12 of the Agreement relating to the completion by Purchaser of certain development milestones is hereby amended as follows:

The Purchaser shall achieve the following development milestones for the Generation 2 bioabsorbable stent:

(a) Restart manufacturing and produce a Generation 2 bioabsorbable stent device within 12 months from date of execution of Amendment No. 3;

(b) Initiate an animal study within 12 months from date of execution of Amendment No. 3;

(c) Make a regulatory submission to support a human use clinical trial within 24 months from date of execution of Amendment No. 3;

(d) Initiate a human use clinical trial within 24 months from date of execution of Amendment No. 3; and,

(e) Make a regulatory submission or equivalent for marketing approval for use in humans within 48 months from date of execution of Amendment No. 3.

2. Counterparts; Facsimile. This Amendment No. 3 may be executed in any number of counterparts, each of which shall be an original, and all of which together shall constitute one instrument. Executed signatures transmitted via facsimile will be accepted and considered duly executed.

IN WITNESS WHEREOF, Purchaser, Agent and Sellers have caused this Amendment to be executed as of the day and year first above written.

	SELLERS:

	VENTURE LENDING & LEASING IV, INC.

	By:	/s/ Jay Cohan
	Name:	Jay Cohan
	Its:	Vice President

	VENTURE LENDING & LEASING V, INC., as Agent and as a Seller

	By:	/s/ Jay Cohan
	Name:	Jay Cohan
	Its:	Vice President

	SILICON VALLEY BANK

	By:	/s/ Eleanor Wu
	Name:	Eleanor Wu
	Its:	Vice President

	PURCHASER:

	XENOGENICS CORPORATION

	By:	/s/ W. Gerald Newmin
	Name:	W. Gerald Newmin
	Its:	Chairman & CEO

EXHIBIT A

Amendment No. 1

EXHIBIT B

Amendment No. 2

EX-31.1 3 v355911_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, W. Gerald Newmin, certify that:

I have reviewed this quarterly report on Form 10-Q of MultiCell Technologies, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: October 15, 2013

By:	/s/ W. Gerald Newmin

Name	W. Gerald Newmin
	Chief Executive Officer and Chief Financial Officer

EX-32.1 4 v355911_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

AND CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)

In connection with the Quarterly Report of MultiCell Technologies, Inc. (the “Company”) on Form 10-Q for the period ended August 31, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, W. Gerald Newmin, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the period covered by the Report.

Dated: October 15, 2013

By:	/s/ W. Gerald Newmin

Name:	W. Gerald Newmin
	Chief Executive Officer and Chief Financial Officer

EX-101.INS 5 mcet-20130831.xml XBRL INSTANCE DOCUMENT 0000811779 2012-06-01 2012-08-31 0000811779 2013-06-01 2013-08-31 0000811779 2013-08-31 0000811779 2013-10-08 0000811779 2012-11-30 0000811779 2011-12-01 2012-08-31 0000811779 2011-12-01 2012-11-30 0000811779 2012-12-01 2013-02-28 0000811779 2012-12-01 2013-05-31 0000811779 2012-12-01 2013-08-31 0000811779 2011-11-30 0000811779 2012-08-31 0000811779 mcet:SeriesBConvertiblePreferredStockMember 2013-08-31 0000811779 mcet:SeriesBConvertiblePreferredStockMember 2012-11-30 0000811779 mcet:SeriesIConvertiblePreferredStockMember 2013-08-31 0000811779 mcet:SeriesIConvertiblePreferredStockMember 2012-11-30 0000811779 mcet:SeriesBConvertiblePreferredStockMember 2011-11-30 0000811779 mcet:SeriesIConvertiblePreferredStockMember 2011-11-30 0000811779 us-gaap:CommonStockMember 2011-11-30 0000811779 us-gaap:AdditionalPaidInCapitalMember 2011-11-30 0000811779 us-gaap:RetainedEarningsMember 2011-11-30 0000811779 us-gaap:NoncontrollingInterestMember 2011-11-30 0000811779 us-gaap:CommonStockMember 2012-11-30 0000811779 us-gaap:AdditionalPaidInCapitalMember 2012-11-30 0000811779 us-gaap:RetainedEarningsMember 2012-11-30 0000811779 us-gaap:NoncontrollingInterestMember 2012-11-30 0000811779 mcet:SeriesBConvertiblePreferredStockMember 2011-12-01 2012-08-31 0000811779 mcet:SeriesIConvertiblePreferredStockMember 2011-12-01 2012-08-31 0000811779 us-gaap:CommonStockMember 2011-12-01 2012-08-31 0000811779 us-gaap:AdditionalPaidInCapitalMember 2011-12-01 2012-08-31 0000811779 us-gaap:RetainedEarningsMember 2011-12-01 2012-08-31 0000811779 us-gaap:NoncontrollingInterestMember 2011-12-01 2012-08-31 0000811779 mcet:SeriesBConvertiblePreferredStockMember 2012-12-01 2013-08-31 0000811779 mcet:SeriesIConvertiblePreferredStockMember 2012-12-01 2013-08-31 0000811779 us-gaap:CommonStockMember 2012-12-01 2013-08-31 0000811779 us-gaap:AdditionalPaidInCapitalMember 2012-12-01 2013-08-31 0000811779 us-gaap:RetainedEarningsMember 2012-12-01 2013-08-31 0000811779 us-gaap:NoncontrollingInterestMember 2012-12-01 2013-08-31 0000811779 mcet:SeriesBConvertiblePreferredStockMember 2012-08-31 0000811779 mcet:SeriesIConvertiblePreferredStockMember 2012-08-31 0000811779 us-gaap:CommonStockMember 2012-08-31 0000811779 us-gaap:AdditionalPaidInCapitalMember 2012-08-31 0000811779 us-gaap:RetainedEarningsMember 2012-08-31 0000811779 us-gaap:NoncontrollingInterestMember 2012-08-31 0000811779 us-gaap:CommonStockMember 2013-08-31 0000811779 us-gaap:AdditionalPaidInCapitalMember 2013-08-31 0000811779 us-gaap:RetainedEarningsMember 2013-08-31 0000811779 us-gaap:NoncontrollingInterestMember 2013-08-31 0000811779 mcet:XenogenicsCorporationMember 2013-08-31 0000811779 mcet:MulticellImmunotherapeuticsMember 2013-08-31 0000811779 mcet:LaJollaCoveInvestorsMember 2013-08-31 0000811779 mcet:LaJollaCoveInvestorsMember 2012-12-01 2013-08-31 0000811779 mcet:LaJollaCoveInvestorsMember 2006-12-01 2007-11-30 0000811779 mcet:LaJollaCoveInvestorsMember 2011-08-01 2011-08-16 0000811779 us-gaap:CommonStockMember 2012-12-01 2013-08-31 0000811779 us-gaap:CommonStockMember 2011-12-01 2012-08-31 0000811779 us-gaap:CommonStockMember 2013-08-31 0000811779 us-gaap:CommonStockMember 2011-12-01 2012-11-30 0000811779 us-gaap:BoardOfDirectorsChairmanMember 2013-08-31 0000811779 mcet:SeriesBConvertiblePreferredStockMember 2011-12-01 2012-11-30 0000811779 mcet:SeriesBConvertiblePreferredStockMember us-gaap:MaximumMember 2012-12-01 2013-08-31 0000811779 mcet:AccreditedInvestorsMember 2004-07-13 0000811779 mcet:PfizerMember 2013-06-01 2013-08-31 0000811779 mcet:PfizerMember 2012-12-01 2013-08-31 0000811779 mcet:PfizerMember 2012-06-01 2012-08-31 0000811779 mcet:PfizerMember 2011-12-01 2012-08-31 0000811779 mcet:EquityIncentivePlan2004Member 2013-08-31 0000811779 us-gaap:DirectorMember 2012-12-01 2013-08-31 0000811779 mcet:EmployeeMember 2012-12-01 2013-08-31 0000811779 us-gaap:DirectorMember 2011-12-01 2012-08-31 0000811779 mcet:EmployeeMember 2011-12-01 2012-08-31 0000811779 mcet:XenogenicsCorporationMember 2010-10-31 0000811779 mcet:XenogenicsCorporationMember 2011-02-03 0000811779 mcet:XenogenicsCorporationMember 2012-12-01 2013-08-31 0000811779 us-gaap:ExecutiveOfficerMember mcet:XenogenicsCorporationMember 2009-12-01 2010-11-30 0000811779 us-gaap:ExecutiveOfficerMember mcet:XenogenicsCorporationMember 2010-11-30 0000811779 mcet:OfficersAndMembersOfScientificAdvisoryBoardMember mcet:XenogenicsCorporationMember 2011-03-01 2011-03-31 0000811779 mcet:OfficersAndMembersOfScientificAdvisoryBoardMember mcet:XenogenicsCorporationMember 2011-12-01 2012-02-29 0000811779 mcet:ReplacementOptionsMember 2011-12-01 2012-02-29 0000811779 mcet:XenogenicsCorporationMember 2013-06-01 2013-08-31 0000811779 mcet:XenogenicsCorporationMember 2012-06-01 2012-08-31 0000811779 mcet:XenogenicsCorporationMember 2011-12-01 2012-08-31 0000811779 mcet:ConsultantMember 2013-07-01 2013-07-28 0000811779 mcet:EquityIncentivePlan2004Member 2011-07-11 0000811779 mcet:EquityIncentivePlan2004Member 2011-12-02 0000811779 mcet:EquityIncentivePlan2004Member 2012-12-02 0000811779 mcet:LaJollaCoveInvestorsMember 2012-12-01 2013-08-31 0000811779 mcet:LaJollaCoveInvestorsMember 2011-12-01 2012-08-31 0000811779 us-gaap:WarrantMember 2012-12-01 2013-08-31 0000811779 us-gaap:EmployeeStockOptionMember 2012-12-01 2013-08-31 0000811779 mcet:LaJollaCoveInvestorsDebentureMember 2012-12-01 2013-08-31 0000811779 us-gaap:WarrantMember 2011-12-01 2012-08-31 0000811779 us-gaap:EmployeeStockOptionMember 2011-12-01 2012-08-31 0000811779 mcet:LaJollaCoveInvestorsDebentureMember 2011-12-01 2012-08-31 0000811779 us-gaap:FairValueInputsLevel1Member 2013-08-31 0000811779 us-gaap:FairValueInputsLevel2Member 2013-08-31 0000811779 us-gaap:FairValueInputsLevel3Member 2013-08-31 0000811779 us-gaap:FairValueInputsLevel1Member 2012-11-30 0000811779 us-gaap:FairValueInputsLevel2Member 2012-11-30 0000811779 us-gaap:FairValueInputsLevel3Member 2012-11-30 0000811779 us-gaap:SubsequentEventMember 2012-12-01 2013-08-31 0000811779 us-gaap:SubsequentEventMember mcet:XenogenicsCorporationMember 2012-12-01 2013-08-31 0000811779 us-gaap:SubsequentEventMember mcet:XenogenicsCorporationMember 2013-08-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 10-Q false 2013-08-31 2013 Q3 MCET 2513461835 MultiCell Technologies, Inc. 0000811779 --11-30 Smaller Reporting Company

40561

0.01

963000

0.01

3000000000

2391239613

1349803029

2391239613

1349803029

470316

17000

3448

20000

178121

199472

14617

11293

323538

210765

280

323818

211045

1085649

1106177

50000

0 50000

46596

49318

1231563

1255495

56026

461753

498741

30587

19245

492340

574012

1723903

1829507

461835

23912396

13498030

18554395

27755595

-43158172

-42254594

-229546

-539134

-1170539

-1079328

-1400085

-1618462

323818

211045

130800

12329

36988

207753

231953

626092

649454

95418

53694

216590

276324

52945

105446

175866

226162

356116

391093

1018548

1151940

-343787

-378764

-981560

-1114952

707

762

2058

7424

-902

60562

-11342

104526

1500

106

171

593

-1573 61406 -13229 99195

-345360

-317358

-994789

-1015757

-42264

-22771

-91211

-71841

-303096

-294587

-903578

-943916

-0.00014

-0.00028

-0.00052

-0.00099

2105332608

1065058664

1730465999

957413780

0.0475

-1753599

1349844

573400

8233860

30064619

-40998344

-976978

461835

13498030

27755595

-42254594

-1079328

11339

5734

823385986

3448

1349803029

7290

9430

3239366

-3232076

10404936

-10395506

323936571

1040493584

794610 1027870 0 0 7290 787320 0 0 0 0 9430 1018440 0 0 0 0 729000 0 0 943000

226162

175866

226162

175866

-943916

-71841

-903578

-91211

-1741294

1349844

573400

11480516

27846025

-41942260

-1048819

461835

23912396

18554395

-43158172

-1170539

11339

5734

1148051557

3448

2391239613

5000

0 303102

3324

-305

-20528

28864

-36988

-868421

-595338

1500

1027870 794610 180800 301930

847070

492680

-21351

-101158

405327

304169

2142

2502

0.953

0.67

4659629

46596

5100000 0.0999 2014-02-28 2007-02-28

100000

2012-02-28

2014-02-28

10000000

1040493584

323936571

943000 729000

5800000000

4659629 each $1,000 of the principal converted, LJCI would be required to simultaneously purchase 100,000 shares under the LJCI Warrant at $1.09 per share. P5Y

130800

The “Conversion Price” is equal to the lesser of $1.00 or 80% of the average of the three lowest volume-weighted average prices during the twenty trading days prior to the election to convert. <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>NOTE 4. SERIES B CONVERTIBLE PREFERRED STOCK</strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company’s Board of Directors has the authority, without further action by the stockholders, to issue up to <font style=" FONT-SIZE: 10pt">1,000,000</font> shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions of these shares of preferred stock. The Board of Directors originally designated <font style=" FONT-SIZE: 10pt"> 17,000</font> shares as Series B convertible preferred stock. The Series B convertible preferred stock does not have voting rights.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Series B shares are convertible at any time into shares of the Company’s common stock at a conversion price determined by dividing the purchase price per share of $<font style=" FONT-SIZE: 10pt">100</font> by the conversion price. The conversion price was originally $<font style=" FONT-SIZE: 10pt">0.32</font> per share. Upon the occurrence of an event of default (as defined in the applicable Series B convertible preferred stock purchase agreement), the conversion price of the Series B shares shall be reduced to <font style=" FONT-SIZE: 10pt"> 85</font>% of the then-applicable conversion price of such shares. The conversion price is subject to equitable adjustment in the event of any stock splits, stock dividends, recapitalizations and the like. In addition, the conversion price is subject to weighted average anti-dilution adjustments in the event the Company sells common stock or other securities convertible into or exercisable for common stock at a per share price, exercise price or conversion price lower than the conversion price then in effect in any transaction (other than in connection with an acquisition of the securities, assets or business of another company, a joint venture and/or the issuance of employee stock options). As a result of the Company issuing shares of its common stock upon conversion of convertible debentures and upon the exercise of warrants both at prices lower than the conversion price of the Series B convertible preferred stock, and due to the Company not paying the Series B dividends on a monthly basis (as discussed below), the conversion price of the Series B convertible preferred stock has been reduced to $<font style=" FONT-SIZE: 10pt">0.0124</font> per share as of August 31, 2013 and to $<font style=" FONT-SIZE: 10pt">0.0215</font> per share as of November 30, 2012. Pursuant to the applicable Series B convertible preferred stock purchase agreement, each investor may only convert that number of shares of Series B convertible preferred stock into that number of shares of the Company’s common stock that does not exceed <font style=" FONT-SIZE: 10pt">9.99</font>% of the outstanding shares of common stock of the Company on the date of conversion. </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: center; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b> </b></div> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Commencing on the date of issuance of the Series B convertible preferred stock until the date a registration statement registering the shares of the Company’s common stock underlying the preferred stock and warrants issued is declared effective by the SEC, the Company was required to pay on each outstanding share of Series B convertible preferred stock a preferential cumulative dividend at an annual rate equal to the product of multiplying $100 per share by the higher of (i) the Wall Street Journal Prime Rate plus 1%, or (ii) 9%. In no event was the dividend rate to be greater than <font style=" FONT-SIZE: 10pt">12</font>% per annum. The dividend was payable monthly in arrears in cash on the last day of each month based on the number of shares of Series B convertible preferred stock outstanding as of the first day of that month. In the event the Company did not pay the Series B convertible preferred dividends when due, the conversion price of the Series B preferred shares was reduced to 85% of the otherwise applicable conversion price. The Company did not pay the required monthly Series B preferred dividends beginning on November 30, 2006, which, in part, caused the conversion price to be reduced. Subsequent to November 30, 2010, the Company received an opinion of outside counsel providing for the removal of the restrictive legend on the Series B convertible preferred stock, which in turn terminated the requirement to accrue the related dividends. Accordingly, no dividends have been accrued since November 30, 2010. Total accrued but unpaid preferred dividends recorded in the accompanying condensed consolidated balance sheets as of August 31, 2013, and as of November 30, 2012, are $<font style=" FONT-SIZE: 10pt"><font style=" FONT-SIZE: 10pt">290,724</font></font> of which $<font style=" FONT-SIZE: 10pt"><font style=" FONT-SIZE: 10pt">125,516</font></font> are recorded in permanent equity with the Series B convertible preferred stock, and $<font style=" FONT-SIZE: 10pt"><font style=" FONT-SIZE: 10pt">165,208</font></font> are recorded as a current liability in accounts payable and accrued expenses.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The conversion feature which gives the holders of the Series B convertible preferred stock the right to acquire shares of the Company’s common stock is an embedded derivative. As of August 31, 2013 and November 30, 2012, there were <font style=" FONT-SIZE: 10pt">3,448</font> shares of Series B convertible preferred stock that were convertible into <font style=" FONT-SIZE: 10pt">27,806,452</font> and <font style=" FONT-SIZE: 10pt">16,037,209</font> shares of common stock of the Company, respectively. The fair value of the conversion feature was estimated at $<font style=" FONT-SIZE: 10pt">30,587</font> ($<font style=" FONT-SIZE: 10pt">0.0011</font> per share of common stock) and $<font style=" FONT-SIZE: 10pt">19,245</font> ($<font style=" FONT-SIZE: 10pt">0.0012</font> per share of common stock) at August 31, 2013 and November 30, 2012, respectively, and has been estimated using the Black-Scholes option-pricing model using the following assumptions:</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>August 31,<br/> 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>May 31,<br/> 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>February 28,<br/> 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>November 30,<br/> 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Fair value of common stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0038</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Conversion price of preferred stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0124</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0151</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0190</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0215</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.78</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.62</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Expected life</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10 Years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10 Years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10 Years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10 Years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>148</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>148</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>147</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>141</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The fair value of the conversion feature increased by $902 and by $11,342 during the three months and the nine months ended August 31, 2013, respectively, which has been recorded as a loss from the change in the fair value of the derivative liability. The fair value of the conversion feature decreased by $<font style=" FONT-SIZE: 10pt">60,562</font> and by $<font style=" FONT-SIZE: 10pt">104,526</font> during the three months and nine months ended August 31, 2012, respectively, which has been recorded as a gain from the change in the fair value of the derivative liability.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In the event of any dissolution or winding up of the Company, whether voluntary or involuntary, holders of each outstanding share of Series B convertible preferred stock shall be entitled to be paid first in priority out of the assets of the Company available for distribution to stockholders, an amount equal to $100 per share of Series B convertible preferred stock held plus any declared but unpaid dividends. After such payment has been made in full, such holders of Series B convertible preferred stock shall be entitled to no further participation in the distribution of the assets of the Company.</div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The fair value of the conversion feature was estimated at $<font style=" FONT-SIZE: 10pt">30,587</font> ($<font style=" FONT-SIZE: 10pt">0.0011</font> per share of common stock) and $<font style=" FONT-SIZE: 10pt">19,245</font> ($<font style=" FONT-SIZE: 10pt">0.0012</font> per share of common stock) at August 31, 2013 and November 30, 2012, respectively, and has been estimated using the Black-Scholes option-pricing model using the following assumptions:</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>August 31,<br/> 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>May 31,<br/> 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>February 28,<br/> 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>November 30,<br/> 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Fair value of common stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0038</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Conversion price of preferred stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0124</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0151</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0190</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0215</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.78</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.62</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Expected life</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10 Years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10 Years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10 Years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10 Years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>148</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>148</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>147</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>141</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

0.32

290724

165208

16037209 30587 0.0011 19245 0.0012

1000000

100 0.85 0.0124 0.0215 0.0999 27806452 Company was required to pay on each outstanding share of Series B convertible preferred stock a preferential cumulative dividend at an annual rate equal to the product of multiplying $100 per share by the higher of (i) the Wall Street Journal Prime Rate plus 1%, or (ii) 9%. In no event was the dividend rate to be greater than 12% per annum.

0.12

290724

125516

165208

125516

0.0012

0.0014

0.0038

0.0013

0.0124 0.0151 0.0190 0.0215

0.0278

0.0216

0.0189

0.0162

P10Y

1.48

1.47

1.41

<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><b><font size="2">N</font></b><b><font size="2">OTE 5. SERIES I CONVERTIBLE PREFERRED STOCK</font></b></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company’s Board of Directors has the authority, without further action by the stockholders, to issue up to <font style=" FONT-SIZE: 10pt">1,000,000</font> shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions of these shares of preferred stock. The Board of Directors originally designated <font style=" FONT-SIZE: 10pt"> 20,000</font> shares as Series I convertible preferred stock. On July 13, 2004, the Company completed a private placement of Series I convertible preferred stock and a total of <font style=" FONT-SIZE: 10pt">20,000</font> shares were originally sold to accredited investors. As of August 31, 2013 and November 30, 2012, all of the shares of Series I convertible preferred stock have been converted into shares of the common stock of the Company and no shares of the Company’s Series I convertible preferred stock are outstanding.</div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

20000

750000

P17Y

11029

33088

11029

33088

1300

3900

1300

3900

On October 9, 2007, MultiCell executed an exclusive license and purchase agreement (the “Agreement”) with Corning Incorporated (“Corning”) of Corning, New York.

The balance of deferred revenue from this license is $488,971 at August 31, 2013 and will be amortized into revenue through October 2024.

The balance of deferred revenue from the agreement with Pfizer is $22,100 at August 31, 2013, which will be amortized into revenue through January 2018.

<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>NOTE 7. STOCK COMPENSATION PLANS</strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: italic 10pt Times New Roman, Times, Serif"> <font style="FONT-STYLE: normal; FONT-WEIGHT: normal">  </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="COLOR: black">On July 11, 2011, at the Company’s Annual Meeting of Stockholders, the stockholders approved an amendment to increase the number of shares reserved under the 2004 Equity Incentive Plan (the “2004 Plan”) to a total of <font style=" FONT-SIZE: 10pt">70,974,213</font> shares. Additionally, an annual increase in the number of shares reserved under the plan was approved and certain prior increases in the number of shares reserved for issuance under the plan were ratified. Furthermore, on each of December 1, 2011 and on December 1, 2012, the number of shares reserved under the 2004 Plan was increased by an additional <font style=" FONT-SIZE: 10pt"><font style=" FONT-SIZE: 10pt"><font style=" FONT-SIZE: 10pt"> 1,500,000</font></font></font> shares pursuant to the provisions of the 2004 Plan.</font> The purpose of the 2004 Plan is to provide a means by which eligible recipients of stock awards may be given the opportunity to benefit from increases in the value of the Company’s common stock through granting of incentive stock options (ISO), non-statutory stock options, stock purchase awards, stock bonus awards, stock appreciation rights, stock unit awards and other stock awards. As amended, there are <font style=" FONT-SIZE: 10pt">22,074,710</font> shares of common stock available for future awards under the 2004 Plan at August 31, 2013.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong> </strong>  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> GAAP treatment for stock options requires the recognition of the cost of employee services received in exchange for an award of equity instruments in the financial statements, which is measured based on the grant date fair value of the award, and requires the stock option compensation expense to be recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period), net of estimated forfeitures. The estimation of forfeitures requires significant judgment, and to the extent actual results or updated estimates differ from the current estimates, such resulting adjustment will be recorded in the period estimates are revised. No income tax benefit has been recognized for stock-based compensation arrangements and no compensation cost has been capitalized in the consolidated balance sheets.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> A summary of the status of stock options granted by MultiCell at August 31, 2013, and changes during the nine months then ended is presented in the following table:</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 79.6%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="5%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="5%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="5%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Under</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="5%" colspan="2"> <div>Contractual</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Option</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="5%" colspan="2"> <div>Life</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="4%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Outstanding at November 30, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>26,068,947</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0084</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="4%"> <div>3.1 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>30,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0011</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="4%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="4%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 12px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Expired or forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(5,669,444)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0090</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="4%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="4%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Outstanding at August 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>50,399,503</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0040</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="4%"> <div>3.9 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="4%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Exercisable at August 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19,017,559</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0086</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="4%"> <div>2.2 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On August 16, 2013, the MultiCell Board of Directors granted an option to each of the five members of its Board of Directors to purchase <font style=" FONT-SIZE: 10pt">5,000,000</font> shares of the Company’s common stock at $<font style=" FONT-SIZE: 10pt">0.0011</font> per share. The options vest quarterly over one year, subject to continuing service as a director on each such vesting date, and expire <font style=" FONT-SIZE: 10pt">five</font> years after grant. Additionally, the Board of Directors granted an option to an employee to purchase <font style=" FONT-SIZE: 10pt">5,000,000</font> shares of common stock at $<font style=" FONT-SIZE: 10pt">0.0011</font> per share. This option vests monthly over three years, subject to continuing service as an employee on each such vesting date, and expires <font style=" FONT-SIZE: 10pt">five</font> years after grant. On June 1, 2012, the MultiCell Board of Directors granted an option to each of the five members of its Board of Directors to purchase <font style=" FONT-SIZE: 10pt">1,000,000</font> shares of the Company’s common stock at $<font style=" FONT-SIZE: 10pt">0.0032</font> per share, the closing price of the Company’s common stock on the date of grant. The options vest quarterly over one year, subject to continuing service as a director on each such vesting date, and expire <font style=" FONT-SIZE: 10pt">five</font> years after grant. Additionally, the Board of Directors granted an option to an employee to purchase <font style=" FONT-SIZE: 10pt"> 1,000,000</font> shares of common stock at $<font style=" FONT-SIZE: 10pt">0.0032</font> per share. This option vests monthly over three years, subject to continuing service as an employee on each such vesting date, and expires <font style=" FONT-SIZE: 10pt">five</font> years after grant. The fair value of stock option grants is estimated on the date of grant using the Black-Scholes option pricing model. The weighted-average fair value of stock options granted during the nine months ended August 31, 2013 was $<font style=" FONT-SIZE: 10pt">0.0011</font> per share. The weighted-average assumptions used for options granted during the nine months ended August 31, 2013 were risk-free interest rate of <font style=" FONT-SIZE: 10pt">1.60</font>%, volatility of <font style=" FONT-SIZE: 10pt">175</font>%, expected life of <font style=" FONT-SIZE: 10pt">5.0</font> years, and dividend yield of <font style=" FONT-SIZE: 10pt">zero</font>. The weighted-average fair value of stock options granted during the nine months ended August 31, 2012 was $<font style=" FONT-SIZE: 10pt">0.0030</font> per share. The weighted-average assumptions used for options granted during the nine months ended August 31, 2012 were risk-free interest rate of <font style=" FONT-SIZE: 10pt">0.62</font>%, volatility of <font style=" FONT-SIZE: 10pt">170</font>%, expected life of <font style=" FONT-SIZE: 10pt">5.0</font> years, and dividend yield of <font style=" FONT-SIZE: 10pt">zero</font>. The assumptions employed in the Black-Scholes option pricing model include the following: (i) the expected life of stock options represents the period of time that the stock options granted are expected to be outstanding prior to exercise; (ii) the expected volatility is based on the historical price volatility of the Company’s common stock; (iii) the risk-free interest rate represents the U.S. Treasury Department’s constant maturities rate for the expected life of the related stock options; and (iv) the dividend yield represents anticipated cash dividends to be paid over the expected life of the stock options.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> For the three months ended August 31, 2013 and 2012, MultiCell reported stock-based compensation expense for services related to stock options of $<font style=" FONT-SIZE: 10pt">1,893</font> and $<font style=" FONT-SIZE: 10pt">9,521</font>, respectively. For the nine months ended August 31, 2013 and 2012, MultiCell reported stock-based compensation expense for services related to stock options of $<font style=" FONT-SIZE: 10pt">10,705</font> and $<font style=" FONT-SIZE: 10pt">32,759</font>, respectively. As of August 31, 2013, there is approximately $<font style=" FONT-SIZE: 10pt">35,000</font> of unrecognized compensation cost related to stock-based payments that will be recognized over a weighted average period of approximately <font style=" FONT-SIZE: 10pt">1.4</font> years. The intrinsic values at August 31, 2013 are based on a closing price of $<font style=" FONT-SIZE: 10pt">0.0012</font>.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  <b> </b>  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In October 2010, Xenogenics adopted the 2010 Stock Incentive Plan (the “2010 Plan”) which authorized the granting of stock awards to Xenogenics’ employees, directors, and consultants. As originally adopted, the 2010 Plan provided that the number of shares of Xenogenics’ common stock that could be issued pursuant to stock awards could not exceed <font style=" FONT-SIZE: 10pt">5,000,000</font> shares of common stock. On February 3, 2011, the 2010 Plan was amended such that the number of shares of Xenogenics’ common stock that could be issued pursuant to stock awards could not exceed <font style=" FONT-SIZE: 10pt">8,000,000</font> shares of common stock. The purpose of the 2010 Plan is to provide a means by which eligible recipients of stock awards may be given the opportunity to benefit from increases in the value of Xenogenics’ common stock through granting of incentive stock options (“ISO”), non-statutory stock options, stock bonus awards, stock appreciation rights, and rights to acquire restricted stock. ISO’s may be granted only to employees. The exercise price of each ISO granted under the plan must equal <font style=" FONT-SIZE: 10pt"> 100</font>% of the market price of Xenogenics’ stock on the date of the grant. A <font style=" FONT-SIZE: 10pt">10% stockholder shall not be granted an ISO unless the exercise price of such option is at least 110% of the fair market value of Xenogenics’ common stock on the date of the grants and the option is not exercisable after the expiration of five years from the date of the grant.</font> The Board of Directors of Xenogenics, in its discretion, shall determine the exercise price of each nonstatutory stock option. An option’s maximum term is <font style=" FONT-SIZE: 10pt">10</font> years.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In November 2010, Xenogenics granted an option to a prospective executive officer to purchase an aggregate of <font style=" FONT-SIZE: 10pt">2,500,000</font> shares of its common stock, exercisable at $<font style=" FONT-SIZE: 10pt">0.246</font> per share of common stock and having an expiration date in <font style=" FONT-SIZE: 10pt">November 2015</font>. The option to acquire <font style=" FONT-SIZE: 10pt">500,000</font> of the shares vested on the grant date and the remaining <font style=" FONT-SIZE: 10pt"> 2,000,000</font> shares vest in the future upon the achievement of specified milestones. The fair value of these options was estimated to be $<font style=" FONT-SIZE: 10pt">576,250</font>, or $<font style=" FONT-SIZE: 10pt">0.2305</font> per share, as estimated using the Black-Scholes option-pricing model, using a risk-free interest rate of <font style=" FONT-SIZE: 10pt">1.23</font>%, volatility of <font style=" FONT-SIZE: 10pt">165</font>%, expected life of <font style=" FONT-SIZE: 10pt">five</font> years, and dividend yield of <font style=" FONT-SIZE: 10pt">zero</font>.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In March 2011, Xenogenics granted options to other prospective officers and to the members of its scientific advisory board to purchase an aggregate of <font style=" FONT-SIZE: 10pt"> 3,000,000</font> shares of its common stock, exercisable at $<font style=" FONT-SIZE: 10pt">0.246</font> per share of common stock and having a term of approximately <font style=" FONT-SIZE: 10pt"> five</font> years. 50% of the options vested immediately and the remaining <font style=" FONT-SIZE: 10pt">50</font>% were to vest upon the closing of a Qualified Financing by December 31, 2011. A “Qualified Financing” meant a single sale, or a related series of sales, by Xenogenics of its common stock (or common stock equivalents) in which the aggregate gross proceeds (before costs and commissions) received by Xenogenics was equal to or exceed $<font style=" FONT-SIZE: 10pt">5,000,000</font>. The fair value of these options was estimated to be $<font style=" FONT-SIZE: 10pt">692,700</font>, or $<font style=" FONT-SIZE: 10pt">0.2309</font> per share, as estimated using the Black-Scholes option-pricing model, using a risk-free interest rate of <font style=" FONT-SIZE: 10pt">2.20</font>%, volatility of <font style=" FONT-SIZE: 10pt">165</font>%, expected lives of <font style=" FONT-SIZE: 10pt">five</font> years, and dividend yield of <font style=" FONT-SIZE: 10pt">zero</font>. A Qualified Financing was not closed by December 31, 2011, and accordingly, options to acquire <font style=" FONT-SIZE: 10pt">1,500,000</font> shares of Xenogenics common stock were forfeited. As described in the following paragraph, Xenogenics granted replacement options to four of five of these individuals whose options expired on December 31, 2011. The replacement of the options to the four individuals was treated as a modification under GAAP. The forfeiture of the option to the fifth individual resulted in the reversal of $<font style=" FONT-SIZE: 10pt">57,725</font> of previously-recognized stock-based compensation expense in the three months ended February 29, 2012.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On February 28, 2012, Xenogenics granted replacement options to four of five of those individuals whose options expired on December 31, 2011, as described in the previous paragraph. The replacement options to purchase <font style=" FONT-SIZE: 10pt">1,250,000</font> shares of Xenogenics’ common stock are exercisable at $<font style=" FONT-SIZE: 10pt">0.253</font> per share and vest monthly over one year. These replacement options have a term of <font style=" FONT-SIZE: 10pt">five</font> years, provided a Qualified Financing has closed by February 28, 2013. No Qualified Financing closed by February 28, 2013. Consequently, these replacement options expired on February 28, 2013. The fair value of these options was estimated to be $<font style=" FONT-SIZE: 10pt">298,500</font>, or $<font style=" FONT-SIZE: 10pt">0.2338</font> per share, as estimated using the Black-Scholes option-pricing model, using a risk-free interest rate of <font style=" FONT-SIZE: 10pt">0.84</font>%, volatility of <font style=" FONT-SIZE: 10pt">170</font>%, expected lives of <font style=" FONT-SIZE: 10pt">five</font> years, and dividend yield of <font style=" FONT-SIZE: 10pt">zero</font>.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On July 28, 2013, Xenogenics granted an option to a consultant to purchase <font style=" FONT-SIZE: 10pt">500,000</font> shares of Xenogenics’ common stock at $<font style=" FONT-SIZE: 10pt">0.246</font> per share. The option vests in equal increments of 125,000 on each of July 28, 2013, October 1, 2013, January 1, 2014, and April 1, 2014, subject to continuing service to Xenogenics on each such vesting date, and expires <font style=" FONT-SIZE: 10pt">five</font> years after grant. The fair value of these options was estimated to be $<font style=" FONT-SIZE: 10pt">117,000</font>, or $<font style=" FONT-SIZE: 10pt">0.234</font> per share, as estimated using the Black-Scholes option-pricing model, using a risk-free interest rate of <font style=" FONT-SIZE: 10pt">1.37</font>%, volatility of <font style=" FONT-SIZE: 10pt">175</font>%, expected lives of <font style=" FONT-SIZE: 10pt">five</font> years, and dividend yield of <font style=" FONT-SIZE: 10pt">zero</font>.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> For the three months and nine months ended August 31 2013, Xenogenics reported stock-based compensation of $<font style=" FONT-SIZE: 10pt">51,052</font> and $165,161, respectively. For the three months ended August 31, 2012, Xenogenics reported stock-based compensation expense for options of $<font style=" FONT-SIZE: 10pt">95,925</font>. For the nine months ended August 31, 2012, Xenogenics reported stock-based compensation expense for options of $<font style=" FONT-SIZE: 10pt">251,128</font>, less the reversal of previously recognized stock-based compensation in the amount of $<font style=" FONT-SIZE: 10pt">57,725</font>, for net stock-based compensation of $<font style=" FONT-SIZE: 10pt">193,403</font>. As of August 31, 2013, there is approximately $<font style=" FONT-SIZE: 10pt">83,000</font> of unrecognized compensation cost related to stock-based payments that will be recognized over a weighted average period of approximately <font style=" FONT-SIZE: 10pt">0.5</font> years.</div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> A summary of the status of stock options granted by MultiCell at August 31, 2013, and changes during the nine months then ended is presented in the following table:</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 79.6%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="5%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="5%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="5%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Under</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="5%" colspan="2"> <div>Contractual</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Option</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="5%" colspan="2"> <div>Life</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="4%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Outstanding at November 30, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>26,068,947</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0084</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="4%"> <div>3.1 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>30,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0011</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="4%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="4%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 12px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Expired or forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(5,669,444)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0090</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="4%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="4%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Outstanding at August 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>50,399,503</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0040</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="4%"> <div>3.9 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="36%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="4%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Exercisable at August 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19,017,559</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0086</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="4%"> <div>2.2 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

22074710

5000000

0.0011

1000000

0.0032

1000000

0.0032

P5Y

0.0011

0.0030

0.0160

0.0062

1893

9521

10705

32759

35000

P1Y4M24D

0.0012

5000000

8000000

P10Y

2500000

2015-11-30

500,000 2000000 576250

1.65

P5Y

3000000

5000000 692700

1.65

1500000

57725

P5Y

0.5

1250000

298500

1.7

P5Y

51052

165161

95925

57725

83000

P6M

500000

0.246

117000

1.75

P5Y

0.2305

0.2309

0.2338

70974213

1500000

1.75

P5Y

1.7

P5Y

0.0220

0.0123

0.0137

0.0084

193403

251128

0.246

0.234

0.246

P5Y

0.253

10% stockholder shall not be granted an ISO unless the exercise price of such option is at least 110% of the fair market value of Xenogenics’ common stock on the date of the grants and the option is not exercisable after the expiration of five years from the date of the grant.

26068947

30000000

5669444

50399503

19017559

3000

0.0084

0.0011

0.0090

0.0040

0.0086

P3Y1M6D

P3Y10M24D

P2Y2M12D

<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> A summary of the status of warrants at August 31, 2013, and changes during the nine months then ended is presented in the following table:</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 74.6%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="5%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="5%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="5%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Under</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="5%" colspan="2"> <div>Contractual</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="5%" colspan="2"> <div>Life</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="4%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div>Outstanding at November 30, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9,277,030</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.7535</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="4%"> <div>2.2 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div>Issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="4%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(943,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.0900</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="4%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(360,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.5000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="4%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="4%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div>Outstanding at August 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7,974,030</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.7251</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="4%"> <div>1.7 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

100000

10000000 2007-02-28 for each $1,000 of the principal of the Debenture converted, LJCI would be required to simultaneously purchase 100,000 shares under the warrant at $1.09 per share 943000

1027870

729000

794610

P5Y P2Y2M12D P1Y8M12D 9277030 0 943000 360000 7974030 0.7535 0 1.0900 0.5000 0.7251 0 0

4659629

5906056606

6138986953

7974030

50399503

27806452

5819876621

9963030

24168947

47049793

2293600

6055511583

30587

19245

30587

19245

1000

122122222

100000 1.09

109000

4300000 4300000

EX-101.SCH 6 mcet-20130831.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (DEFICIENCY) link:presentationLink link:definitionLink link:calculationLink 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (DEFICIENCY) (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 108 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - ORGANIZATION AND NATURE OF OPERATIONS, BASIS OF PRESENTATION, AND RECLASSIFICATIONS link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - GOING CONCERN link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - CONVERTIBLE DEBENTURES link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - SERIES B CONVERTIBLE PREFERRED STOCK link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - SERIES I CONVERTIBLE PREFERRED STOCK link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - LICENSE AGREEMENTS AND DEFERRED REVENUE link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - STOCK COMPENSATION PLANS link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - STOCK WARRANTS link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - LOSS PER SHARE link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - ORGANIZATION AND NATURE OF OPERATIONS, BASIS OF PRESENTATION, AND RECLASSIFICATIONS (Policies) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - SERIES B CONVERTIBLE PREFERRED STOCK (Tables) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - STOCK COMPENSATION PLANS (Tables) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - STOCK WARRANTS (Tables) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - LOSS PER SHARE (Tables) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - ORGANIZATION AND NATURE OF OPERATIONS, BASIS OF PRESENTATION, AND RECLASSIFICATIONS (Details Textual) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - GOING CONCERN (Details Textual) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - CONVERTIBLE DEBENTURES (Details Textual) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - SERIES B CONVERTIBLE PREFERRED STOCK (Details) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - SERIES B CONVERTIBLE PREFERRED STOCK (Details Textual) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - SERIES I CONVERTIBLE PREFERRED STOCK (Details Textual) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - LICENSE AGREEMENTS AND DEFERRED REVENUE (Details Textual) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - STOCK COMPENSATION PLANS (Details) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - STOCK COMPENSATION PLANS (Details Textual) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - STOCK WARRANTS (Details) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - STOCK WARRANTS (Details Textual) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - LOSS PER SHARE (Details) link:presentationLink link:definitionLink link:calculationLink 138 - Disclosure - LOSS PER SHARE (Details Textual) link:presentationLink link:definitionLink link:calculationLink 139 - Disclosure - FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:definitionLink link:calculationLink 140 - Disclosure - SUBSEQUENT EVENTS (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 mcet-20130831_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 mcet-20130831_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 mcet-20130831_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Going Concern [Abstract] Going Concern [Text Block] Going Concern [Text Block] The entire disclosure relating to going concern. Debt Disclosure [Abstract] Long-Term Debt [Text Block] Long-term Debt [Text Block] Series B Convertible Preferred Stock [Abstract] Series B Convertible Preferred Stock [Text Block] Series B Convertible Preferred Stock [Text Block] The entire disclosure related to series b redeemable convertible preferred stock. Series I Convertible Preferred Stock [Abstract] Series I Convertible Preferred Stock [Text Block] Series I Convertible Preferred Stock [Text Block] The entire disclosure related to series I convertible preferred stock. License Agreements [Abstract] License Agreements [Text Block] License Agreements [Text Block] The entire disclosure for license agreements. Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure Of Compensation Related Costs, Share-Based Payments [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Warrants and Rights Note Disclosure [Abstract] Warrants Disclosure [Text Block] Warrants Disclosure [Text Block] The entire disclosure for warrants. Earnings Per Share [Abstract] Earnings Per Share [Text Block] Earnings Per Share [Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value Disclosures [Text Block] Subsequent Events [Abstract] Subsequent Events [Text Block] Subsequent Events [Text Block] Statement Of Financial Position [Abstract] Statement [Table] Class of Stock [Axis] Class of Stock [Domain] Series B Convertible Preferred Stock [Member] Series B Convertible Preferred Stock member Series I Convertible Preferred Stock [Member] Series I Convertible Preferred Stock member. Statement [Line Items] Assets [Abstract] ASSETS Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Grants Receivable, Current Receivable from warrant holder Other Assets, Current Other current assets Assets, Current, Total Total current assets Property, Plant and Equipment, Net, Total Property and equipment, net of accumulated depreciation of $40,561 Other Assets, Noncurrent Other assets Liabilities and Equity [Abstract] LIABILITIES AND EQUITY (DEFICIENCY) Accounts Payable and Accrued Liabilities, Current, Total Accounts payable and accrued expenses Due To Related Parties, Current Payable to related party Advance From Debenture Holder, Current Advance from warrant holder Advance from Warrant Holder Carrying amount as of the balance sheet date of obligations due all debenture holder. Convertible Debentures Convertible debentures Convertible Debentures Deferred Revenue, Current Current portion of deferred revenue Liabilities, Current, Total Total current liabilities Liabilities, Noncurrent [Abstract] Non-current liabilities Convertible Debt, Noncurrent Convertible debentures Convertible Debt, Noncurrent Deferred Revenue, Noncurrent Deferred revenue, net of current portion Derivative Liability, Noncurrent Derivative liability related to Series B convertible preferred stock Liabilities, Noncurrent, Total Total non-current liabilities Liabilities, Total Total liabilities Commitments and Contingencies Commitments and contingencies Stockholders' Equity Attributable To Parent [Abstract] Equity (Deficiency) MultiCell Technologies, Inc. equity (deficiency) Preferred Stock, Value, Issued Preferred stock Common Stock, Value, Issued Common stock, $0.01 par value; 3,000,000,000 shares authorized; 2,391,239,613 and 1,349,803,029 shares issued and outstanding at August 31, 2013 and November 30, 2012, respectively Additional Paid in Capital, Total Additional paid-in capital Retained Earnings (Accumulated Deficit), Total Accumulated deficit Accumulated Deficit Stockholders Equity Attributable to Parent, Total Total MultiCell Technologies, Inc. stockholders' equity (deficiency) Stockholders' Equity Attributable To Noncontrolling Interest Noncontrolling interests Stockholders Equity, Including Portion Attributable to Noncontrolling Interest, Total Total equity (deficiency) Balance Balance Liabilities and Equity, Total Total liabilities and equity (deficiency) Accounting Policies [Abstract] Basis of Accounting, Policy [Policy Text Block] Reclassification, Policy [Policy Text Block] Fair Value, by Balance Sheet Grouping [Table Text Block] Fair Value, by Balance Sheet Grouping [Table Text Block] Schedule Of Share-Based Compensation, Stock Options, Activity [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of Stockholders Equity Note, Warrants or Rights [Table Text Block] Schedule of Share-based Compensation Award, Shares Under Warrants [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Fair Value, Liabilities Measured On Recurring Basis [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Legal Entity [Axis] Entity [Domain] Xenogenics Corporation [Member] Multicell Immunotherapeutics [Member] MultiCell Immunotherapeutics member Equity Method Investment, Ownership Percentage Equity Method Investment, Ownership Percentage Equity Components [Axis] Equity Component [Domain] Warrant [Member] Related Party [Axis] Related Party [Domain] La Jolla Cove Investors [Member] La Jolla Cove Investors Investment Warrants, Exercise Price Investment Warrants, Exercise Price Class of Warrant or Right, Outstanding Shares Remaining under Stock Warrant Convertible Debt Convertible Debt Potential Proceeds From Warrant Exercises Potential Proceeds from Warrant Exercises The cash inflow associated with the potential amount received from holders exercising their stock warrants. Debt Instrument, Convertible Percentage Of Equity Instruments, Maximum Debt Instrument, Convertible Percentage of Equity Instruments, Maximum This element represents that, the maximum percentage of outstanding shares of the entity's that the holder of the debt instrument would receive if the debt was converted to equity. Investment Warrants Expiration Date Investment Warrants Expiration Date Securities Purchase Agreement Date Securities Purchase, Agreement Date The company entered into a securities purchase agreement date. Proceeds From Convertible Debt Proceeds from Convertible Debenture, Principal Amount Debt Conversion, Original Debt, Due Date Of Debt Debt Conversion, Original Debt, Due Date of Debt Debt Instrument, Maturity Date Debt Instrument, Maturity Date Debt Conversion, Original Debt, Interest Rate Of Debt Debt Conversion, Original Debt, Interest Rate of Debt Warrants Issued Number Warrants Issued Number Number of warrants issued during the period. Class Of Warrant, Exercisable Period Class of Warrant, Exercisable Period Class of warrants exercisable during the period. Exercise Of Warrant Upon Conversion Of Debt Exercise of Warrant upon Conversion of Debt Description related to the exercise of the warrant is required upon the conversion of the debt. Maximum Conversion Limit Of Debt Maximum Conversion Limit of Debt The maximum conversion limit of the debt. Stock Issued During Period, Value, Conversion Of Convertible Securities Stock Issued During Period, Value, Conversion of Convertible Securities Issuance of common stock for conversion of 4.75% debentures Stock Issued During Period, Shares, Conversion Of Convertible Securities Stock Issued During Period, Shares, Conversion of Convertible Securities Issuance of common stock for conversion of 4.75% debentures (in shares) Stock Issued During Period, Shares, Exercise Of Warrants Stock Issued During Period, Shares, Exercise of Warrants Issuance of common stock for exercise of warrants (in shares) Number of stock issued during the period as a result of the exercise of warrants. Proceeds From Exercise Of Stock Warrants Proceeds from Exercise of Stock Warrants Proceeds from the exercise of stock warrants The cash inflow from exercise of stock warrants to purchase common shares at predetermined price. Debt Conversion, Converted Instrument, Shares Issued Debt Conversion, Converted Instrument, Shares Debt Conversion, Converted Instrument, Shares Issued Number Of Warrants Remaining Unexercised Number of Warrants, Remaining Unexercised The number of warrants remaining unexercised. Proceeds from Warrant Exercises Receivable from Warrant Holder Proceeds from Warrant Exercises Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Grant Date Intrinsic Value Fair value of common stock Share Based Compensation Arrangement By Share Based Payment Award Conversion Price Of Preferred Stock Conversion price of preferred stock Represents the conversion price of a share. Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected life Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Volatility Balance Sheet Parenthetical [Abstract] CONDENSED CONSOLIDATED BALANCE SHEETS Parenthetical. Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated depreciation, property and equipment (in dollars) Preferred Stock, Par or Stated Value Per Share Undesignated preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized/designated Preferred Stock, Shares Designated Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Preferred Stock, Liquidation Preference, Value Preferred stock, liquidation value (in dollars) Common Stock [Member] Title of Individual [Axis] Relationship to Entity [Domain] Board of Directors Chairman [Member] Board of Directors Chairman [Member] Range [Axis] Range [Domain] Maximum [Member] Preferred Stock Purchase Price Per Share Value Preferred Stock, Purchase Price, Per Share, Value Preferred stock purchase price per share value. Preferred Stock, Conversion Price Preferred Stock, Conversion Price Conversion price of preferred stock. Reduced Conversion Price Percentage Reduced Conversion Price Percentage Represents the reduction in conversion price percentage. Preferred Stock Reduced Conversion Price Preferred Stock Reduced Conversion Price Reduced conversion price of preferred stock. Conversion Of Preferred Stock Limited To Common Stock Outstanding Percentage Conversion of Preferred Stock Limited to Common Stock, Outstanding, Percentage The percentage of conversion of the Series I preferred stock is limited to common stock outstanding on the date of conversion. Preferred Stock, Dividend Payment Rate Preferred Stock, Dividend Payment Rate Description of the preferred stock dividend payment rate. Preferred Stock, Dividend Rate, Percentage Preferred Stock, Dividend Rate, Maximum Percentage Dividends Payable Dividends Payable Accounts Payable and Accrued Liabilities, Total Accounts Payable and Accrued Liabilities Dividends Payable to Series B Convertible Preferred Stock Carrying value as of the balance sheet date of dividends declared but unpaid on permanent equity with the Series B convertible preferred stock. Conversion Of Convertible Preferred Stock Outstanding Conversion of Convertible Preferred Stock Outstanding The number preferred shares outstanding which are convertible into on the respective dates. Fair Value Conversion Feature Fair Value Conversion Feature Fair value of conversion feature as on the date. Fair Value Of Embedded Conversion Feature Fair Value of Embedded Conversion Feature, per share Fair value of embedded conversion feature per share as on the reporting date. Accredited Investors [Member] Minimum [Member] License Agreement [Axis] License Agreement [Domain] Pfizer [Member] License and Purchase Agreement Description License and Purchase Agreement Description Represents License And Purchase Agreement Description. License and Maintenance Revenue License and Maintenance Revenue Income Recognition Period Income Recognition Period Represents the period for recognizing the income. Deferred Revenue, Revenue Recognized Deferred Revenue, Revenue Recognized Deferred Revenue, Description Deferred Revenue, Description Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance Shares Under Option, Outstanding, Beginning balance Shares Under Option,Outstanding, Ending balance Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross Shares Under option, Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period Shares Under Option, Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total Shares Under option, Expired or forfeited Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number Shares Under Option,Exercisable Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted Average Exercise Price, Outstanding, Beginning balance Weighted Average Exercise Price, Outstanding, Ending balance Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted Average Exercise Price,Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Exercised (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Expired or forfeited (in dollars per share) Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Exercise price,Exercisable (in dollars per share) Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Life, Outstanding Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Life, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Outstanding, Beginning balance Aggregate Intrinsic Value, Outstanding, Ending balance Plan Name [Axis] Plan Name [Domain] Equity Incentive Plan 2004 [Member] 2004 Equity Incentive Plan Member Equity Incentive Plan 2010 [Member] Equity Incentive Plan 2010 member Award Type [Axis] Equity Award [Domain] Replacement Options [Member] Replacement Options member Executive Officer [Member] Officers and Members Of Scientific Advisory Board [Member] Officers and Members of Scientific Advisory Board [Member] Director [Member] Employee [Member] Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Share-based Compensation Arrangement by Share-based Payment Award, Award Term Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Date Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period Fair Value Fair value of options granted. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation, Total Stock-based compensation Reversal Allocated Share Based Compensation Expense Reversal Allocated Share-based Compensation Expense Represents the reversal portion of stock based compensation expense. Allocated Share-based Compensation Expense, Total Allocated Share-based Compensation Expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Number Shares Under Warrants, Outstanding , Beginning balance (in shares) Shares Under Warrants, Outstanding, Ending balance (in shares) The number of shares reserved for issuance under stock warrants agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options. Share Based Compensation Arrangement By Share Based Payment Award Warrants Grants In Period Gross Shares Under Warrants, Issued (in shares) Gross number of share warrants (or share units) granted during the period. Stock Issued During Period Shares Stock Warrants Exercised Shares Under Warrants, Exercised (in shares) Number of share warrants (or share units) exercised during the current period. Share Based Compensation Arrangement By Share Based Payment Award Warrants Expired In Period Shares Under Warrants, Expired (in shares) The number of shares under warrants that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Weighted Average Exercise Price Weighted Average Exercise Price, Outstanding, Beginning balance (in dollars per share) Weighted Average Exercise Price, Outstanding, Ending balance (in dollars per share) Weighted average price at which grantees can acquire the shares reserved for issuance under the stock warrants plan. Share Based Compensation Arrangement By Share Based Payment Award Warrants Granted Weighted Average Exercise Price Weighted Average Exercise Price, Issued (in dollars per share) Gross number of share warrants (or share units) granted for weighted average exercise price during the period. Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercised Weighted Average Exercise Price Weighted Average Exercise price, Exercised (in dollars per share) Warrants exercised price for weighted average during the period. Share Based Compensation Arrangement By Share Based Payment Award Warrants Expired In Period Weighted Average Exercise Price Weighted Average Exercise Price, Expired (in dollars per share) The number of shares under warrants that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the Warrants Plan. Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Weighted Average Remaining Contractual Term2 Weighted Average Remaining Contractual Life, Outstanding Weighted average remaining contractual term for warrants awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Intrinsic Value Aggregate Intrinsic Value, Outstanding, Beginning balance Aggregate Intrinsic Value, Outstanding, Ending balance Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of warrants outstanding. Warrant Issued Warrant Issued Warrants issued to purchase common stock. EX-101.PRE 10 mcet-20130831_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R17.htm IDEA: XBRL DOCUMENT

LOSS PER SHARE

9 Months Ended

Aug. 31, 2013

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

NOTE 9. LOSS PER SHARE

	2013		2012

Warrants		7,974,030		9,963,030
Stock options		50,399,503		24,168,947
Series B Convertible Preferred Stock		27,806,452		47,049,793
Series I Convertible Preferred Stock		-		2,293,600
LJCI Debenture		5,819,876,621		6,055,511,583

		5,906,056,606		6,138,986,953

- Definition

The entire disclosure for earnings per share.

+ References+ Details

EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!NZ_1[_P$``.<9```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F4%NVS`01?<%>@>!V\*B M2:9I6EC.(FV7;8"F!V"EL268(@F22>W;EY(3(PA<&T8,Y&\D2"+G/W'Q%C.S MZW5OB@<*L7.V8J*Q;JG7L72>;/ZR<*'7*3^&)?>Z7NDE<3F=7O+:V40V3=)0 M@\UG7VFA[TTJOJWSZRU)(!-9<;-=.&153'MONEJG3,H?;/,B9?*84.:=XYK8 M=CY^R!B,[TT8OOP_X''?SWPTH6NHN-4A_=!]QN!KP_^ZL/KCW*H\7&0/I5LL MNIH:5]_W^03*Z`/I)K9$J3?E>"][W=DG[@/YX^+(QYLX,\CP?V/A$SDD"(<" MX;@`X?@(PG$)PO$)A.,*A.,S"(>8HH"@&%6@*%6@.%6@2%6@6%6@:%6@>%6@ MB%6@F%6BF%6BF%6BF%6BF%6BF%6BF%6BF%6BF%6BF%6BF%6AF%6AF%6AF%6A MF%6AF%6AF%6AF%6AF%6AF%6AF/7BK_BXQ#S5.#WPQ1*!A;-)0LR>;CV.:^3\```#__P,` M4$L#!!0`!@`(````(0"U53`C]0```$P"```+``@"7W)E;',O+G)E;',@H@0" M**```@`````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````C)+/3L,P#,;O2+Q#Y/OJ;D@(H:6[3$B[ M(50>P"3N'[6-HR1`]_:$`X)*8]O1]N?//UO>[N9I5!\<8B].P[HH0;$S8GO7 M:GBMGU8/H&(B9VD4QQJ.'&%7W=YL7WBDE)MBU_NHLHN+&KJ4_"-B-!U/%`OQ M['*ED3!1RF%HT9,9J&74"T\U<%J"`=[!ZH^^CSYLK$SO+=N5#9@NIS]NHFD++28,5\YS3$$X4UD^&'!Q0]47P```/__`P!02P,$ M%``&``@````A`'IDP"T8`@``_!@``!H`"`%X;"]?#TSBI.4R#FT!')-TQ^P2&M+1):$=MO&_SZ+6V0' MFA>[/RW?WKKLU^^S$T?5<86BQ-YKNRKYIN6YB?SP^7-R8+ MT765:_O.%V;O@[E?7WRY>_*MB^E'H6Z&D*5=NE"8.L;AJ[6AK/W.A44_^"Y] ML^G'G8OI<=S:P94O;NLM+YJ\*,CQ6)R9[W0SKZ\\W[S:8I M_?>^_+7S7?S/&?9//[Z$VON8-G7CUL?"3$O!'KXA621F8S_`2?70Q;E!.+Q2 MQN$5PI%;91RY13A,RCA,"$=R91S)$4[.<^*$N&^3-TRR^ON,SK^>\_A)Q4>" M:>F?L*\1S*RUF$[^&(81#&FKFJ"J.86"JN?Q$E6'M4V&H+2'3V@MLS*FE@;5@[`QAF@&C[GD#C$^U,$!@*N;;QY=#X MKI1M^`JY,&G3$,1A[6L"PVL":U\3&%X31-N2!7NRMJX(ZHJT!PJ"`X5H)Y;` MQ,IG3:S2M>6WVC7=<<:9EI#=S`IQQH`#4U.[7V"[D'9I"-:&M2<*AA,%:T\4 M#"<*T78^@9IR\F3I>1Y6A'.$YPY=D/3C>D MK7&"&B=MC1/4.&N+BJ&H9%91G1&=`GM'M&4EDZ[LN_\LUF\```#__P,`4$L# M!!0`!@`(````(0`67;(HKP,``*X,```/````>&PO=V]R:V)O;VLN>&ULE)== M;Z)0$(;O-]G_0+C?\J5NVU0;E&-+UH(+:).].:%RK*0(!G"U_WX'J#AXU-4K M'7#>,Q_/#/CPN%U&PE^69F$2=T7E1A8%%L^2((S?N^+$&_ZX%84L]^/`CY*8 M=<5/EHF/O>_?'C9)^O&6)!\"",195USD^>I>DK+9@BW]["99L1CNS)-TZ>=@ MIN]2MDJ9'V0+QO)E)*FRW)&6?AB+E<)]>HE&,I^',V8DL_62Q7DEDK+(SR'\ M;!&N,K'W,`\C-JTR$OS5RO*7$/Z?)FBCUZB3'J1"PN;^.<@_2VZE#O=26JG:*7Q:EF(9LD^V="E/8OH9QD&R* MGT)I/VM+@P`VY:W7,,@7<%^6Y?K:,PO?%_GN(LA+2+^L()Q3?@IQF=ZN(E2/ M`TKB/,P_J1E7U0\3:&%1=1,R4T0AO0_A2VH&2A$X5AG8ED$LEQ@4OKGVR#1T M#XR^/M*M`4$J*E)1KU.!`.I@-"13UON"8%P/8GK!P;202NO"8+Y4<#!0_+HR M[>MDH!QU3ATD4Y)Q>4Y0CEKF)Y+Y>5TT4(]:!J:W3NKV4,9VGG3+_*-[IFU1 MW3*HI7L3AU![2.UQH\*8FKM#F2?;M)X*8@;$L=#9+4R)(A^Z@<.4.)[9'Q%J MD#ZQBK-=[(_Q4#A87>*8Q*7]XN1::.R0(7$<8F`=#(C"X?JE8_Y?!Q.B<+R. MS$$Q.U1_<@@`:GEN65.C"@C'@Q%1.&)=SQ[\@F!>QB!7]68,\]>H#*9#X6"M M%%YUQ]$A"GPRQD'AZ!S9KDO'Q*'NL^XT^G^',%(X'(>ZZ="I/IH0^D)T%]I8 MIH\.;L/NJSE4.!#=2=\EOR=0,TJF1>6P*V9/X>`[SW!COC&.L(P/=M]YG!I" MF$N5Y_)$_ZCGOT4,9X:Y5'DN2YU=%ROO#+MC'%4>QT8SC[AC"E6.PA,]/:*# M650Y%L_W!R].>([N&:D>JGAU-K8,-5CNAU%&/;;-USX\V^N-IS;BX5C%RV*_ M=79Z2*>-9T7ED3V[?1IYX>%1.8#/

HU9FUL9!V"N`3>PP#W,'3J'$`GU]D M6$C#(P7&X4B=FH2R>R@S#4\4&%?IX(`Z8-1[1N.@;B[&(TTOWLKV_AS,Q_V/ M0*AAEL$X2*BY:(_%@2'6.(B/^Q^+`T.L<1"?&O)JNG"#&NCQ#!_N[UU*94A( MIX7)`P/J(I5\P^OLS(]F\)Y=?)0OJJUVIUJNTNZO1N\?````__\#`%!+`P04 M``8`"````"$`J'/VP+`%````%0``&````'AL+W=O_G,4-JB+:4"9F?W MWY]#*,1F9Y:9#],V?FS\V(X=\O#A:WVQOI1M5S77O\DMS+??VM[*S/SS^_-/#2]-^[LYEV5M@X=KM[7/?WW:.TQ7G MLLZ[;7,KKR`Y-FV=]_"S/3G=K2WSPZ!47QS/=0.GSJNKK2WLVC4VFN.Q*LJT M*9[K\MIK(VUYR7OPOSM7M^YNK2[6F*OS]O/S;5,T]0U,/%67JO\V&+6MNMC] M=KHV;?YT`=Y?&<^+N^WAQ\)\715MTS7'?@OF'.WHDK-TI`.6'A\.%3!08;?: M\KBW/[)=YKFV\_@P!.C?JGSIC.]6=VY>?FFKP^_5M81H0YY4!IZ:YK."_G90 M2Z#L++0_#1GXL[4.Y3%_OO1_-2^_EM7IW$.Z!3!2Q':';VG9%1!1,+/UA+)4 M-!=P`/Y;=:5*`R*2?QT^7ZI#?][;?K`5H>LS@%M/9==_JI1)VRJ>N[ZI_],@ M-IK21KS1"`?O1[FW#9DK_7"]$4`.GL#G;(1[(HQ6N.)H6D.4TKS/'Q_:YL6" MT@/'NUNN"IGMP/(]/)K,%+#7X@6!4D8^*BM[.[0M"$4'2?[R&(0/SA?(2S%" MXN]`(@Q)[A"5!64VO2_,9AE6R>X(50+`:*(%$3=I?3_;=^\56'E_?VZL%\#V M1,?#STV6B$!B2+J$$"/9$F$8073\]]!1X+T-QB?O0Q?[%FM(-&2*>;Y'?$]^ M($]-N1_(B&0R>UV.:,%^6)\E!8;=9](BU1!K")\2F="%E"YDQ@)R#?;">M<4 MF$2I>;NX#S`@!0!0A$%!)"9`,\+6##G%#%3IQ&C2[_= MSA28,".>QQJBF?DB8(PXEB"`5).*4#,!S&61X"3M&4(PP22?\XK(R?>04V!" MCO@>:X@FM_&Y'T9D%B48`?*`I#Y%"!DQ$@ M29\C_L4UH$D*2.[C$<.'=K<)74(@(7*C['5+ M&.5C#CU7D`=D&!#RUUH"4S/6H*;.-S[DX^T=-&@1BF1$QB-FI"C=.?FZ.8QR M32%PQ9*C'O\C1\9\3DQDR`1SN?#F4L<)5//68/D#=GHZFP>$B%1WS#1&LR/" M9!1JSYEPB3Q]2SE[71E34H-Y/24]QA$E>CA@]U&OCJ?^',DQ7::4N42<(F46 M$ML9$@NC66).:D*OYZ3G.>)$*B16;S+0#N\U)$+2IA,$"!A?$L,6?(^>!3-D M0DHXF4RC`+-38WH].SW4$3OB?,S,P0^='`X/I-02`F&A3UM%BB%2\C`B>SG# M$!AG(A1SR\(LU<@V6*YL*'K0([9DY,3,/`QL.!P'""+!",\+:1VF&"&9QQ:5 MBIX2LHC/"$Q4S>_W$]53'Q&=ZV78:C'3&/WVL?%=WY5DNR48HHY>=(:G&")= M'UZ$I\(<'I01"/>E<<[!9-4T?S]9?09`9`F3F&F,U).0;7V)_[+-(LM(`^X) ML$*TT$CQ,\2680VQT,BPAMQ&6$.:&BA0<%6S"!2'%O+VQ!FT\#RE^8Q'C&YE M'ARG?1]><&HWGKBR5] M95*7[:E,RLNELXKF65T:^9#6:76ZT/KHJ3=0LAZS'5QP+-=3N``;UIU)`>Z? M;OFI_"-O3]6ULR[E$1[E;M5=4:MOL/2/OKD-%SA/30\W3\/7,]PTEG!UXFX! M?&R:_OY#79!,=Y>/_P,``/__`P!02P,$%``&``@````A`!6=C8%Z#P``>U8` M`!D```!X;"]W;W)K&ULG)Q9<^*Z%H7?;]7]#RG> MFV";(5"=OL5@8V,S&D0YTDI(`^?#CC)0R?]L;0U>&FP M9/S]?_^\OMS\O3N>]H>W^Y)1KI1N=F\/A\?]VZ_[4C1WOMV5;D[G[=OC]N7P MMKLO_;L[E?[WX[__^?[GGY?'YOW=Z>'IYWK]M3^?"^ M>V.?/!V.K]LS^^_QU^WI_;C;/L:)7E]NS4JE?ONZW;^51(36L4B,P]/3_F'7 M.SS\?MV]G460X^YE>V;E/SWOWT])M->'(N%>M\>_?K]_>SB\OK,0/_M#R_OU=CAN?[ZP>O]C5+SX/Q#^=?]P/)P.3^[/2?G[YO1\^-,_[A^# M_=N.-3>[4/P2_#P<_N)2[Y$CEO@64COQ)9@<;QYW3]O?+^?P\,?=[7\]G]GU MKK$J\9JU'O_M[4X/K$E9F+)9XY$>#B^L`.S?F]<]]P9KDNT_\>\_^\?S\WW) MJI=KC8IE,/G-S]WI[.QYR-+-P^_3^?"Z%")#AA)!3!F$_99!#+-<-6N-N\]$ ML604]CN+8M[5C%K]$V6IRBCL=Q;ETV5A=8^;A?U.HM0^7Z.ZC,)^RRBF63:J ME<_4IR%CL-])2;[0MJR_Q_5AOY,H]<_7IRFC&-RFTBU?*(R1FH[]D<3YO.N, MQ';<[TF8KQ0GN4Q&UL9?Z`1&TL8&:Z:DD1DKVH=8F\:7R,P:Q6B6&T:E:34^ MT1631C&SSFA6/G^IS:0W\C^2QOU*G*0_FDKC5@N7YU8,5_'HU]N>MS^^'P]_ M;MBDB@+2\L_2"1)7#\!61I2E"!1)$F&`HB)@;?!B()Q`K*@%BWL)$?3 M).TT10VM4"@DZG4EY9\EBJ3\()"6O@]!H2Q0`5-!\?)21(@`H:9(@2 MJTE:=I2G:>@M-\[3D/%I@IIJA0P3TSP-J5:(&J*8H8)6?(X2$B1"!0VR0$FU M0CRUS-.0K%:H(8HU*JH58N]-CH:.;.UVGB@;E;1NS>9CUAX4T/@%-$$!S;"`9E1`,T:- MU216F*"F6LFN9Z&K'"B`II%GH8,5\L\#1FN5GD: M,ERM"V@V!33LSCON$:H1JY4L,ZW+L76JUN4NSZ1)?_31:Z0J:GF*,0TZH6!*04C! MC((Y!1$%"PJ6%*PH6`L@:FN(RNBUW5Q5M-NJI%%I-JJFD8WXFN/8C@4XKGYU M?!0,*/`I""@84C"B8"R`O$QY MO7RB*F1E].LXI4%#-4GN,#A3%4;>0#E7%;DQ(E61&V.A*O+JME0%;%^?%T2O MVTHH,CNL*=A0T&XK1#,MVSD%T_)]T,N3*D]%34MN"SM"DY6R2T&/`IL"1X!F M/+L99=F@TKP5P_Y&AM4^#>!2X%$PH,"G(*!@2,&(@K$`HMSL1*A*5O"3*Y]/ M:(Q=V)3[/S+2F M8$-!NZT0S?+LW``L?WV!](#80!P@?2`N$`_(`(@/)``R M!#(",I:D+O;"3D`&0'P@`9`AD!&0L23I"M2JR/L547"R M4SY!^5U3_=$=,X7\0B`S(',@$9"%)%FYV0&:\D/*O02Y)??`8(05^^7:GJ1)>F7'$"+5Z7*;O2)OA^Z:]C>RD]F#5+8D M;);@CUVPYZ+J2GO&SB4Q')JBT5"MT+R#7/N0JZO',,IU0XN!)?<@Q@"(#R0` M,@0R`C*61+:)438MJ--$U[!VTRN`-9A"/J$>@[4"9#/3)76:#6ML2Y0M)]JF1IW(,DMB2I3ZID&>1<$_0AI@M)2,D]2#(`X@,)@`R! MC(",)4DK6">;.)-K@BG$#&F2!HDY`X$^N\PA9`1D`3%()DL0Z)FL(.0:R`8( M\[)B*]W+_%3A"UX6AQ&ZE\F`W.$/7B8K_/C6I9L2Y3;:`C_39':19$X143\5 M)?>[;DHN%,E+14FR`1`?2`!D"&0$9)P2I4!T?V)21#1-14FIPY1+(Q3=]62>ZQC*.8MT MO2!RM"(+IA[H;4GR]<[%3_L0S;VH]T`_`.(#"8`,@8R`C"7)K]?DXJ=3B!9> MU,\N?CJ':!&0Q<4(RXN?KB#:&L@&"/.K8AW=K_P81/7KY6,._J0ZO24UZ>&< M%(GCJIK9K)*IJ"L%V5*DIR4Q*K4J/2"P(8VCIVG4[NID][FO*4RS;M3)1.)" M5`_(`(@/))`D.:$S#),LC(:09@1D#&0"9`HD!#(#,@<2`5D`60)9`5D#V0!A M]OOHL(U_=T&S7[$'#N-D9&.7/MG;D:+,95T@/2`V$`=('X@+Q`,R`.(#"221 M7:?1H)4:0I(1D#&0"9"I)!]F%$*2&9`YD`C(`L@2R`K(&L@&"'/51^=9_(LP M7W&5.'[0)V$RIG3BV/>:ZGI:B63/)[8T-*1PMA5%IT`>, M^YK`,ALULBOH0DQ/2U)C0RP9"@>:H%EK4NOYFL"HUXPZJ4F@*YI6M4):9R@5 M6>N,@(R!3(!,@81`9D#F0"(@"R!+("L@:R`;(,RO'QUOF7G'6]=WS>)D=!0D M]SP=*1)^M?B>IW[?UY6"[)+T@-A`G&MA^Y#$!>)I0>[X8RMZV0:0Q+^6)(`D M0R`C(&,@$R!3("&0&9`YD`C(`L@2R`K(&L@&"'OV_Z.S,/YM/Q@C"W@NYRR, MKG4Z<6QY`"=N5(#T@-A`G)1DMWE5DPQU_524W,&Y0#P@`R!^2I3,+&+((!4E MF0V!C(",@4R`3(&$0&9`YD`B(`L@2R`K(&L@&R#,71^=>/$O@6KNNGQ;$D)E;HWR_Z&W=FN3*".;+Q8JC%MT#B?S:8/(5P@'I`!$!](`&0( M9`1D#&0"9`HD!#(#,@<2`5D`60)9`5D#V0!A;E.NGG83R[\JK+F-WT44&,O$ M-KRVWK/(LJ@3QU8MTP72`V(#<8#T@;A`/"`#(#Z0`,@0R`C(6!)Y2Q"?B>G3 M\0323(&$0&9`YD`B(`L@2R`K(&L@&R#,1Q\=OYA\+UO=#"GH([$%KON(K'P[ M<6S=1\K.>3Q+]D!C`W&`](&X0#P@`R`^D`#($,@(R%@2X2/YH"4U$JWZ%,*$ M0&9`YD`B(`L@2R`K(&L@&R#,2$HU]`&);P]_P4AB5UDW$MU=XZ\DT>:P+I`> M$!N(`Z0/Q`7B`1D`\8$$0(9`1D#&0":2)/N\9;*Q.(44(9`9D#F0",@"R!+( M"L@:R`8(3CXX9ZQVBQ%[$A]XP6 M>Y$:E(0^-%GO'&/*.V>KDE:=KMMA;15#?,UOLY2+(;;/%WC'"^&W: M$.S-G^_;7[OA]OAK_W:Z>=D]L;:ME/EW(([BW:'B/^?#>_R*O9^',WOG9_SG M,WO)ZXZ]UJU29N*GP^&<_(=G\"=Y;>R/_P,``/__`P!02P,$%``&``@````A M`+*RJA`O!```&`\``!D```!X;"]W;W)K&ULG%?; MCJ,X$'T?:?\!\=Z``R00A8P:>GMFI%UIM=K+,R%.@AIPA$FG^^^G[`*"#9U! MG0?YX?`-'B35ONT M8!6-S'?*S:_;W[YLKJQ^X2=*&P,\5#PR3TUS7MLVSTZT3+G%SK2"+P=6EVD# MK_71YN>:IGMI5!;VPG&6=IGFE8D>UO4<'^QPR#/ZQ+)+2:L&G=2T2!O@ST_Y MF7?>RFR.NS*M7R[GAXR59W"QRXN\>9=.3:/,UC^.%:O370'S?B->FG6^Y/LT%C@SD:BXSF'=FB#I^UFG\,,A.Q&30^1^4C6"0E->[N1`OV7TRL? M/!O\Q*[?ZGS_1UY14!OB)"*P8^Q%0'_LQ5]@;(^LGV4$_JJ-/3VDEZ+YFUV_ MT_QX:B#F`3/G M$-/7K;MR-_8KQ"%K,3%BX-ICB(I(Q@B7.#W&!L8];1!N2'LZ>!T[`1;L1#`% MW1C_&%)9],-(1#*!N$$4)B#:D(D0T(6DO,](&$4F#-)KX:X\E4*,&%^JN5@Z MRR#T5BHD08@G\WVH#N32D--]+@*L<_'5@6+$(!?7P9\*21`RY@*+8CX7`=:Y M+-6!8L1X4I=;=F#8NF^B``P%6:HDY@5)&.EDM`C$B$%A'OSE,O0\+8X)0L;" MP&H9"C./DS#2.06:0(A!3K[CAB%<5$@RA(QR2U%.M+U!?;B?2@*LLPO5H6/$ M(#L2.F3E^QHD0I4;6F0HM>NUF=2]?E;5,M+XP,_(3#2+0&X1T'9D=I>6$LA\U M"+'YTL/_ZPXJK?1%H[>*%@0CW_ILH)7P9!)TJZFJ@I]J)&2BDP1:T8M;D,(U MU`I5TH/T!D<^U4VDE29B.*H\V"P^6-3X<6*]:(UC9JY-=)!P5&6&+43L1M0. MDY"N?XA]Z.VC&DBME_RBUDPTD7!4:Q#T@4ZCEH$'%-R+E[0^TH06!3J1_IO4QK[A1T`.8.M8*5E2-)QM\:=A9[O1W MK($3B7P\P0F4PE[8L0!\8*SI7D1F]6?:[4\```#__P,`4$L#!!0`!@`(```` M(0!],0W&B@,``*0+```9````>&PO=V]R:W-H965T>WNO)>J9",-UL_FH2^1YN"EZPY;?T_OSU_6OJ>5*0I M2<4;NO7?J?0_[W[^:7/EXD6>*54>,#1RZY^5:M=!((LSK8F<\)8VL'+DHB8* M7L4ID*V@I.RN](?:\NUE].#1?D4$'<;]&,%#UW]S*BKUDA MN.1'-0&Z0`L=Q[P*5@$P[38E@P@P[9Z@QZW_%*WS*/2#W:9+T%^,7J7QVY-G M?OU%L/(WUE#(-M0)*W#@_`6A7THT@7,P\G[N*O"'\$IZ))=*?>777RD[G164 M>PX186#K\CVCLH",`LUD.D>F@E<@`/Y[-<9&*UW]K4'2CTB33&TD,ZF_KT\EL.E\L?X1E=F.!Y_^7`J*[ M>.#YXU("G9PNUQE19+<1_.I!`T/XLB5X'*(U,/=)UBD9TOY1UB'=2/*$+%M_ MX7N04`FM\KJ+D^DF>(7R%C=,.L8D2QNR[R%83.3->L._O)'MDO<(["0(:8@+ M"F?&]=]-T\M',,KO]TVU`;B'>)QH]F-$LK*E96.(0Y*/$0:)%0[TGQD.EFD! MY;H?%CIM?=ADB").8EMDJC&S(?2]:\AZ@\DRLUGR'N-6`1K>E'U?+H)=N7-[ MHU1C#+FN(=.&9=>$BWD(?S9%;GA8*89T/JX5P:[6Q-XHU1A#JVO(>H.9VH7- MDO<8-[6)+1<[(H8[]GZ*T%V48]QRX+3AW&?WB\'@AVY M"^>"2S7&D.L:,M>0&P8KI2M;VV,M@TZ.1O?>3C5&G[DH=D_<_OYR9B['*]<[ M_W#9B@TF$2OQC]V0G9<;G=LP-Y!1@I$E&RQFS[C7_0`:FD8//_J#7%-QHGM: M5=(K^`4'FQC.X&`=AJZG*5[6CCV-UO#U'-LS'-+0'@P.,".UY$1_)^+$&NE5 M]`A;A1/\G`@]9>D7Q=MN/#AP!=-1]_,,TS"%[W(X`?"1<]6_X`;#?+W[!P`` M__\#`%!+`P04``8`"````"$`).FM&0L#``#K"```&0```'AL+W=O>80/LY3YR)`Z39-*60@;+=XB2+T8,7K0?(F4VU/[\I MV8N3_Y;(V7[-:?J55@3,AC*I`FP8>U;2IU1UP62G-WNE"_"=6RG)\*Z0/]C^ M"Z';7$*U0TA(Y16E;TLB$C`4,+8?*E+""@@`?JV2JI4!AN!7W>YI*O,8!4,[ M'+F!!W)K0X1<485$5K(3DI5_C,AK4`;B-Q!H&XCGVP,_'(T_0@D:"K1'RD=# M&300:!N(/[']<>B%PP\D!*EK5X8MY3]<&340:)M0`.(-W!L"<4R5=-&76.+9 ME+.]!1L)ZB!JK+:E%P'W4&U3F[;^_RH_U%U!'A0E1C`?*BM@R;[,@G`\=5Y@ MG26-9M[7^.>*Q05%1[(T$O@]>='D'//8UW0HJPN*CF1]0=*^Q@'O6@-AB78- M#%=XN![_4).67VC[*P'FW8]'M6)J.L\R';AN2ICSV-6%X+EF]+UGW)4%P M]/@L>=A9I\E?3UJ)8P3T8^T&WGEX$^P-`)]0!I33F?` M5=(EKMX97Y^.>VK^">',##@A;C=#B3MF#+MF&,U`F]'UXKOM,_]R+8 M`OW^A1?!3H!^IYT`=TV-M^0;YEM:":L@&;S*M4=PPG)S6YD'R6I]NFV8A%M& M_\WAHX+`;G-M$&>,R<.#>D'[F3+["P``__\#`%!+`P04``8`"````"$`$,'R M_BL'``!Z(```&0```'AL+W=OIF8I*=BR%\ M_M66?[6D-GK\[?OQ,/J65W51GM9C-M'&H_RT*;?%Z64]_OLO_V$Q'M5-=MIF MA_*4K\<_\GK\V].OOSR^E=77>I_GS0@BG.KU>-\TY]5T6F_V^3&K)^4Y/\&5 M75D=LP:^5B_3^ESEV;9M=#Q,=4V;38]9<1J+"*OJGACE;E=L<,>L^OIZ?MB4QS.$>"X.1?.C#3H>'3>KZ.545MGS M`9[[.S.S31^[_4+"'XM-5=;EKIE`N*GH*'WFY70YA4A/C]L"GH#;/JKRW7K\ MA:U271M/GQY;@_XI\K=:^GM4[\NWH"JV:7'*P6T8)SX"SV7YE4NC+4?0>$I: M^^T(_%&-MODN>STT?Y9O85Z\[!L8;@N>B#_8:OO#S>L-.`IA)KK%(VW*`W0` M_A\="YX:X$CVO?U\*[;-?CTV9A-KKAD,Y*/GO&[\@H<_Q4BUH42 M0?0NB`&][Z[K$U.WYHN/1#&[*/#Y^:Y`I]OG@<__T959%P4^KU$^ZLJ\"P*? MU^=AIC;[@+,P3<7P\,3X]/BPRRC#2'5A='-R7U^F(F/:!'2S)GMZK,JW$I4;U>T3?Q!1"YS6,$&(0]^&G0B"H,IJDWCH5& M?F34M:17]%U+WP\[A2&YC`L,A3(NMY>"WGZNYO;W=[)[<'U$7>V^0Q6SI2IQ MJ00%\:@"!_&I1$=1`B$!!CT$@@&RX8:#!#ZG&,E6[HF%)/"Q)J&1I MJ#=*WY4HKL.VH[C^OMMW"=$8:)UI^D MU_1S/I6`X@GLHA_PA*O78\CSRV0T3+2PV4)CM>O\M3)!BD$E`LAY)#L?R^R<];8>NOJTN[ M(=I"<^V3@X&+@8>!CT&`02C`HAU@\%:=CA&6QQ@D&*024(R"[5,QZOWYRM78 M(+16V$(C&82!*\"R?3AM8B"'/:SW,0@P"#&(,(@Q2#!():`XQ-_QY`+M?8>X M&CN$EFU;:"2','`Q\##P,0@P"`5@6F?SPD))A!O$&"08I!)0+%HBB^Z;;;P5 MM@IUTA8:R2H,7`P\#'P,`@Q"`41"LHEN>@\H)R-9H4/)OY3_+8@^QK=(,$@E MH'@)`Z;F&S?3A'7N_;QKFV$W9^J0VYU(LI,0EQ"/$)^0@)"0D(B0N"/PP5]8 MEI/ELMU%^O\,XFM"8J0R48WDQ;X\<;F1S!JL`/EK'LG+.792B&0G,7&[0%`5 M2#LY>N'R+J*^BO`)"0@)"8D(B0E)"$EEHIK'ZVQLWG#US%]@B7>HL+4[D>R= M:'8E;J?I,D.;,#0A/1+$)R0@)"0D(B0F)"$DE8GJ&Z^49=\&9JTHK)5BST*[ MO5$M&WK? MWL)$+:X:BZOH3B3*:#:S=`W-3J=3R,:*P#]OXY$V_N!]`M(F)"0B)"8D(225 MB6HL+YT_8:RHN%5CT>2T^4^GL`QT)NF6Q=!.Y'0*V=BA-AYIXP_>)R!M0D(B M0F)"$D)2F:C&\E);-G9@"1"5N6HHKJE97[[S?1*M#\[E8K^%N!=R0^Y=+O9R M_T)NR(/+Q5X>=D2,KF&::-)$`]=C$C$A))6)ZBXOTV5W[UP/1'6ONHR649M) MKP#MRYY#B$N(1XA/2$!(2$A$2$Q(TA%AO3Y?:#/30I,O531LIAES7;MNP:J9 MO*"7S1Q(55'_JR;BBIT)49<=FK5`I9/3">2I/]#$(TU\Y2YLJ9NH&P%I$A(2 M$1(3DA"2RD1UDY?TLIMWIJ9X$U!=1>NES82H?T7I?F[I"V7F/:`5P^D:R"Y_ M,(1'0OBX%_)+$/Q->A&0$"$A$2$Q(0DAJ4R448!CPL^,0ML,O3]9*'7M3B0J ML8>EAJ:>HUR?:=8,"5Q%\,"882*%IRB8!M,;I8+?*:XC&Q`2$A(1$A.2$,+/ M7/E&WMY+N"R.4,4)UC&O7G(G/QSJT:9\Y<>C/#\O]')T^Z5MC[C-5G#:!)L* MXBY;P9$2Y3%;P7D.Y;:^LF_%=_05_'A,]:Z^@M^0*??T%?R43+FOK^`79>#3 M2T?AY/>2_9]5+<:I'AWP'CZY-YE#!5.+L6'QIRG-[OO=<-G#FV_ZYAS/^ M',[$M`F(=V79]%_X#?B9=7M`^/0?````__\#`%!+`P04``8`"````"$`>%/M M=V<#```%"P``&0```'AL+W=ODDEJ$DP)+B%_L:"U.:F5VBUR)^?.^ MOLM868/$FA94OC6BKE-FLZ=MQ3A>%^#[%0UP=M)N+GKR)%?J4JULPV>_-?FP*\(,[.=G@?2%_LL-70K<["=4>@B'E:Y:_)41D MD%"0\<*A4LI8`0'`MU-2M3(@(?BU^3W07.YB-QIYPW$0(<"=-1'RD2I)U\GV M0K+RKX;044J+A$>1`41_'!]Z@W`XGGQ$!9[7A`*_)Y71S2J^]M6D*<$2+^:< M'1Q8>A"YJ+%:R&@&RJ?\:#=MQJXE##*E1!Z42NR.70=R(:#(+XLH&LS]%ZA, M=F26FH'OEAE-3&351Z)H:#))GT$FD?:)"`4MXX/QUCU4INO^\JHXF52P,JE6 MB7*]U#>ZCJ)HU#ZH85;'2:A)R@!!U4T@Z8N$)I%>(,Z(82?ZB!T%QRZ(M_5` MXW.:M$/-3'5%O4EZ%YFQK;H`\@8](#$!-#4_/3XU^=#$IUW><`Y;Z_9"*MAV M?LZH=JX9[1QY\&`+6)G`$`7=#^KQBT2H8<&AG?(_9DWK,.NO=VZ M@FWK5DV7FD%!4W7D32Z8-Q"(==0U'UQP;TT8CZ^;:_*?&A.0-[)6SM5LC#Z2 M#07;V;#VYU(S4)MVFT31V-H%-S#)#4SZ/F-4'=ZUMU==P;9/R\-2,\>J6^^! MU7N#R7N#Z95!PXOJM3IGT/MO807;7J9F/9:::5?PP/*ZLL>M@_FK\[:#<)'%"!!_"&,7FZ4)W2X=3` M+OX!``#__P,`4$L#!!0`!@`(````(0"PDO>&=`8``!(;```9````>&PO=V]R M:W-H965T'V4H>J\L>?0?Z16QA>/G^O3MJWHFG+^KS5 MV<+4M>*?FHFZ_ML2@Z M#2*VC%:E3\2KLJ:K^^73WE= M72#$6WDJNQ]]4%VK\LUOAW/=9&\G\/V=.5D^QNX_D/!5F3=U6^^[!80S1$>I M9\_P#(CT^K(KP0%/N]84^ZW^A6U2R]:-UY<^0?^6Q4*OKKUSZVXXC:&R0UG$_`G\VVJ[89^^G[J_Z(RW*P[Z"(VYL ML_L1%FT.&84P"VO)(^7U"3H`O[6JY%,#,I)]W^H6W+C<=<>M;KN+YWJZC\A8D,H$<0>@L#?(0BS%HZU7*V?B>(,4>#O'.79KD"G M>S_N%,1R%LPQW2?LK(88L$;&G(#_V[DP1%[[80JS+GM]:>H/#>8^M&PO&5]) M;`,!Q_$1V9Q&[&<#!B/%@WSA4;8Z=`S&HH59]NW5-M8&?F@\:F&J8I@ M5/!IP,.&`HC!Y"`:%?-]4(QX5(PQDC'&W,0V/?7&Z14-,R>-`:F:\@434<[7 M]7D\IH6+>5K&SO@CF#MC3;?I+0=4X:+>AE1BH2B1D("M:3R0(J8*?)^$2FR& MTIU>T\RW4C('J^_QS'&QDCD,`@Q"#"(!Y"1XMIKM^+XDH1+;G!WV@Y;>UBA9 M@-WC\2QP<;_W3<-H,V3!%QIGFF,!!B$&$08Q!@D&J0"N6-H><^9YH+B#[4UV MQW<3&\Z,VZN$-\(N'76@?*&17&(08A!A$&.08)`*L.Y=,I/_3-U0;,+N_;Q- MW@C;7$[Q^XGD"XUD$X,0@PB#&(,$@U0`,9B.Z;FKJ1>*2]C.99>W!Y&+L3MW MBBO<"8WD#H,0@PB#&(-$@,$,7^;.W"P"@#?]MAK\86T13S!Q'LD=(^C4[M M8!*-Q4!(2$1(3$A"2#J1Z[=7AI?Q4@=-^Q5L>W>R(`HD..QG@]:\-XIYWX?> MZDH6K/F>)(&W2_-\2*@D\=K$A(U%0FJG]>Y#SO7Y1&JG]\HC$A&@?46JU7 M:)8'BF3E.:[T=;(W&PZ*.8D1(3$A"2&I3-0$\,)'2L"='5Z42:IQ^"E+KP8CA)C$A"2&I3%3'O*9YW+&H@%3'Z-#VF1`)"XZ[ M]-!:"`;!/(SA1*XD*9HNCDF*"4D(266B.N9EC^3XL>];3!1+BG.\C_N#:#86 M$!(2$@UD&/+U6/2JXQZ3=@DAJ4P4SQ:JWQ[SW+="^[N-ME=_$$F>"0D)B08B MS1$+3:.8-$H(266B&D8EV^V%;%TIU4QB5(@\42XO3+[5SC]('0PAY[2$A$2$ MQ(0DA*0R43W#Y)0G]AW/7(T'%]=JEA`YO6>\>4T7QW49#F28R:YIH94?D28Q M(0DAJ4Q4QZADN^/X2JEFH\+3A^?Z/"W#XPQX((O/TV!0R".+B[&(:&)"$D+X M.X6I1A`^Q2L"\>RY*II#$12G4ZOE]3M__,^_OT]T>C7QI7\S@;C/-O"D&`8* M\8AMX.DOY;ZU\:_%":P-/$2D^M#:P+-$X,9T`W@C<&PO=V]R:W-H M965T(,EW/*](SI.<*$7-;7CNV[L-)BVR#"L^"46LZ8!B1VLJ7S0ILII\=;]O&<>[&O)^ M]D*`O!.5(?%/)'`]D7B1'?K18OD1EN#$ M`MDI5VZQ1)OUIP=+6@]$"XZK!K96P'QV1Z33&_8__P"HQ3)C6)) MT0)98(6`(C]M_"19.T]0F/R$V1H,?/<8;XS(S@A53Y#7:P3;AAK?+MU9B@(K M*:J42MO6/!C&]2=QWT"\0D9*P*'+E2APBH"\3SAPW7'HK<$LM65AX$5+;_$: M6NO/1A#?C$H"7N6D;KP(^H4>*IN4I"MP21:'9R1B3O\3,"9`8=Z-PZK!]OD M*IJ8LC68'0@X]#@PA]-JUD,)&I5APEL3]I\LP@YB;` MUKC2GDMN9%B,`,I8ZF9>3\7HN;:9+\'<*B^OZ?4HJF@:!QP:S"FDR-/ M-\H8D1G$7%(REQ1"2=^7I!9-)<7C@%N#@>FB#J3$3L;]&WRYFG169A;,%0+% MR+7WI6GT5-MBHNT$BDTO>7&R'`/44%09#L28&6=.[X;P/&PO=V]R:W-H965TLU)`GZYSVMYBE:FUX0K MD^;I4-^DHJPAQ"8OO.+@-><(,;(1X0NFW#+^"R?9H]J/.P+^-E?%MP7I#F%% MN+!Y]OK`90J.0IB)IS%240``O%MECJ4!CB0O^O.89VH?,W\Z"6>.[X+ M$I4L%XTX6E!P@"OK!,O7G4.4RV;``E![C^*8S9@%ZY20P>=E$+@+^QE<3UO- MBC3PWFD,Q7JL\%VGBV(#6$<'-EU/AV*D0[\1=T5?]%&\[F>T8GU!<98,2,"; M/@D6CP\E^+Y?."EF\".=%T%PCD^0I`FUFY$W@WHZ>T&0I`AT@,7O5SI.,AEG!B-I(BJKR2ST@ZCW,DQ>DWIL833&^W@CXB03[];`(\WM MQ:JGL3&,"RW`-.MC&CW+Q(D,G%9$=L&Q),(RZUZCGHH@D*A1DW"QVQKIO(*0 M>O2@>`/H\B"916=&.A>5 MO-GQ-2\*::7B@.=!%UI"]VUW5KWW]%[K!N"H6"<[_CUI=GDEK8)O8:H#;8Y9 M#1TVZ4:)6I^Z-D+!(5%?[N%/`8<#BS,!\58(=;K!AVSW-V/Y/P```/__`P!0 M2P,$%``&``@````A`*+8U>&3`P``[PH``!D```!X;"]W;W)K&ULE%9=;Z,X%'T?:?\#\OL$S$<(4K.2+/2:K4?SPXX"2I@ M9#M-^^_GV@X$FYFTVX6]I) M0$I0R3H%Z>Z%P-;6WZ$KB7\^=Q_+EG;`\6^;FKYIDF1UY;K;\>.<;)O(.Y7 M')-RX-8/,_JV+CD3["`70.<;H?.8,S_S@6F[J6J(0-GN<7K(T0->%SA"_G:C M#?JWIAZ)$[O\SNOJ>]U1KGW0&_N1>10_D MW,B_V.4KK8\G">E.("(5V+IZ>Z2B!$>!9A$FBJED#0B`3Z^M56F`(^0U1R%L M7%?RE*-HN4C2(,(`]_94R*=:42*O/`O)VO\,"%^I#$ET)8'_5Q(<+N(P25 MM87.OG/$,ALAEA)PZ.-*%%CG?-PX"IR0=P:3:,F"PIZ:I$JJ/27K3(D32UR1(6!(\I@ M+%&AZ]"`<44M;5'W*TB!;3%Q$CMB#&9E\A8%J\!16QC`/%?0(U-[[BM18%M) M%#C%NS,8O9%)S.2%5;OJ,G(Z/8*3\+X"M\7D5YE MNQ4GJ;WG[@HRR"4[J]DAA#H9WXYSS4.HCGOG M_4[-._H:&'^`<:,G1_H'X<>Z$UY##T`9+%35<#.PF`?)>GWI[YF$04-_/<%@ M2>&F#!8`/C`FAP>5_7%4W?X```#__P,`4$L#!!0`!@`(````(0#!4GF9F`,` M``L+```9````>&PO=V]R:W-H965T6">Y:-9^N$"^QYI"E+PYKOV__GSXG/F>5'E3YI5HV-I_8=+_ MLOGMT^HBND=Y8DQYP-#(M7]2JET&@2Q.K,[E0K2L@3<'T=6Y@L?N&,BV8WG9 M)]55$"%$@CKGC6\8EMTM'.)PX`6[%\6Y9HTR)!VK<@7ZY8FW\LI6%[?0U7GW M>&X_%Z)N@6+/*ZY>>E+?JXOEUV,CNGQ?0=W/89(75^[^849?\Z(34AS4`N@" M(W1>,PUH`$R;5N": MTO>*LU2B_L>`PH'*D$0#20SJA_?1(@T1C=,/20(CJ*_O/E?Y9M6)BP=-`TO* M-M]063=:=(P@=(8X2<,A6HMU* MWFR#JR*=M/9AD5%`@E_YC4B#P;UUF"*","&(C")ZT,X&D3#.:$8HCD>0HS29 M*XVA[=_W3B>Y2G$RTANA!I*,]NZL@",`;/EUJW22*V!NE<$8JZ(T0R3!TPVU M(4F*$IK2-VPB=_GY9M\/[W:/!$U7DE=>TC\%8OE@!9V7JKGS;2=-)$P6S MDV8PPTG+0IJEA$33F\@&P5G$.`QQ]D8+A7"L;C>I1T\TDLGRVP%DV61'')]" M?6E:6W2;47W61,7,J0%DK$IIFJ!XLIT[!T(IB6V(JU-?LI;.]ULI-%>R2 MR2G?#B#;)9/61]S5_]?%#1/%Q_TT@(:&0C&E&+UVBKFX'4R4A"2C23J>2:/4 MS![FVURS[LAVK*JD5XBSGBLB.,=C=)QY[B)]#T_B6ST+Z7@POH!1I,V/['O> M'7DCO8H=@!(M]-C0F6'&/"C1]A/!7B@80OJ?)Q@Z&7Q&T0+`!R'4]4$O,(ZQ MFW\!``#__P,`4$L#!!0`!@`(````(0`G@FT](P8```H;```8````>&PO=V]R M:W-H965T&ULG%E=;YM(%'U?:?\#XCV&^]5Q[+=UL>GC?_/WY]N$M_KA^*X+0[ML=KXWZO>_W#_ZR]WKVWWW.^K M:O`@PK'?^/MA.-T&05_NJZ;H5^VI.L+(KNV:8H"OW5/0G[JJV(XW-8>`A^$Z M:(KZZ&.$VVY.C':WJ\OJH2U?FNHX8)"N.A0#\._W]:E_B]:4<\(U1??\?GXZMEWQ>(!U?V.R*-]BCU\FX9NZ[-J^W0TK"!<@ MT>F:TR`-(-+]W;:&%2C9O:[:;?R/[#:7H1_3NS^-&?BS\[;5KG@Y#'^UK[]7]=-^@'1' ML"*UL-OM]X>J+T%1"+/BD8I4M@<@`/][3:U*`Q0IOHV?K_5VV&]\L5Y%<2@8 MP+W'JA\^U2JD[Y4O_=`V_R&(Z5`8A.L@\*F#,+Z2/(J3)5&$C@*?)LI,*@$N M:U3IH1B*^[NN??6@](!X?RI4(;-;"*SD$2#R97E`%W7/1W73>"N@>\CIUWO. M[H*OD(920[(+$!>17T#P,R0`>F>.()O-\3HW!88U^)[A)LYA1_H90N28(K6> MW+K@3`Q1YD^LP!L?0IF))9D8(`'`%FS!$+ML-\L128<%J[4V8(T9SDFL7N>.Z,,YZ:+#NTUDMH M*3"A1:;-$(*T!!>12`@O&\!9&*^-V`ZQV"4V;^>IFPA!,G^&$)JJL?+SRV,. M+=7X+$.XOMD4F-!)73DRA"`=GIC:04+OC3J4TB64%-BE),BD&4+.*4P8D3"W M`9RQ4+Z30@9..5^L$>U:DR`&D&F,Y4WV%4<5]G/6C;9KVY0P)H/^.$;>^'KK MA4FTEB2KN0MA(6Q/LU%DA!NE%(?QS2R[702X!7&J+ M_)U-#5Y0@]>8RYM/#_Z8UB)W9U-[%Z939U>6&*5RMFNSCC@D5K4H:Y#H/LX1P7R=3H M[M(C5G_=4QF:-%3;^2!!>TRF,;9-O%F[.@S;AR>VR-!'-+%/LRJMC6W:D[V' M@[K(UR$W27=I$5.?U_[8!7(O_G4_^79.Y, M8\!NSWM7DAZ17\>X!$DGF%E_Z/:V@5C5HW5$C&4@W+KBDECD^^JIF/B^-!:@ M)T<,[3;C8*X#T$&7$O%[I4OZPZ=6/O5]:2I#4[-]'ZH+K'_2+'4<76`"#"2T MCI@NT47.S]'#H<1-]9"C::8Q;]4-74=8;4=+B'$0P^,XBB(+XQ)!=)LRESM!R-L:S8ON(J]%/]0,SH!QICDWBO'XA%_6!$ MNPK0399I#*8)?NE)Z`-,?@WA*D0ZP_7CD)AVA&F1VQWA,KDK")<*01B;!+6%9<$\?0?I&GJY=,:0@P]-F!# M%)<''4KP$F*!^XQHMZPGE:,Q^',OZ3WJG8[J6UQ@0+>RM$-7-=GFY)@;G#*E*"9GWRV^);MO]0T^TY+`M&&=9(KL&+L64J_ M9?(K&.QV1C\U*_"SMC*RQKM<_&+[KX1NM@*6.X09R8G-LK='PE.(*+AQ1J'T ME+(<`."O55"9&A`1_-K\W]-,;!>V/W;"B>%F&X[G[`@%,6TGV2.$:Z/1FV:W@0MMOQY"`#;ZJ_/E:2J,'S',^D&S1K M<,%'X.0@`RXRX)0D;."BL>]YGBY(S@@T0$C=T^B=3SPIUL'&QGMC)0E4U`RF M?IN&,[X%1XH-'&.58B7IQ^FW:3@3'>>Z[2D'&5C'G=7LX%A)!G-KT*S!R>YV M4CO.+YT4&U"^OCRQDJBZ/C]M$`$93:ZT/8J`W$T$!L-1<8-=5%R(_U"%7?M0)LQA,I M3="T.=E9DM-O]$C)8GR2;-?M!*1*N`9Q7`JU%5J-BAB:0-+I(4W."'1$HQ&< MWP^HVP$ZM:S5M#LB"(P.D0S;=3"C"5P`ZU9_LS/&Z+2Z^SU@@W8=S"C^5RYJ M3Q?H'#^4INWM\J!E*!)Y?(/]WJO0(8V6<"5DMS>$G;UZ:`#RP*C2_^0;'>)# MC0!U.T'827^E:0N&++EF^@\+=,2;V@'JZ0?&F^-6T]\\!XPZTDT-`"X0G0Y@ MMO-6,X"D')A&A:3N%NKL7>$-^8'K#2VYE9,UG%`]1Y[A:W6S4`^"5\4$ MW`B:CUNX`1(HDYX#XC5CXO`@[R[O=\KE?P```/__`P!02P,$%``&``@````A M`(7Q[ODV2```9OP``!0```!X;"]S:&%R9613=')I;F=S+GAM;.R=V6X8=T@(;(P:*+)97"31;OYB%4]EE23ZRA?S M"'-S@!F@<1Y@'J(?Q4\RO_\72T8N52RU[;9G,(`7L3(RXHMOWR+RZW_Y=#O. M/A2SP/KT>3 M(CN9%[?E?VO.YD$]*ZY'Y7R6LX&W^6W1'/5F,9Z/CHKQ.+LH!C>3Z7AZ/2K* M'CL<;#7'^AF/0,8L'S-D6'S*?E/<-\<=+68SQF0O1^6`<;\O\IFPD;W(YZWU M_9PO1^-BEATQX'HZ:TUX?IN/]?RLN)O.YC!'=C2]O=W^2SHLS>+>;&?,S8?"U2X^+^KK6G M_O;F;YLO',)"0V.CE^-\^72GQ6PT%9MU8RLNZU'KA[^$1_/CZ^.,\>OS]_D6U\ MV5SX[?0#/+YM;+S3?'AX?LZKS5^/\O(F0\RS@?Y1_-MB]"$?PT*M39T5@X)G ME^,BNYI-;[./^O3PZ?G[P^N3@Y/L\.W[[(CG_[_N3B]]GC%\_;Y%CL.!J;DR MN\OO#7':!"#/%H!;?$)=ED4+SZ=^['R:S0JWL[L<##3W<3C\D$\&:Q'C:#I! MT\]'HMVPN`2!"X2L.6'0'2;H#H7#XJI`H0R!Y$,Q6;3$K4[!\2B_'(U'<[18 M<^ZWT\EF(/2*82\:ZT4ZAW<];,WI7R"['R#\AR(+L]]'[('(A/Q?"7V4YO]Z#?V]D]Z#WI[]JN^[W= MO8/>LVU>W3D(KXS*4O(@V9A6:C_+,?N+ZP7>1C#:-@055]Q>HEN"FNM!Z/*N M&(CZXPXI&<*0TPF*YBX?#3='$Q3=W0C%TT0&PIJH$N%LWASBJ+P2ZX8LIQ++ M_[(.#9`,F'(^FX[',I^CR;Q@/\N4I33@`T1ML:*A;8T7HY"DZJ)B$3/0V1_> M&/9;+H]_^03WH)*P=5]>T^:=XAK@WQ7S$;[-E\ML8)V.=]$D]+*[3EN2/88G MAJ`_GY4M#?X>1ZL<74_,P#!7JC"8,`A#.D>&O7*LW9JMPH>7J9;0?%4MUV2^ M92\[\5EW=")AS5?JXOZY>ZN_W=K8ZL7\\.ZM=,Z\8A\M1(T)+T9#YQ>8[DK) MU2+2$F8\O\`/>W/\%N?KWGQV>'%"1[:,C;<73L8:3EJ9]W&]AV,Q290 M$LM5C-<2;] MFY=YB:8>$`'@NAA"F^.<]I'/MAK4U].R='ZD'SN=M)P&YT..T(^W1?;8;[I% MKQ.O,0-6FA`=W>38611K=I6/O/&2>XC3VO(9FN^^(E;-,('#47DW++H,'6& MR[*610DKM"999>":X#S/R]'`^.S%:+R0&VZ4/44'>KD]EV.02MP*!=F>[;MB M='W#M)N'>+`Y=$QGK<6)MH13)"T>64NF.QSZ9<)MA&RBXG`878U3[VH<.5=C MJ=4\*^9P&$@[SF<3)+=<.K+A)D1&6V:/`YKDV2Z=]'D^MA`"5RN-'%LA4Q@G M2^DQ+/=LY3LG>'4V.?*"`$=',B-]X]UPI9XD3GM;3_>_6!&8_!53K6**E=,6 MGXK98%06@L]'NBU1_.P)5D$3<.S;TK$&W*UW?KK8UEW%)BPOBLNY=U3%@[WLW6QT/5*,H"?*P#DG/#O# M[Q,'Z.?F)&L!=W1X_NOLY>MWWRWU$RS_?JR;0ZQ\KI"F,YH^'/Z1N,@% MDY8F0-\/2.-5=H%?92,LI[.0S98=BT9Y^5&?UL/#>I/@(EI?EVRVE#*FQ0%$//)^O2)X)']/-A1%X\N[P'J0\OUP3Q M"@&!RU8R9AU$.2.I'K6@9ZDVK?RTBH89MB)?/\_5N==UX-:+PV)`K0*-#\<9 M/==)BAJ2N@;*/EZ2_Y_(K$N%('RDEYO,L_)]TM;+WSQ?W-V-"^D`J2W$"W]0 M63V]8;.^1*>@R6*UY!>=:RLI8B9YY'5>F_/S$8K33L^-SXC4; MW[,7SHZ/7I,%/R%AZX*WYF:]CA#)3J=CISZWSBE5Q/ M]J3D'1=G`@:.L1&#<+04E92%XN=%B<.'Y_ZB*`>ST9TEJ\5`G4M?%)_FV?,Q M/EQK\;?O+HZS_E;V,V!EK26:J%P51&2/__+G_QD'_.7/_^O+7G:3E]G\XS0K M%Y?E:#C*E;#M9?]:3*8$LZ-!"7YG9'^=1='[U2--8-8A3IF=W-XN)E,%6OE= ML2!AQ%RJJ[F5CRY.],Y6DD!5RJ[,#O:W=K^0!$EU)2F&D*I\C/G*99`V1U>; MWHZA4;&V-1>7,'E4?JEY*B#;B^5WJ.1/(VJEY"VS)T__I@N_88];V6&9F?4' M#\4([M.V0!W!P1TE/'"064H+S$\K7#`,G`MWV*(/OU381`-1U?DY7B;VD]!NKJXS09D0KRAO%G<0K(QN8_9 M+YF(F2"<\JV&C9$8I0`-!/A48Z2V5;&-L@EDDD[[C>5=)GFL'6F3L^GB^H;D MX8+*RJ:5>F5@S]X>DG8O^;\O-Q%]!/XZNYV.B\%BK`TOE&TQ%&47I!TWQZ/O M"^JK@^)N/IV5V>.+UV":(WU(8FT]L[6>/W[PXW-S_,K-H(AMRE&_.K_/1A$S\]\5]-E_@VV7S?`:/5#C(23N`%/?*]'H\O5RP3$5O MHZI*W/>_M!4>CSY\"5*&5KLS2DP0[B%4S'FOV*S^B2.[8!\B"A44R"Y6N?F8 MWV]E3:Z[+89*#8OC1@.5NKH8K\P03Y"#*,.E#!).D-4??V`/Z-M-CQ)PF5V. MIOEE.9U=6GX%SE+I46^=#`O6>3Z:GNNWO_SW_^A51I1*F>>303X;CFS3#JNP M[)T$0XT75$1A+6PX$&MXV9*I3D/6)7@Y9483:#':8I(OR$.P0=A\J`JC_L"2\[A9/1SA``&%7.D4&@ M("5X43/E^+0EO&7A=V'E.G;*/", MF!T+(AB).-&Z`5%5.A5CM(:2``7F";JE+//9O3%P[I*D$#3Z+`F=/0Z'0`9" MQ0[7UX0MS#*_D>*\X:W/8KM+:=[<$`?T?UQ,<";9J)D=85);A#]=A%#Z MQ1NU3\A-%E6,'`@V`H;11`K/ZMZ07.!707Z`0S*C)U>N)2CL3RS1W."NV\$2 MQ7'ILX76S24+QI+-&7:<(V=:`?["Z$(W=8L(@AHE*B6UFL(MM?B@$W]$<@%S ME9�&I30K#E4#JIH%JRVZ@H+61#3' MI#8PNB#)JX[8YY`*($P-D.8V>;U:D\\*OMK^/-F-X0),@>/"WUTP.B9`D"OX MO(5"$\"PTZS`X1B8^&C/<^OB<BMMVMK*5RUY\MB;M,,;PUH+2WS6*ZOLQ#"`?LUQI^[PJQOA^ M#XD8K@'<9$8"QT/1PBEKX\Z=7&8#_$[S'JFHY0H>X$RBJ,W^SG[/G!_8*T23 M\JR'"V0@\B)FS!*R@O,*C7P-8EGP5CV>F/@,SZ*844)4+Q@-4N@E`AD<-)MD M,=/<0I&KQ6*8M/+>DWVS$?;O9_O=B^&1W,IZ6X!#XDH$!.5RV'!#;(]=.XN! MZ5_^3+A6\W-[V7"V0%-2SA/WK/)Z:V2PF2H'10Y"H7([^]4T/LXKIXL9'H?A M*2:1`AI3"U&'6AB_GN6WL&:DK%P\C*YP3ZCWJC?3NZ(I MY32/L::+-6/C;0*[S,0`VP%=`I?9]JX6:IUS^4'O(L8T/!SL$H@**!1*X0C+ M.X2WYR&+V9ZQP54.-GQ<='Z=(;?P*^1U:J+`^[ M-W%4"[LUY_>^3S/8>(M1PP?J!5/U=Y+NBP^$L?;$-A$ZZDD@IJ4 M8^I]?2'$/ZAW;BHF*4=2+?FD<,ZH3[,;Z4.&7;F,#1K[#ZJ"^RK%#EO+Q=SK M/=FG8:]JSYO1VX\J`?L00C"Y-#ZA'O$:N`I]P%(Y.;&U*RF;NG[2VS]X@EIK M3-"YJ2U:OZ>+,?T#PAM#G'&"56,)P8=NXM=JSE"<1>?=P18QG[:QO]7/;C%T M'IN6Q/YH*\#(D8&8/V$\I\\:E!N/R#N4!I?I`%<\,:+RMLS5-52^EC69?J3O M!OUSQZ1@?SA%T,9+)AZ>`[5*^A=(9R&[S/&Q=" M9Q(Q]Y0D^*/\0X]:0Q\V((G\7Q]]FXI&F"G_D(_&KH7X7E)4]9+"#TD'00-- M[5[9"W.?KD@2FB+`[13WLGFI!2EI-@;="#==J*`,UR7IWI05C-0!&+82.1(Y M;KE++(CH2)+A+3QDN5XDK-!PAK\'R"7N"E+$2E&R1*V:14R08(YS)$ZP!\82 M@!#:@<@U>N-@:0I+:=@F*T4>5&JZ10%$)M'YA-$KP>U'.3G#>6DI!8U#DN3$ M!#MKE%+K1#[&:,R^+SA7\R8F+0RIY(!)`K%>/G``>:,J0R4UXP-X@],E(C59 MR:D$,47I^HSK/&#S>AZ!F[["=;MK-FL*FV&2P+/.40JD'=KSJ,!3U+-++";= M.DB)LHPY!A6.)-`E,Q\I#I$$TJ$Z]9!R=X<`-\,^HL'?'9]=G#Q_?9R].'Y.%9%" MXWESE+I"DM+KBO#P-0IH4]Z!=9)D?W@H/MS=4D"Z!@A5BA8?P_)YYCKF69)< M/0V6NG)&S&LVK81-;ZC_[:=92+O6#:&REO0\)RG>CS9\2%-.%Q.%;FH\@,;?7>TP*P,CJIUYZ##=-20FH%;A,J9 MG/'V%OH[<0O0",PP3-!3+9V$H+;_Q$Y)<1XP@1]&-<@XK6<90($79]"^J`_P MQ,"VU17L.CLY;>*QO^=DKGH?Z>/DCT)=D8IR"HSL>M^4XU!B3BWE[J00N#&/ M!?'P>LVY7;PBH*:N<(P6%+R6*0;7:/5Z_C2NG>Z2W+K.6[B-=AJ>!?[+E+1H M])\>5+H.N!K??.?.AUFN&ZBQC=&10T=B&@&^X9[VPA"36:D0VZRJ,J0O\>Z% M(PQ0R/$+RCSRA$HYE4N?9R36P3/>67#!12A:%^K>SO;3G\05ACV_Q09CF!]D M#L\JUD`J:Z42:8=H>M+9"3#NO.?MQ"FT35+!;88+(%;EB9HHU7C8QQRX<+'` M`0Z[@PGGXB'OSL\WO5LB&0HG!@B5NG&]&0[>B^<3:B>`P,0FWJW1[K!%(NTU M$-'J%NHYU5%0;+B0=X7O@6\IW2U&RE4W<36W(D<';?1U$"F`4Z'!*Z!BZ#<> M`X`5VX\[#CK([ZJ*\U+R=$59;8_TQQ^R]H_L*]$NT"15EYV"KL5$]OD(,C@I MC6K(%+\P.5G8^2A(XP$?4F&:D0F$^8D<->3S*!"R6,I3,T&_SP%3IE-NA;F\ M`QAP?V1T,QX]-3%O![[-^2"<-N2F^SS0?`)(<,"1A!_PM-J%R MJME:(62A*G!15Y:X2CF8:E^)(O'Z"BZ;9<^VOP@;)J%BC>E>%%Q6FOA>"O[# M=+RX+38_^B;V+(PU!:@PRMQH`3C_"/P0QY^B'BKIPBAY1TZ,"OH'3+GSM^>3 M+:?#_5\09^.@M[>[;39SXVEOYR`*1+0#LCUH]MXV9V/W#G9[^\_V;/CNSF[O M8)=X_6G?JH+LVI(@[ MR_5WA/XC6LX4V<[3WK.G@8P')&2PQ"%#^M-Q>XCG("GSZ+O-OT?B?'.EH:[R M@^J,E\`;8"5P6?MTIA%+E2._%FSJ][;O3H_6>(#40]**!+N&U\2`FLI"O4![ M_;@2IFI/!@%+A?9@5P`TX)ADH\]QTF>PB_",1DL:;5)=[[G,'&T-)-RJTE&E25#SAAH73=R!D9A8V]]Z1KW`Y=6\<+%U MK9@&S*EN0$E;H.",K[>\;GZ(O9;SD71M5*F_5JKR`3B23*UM[CM_@P%&M>&( MACQI1WE;&TV2G'5,BZ0;^T\XW?QD2[T%AI9("._)&4?<43^%8;PJ-_M#HE!N M<2R7NU/$J>>N!+[9`0D)^0 M\.)F:T]S?R=0$9B,L?[.;2UM/5[O]8?2#$2H/P7VBX:L/Y_2YR9V?H$# M9CE7*^`(VSZ%*VH&8H<"#-E9I>:]1VH!I#\W;Y2W*-7[N.;<-TPW*O;*W4WA M8D]8EWN*Q#^DYYE+%&0.8:8/]/+0R61\K<@< MQU7`A7@,_Z/2=(V%G2?9@8(D:T%@&LZ0]Y^F^T!=1$IZ3K5<2><:ZXRL2@ZF MU3^@4LBHNFVW^%9TC),&/PG%C#E7_Z;^3;4N5RB1!C!PF;&UZ]M49C$B,,5:@W[5YF(R@DR: M)FK!S;KZ/<[JT66RZ9M)!537M*;8W71+<(9[ MDM1N[,8(2\14F5X9"($7<23>]33$R%FL32)IJ;A,FF5`EB)ZJXZU[:48=;K?%"_*6X#_!&>+ M?OPX,5_3M5Y!!I-*-45[/?K806]3\)@9:ME`)K9R2W6(7>M4>U5J17 MAC,J)A!N7K9YQY(,R_Y(JQ"A+5*R0%F@855NT6Q2V>'(;T&"9GI?L(19,I>O M+,G`XL*FS4!Z+U!%[TL=>)YG=3D1-01;*BS!#F-2(@U#MMG"N*B\*` MW'7GD>VV-9:'T8ST=:GF:@4N^-G9R]A8:G15B.8 M;8^M:?A.?[\UO.4V;V7-=&>BK"(65F"T0X,B5\K\N1(7'"CG>#H!:WX:$`]Q M6\DP=K/6@B;O2Z=(B)K6'AVSVUL_H?9?XW3/;D$VX`NM:;4&'E64WVKG%7F' M^H4=U6R\EDJHIEL+$XO8=F2K2WK=O8;FOU5]LNYG_"YOT2LQ7HDM2ZN.HTPT M1,E8+8JL.85TMJF5AHHBG.N;454<\)XDC=C.C@34?82'TW0O`B@Q,^Y)@PJ# M5]R^%E;0\^:!H@95GO8-BX(C"+-+UK(!UW.NIH-Z8MSW$++BK6L3-"28LU.Y M/WY7-T1,+K;762@A]#MY!.=SBAMS&J`6,X*F[)1FP,*=6K=HIO^%]0G8J:># M+\S6JG_7/!RAQ5C*,J7H*_7/26'A95`RX0]OD/H[7YB$:R.WSG6(6]0DH61E MO=#(GXP3'I4J-3)$.CSJV7"3QM^'N"&@`I:.&2C4?I+O!CVK&7B=`FCNY8& MQZ==[IV9X(_6UEHYGI4*`I& MI.8H.VLM.-\T9O]J!Y3>"6E2DD33#PB$1WJ,Z1!/17IPNV?)B`9O-;K"KY"_ M8KNX//R/55,0$&)+=NQ1&QO"K,KKGXQM5$0L[D^H7:IY%5F,CY(T7,BR<'"0 MJ*2%(@CM6NYM(3P",B@^&5/Q5#4O.%3;L_J!#2A53Q_J`0D)+COJ@2_5Y00X M)\<]:L)(8E^]A!N4('I/\2<@@TL!;JB;>K__Q!ZGD*'P:+\55UC<<>\:>VL" MLY)"SO;S^J3`R%I-HOQE&D*32E@0YC`N%4:3),$Y(>#(IU1<\+D M5VA*^<%N?]<8`*=6?2XC<.`Z?.9XQCI;$(W0';6F&<4F*G@E?3P4L4D$^]NM M0BZSD34VP]I!-U"NW>A_=GM[>\\2;WS-/>!UV>LIO1$.%J,&I3*_3FL6B"V2O?J67V*6+-+``21T[:0V!R?:2[-]_ M1I^+'-CM/K=:*NZSPR5P:@K"EP;I1O^@M[/'*5HW/DDDB+R-\6L71M+2EQ,F M^FFQOEB1"EJ%8BY!\GR<#[[?/!_`6+"8"Z@VY?9K`"=IT8/5X"OJ"M./>F*G M0*Q;I&Q=T.!8XLWVM11I MS6DVFC\<537E&.=4JLZ<[N8K9Z/R>U+I!*"P'LR,$R#_ICGLB^8/Q];XCP"- M1U>MT=3A?B^_IOG2B^!"W8^*<>N.C\WF\-_I(+LNRKUO/EF;I;$,=M;`"O(; M!]M.HO`5-_JZ8W6G5EK6D<-PXDLJ3F+R8!VQ+FW!!$8.C;K;U*L=U(J%BT&\ M<4\KM46TTDV5/G;>2WMLASB'BUK&V7I!_:N MH_%5T>8G[;W)!B?.4M>R;)11**=P)`?M2+2+;)O#0Q.(]W&BEL0/!>_<=,AP MNG1FN-LZ-1W_I`QC5W:;4?\KHR"4ILM+8KE'<]^7=TDVUZZ5,=\;[""T.FP" M(+@J'MR0;JJI>!HDK`6<%*8\.?;LKC?4IC&))NFQ2*"4EAWQK,*J1NS$4FO9 MK!NDUA>XR&?&T#)QK*([A36]0I^X,AF1CWE]42IN<[Q2L<-B/%8C//F)!-=K MP=*)41S%4#:1PXW.OW,-9JPE&:LA:A6"6]Z,K_]P;^^[JM_T=*W:U0-W_3Y4 MNWK@]8=J5_NQ=O59L%^`+2\IEKCI*-R(FD+J_Z]=C8GFD]K5CO5K!&<-+'F& MMN,Z=.>X/M^&8;;NRF\7S-3?55<#^MFPZXD@[XE6/L52RJC(9T5[X.JX4U.5 M!*]I;YP[9I-$/]A92YUP)$@5J2.VEIB-17;X MZNS87X"LSQ_PV0-7WCX[_MWQV_?'31OVFM*'+M2)3>>K;M+J&OR0`J##XB>! M-M.79=Y-,C[Y,M4]\@?&E4_3/@O*!0.[RU81U2>4_RG_I.OW^6#/]J.OOOF:]B',)'QRRQ=Z^OIE]I*3S^#?OC*)K4/^ORBO$/J?O4(^2V+V8?BT3<<.,55,VG%Y%7= MR7&'NO3,[2SH3*LTRU3[0Z"TO)0DQ%A^H>-8!,HNTK'S`;$YRS3QRWSG[>:> MG:0!U=R19OP=3I;H.`U1_-AB;6M\,0^!V:TGV!U95JN)NL9UZ+8DS3B?3C'# M^,I<-27\<\S9SB3A#G'R96YG=,VA"FFC].@J]+!ST.EOU;2EVT=XD0"2?[)- M7T;6I4$6='&8.G%BP`1GB/@^SJB\I7ZAOA>NEK>RI?QRFJSXZH"'GIN@#E^\ M.?[J8OK);4?5LXBRC)8:'$^I3=YL'04LN1U05YRH@%9\\K?">`:&!*=7G%KB MM`$,Z:Y$.2V_:S_E-W\PV,S#65+AKS6X@SP&P*+_7I#N%A8Y<.VV<< M&:TG,@#4+R$(77SAG/S6A1T/!6*[MHX:A1U`(2TIT0S=/_[+-"$"8\,!(?QS M8P_X#NAI)NG3E?^*YR7==;7!!(^RB(KE55O.) M8Y$`3&4GS"($`12*7.8PK`G4[@!$V.%26H0W8MS=N8881V1/NC_)$-!/XTC8 M._!-KQK3(I!^;!,IT+0+HUU=W<+-&J0#QGA4)T&2>'AC9Z>G'J`V&4-POB8E MO\40V4GG[?ZSEJ=CC7H$0F].<7C<-:.G?'6K?>X/,^/N"9.W)RG!+W!"><9U M"3+N1]-2S3#G\N7\5Q-.7;"XR@UZ\5=._)#+Q%&G]?8(;YN/Y/QV]\T\_A?T MBR-2U7;HJIMOJ$)*P8"/R8(\183`R9##I>VBFGBZ,O9D/TBWE8:/4D1GBZC6;8Z^WT M=[T'C>M?NUI$`+K=1="\+*T#G4XY6Q<:1H+RE&U8YX3=W526$9&>M"W'3J7E M$TM1Q.I]A0.WBI+UL@JZ28J^XX5=)Z,V2*J_H="M2\P)JN3Q>GJ:!N!YXW>R M7R;VS5-$RRA@"%?M,NS&\G)"7L0F*^[[\YP^6,%_KIU^LPJ>FOHL@-+ZD73_ M8!_X`EB`EL]_6(-@#32I)IC*E1]17WAW.MI.&M;I=!R\:RLH8H-'=W;KCR3$ MY"'+Z6H8QIM55#ARBGIJGAO?Q-1Q(%7C)]P:POE'W:(64!P9AEB`+B/F%%RI M7`[2N#'8,7,1O)@RE9<8!X[OT,H>GYR_HSF1CXAPH2FE+:Y0""U^?DCH\:MB M(-M)^/ERJI-A;G?A-\E`_#2?<^7"(VTTX$(FR9G-%$46DOL3N<:;<+N"5FS" M-@+\M+_]XP]5#%S;>#V=Z.\9$BOA"BR6H=]J;@O&GM3CJ'KAC_TGY\]-$O6 MCX#-OWEU>'C*&3)*DJ95I33JU/6U:N_2.\_0I90="PVP6V*GJGV/4!"7V-Q( M+M8W#TDQL4OQ:P%)NAC`7G/:6'?%SCCXIMJJ5YE=ES<&VXT4(3C`K7@9)VFL--1)*AQL[&1WNW'>K2,AHW1&R8VT2?%X5(\6XI7/[_"/Y^PQ, M'@Y$=%B?KBJ[ M2SCXTF2??-D\CD!JE=1VDTB35.VV+@B]5#_$H-9PX)$:Y_#E^0_TLV"MWMJ- MG8I(YOFGJ.UB1CU$+[!&Y.:.SU`Q)[VP[F94ES@@,88JJ#PSX^PX;6Q)=@PM M-"FZBG>-!G?5-4"T/,5#T'!KUZYYU6NJTFQ7RGY<$JL[.<36]TGHWN7%2O4Y MH:H="TV=;X"$O^Q>`OCP3O;8Y@X2%DN^]C6H5K$W?$FIF:@[)`#D*'?SYW-+ M0S9_/0MW.34?'(8[D)H/WLM?:_YX_,F=@6S^?D3R2G=[PZC-1R<\0:^,!LT' M[RS/TOSU5*W7S1]?=]1T?R<+VASX+CEK!+5"73M^<[(Y?I>[INQN@N:#5X[^ MS9_#_ENU8LK/=NLPTNF%O?TAZP9PC2BLN=3NUD$W:!X&U^'?"H^;T^QL[71/ M\VX2(FM_H\:N\Q^K%$9'B26(!;K5.172R2&LE##:;0^WYJZ:5"F/U3&/=/#" MWT^PKX,UZ>$:+YI+O2((V^K_<%HW^$)2V!DGP6>D/T.J1(>,W%4=R5D)=`?A MCVM>][;`ZN)#?R`JNN&F/8,=D/9UFAK+I+/KZ1T75F4T/#7C$N&G`Q>=.$V- MUT/(JGM.2Y"#YO$4TRXPW.S$N#&Y0],$&0HXC5@2]"3&-80IJS$#VE&17@V M?Y:G"(()O]4U_BZR\1',S\Z!7:"W[Z?Y^3NY#>RQP?ICCE4C1YV=,;5X%Q]E]9T::M`59*H2* M`;WW[>)H'^!`=EVPP9P^3UI_*3"M4A=Q?FPR$5-2?I=DXOS)'?(^LO]H30VL MA$E1!;68&;U&RL8NLG;&(QDK"-G=,GL4O@FC,;,E@M+8^ONMS`U` M_+"*_MD@YES`]KYEH#=V=WI/N7*X`?.A^?T-$Q+2?S"]I=7CI20;N^;^"QN+ M29(SP!-HI`"2,FU*`=_*)X%&>D,U*9G)UTF#H:JN5+U]"!TG"3ZU^KC4`T,XR#\MWT/&B5P<*HMLG_B=S#C](.JZ\_"Z8,`` MMC*+KS0(!&]C6A4C&+&^?LT9MO?-?Z+:STIZNRN^ M4W9=6OFA(8WBCTJE:]5_UB[TB->K_IUPK@D39?>L!%/(D4PM_N]52NZB+7B.U5C;Q>D<]P17)H)OI#.%F>Z:ZJK M:>KH]-:V'F'K-4,IN;:'L8)UTF:,NVX3=A M\-D563B.J^%8S77A8@36@C(/<2S^U2%.>3@<5$L*$W*+G*7R%!5=DT<@HT46*+8_4,*;S;[`B,=W;,B,)-3W:X$OU M+4^#NR6VI'=4>:KI%=\`4?]DDJ2$"Y.O!="HW"R,@YWFI1<*E!*B6&)N9^]) M%>N)D6M$%VFY_\?J,RI)1>(9E:@7I#NDD?ZB8@/MQU_+'DKVS"X>@"J(K+Y< M*$/JDPZ&$)=X"OQ4W<]&?;:>D;5\:BA7N"^IQ"LZN,MAQ($7JUNRHO#IOHQ% MQRI+DG;UCGWCOZ,B M8ULI@ZA\`GI`B"NOIPSKV=0K!%2SZ$[-IE<4RHVZDEX-(N_5K%VW;_ M9B,A_[?E;2?-8+GN>E=XW,KV*]49L.`Y.+T_K\V[>L]2&^S0V#8R:G#+M6SV M6RI5CDU?QH\94>N++369>91KE]8THRXC>K4^1+H=)DEVJ`.C4EAN$`7*'1!)H,V MHO?H-,YG"_*3`R)%-$HER,FG;?[>@DP!K",]V!1D6$5$JCAPI23#%!T<80D] MV6)QFD-NBY_1-E/YF<"1:H(8O7?;#36G5")?$=1]E&G76F6ZU,7*=^BH M\->M^`\B+P$[D;6.E2\D_+7S^S#_0W[7SL$S\VZCNMY]5F'X[ZVNM[>>[;7] MKJ>-LL/GJ>NFXX5$68.T_VP6Z8Z*ZZ+OA<=?J0R[[]?G?&IQ0?"UO9/]``.W M0P`G*'XA,:XUWKE8UYI&73,>\^H"%HD*RBXT7#0V$4X[.->%786F>?<#YS?E M"!Q271C[@CL_K:[VHRT3U(2E?V*Q_RW)4QWD,[D,GZA9=ZB$(!WT^Z+"WC:$X_+S:R3/WI02F^">I MG6QO[2_)SKCC*]\=GIT=OKUH'B]!?#L= M_="1FF?A2,TRF,Z5;C5?\8A:%%>H6CI*/YHG0P)L;@?&7(.T'$=T=_*]<=0L MZ3Z=VD66IHOK&YLK'@6!:%QZ2ALQ85:K^3HT6)M/,B6;9T?S5/AVJ;]T%EJX ME6^U,FGTK"IS)&9_ M&`^/I?4,%^16[]H1,W9/&55G1+6MZH9\+W^@O'6[?/@@F5T<2#];[7+=VBSI M07)?8#'X0&Q\RJ.<.8]G[[_Y%K=/&^1ZYPZ:4 MA*KTXPO^FPCZ&:PJ5O*][KK?6,;(_ZD!771IH-ZF)KV;=NFO]8$)JT']W_9U M*X2_MG^/0L+/GD/RW^9S5X%OX;D&>VUE+SZC`!!Q M*Q&+^,;,E=<,_C6+OG5RV;ZL\UE0XZ`84ST`]>=]6^@SH'[J/@#4UK'+CR!$ M50[!&CT&SGMX;_[ MG1Z?9>>_/CQKW3IRG-M]%&5V2N'E7!6+%5_E[!K\D+T_X-:1E1`\SSFCP&7B M2J,"@UE0%9PPF'=VIPC1CX261@]^]=P=NDIB[V5765]O+1.#6@M9TA;I6M-@ M^!%7AV$R?W:XY(FI'.KNYZN'X$<>HK\$6_0/`+7JP_.?Q3A0]%2'A>R MIH$0ZV(_4LLPEZ(C!F)<9N"%WU#6@6)7?W)H=_=%5=\@,-K`I%03$EZW?8'S MAB:S)(3?M_:K.TATYV7[ELOS]`L$33US[@HKSY&LZE.UIY'\]NZ2=U9>8-9\ MQVQ(]#2;3RO_-%X;[X_>X?<;+Y4+59-5A@OWDJD3J9*;5OD'`WBKJ\&%270/ MG[!W*:":\UPU2$30#*]Z*92>4F^MM-@R^O;4[-U'">#KMXJSR"88S=VB#[AS M5:%XPW^/[!_EX%605)\4"TZ/1[%+I7FO`JVJP]/)!U`_[ZN5+EM7W79AW[\J MS<_PT:%2>%8*9T7\_*I`)U)B0;P"^CC!8;X9\;E>]8-%WO$%MX.M@X,O@HE) M>XPKMJE/Y]Q);V,:%PE4+-JZZXE8[/._/E;[EIG7!\9[=NW/\C6HP"2'\Q[D M&.O#^;D^!/;R\.0L^]WAZ_?'V9OCPW.^&?Z&3X>WTA0OE4FWEO0\0U8<**T%.O+\#(\H1[LE5TCF>S8;&J"."Z^CROZ(B&ZVJJ2H2T M<\S4EF#G*$83G)^V:O[+G_^CJ0I?4S"C6L9AKK_\^7]0'D6M#&LM6I;9UD=O M<"9<(Y2[?LI=V#3(QV$?["C9QB^[%YI_G-I")P:@;X]`FB8D]`(@#G@G8U8\ MXK-UN':NFQ,%S4(J@Y'AF^LO[K>??9"+84WK2Y:U.WFUP_>3Z@6F$9K"Y6EL MW'68A)861YODZ$-(\`@J?[M5RWX:/3%H^LXD>U#1+IG![RIB.-PNBIUQP2.4 M;;D/K_TMZLNY0^4%=2_(BBDT<]YN.QXQX&(W$K=&!U>&#;DCUM9QN\*Z.[?` M[JKF3FH2VDV$A]GM4FH;LM,<8CSWXP_]);\O&]]:Z@7.!!=8BC,#Y[6N>%Z9 M&Z.0(M-925G0WL..F155Q":YP"IZO=ZZA(H?:_A6-\-6:6G.L8^J*+Z>.X/PF`>G(L?[5B$<]9"JJCNNQS[:#Z^$M`^36)*;$-5E MLL8^#6[&D:634JY_<[W:L:5E^[JQB__N[.PD7JJXTYL,3;AI]LY_,9C, MEB_G5=R8NOKN?9W6^$?<5I-SUCK#_B@6NOU5/K#=^'8XD9B\POP6W^/OG_ZXIFY@6+1I/YBM!@:EQ;XX!^C#G,PFJD M3+K26TJK_$PW'@^L-!OT,:EV?1UCC,@:DGE,B#.7KHK?^^R_+'ID`[;U1^STQ>2$8T(>63D8H@ZC:C)>X+KGBJV99W/R5OMS`(9Y$"+&FVC`, MUYE0EVQ#ME<,6)]TF1!'O3!ACKYX1!'$IQQF4X@1./CR.+'$$$+UXCR%._"N M]PM$OAP_5_/!+J1R2L#?R"@LL%.8P19X8IR!L"3&7(0X1&K*TF_MG,*1_OU/ MMW%V-1:4\S__^)<:%R-,^5,UY]DA(A2H77?%A=F)&Q..FS;7FIR><6^/_S0! M8V+P7C?N7FLKSG6[:654[9^-K$JG7?O]3O"$CS8UG)<)RO:+Z[O[AJ]'>SI\MRZ[4$]@;'8&7N?V7;A_O MGCX?+[N-T7AG+`\/#K?'F*?Z?-G)!X?;FZ]'X_'.RYU->]LM'9"_#8Q\^KCD MI.*4TT,SLI)OC!:U4M[^ZM[Z_P]8JH=2;)1+#R%,_"[?^@(K.!CVFP56W-*1 M+%(];C;1(X5ZXV/C^%PSS(\_"++_BG"@:UGWM_JU&YC`$>1<@PK)KG*QBAV\ M):!-,!KL'H[O;Z72;GYHY4UN;AV%VBC5CGCGQ(W%->GC^D5C#ADI21"MR,:^ M.1*A:X$UQ;29O:7=2+AO&H8;8:`2,J+#G'K-+D`GW1?$3EJPZFZS5[8U*,%G&7G^]AA2 M9P?,Q7Q0RVX_^ID.HN>K_%IA!ZW2L7-Q<7NI?M[CZPE784^`#!M=OMK?V7LE MG'%S^W#/+9437S\V.,:`2T-7!%$>/6X/UQB2DQO8YE1]H?GW)8FYF7&0RK&O9!=,H? MA#MX>A)\UO8',1JR/Y]_;5;>KJI';%JVS;/W)VN#/0*!HHQ0H1G&L MT'P<`2L^@^?J[\N&,QZ$&81I+65KHMGM^F;:W:%\O3-T$DKSL:0CK557]JO[ M9M\*G,U9\TE`)"SU9IGX.@)466;9.'G2^WW:2ME)S;7$'=2>S8E,W6/I>YKD MO6QS4Y0=Z="_'@^.\EJ(B0HAY3<^8+M\'$]<:LTB!-*46S-36[R+,8.3^<4\ M"2ATP'^O;D'>WTG40K+CBL!/#!C=5^[^=_*$)CT^#W7H`WW+V?E3X\^:NB-> M4])'DSKW;9:H81BUV=R5$6'3BB^G$V(@UPD``5DV09ZYKO/1O5A])/]&U8_) MA_P_+7"(X!&$9FAZU>\4N2-W7EZ\M&@1B++YN,.K"AX:VSV%ON33EVYM$/-&N-=7+L] M1%OQV^[AS[_H\/_JN]'I)U7A.US]1ZW'62Y!OE!0$WN%/5<_.^J(@B3/WA`FCKR7/-WEA\788%1@%SYDJ7P7;8E;XLH[YICU M?/:2UQ0>MS2$YX-B@AN.0!7^7F4YW)`9I'Q^IX&YH).U!MB3&&7S`]8>)<2: M"D=@-RV%Y*`;MA85^JV)Y(A''%3;6'T19)]3QH2="P]2TO&'N5R4J@$C##WK MVD3YP2%&T0FT6;XG/?F8JO*3H@\(M+^)\KNL"_ADV8HR:L%^KAB+QE3IP44` MI_`BG?]\HT)2AR+0OM"/.^P1P&+1"`PC*1)R405,(B$3AC^G`9CK5,[G.,0I MGF1ZW77<\*G:D9*)1@)7814$V)*]7Y5D`?E/P^`PZ06/LKHVFHRQ(W9`S]6' M0X]\>W-V??Y51$-15]<':'[@AI7)J*6SQRJ7?I90WS&^+>")/W+;_Y)10`8D MQ93%<->`^NX)5R&19DMG?/.'1WJ?AES]!-M(R`G+(H(G#E='R!8AV;G>0QL" MS3&!)VN/-+Q:)G)1R:1BK[.]D6%$;7>`YL)F$DAN`%9)7!Y(BK\KV,7#C^K@ M3_$QY7=5PT*`<7.-9$TV%I,H&RI^CH<](]_RD^Z!&.@K/P-E(\D^SL_P2_8& MZ33P,A2U3?6A4S'NLX'X#Y=3L'S9QJMC_`5+KPFH?RQ'9"M%PB3YAMC""\QQ M%0?2E[(%S[D'ZP37!DK9"K>DL2W6Q;98?5K^*#OO2\G.-AQ;6V=*5-GTG$5. MZPFT1,]K]$#)+RKP;.3WF:DSD1M[BDB50]E/Z+QFF5C]55=-38ZT?,:[D!,> M#57"#H7KW%94NV,5$M%;I'"B>E;[C1Y?-+%')X,)0P^(*NU`E"K]@_];,<9: M%(-C%-\@MEL;(89$*%'"P0JE`AT>?YE0*.""40'$K9O-GXLHAEA2R($6%FUJ M,'..&]J,ESE_594`XR%K*IZF9WL,U7#=0J78F)#DDUL=$A2I<'ZYAITF[&K% M,F`_-SIJJNF\&[H+UDBE[G7>#BW["U@BDW$K2?FA^;K)!`T`@<76S#,C/TH_ M2#$+R@7X>2)7MSD^OC1-1+V"5MKI>N9ZSFK.+RT:R24A]`"`8'[7*!I30>TK M['%6:W&P5'A^J`:E.`@I][(->JBV.RLYO(GMB8,9G$R6LPV][^B2Z8F&$`H! M.:G:TSE#);VL6[(`R>EH;E6W]E31C.:+]IY[WOM6-=&A866S+GOS!7/<6A@5 MX*5@+.5[L702!GM($JVW`SJ3QA]]H0LJ\$!W%?.#E./-68(!=I\NM1QJOB3%P@[T63%BSW^@I#[_7=[)/=== M-]L=D:SB/E.=04(S'&*RB[-0+H M@%A5VOTIE1KZ?PVA3>J+G7J`P0;6_EVU]LON2"+0RJT2VUI3;(ZX_WW"7A)] MV`BX$>>UF,-E$_?_,DI<,+Q/J,'-KM5#(B$5#$_9#)B53J=+7E(X'E_*#2HM MA!G1`N"]/%*H'/__;!2>FTB(9`:/E,.Q8ICN:5!\&^KX<_][^?DFT=%B'RN7 MMP4M7]$-=G/2J'^OH[!(,*GU:(0';KL2,I#J`/HMP(4%A[Q M7L"RRBO4%`KS6P%V=I(#J5=\'NUO_LF%=(!W1`Q#@$[']'<]MK]"+%-->5-! M5#K1,HYSV?D8#4&E[O9A4+L-T;KKMP9>W;W7`6AJ:/*5PAE&/Q]X>%_HJNPE M6^QOP10-6EL!%4A@965D8]SPLN!7%DGA%_RN*R5H9M M>*'?(R?:SV!T&A)"O-@Q:,??8$;U>]!PM<]VN[TG4JV4$&$^@4HU["&*M:XT M,^Y1ME#&>(<`G/*]!PKL)O:R-UQ2(_32NK9PI##?UN])7\ZTZB9HUI@[.('% M7;<WRS MWORF2O(0)>/,=2S32C3[J&+AHOXDO[1HJOK*1T9@J*4(@QA?T<\2`L&E`X9. MWWO`S)YI<9QIY$D-C"ME?-C&U7L3E\+]/;]*-D^X_V&(E/5V45`81L'U6I*E M^&0PRZ37<#'BJW=T]GSSN^GTYH?_`@``__\#`%!+`P04``8`"````"$`TG6QE+BY:H%<4E$39O/"A4E1BWZ'?O3/+UZPDDDMJJ770$RZ6 M*.W,;YX[.UR2U]\_^9[VV8FV;AC,],'KOJXYP3)KWM\M'Q[>WK<.,$ M\,TZC'P[AH_10V^[B1Q[M<5!OMXA""-[X0'4IX%I+S/:[,,!>=]=1N$V7,>O@5PO7*_= MI7.(W!D@/"6H1=&6@Q6 M!OG8D<#VG>07<]MS%Y&+/UO;ONL])X<-/,`<(_V=[X*9\&`OX7!>/@M$D\DT M01B<3$,\0F7R020;#U;+9/]\1":.UZB>URGZXW@Q*:KEDL;KT"\.='@*K]Q6 MA$_TL)CIE@4Y9-#OHUJIP3IB-IWW@=_9F%V.SB;9T!I:8ZF2<;YX:#=D.+1D MJK*&H?5F_/9LZI3/K$RZ-`V?*P(PX.1JT870K8COL86O<_C)F2>T;BS&J')) MGX5>D1OO7=_9:A^<+]J/H6\'J%@ZJ;%?T7?,(G=>@CZ? MG`ZCI94!=C1(")_C/MN`!3/U%GS`];R\KAV.L/*#(S?74&+'3A18\$%+W]\_ M;Z#N"V`U@,[32WY7\^N'R'X>&*SZ$1NP#3UWA2@>YJS:3!4ZO[RSYG>,+T$F MBJ*$J&7-QQT0O;N=SN4CG4^GLHD:%KPD$WTSPI=DHA;\-Y>FTS1V3%D@[08KY\G!!:,T-1TB&`&"Z7`RO30` M2-^<,%9G13`$`./1:#(:3`T3_F<33/<(9.MTI*NV*D&@R*H$@2*KL@5*3T+F M3R,%>C6*8Y4@4&15@D"15<>2,_!8N54)`D56)0@4696UU23&*O1`%<\L(BW6$.G"2^V M:H1UZB*,5G"R*CL#,\"5:G+LYMISUC&L2"/WX1'_QN$&_EV$<0RG=FZN5Z[] M$`:V!V][V8CL;\5(./D%Y[EF>OSH+C\!,ZZWDN@F8=$5ASSKF;B:,,=F?VR. MC,MDP2:)M>^LW)U_*%W.^ZA?@AI1M_6"$QT&.9/4'8K^7@^MD)I/<`0S-;.T MX`#PBP94WZ M_:2M*,JGFB`!?L1CCH,@8P[U63ODB$9KQS25%?++06S<&OABU?$126M&',I9 M,^"(E#4C1&7D_2:S+D<\;UU@>CZ"9$_?W,_;P0!&R<`,SUX23/,3-G"3$Q[" MZ>ZXN+7DB=1`X<3I:D]?LH6I)7^*,,(&(4R$QU0Y2UH70)FQ=#SO(T[\_UCG MM0:T[VZNG]9D6P;LE<%]"[CK`]]"CSQ]F]05R0>P9=D@HW209F\VWO.'G;]P M(HMMH&$LV%'LQ1>?;EE!5'Q^X[D/@>^P!J2>D/DA"F-G&;,-/NS<01F>80F> M04I(!,\I_&$7RE$E@IZ$]7$*?VAP'>4/>E'*'YQ+F+],?\"M3*E3@PFH4U?A MD8D`VA@9`C"""@2X]2K5`;BG"@2P/,P0@(,6"`!.A5><$@<#DLW`!PJ6P+\K MEI!C,BDYEAU*699^@7^%E!:7?D]2,\FWX.B%FN%#!8"36):E6%4IAI@=(JU0 M`7RH4($%LZZ<*0\:"+G?@0X*`,H40I(N!PC20)5&Y'DER;G`4U0CMQ+K$.(4 MF(I40P`X2B`00PP4S;\#BD'1#$R]0=$43"%P<#/&&=5`(*C*D,0;#%4IDF)0E2,+4QBJ4B2!H"I#4DNH2I$4@ZH<24RA M*D42"*`1)1F26D)5BJ085.7(PA1#52F20%"5(8DEAAVGR!YMFR9-5-(_'0]; M]4^UIW5M(W50MF@"NV?#D]53LG($6["U%%E*X\5N=M8[U1[#R/T%%IEXT=L2 MFJE.I.-%DK&[I$>^1/;FWGF"I6AR?NMI7=[K!219?V/?&7F$I9@*_M#WUK4F MS*7KYP0LIRNB5G+LJ]3VY?<<@^]MUSI(+0;66%`-`G6=8I#N`I)"!"-7M9I@ MDE2.@?5<52N"^@O,VF()RP+4F`%;I-3:*#H7H)]WV]A=/S?,JN@WZ;D!`,K5 M>GQ.;Z&B5HAP*?C"$(%?O"Q$PBKJ9"+NTF5PC\@+\N`$3E$I9'54HZ`OTQ?< MB6!O`N=C+&N]-4I+$A78"3ZVI:>]A8?[[8FJ)&6Q$PIG5-]YT,ESQZ[QGFKL M_3[0RS+V6=!)-';'>$\TMO3J0V(F!&Q5KEV&D2MYK8V M"`&'6.U6:L1&8!)3`%]\E*J#^G0[1%WJJ(V+#&0#:N(Q>,KG M_\@^+9*R;.M0!Y:2E+L$*#JIDG8AC?B:`N]XPY!/!"V*:%'0F)NSUAY)4\.. M"Y5#']3P1@9)!PBV.O<.>N!EVJT&^D*U>_855)UVA=P`>XM5-1COIJW*BT._ M:.\,AW";>T,K(4Z-/:6-HNK%[B^ MH:4F/ULT2K:M5"AH8H!UM#*N@?N5I"Y^OJ@Y"_(2:XQS"R`G=97[_<$J%]IKQ1>HJRR@#6K=).F*@*N&WF_E)7ZP2Q]"3)><$`+12LE2EMHV9VJ0,A+-BQ,`$K3Z=T8V)XIL"16:)TLQ"HSDS6XOH^*J0L[W0 ML/N9W$N"OY-$OE=:PYMSP\-$^K_7+K0W2U107M;AZ97%SO7@SG`^]B5L M50O]V^1@NO.XBE8^X:/_45H0E$UI`84DC@V\MH'@@O3:E%:>$X8@+:$%M]EH M3`NN-TEPP9VK.5JPN[0I+AB2TN)U/Q+4O7G,CNP:+:(O$%D$%Z55V!$K:$(+ M1&Y*J[`C&([2`I&;TBKL"`@)+1.8-*55V!&L0&F!NS6EE=O1!,,16B-!W5\> MM2/OJWA!A0@N2JNP(^^K0T%?I;0*._*^BB(WQ578$:@2?9GP15-:A1WY/&$* MY@DJ8V%'7OXPU!CT^H%+:#=T1'>*I01$<)E<)JO)D6.P\> M!Q;BP\38!4-8)Q.!L)'9@QV'TK.%% M0CDYWN@C07)_"L-<1SP%`SZ*`/HS/'H-GNJF@5[229Q3$-:"3!_W<5$C3B*$,%NC@B1>S>&FTAF08WPX(;NW7+X>`$6MG+6]\^+[_,N97KS_ M"[L]*SA3^JL?W,]AS$C,].+]>[SO+40QG'B'=/-^"_=2A;_:+G)G^J]WM^/I MVSO+N)CT;R<7YM`974Q'MV\O1N;\]NU;:]HW^O/_@LKP28Y7\"C`$YZ4R)[H M"!="#LRKK0?/4XQ285/P'XMC,YU\2."SFUT";-A)D@G1V^9/FKSY'P```/__ M`P!02P,$%``&``@````A`/MBI6V4!@``IQL``!,```!X;"]T:&5M92]T:&5M M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*V+&;K4T;Q&Z''FF9EEA3HD#2 M27T;VN.``<.Z89 MUC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5_+S*UM4*WDP7,;5B;6%=W_S2 M=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU>[66 M\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0VJ']?DH]ATPXVRV%;P!\HYK" M%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG9()]B.(NCD:"8LT`;Q)__/QY.1`R:"'1BR^?_/;L MR8NO/OW]N\*1R5D1SBB!4-?A.KL$S(P5SX15Q/*O!T0!A' MO3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC>1-S7D3N\&DWQ%%2AAW0."QB M/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG%X([-'!$6@2(GIF)$E]>)]R) MW\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>];=C$RI)G]T2Q7H7[#Y;H'3R+ M]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM&Q+;:YO..UK9>$\H8P,U9^2F M-+VWA`UHW(=!O-29#`P<7""P68,$5Q]1%0Y"G$#?7O,TD4"F MI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/C^WPNA[.CALY&2-58,ZT&:-U M3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9F]B(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP$E`[F8XL+B8GB]%1VVLUUAH> M\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/99/G"FZU,,3<):G#[8>V^I+!3 M!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2CLTFQO@'!\*])`79T74LF$^*K MHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!GS&5<.-A*H)^@>LY;6TSY1;G M-.F*EV(&9\F_W4`BA;JI)6@8,[F3\N>]I!HT"W>04\\VI9/G>:W/@G^Y\ M;#*#4FX=-@U-9O]2!=(.SB"QLD.VF#2I*QIT]9)6RW;K"^XT\WYGC"VENPL_CZGL?/F MS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<8[Z4%3]F\=%]XYO M?)G?OK2-]\RDXJ++2>2'Q&-=(4K>K7+R^]?CS81X2M.NI(WH6$Y>F2*WBX\? MYALAGU3-F/:`H5,YJ;7N9T&@BIJU5/FB9QW\4@G94@V7H*EZP!U&L6]9I))&LH1KJ5S7OU8ZM+2ZA:ZE\6O!M,` MF!;SDH,#$[LG6963NVAV'\4D6,QM0'\XVZB#[YZJQ>:SY.4WWC%(&_;)[,!2 MB"<#_5J:6[`X.%G]:'?@A_1*5M%UHW^*S1?&5[6&[4[!D3$V*U\?F"H@4:#Q MX]0P%:*!`N#=:[EI#4B$OMC/#2]UG9/1V$^SL59:M'\1 M%&VID"3>DL#GEB1*_21.L\D%+`%69`T^4$T7FAZ,9L"\'29RB`"J<25!&8:HV'6GAVH=]D9/-VD&/#5QU>,+-. MLLXRQ[PUBB`\5\Z+X^#"<[UE!NX'F%<] M7;'O5*YXI[R&5;`T]#-XUB5./+S0HK=38RDT3"K[M89_)@S.WM`'<"6$WEV8 MF>K^ZRS^`0``__\#`%!+`P04``8`"````"$`RF1>DZX"``#0!P``&0```'AL M+W=OP8$ZP"1K;3M/]^USAM<=>F^7U4U.C1ZZTD&V. MHR#$B+=,%J+=Y?CWK[NK&4;:T+:@M6QYCI^YQM>KSY^6!ZD>=,6Y0<#0ZAQ7 MQG0+0C2K>$-U(#O>PDHI54,-#-6.Z$YQ6O2;FIK$89B1AHH6.X:%.H=#EJ5@ M_%:R?<-;XT@4KZD!_;H2G7YA:]@Y=`U5#_ONBLFF`XJMJ(5Y[DDQ:MCB?M=* M1;#$7TCF)):EB8`.N*$CG.>DSD!IM6R$)"!M1TI7N;X)EIL M9IBLEKT_?P0_Z,$WTI4\?%&B^"9:#F9#F6P!ME(^6.A]8:=@,QGMONL+\$.A M@I=T7YN?\O"5BUUEH-HI)&3S6A3/MUPS,!1H@CBU3$S6(`">J!&V,\`0^M2_ M#Z(P58XG69!.PTD$<+3EVMP)2XD1VVLCF[\.%!VI'$E\)('WD22*@R1.I[-+ M6"9'%GB_L9PIA;BT>I=NJ:&KI9('!)T'PG5';1]'"R"V]DS`Y-/V@"]VSXW= MU&\%M(:2/JZ2+%V21Z@#.V+68TSL(S8G$&\0`OI>18)O0Y$?B[/@',/S55R< MS?W0:X>9]=(G83J;^NN;X7HTCY.WY#Q=8-CYNBS8UY5DF1]W[3!)WSS6ZTP`T<&$YXC]L\U.-(?GQ8+ M]B./'7$8=UK>]\;I-:?'7PMD,@RG45+DKV0V,[/IK M92L-7*7]9P5_3@XG(0P`7$II7@;VTG_]%Z_^`0``__\#`%!+`P04``8`"``` M`"$`+ABA)X<"``!5!@``&0```'AL+W=O"<8QJC`6D:?_]+I`/.^FF M+`_&F',/YYY[(?/;5]$$+TQI+ML"Q6&$`M926?)V4Z"?/QY&4Q1H0]J2-+)E M!7IC&MTN/GZ8[Z1ZUC5C)@"&5A>H-J:;8:QIS031H>Q8"RN55((8F*H-UIUB MI'1!HL%)%$VP(+Q%GF&FKN&05<4INY=T*UAK/(EB#3&@7]>\TPZEKO/BI=/O&5@-I3) M%F`MY;.%/I;V$P3CB^@'5X!O*BA91;:-^2YW7QC?U`:J/8:$;%ZS\NV>:0J& M`DV8.!E4-B``GH'@MC/`$/+JQATO35V@=!*.;Z(T!GBP9MH\<$N)`KK51HK? M'A1;44>29$\"XYXD3L(L&=],_X&*Y4@KV:3F7[HDAB[F2NP`Z#X3K MCM@^CF=`;.U)P>3W[8&4;,R=#7*A@-90TI=%-DGG^`7J0/>8Y24F&2)6[R!. M$`SZCB+!M[[(?XNSX`+!\R@N3?+AUDN/F>ZEC_/)<'W57X^.:P--8-;UFBSX M3%-TRM69NO28S#6.=7G5^S#8.1ON?%W);-!003;)CIEY!1XS/KER[MO*(YS& M@20X"GTSK*3LKX?LT$4V:"@IC*N#AE6@,@IO($+Y>\%/C.Q<;Z^E@?/L7FNXOAF4)`H!7$EI M#A-[\QS_$!9_````__\#`%!+`P04``8`"````"$`#C2=?)P#``!W"P``&``` M`'AL+W=OZWGRH,=.R,9N@;$LQ'U>\J5U';#R]UY3TS MJ;AH4I\$D>^Q)A<%;XZI__7+X^S.]Y2F34$KT;#4?V7*_[#[\X_M1<@G=6), M>V"A4:E_TKK=A*'*3ZRF*A`M:^!)*61--=S*8ZA:R6C1O51781Q%R["FO/&- MA8V<8D.4)<_9@\C/-6NT,2)9137H5R?>JL%:G4\Q5U/Y=&YGN:A;,''@%=>O MG5'?J_/-QV,C)#U4L.\7,J?Y8+N[N3%?\UP*)4H=@+G0"+W=\SI[;1>@;YQ=U-5_3YW$Y2_)BW]XPR#:D"=-#Y]9Q7+- M"LB<[V%&#D(\X:L?82D")ZH#T(GZ?W!S'Z.7<'1S_7]P^=BE[3_I%:RDYTI_ M$I>_&3^>-'A:0!@P&IOB]8&I'-(`OH)X@59S48$)N'HUQ_,$8:0O1ATO]"GU MDV6P6$4)`=P[,*4?.9KTO?RLM*B_&XCTIHR1N#<"OQ?S/%X&9!XMWV$CZ6W` M;V^#Q,&*1.MD]5LAH=E4%Z\'JNEN*\7%@],*LE5+\>R3#1C^>5`@&LC>(YSZ M*TA;ZBO(S/,NVH;/$/N\)_:&@.M($)O(!@+3!QI&(1"9Z4(01B&8+52V-PO7 M?F/'[RV1C(0E!*(P70C"<""N]CL?K1IEANB*HEO(KA8LO_/W^$4X]6%/8YP7 MCE]#P'4DEC:1#82;"3A,TP.`L"UD9;O9&V+>'9<[0E:KM0UD`^#J6+Y'!\*V MCCO;S=X0J*/XAEQ)0VL*PF._O30(&Q+5 M8Q86W4F*%R29+\E=\G;NK6HBH&!Z@#K:D>,6 MQ4IX-0IP4I!F!C(W6K3=$'`0&F:7[N\)!EP&']4H`+@40@\W*'`0`,9\Z<,S/V_/$@6[3CV@C5Y3B)8HQXQU0INCK' M/W^L'J88&4N[DK:JXSD^DUIZ4/DBU)XWA,)!4=#@R9OH=#595@?*G85O+.!A+-6VI! MOVE$;TYLDMU#)ZG>;/L'IF0/%&O1"GOTI!A)ECW7G=)TW8+O0S*D[,3M%S?T M4C"MC*IL!'0D"+WU/",S`DS%O!3@P)4=:5[E^"G)%B-,BKFOSR_!]^;B'9E& M[3]I47X1'8=B0YM<`]9*;1STN72?()C<1*]\`[YI5/**;EO[7>T_E]PP*"C01*F7P50+`N".I'"3`06A!__P=!` M3M-3-X))!LS.V1CJ\[XS4.-BGER0#P6T@6[LBG0VFI,=E)"]8!;O8,X(`LG/ M"B#KI8*_9W;@',/](O/XS.O5+0)FZ#MZF6CP-I&S.OBG51=TG7!RE3!@DMA7 M(HYFHW1V>;WJ>^-[^#]R7-"UG.F5G("Y]0^C=EGH^_R[H.N$U_X#YNQ__/H_ M&`[[*HQ=3VO^E>I:=`:UO((>Q-$$"'3856%A5>_':ZTL[`;_VL#AQV'VX@C` ME5+VM'#[]GR<%G\```#__P,`4$L#!!0`!@`(````(0!;0AZ]8P4``-L2```9 M````>&PO=V]R:W-H965T&=RVT1BW!U.&/<6,%RZI7WJ^^O"<;KJA)NRFY$KOL`O!](V90^W[='IKBTN]X-3 M(^P,%926XAQN#OJFKEG3DT,^` MSF$/:L:<.(D#3*NG?0T14-FM%A^6]C-:%"BPG=73(-!?-;YUTO]6=R*WK*WW MW^H+!K4A3S0#+X2\4M-B3R%P=@SO=,C`[ZVUQX?R[=S_06XYKH^G'M(=0D0T ML,7^QQ9W%2@*-#,OI$P5.<,#P%^KJ6EI@"+EQW"]U?O^M+3]:!;&KH_`W'K! M79_6E-*VJK>N)\W?S`AQ*D;B<1*X?D)RQ]'GCL'HB*35[SC"LPV/#5>^(DIF M,7(3/P;HCF/$'>/)\;$5H6&&%>'Z6W"SH M(LA!=RUI3Z(%D(E,LV#'W/];ZB'GE.29LBQM"!^RVD&]OJ^\!#TY[U!C%;=9 MFS::Q498T(*BM%L=V.E`J@.9#N0Z4$B``R*,2D"=_0]*4!:JA(AA+0!)&E68 MC;`0+EL=V.E`J@.9#N0Z4$B`$C9TBQSVYRTN\DR-H9GE/`>!&LZ:V[!FIFG< M&,C60'8&DAI(9B"Y@10RHL0)NX$<)RUT+YR-??UPJ5,>:!9H>:G6/4T#9N3# MPTQ&P5PUVHQ&8^(-9&<@J8%D!I(;2"$CBBP@@"X+"F=TO^M/=?6Z)A``=,PG M9>%#G[/NIQR#)"*0-4>F-MAP9#XVQI8AOLNV"Q?YJCR[\7?!FAHN[ZHTJ4&3&32Y0I,DD6_0%#*-(@4=3J63[GZ"J;$J!4,\:*1)BD"7@ANQ MF6@XPD:W40J&!-Y0]Z'K)PG\T;0P>#*#)U=XO`!%\R2(59Y"YE'$@*/^<3&H ML2H&0]2Z"+6$;KB15!>CVR@&0WA=>/'10Q$`S(CZLQ6*MR<$@MCM`8;^@R]-29&F5R'!41$+3T6&@HULZ.5%A-7)F` MAO>"83/).<1KS?,2/W*U+!7";6!29:&3DM0Q;#;\R;,!L7$+SDL1X9I#6O5H M6=\(*ZE\.!1.7#L!Q:R;YBB9QU'D:=*G)EDF/">R7$",+'+#,$0HG.MUI)"I MBM$A2U+L_AZ#V$BF2,,@J40VW$J"MAP*IZ-E)Z#I;$E-QTQ838ZY@";'0G%4 MXZ/3E13??ZL(-J(I83,(*D(4R09Q2$X_@Z+IM-QQJPBQ]"$UDN($86(7^>S*,D--(O/YDJ#YVR[LCSG5QAW_ATF))F"WBQU[=;#@V= MS59DK^[L3:[![1%O\/G<615YHZ_E=!>LU_33P^?V*^]!;QBF#QK?P$SN8D_!XMG]@E#7R!8P+0*#L[X`WQ:N)9' M_%O9'NM+9YWQ`6)TAXVH91\GV$W/]7TA/7Q4&*0^P4&PO M=V]R:W-H965T*^Q@+?*3BK%H& MG<_2/EP3+-M4C'$!B9.W7SV2FM;,K\4VJ9V+@+_I_IM1]XPT,_#YCY_KE\&/ M:KM;;5[OAM;9^7!0O2XW#ZO7I[OAO__E?+H9#G;[Q>O#XF7S6MT-?U6[X1]? M_OF/S^^;[;?=OD1N?5B^^W[VZ?E9OU&$E]7+ZO]KUIT.%@OI_[3ZV:[^/I" M_?YI72R6K%W_`?+KU7*[V6T>]VM]UW@]VSYMW=[MZB%:O%5UMRI/*P-?-YILR]1\4 M(N<1>#MU!K+MX*%Z7'Q_V1>;=Z]:/3WO*=V7U"/5L>G#KWFU6](5)9FS\:52 M6FY>Z`/0_X/U2I4&79'%S_KU??6P?[X;3J[.+J_/)Q:9#[Y6N[VS4I+#P?+[ M;K]9_[M)KZWGU<<< M2;;N,+VVCN/+CWE>M9[TVGK>G%U;Y[>3Z^,?];KUH]<3.TF#M/ZL]'I:)V]; M1WH]L9,656!3$*H4FV1_K)O6H93HS8D=M;B"U)O3NFIQ#:DWIW:6J\B2,OI@ M9[F,U%@[M;-<2)94T@>+U^):4F].[2Q7DR7E],'.S>%NK&8DV5',]7S5`_S&!_-X'1S*54_E0R=T.Z"#0W M[6C6_?'%NKSY//I!,^6RM;GOL=$M9FRAID4E.S>!;0+'!*X)/!/X)@A,$)H@ M,D%L@L0$J0DR$^0F*$Q0=L"(\G5(&@W*_T?2E(Q*&E_N>P:2Q;&1(;9@E[D) M;!,X)G!-X)G`-T%@@M`$D0EB$R0F2$V0F2`W06&"L@.T#-'_QC` MHTAYT0U?&T6W>@;N6YOFAJ\&R0S('(@-Q`'B`O&`^$`"("&0"$@,)`&2`LF` MY$`*(&67:$FBFXR6I./)4=8T2](]0N:XJW,C.XW1A,JB8V3I1K.#T6$4`;&! M.$!<(!X0'T@`)`02`8F!)$!2(!F0'$@!I.P2+6%T;S\A8(!\8$$0$(@$9`82`(D!9(!R8$40,HNT;)# M#V(G9$=9Z]EI2'>@`)D#L8$X0%P@'A`?2``D!!(!B8$D0%(@&9`<2`&D[!(M M%?1PKZ5"/6!?3I(<8@FAAWFX/181`!L8$X0%P@'A`?2``D M!!(!B8$D0%(@&9`<2`&D[!(M<[0:TC)W_/%`6>O9:( M!\0'$@`)@41`8B`)D!1(!B0'4@`INT1+A=H%T7+Q^Z.HEM(3U2)C'%T8XTBL M#@,)D8W(0>0B\A#YB`)$(:((48PH090BRA#EB`I$I8;T;*IU;7?3X?C(4AM9 MQM!J4?<&A6B.R$;D('(1>8A\1`&B$%&$*$:4($H198AR1`6B4D-Z>M2BMIL> M-=AH4Y:>!4_=%6J6Q[1FXB%SKS84*9G&6+LTQ]K!BAWGXLC(1N0@JWF\S_,=::Q;*6L7;]W%DUJ:W=)HF< MBSDB&Y&#R$7D(?(1!8A"1!&B&%&"*$64(GI46O=$]+3+(VU]#2H M.=.J=TUG:O>+%>?5822[A"XCD?<8Z?+7NKPO M5BP?,!+YD)'(1XQT>6-_.18KED\8B7S*2.0S1KJ\L?&6BQ7+%XQ$OF14R^NI M5FOI;JJ;K?9Z);!_7BV_W6\H-72OZQFA$]I2;S?:FQ6Y5@$-TBJ@1=+)N3H8 M46/VO-Z='Y];QCK!%@/NG].BCK++2)0]<53[_JCLBP$K!RPC5RYD),J1./8K MQV+`R@G+B'+*2)0S<6R5C:V'7`Q8N6`942X9UHAK\C)@,M( MHGN,CD;WV8JC7T"X@$TD7,A(PD6,CH:+V:H)-SF[@7`)FTBXE)&$RQ@=#9>S M%?=NK%_:6XA>L(=$+QG5T?7:4CL*)]16LP&AU5:#QG0?[]26,47-U+FQJL#F M:R3->6FO(]16:W75UM:8TFN(.RPNNQ,I+H$:.CT6.VXNB47J.S"9M(N)21A,L8'0V7LU43;GQF76C51:5M1"_8 M0Z*7C.KH>G'10\HIQ:7,C=V.!AD3ES&;S-1W`51QR>":,Y)!8#-J1M+X[-IX M)G/80!^0QM:*RU82S&,DP7Q&',PR'E\#-C@:+&0K"18QDF`Q(YXC;HS'P80- MC@9+V4J"98PD6,Z(@UU!B?3FS+B,)!4ZJF-M>KID7&E&2NV]E* M1LV9CK3FY%-AZW$T64D\AXCL?(9'94/V$H<0T8B'S$2JYC14?F$ MK<0Q923R&2.QRAD=E2_82AQ+1K6\GGVJT1/F##4S&'-&BXPYPUC?S=A*BGW. M2(K=9D1[")WLFQ,'6XFCRTCD/49BY3,Z*A^PE3B&C$0^8B16,:.C\@E;B6/* M2.0S1F*5,SHJ7["5.):,:GD]^^9VWO&5",WXD/T&&6/?F!!GK6/W<8215*G- MJ+T;7T#>>V,9,YW+*C*4/$82RV?T-[$";M=OZ$:LD*TD5L1(8L6,.)8Q-A)N M/QHK92N)E3&26#DCCF4\;Q7.R$;D('(1>8A\1`&B$%&$*$:4($H198AR1`6B4D-Z,M6VW,<7 MBS2[0L;:C;W._GQKI:4'K&RT_'T')%+?7NH]ER.Z6O35!EF-PZ MGZHC^+X6^@D4G?[VM8RII7Z"!+4)M=0SC-DRIA:Z5Z$:_=+JSWXMDNJQOZ?@ MO?84H%?_@O3KS5[S(]'U[;V\='5[+RY=V]Y+>SVEKW5AQ^YOIO2E(>1TVC15 MQP_80H=.4W4*@2UT]C15)TM]+9?4TN=#QTY3=1B!/G3Z1->VKX5.Z*;J_`U] MZ/B&6OI\Z'!NJ@YJT(?.Z*;JO`9;Z*ANJ@[B^EHNJ:7/YYY\[GM;Z"1S.NMM MH0/-J3JNQ#ATT$4M?7'H+'.JCK30AXXTI^IDBUI&AV*B7^6]+9ZJ>+%]6KWN M!B_5(PWH\_JX;MO\KJ_Y8[]YHVF=?INWV=/O\>JWS_3[RXJ^FG^NOC/QN-GL M^0\5X)U_T?GE+P```/__`P!02P,$%``&``@````A``./21?6`@``(`@``!D` M``!X;"]W;W)K&ULE%5=;YLP%'V?M/]@^;T82$B: M**1*5W6KM$G3M(]GQQBPBC&RG:;]][O&A$(3I>D+X,OQ.?=<7RZKFV=9H2>N MC5!UBJ,@Q(C73&6B+E+\Y_?]U35&QM(ZHY6J>8I?N,$WZ\^?5GNE'TW)N47` M4)L4E]8V2T(,*[FD)E`-K^%-KK2D%I:Z(*;1G&;M)EF1.`QG1%)18\^PU)=P MJ#P7C-\IMI.\MIY$\XI:R-^4HC$'-LDNH9-4/^Z:*Z9D`Q1;40G[TI)B)-GR MH:B5IML*?#]'4\H.W.WBB%X*II51N0V`COA$CSTOR((`TWJ5"7#@RHXTSU.\ MB9:W483)>M46Z*_@>S-X1J94^Z]:9-]%S:':<$[N!+9*/3KH0^9"L)D<[;YO M3^"G1AG/Z:ZRO]3^&Q=%:>&X$W#DC"VSESMN&%04:((X<4Q,59``7)$4KC6@ M(O2YO>]%9LL4Q[,@ODZB9`9XM.7&W@O'B1';&:OD/X]J+?4L<<<"]XYE,@N2 M>3B)WB0X9#7=?XT7`00/M\J;M]8HHN,BSL][09:;*AZ7LJ!QU)=9"R5 MG)9R,WKP`5QLT.T;JW:1L>KLM.IBK'K>H`./I;K(\7%%,-O>VHFO(S>6WCFP M=N=8Y1`:.YJ?=@3S=Z1\WE*+?J/F)\?@P_+SV(\KR77!O_"J,HBIG9NU,0R@ M/MK_!S:Q:^&W\>ERX_\/I'\#\[FA!?]!=2%J@RJ>`V<8S*%0VD]XO["J@3QA M2"L+@[E]+.%/S&$(A0&`&PO=V]R:W-H965TS&UO:-EHTRAMI%:JJEZ>O6#`"L;(]F:3O^\8LP2RJV3S M`G@X/F?.>!C6UT^B1H],:2Z;%`>>CQ%K,IGSIDSQG]]W5TN,M*%-3FO9L!0_ M,XVO-Y\_K0]2/>B*,8.`H=$IKHQI$T)T5C%!M2=;UL";0BI!#2Q5272K&,V[ M3:(FH>_/B:"\P8XA49=PR*+@&;N5V5ZPQC@2Q6IJ(']=\58?V41V"9V@ZF'? M7F52M$"QXS4WSQTI1B)+[LM&*KJKP?=3$-/LR-TM3N@%SY34LC`>T!&7Z*GG M%5D18-JL?BJ>/Z=-PRJ#>=D M3V`GY8.%WNZ[[@1^*I2S@NYK\TL>OC%>5@:.>P:.K+$D?[YE.H.* M`HT7SBQ3)FM(`*Y(<-L:4!'ZU-T//#=5BL.9%\3^'-!HQ[2YXY81HVROC13_ M'*8S-'"$/0?<>XYH[LT6?A2\3T)W`(`'B\W[` MB,5N+3C%"XP@5PV'\+@)XFA-'J%P68^Y<1BXOF`&!`'101G4+E>V8*ML*VM3 MN7&!L4QX7B;ZB(P%IQBN+\G'\<#KE!TF[MIE["?^B)`%0\GG$Z79*Z4>!%9' MZE!4^E^LBI'3N/1^W>V8G""^S8C5.-/C*ULSQO9S65?=N.!4^E^LBI MG0`&V8F?8.6]>SK=QJG(,30UM#IO"&;M1/AM1QWZE9J;$Z//R,U>-YP$4R7[ MPNI:HTSN[5P-8=P,T6'F;T/;L*_C<;)U_P(RO(%9W-*2_:"JY(U&-2N`T_<6 M4"CEIKE;&-E"GC"2I8$QW#U6\-=E,')\6]5"2G-<@#(9_N.;_P```/__`P!0 M2P,$%``&``@````A`%?J+^%U`P``?@L``!@```!X;"]W;W)KI\\:DXB)?N&3@NP[+(Q'S?+-P__Q^ MOINXCM(TCVDJ*J0C,;F4)9Z@>^/O8SRW+4(,WD-AD@2'K$G$>TREFL+(EE* M-<2OMKQ0%5H670.74?FZ*^XBD14`L>8IUQ\&U'6R:/:RR86DZQ1TOY,AC2IL M\]"!SW@DA1*)'@"<9P/M:IYZ4P^0EO.8@P),NR-9LG!79/88^*ZWG)L$_>5L MKQK_';45^Z^2Q]]YSB#;4">LP%J(5W1]B=$$A[W.Z6=3@9_2B5E"=ZG^)?;? M&-]L-91[!(I0V"S^>&(J@HP"S"`8(5(D4@@`?IV,8VM`1NC[P@V`F,=ZNW## M\6!T[X<$W)TU4_J9(Z3K1#NE1?;/.A$3E,4RH3U139=S*?8.U!N\54&Q>\@, M@#&F$)19A#K*4T%"=`BR0I2%>^\Z<%Q!9M^6)`SFWAMD(RI]'JT/_!Y\:@\/ MHJE#@C":(?6GIV)&9V3&=&$HC];0I#D$TJ();Z%!9\A,,_@PK,.WS-9G:-+= MU#.\A0B=H1;C%M/PB*ETLI5M4D$?-%.'U1R1P?W))JNRB.<,:YW&T@+9/)0K M'-5QM#()P399SQ<,G=M4I:6;..BG)BZJ"_7#*RJ#!]LOU&.\V664*.UU-\#XW M4F6J,YX,+O::.7C$4LZ&MJ;)"4TWS0=2SH/Q84)4IAY->(4;FLZ7G]@+#W>U MOC65J=UKTQ-";AH,I)X,![;29#X6K1N)GY6F$"Q..`GQNW+A^IB31]5!,#"U MJC/T3XBZ:1C@G#MJ[\K44YVC>7"A.MU!0/HFP9"<$'+3*"#=65"9>JK3-PW& M\"V_6)SN-"!]XV!XXI,'VTVK+:;W7;L2I$QN6%?6)HJ)Q([ MW&0"V`5J:[UEK0*\,\S?+>RY#/8!'[.:"*&K!R2H-^?E?P```/__`P!02P,$%``& M``@````A`.)GI7EJ`@``:P4``!@```!X;"]W;W)K1;0K\^QW' M$%'HIHZ+$-O'C]_WG.,L;G>J(2]@K-1M1I,HI@1:H0O95AG]^>-A=$V)=;PM M>*-;R.@>++W-/WY8;+5YMC6`(TAH;49KY[HY8U;4H+B-=`IAJ5Q?,44ERT-A+EY#T.7I11PK\5&0>L"Q$##'>JWM>SLD:;$>W"* MF^=--Q):=8A8RT:Z?0^E1(GY8]5JP]<-^MXE$RZ.['YP@5=2&&UUZ2+$L2#T MTO,-NV%(RA>%1`<^[<1`F=%E,E^-*K,"$ M(B9*IYXD=(,"\$F4])V!">&[_G\K"U=G='P536?Q.,%PL@;K'J1'4B(VUFGU M.P0E!U2`I`?(&-4?UM-HDDYGU^^@L*"H-WC/'<\71F\)-@V>:3ON6S"9(]D[ M&V-^@H[!Z]^LHD4X':+Y7G)DW&R8"^84W&(N7LCYG7$ZACA2X'R M!HWH_%3CVUD_2O'!7HJO@M=V%R:0/6A+S\Z]C+BZ&4)>*<$,G2HY9NO?BORF MC.(A@X`DG@W\(#+$)'&?NTDTF\:GO^33Z%SS?VP(#D)SA]HK,!6LH&DL$7KC M&S?%@X?9X4XM4Y_&L_D[O&M]9[)A`7N]XQ5\Y::2K24-E(B,T04E)MR6,'"Z MZSMNK1UV>?]:XT<-L$QQA,&EUNXX\$TP?";S/P```/__`P!02P,$%``&``@` M```A`%W1"!I1!0``IQ0``!@```!X;"]W;W)KXX;;YG5=;.^('5,+/E M395U\+/9.>VA8=FF7U25#G7=T*FRHK;1PKR98H-OMT7.'GC^4K&Z0R,-*[,. M^+?[XM">K%7Y%'-5UCR_'.YR7AW`Q%-1%MU[;]2VJGS^?5?S)GLJP>\WXF?Y MR7;_X\Q\5>0-;_FVFX$Y!XF>^YPXB0.65HM-`1Z(L%L-VR[M>S)/:6([JT4? MH)\%.[;*WU:[Y\<_FF+S5U$SB#;D263@B?-G`?V^$4.PV#E;_=AGX._&VK!M M]E)V__#CGZS8[3M(=P`>""B#2%1J@TX@%[.4]G/@VB M>((5!QGU#CYD7;9:-/QH0=7`GNTA$S5(YF#YY!GR&'R]YBKX*(S<"RM+.[(M M\**%_+RNB!LOG%>(:2XQZPL8'9&>$"(50&_@")ZK'"]'_41%@`45D07!;8T# M8'O@1HU]SQ%A,D`T)A"AZ4P$&#*M;$S8I^K\'7']@(X)UV)'H*[5X-U. M:(\VB]P\B1*D5+DZHN\N%%))W0>[HYZJ,D"(6>D$09>3)BS[5;JD$CI*M@S2 M+;F7%CZD9PC^![6%,JWESBR<-4&0FCME1,L=-<1\6N[Z569P1EW$X$B0]-^E M41P9\4LU2)3XH7+]T6D:JC^1Y@7UIV;OH0B2IXS$;JQTYMZ35(=X+DF\T1.= MIY#L3VLM1:'7!,,4^[4$(<_8C]SS:*(91/@)#>-K+(5L?YXEBKW.TNP(%$$R MFI1X@:EJ.@(NU208M4L-$EA=ZA+*#/$%J`R#B(_O>]-)6U$8= MT6-E=(K;6DAN!I2-PE\&,W\4V2XNEHG(]H8BH'O@OALTG% MFAU+65FV5LY?Q)L/A6^Q871XC[JGXIO>&%_#.U7_J.,,$_!,=,AV[$?6[(JZ MM4JV!9/N+(+:;O"A"7]T_-`_UCSQ#AZ(^C_W\"#(X(7#G0%XRWEW^B'>3X8G MQM7_````__\#`%!+`P04``8`"````"$`ZK($*FH"``!K!0``&````'AL+W=O MZ!9R>@!+;Q`($EJ;T]JY;LZ8 M%34H;B/=08LKI3:*.QR:BMG.`"_Z3:IA:1Q/F>*RI8$P-^]AZ+*4`M9:;!6T M+D`,--RA?EO+SIYH2KP'I[AYVG970JL.$1O92'?HH90H,7^H6FWXID'?^V3, MQ8G=#R[P2@JCK2Y=A#@6A%YZOF$W#$F+K)#HP*>=&"AS>I?,5R/*%EF?GU\2 M=O;LG=A:[SX;63S*%C#96"9?@(W63S[TH?!3N)E=[+[O"_#-D`)*OFW<=[W[ M`K*J'59[@H:\KWEQ6(,5F%#$1.G$DX1N4``^B9*^,S`A?-__[V3AZIR.IM%D M%H\2#"<;L.Y>>B0E8FN=5K]#4')$!4AZA(Q0_7$]C<;I9';]#@H+BGJ#:^[X M(C-Z1[!I\$S;<=^"R1S)WMD(\Q-T#%[_9A4]>LB=I^1T1@ENMUB>YT423S/V MC#D5QYCE&S$O(U:G"%\*E#=H1.?G&M_.^DF*#_92?!6\MF680/:@+7UU[F7$ M]&8(>:$$,W2NY)2M?RORFW**APP"DG@V\(/($)/$?>[&T6P2G_^23U>O-?_' MAN`@-'>HO0)3P0J:QA*AM[YQ4SQXF!WNU%WJT_AJ?HEWK>],-BQ@KW>\@J_< M5+*UI($2D3&ZH,2$VQ(&3G=]QVVTPR[O7VO\J`&6*8XPN-3:G0:^"8;/Y.(/ M````__\#`%!+`P04``8`"````"$`0T)Q<,`&``"?'```&````'AL+W=O'Y>[MG%\:E:3*3UD#XZ^/Q;5NLYUWMZ0[9]6WM^MB M5YZOD.*E.!7-3YET/COO'GY[O915]G*">?]@;K9K<\L?@_3G8E>5=7EHEI!N MI08ZG'.P"E:0Z?EQ7\`,!.VS*C\\S;^RA]1F\]7SHR3HWR)_KXV_9_6Q?$^J M8O][<7TO]LWQ:>ZLE]RS M'`;PV4M>-W$A4LYGN[>Z*<__*9"<49?$UDG@JI,P=G<21R>!:SL2]^81`%). M`ZXZV/9N#H:)RF"XMG>&F=PX][4.AMNUP?<3"+M1C@"N[?#=)7.M]>>+L%(+ M*NLCS)KL^;$JWV>PZ6#)ZFLFMC![@+RB,-P/"P,J0L1\%4$R%-`U5//W9]]_ M7'V'`MQIR&8$$F#(=@@)+`P)1R`,0Z(1B(TA\1#"70Q)1B`<0](A)'`ZR`KH M[#B%LC`Y'=]D+9<"_#2'_SLN`S*XC8+XDN@%\[C#`\JE"7&@M[IK1B"A"5FX M5A#XCDON%"%,X*T#CZQK;"*8XP8^S9&8".XYKD46-34!ONTX_KI'(!YAC]_. MHP`3'LD*;A3$E?U-U/&6&D)JB*@A5@8NUX(QQR$L)Z9?S+ZK$+ES4M,MY\X# M?]UAT.RA29FS%SO3@<8_74TBB+#0IY=#V"B(FH%GTRVW-=T+QW9LRR,90@5Q M)0?]TLGLT80OGO`E$[Y4^=2(842!L^Y'A"B#QD4I^[R9B2!"F=>MB*),08S" MH8:0&B)JB%N#Z):$M&3"ERJ?.7GN]3T031\.&3K]SRM&!)'IDSV_41!=,0&T M%C+^+0+X'M0,)C!4@/&*F?#%$[YDPIZ+YJ[4/;&N3_=5008S]DCC6VC(.J^MKUF:W(( M;S\#A`HP7B,3OGC"ETSXTG$?(BFXAR0!QB3YO3Y0?41!%$D+9C'N<=)JM@HR MRD*(P@/7"5C?!U7W10B/^6[?*20@GDB?3/C2<1\BB\'A='M)232FBQFUJOC2 MH)8PSV4V%4=;A+$]WUU;-CGX0X19N"QPH41)CXHPB%FN[U,-%2/,N/Q!D%'] M@Q",N;[%C87$G`K1>?,V94JB@K[JM"04&6[%&PTRNM/`$@XLT<`2:XM:FS$E MA``C4@CY-0WX-CDF(T1!DY9WR&W2C1BM#ND*%S6IN7T-8[9%#+T=C:5 M:,5LTM;&%,@L*VH)!YAH8(FU1:T*/*`0DI(N8N1@3%%P2X'='\^8!"$K#1)N M$]A,B5&3C(!TX8W&J#E`G^Y70;:U+?)#,3@!YQ9)$FK0Z%I'4\YXRIE,.5/M MU'O:6T1IJ4XXX4QW9]P!#W&`2A`XU2)A6XDRI5G/R`RFN,;IN/.X; MC\NZ`:DL'R-"G6.T,*(I9SSE3*:SI62KR=9`DS.%45PL@L#U M?%)-6PT9)2,D\9;#Z3NSB$"8S8@HBZ?ND$PYTP^LP[C./*+4(@QCS+$[?N\4(,RJ>$()T MR10YX143@W\?G'SV79IG;*#_#082T].*LK]8%)_6C*J_Q4\%(V M\&%(_GF$#X$Y'./6$L"'LFS:'^(35O=I\?E_````__\#`%!+`P04``8`"``` M`"$`>P0C0L,&``#$'@``&0```'AL+W=O^@T+TEH=V$[0ZL?=_7&Y:01;0D%(#;W6\_64`AR-_MP.ZY M"/21^5-+5E91=?_]U_F4^FG8CFE='M)*)I=.&9>=M3LGZV(\I'\;3OK[X[__W+]9]@_G:!ANBA0NSD/ZZ+I7-9MU=D?CK#L9ZVI< MZ,G!LL^Z2W_MEZQSM0U][SF=3]E\+E?.GG7SDO855#N)AG4XF#NC;NU>S\;% M]45LXZ2[5'[G:%X=J7;>)9$[Z_:/U^NWG76^DL2S>3+=WYYH.G7>J9V7BV7K MSR>J]R^EJ.^DMO<'Y,_FSK8]RY+2X_W>I!J(9D_9QN$A MK2FJIBFY=/;QWFNAI6F\.9'[E'.TWEJVN>^;%X.:FSI*=,&S9?T0IIV]0.2< M!>^FUP5C.[4W#OKKR9U:;VW#?#FZU-\EJI*HF;K_73><'34IR63R):&TLTY4 M`/I-G4T1&]0D^B_O^F;NW>-#NE#.E"JY@D+FJ6?#<9NFD$RG=J^.:YU7OI$2 M2/DB^4"$KH&(*$)"YV+@3%=9@DR^6E)*95&"#]Y*3[VBTS5PS&>JI5*Q7*U\ M[%@)'.DJBQMQ3%AL&D'>V^D:B)0R%25W5Q`O3ZA!@1&TONCWH/F355X).XYN M/E=]I2#?2C=?;P!%=IRX^7H3E&5AZ.:332#[4;EU9,((4.[D6^GFZTV0E_TG M;K[MMY2-&-03#M77>?C_F[PGWV)^7376#SA#9*W*(F+43R%+)U#AH<-#EH<=#FH,-!EX,>!WT. M!AP,.1AQ,.9@PL&4@QD'#[A7S(P5.&#TTC/Z/ MZ!$R(GIDOS])$`DG%BK20KK4.6APT.2@Q4&;@PX'70YZ'/0Y&'`PY&#$P9B# M"0=3#F8>3,JLSFJ M%AJ%>05(`T@32`M(&T@'2!=(#T@?R`#($,@(R!C(!,@4R`S(',@"R!+("L@: MR`;(%HBF15$L@FBM]8D($M9>!,E^?_()A8LD-2!U(`T@32`M(&T@'2!=(#T@ M?2`#($,@(R!C(!,@4R`S(',@"R!+("L@:R`;(%L@FA9%L=B@1!&+#7_1FQ'? MD^[1W/UXLOP/\7?FJ`(M;OTEKQ")ATQ`;NN86D"J81#5?5*@KYA(%F*IJA$: MR=AK`FD!:0/I`.D"Z0'I`QD`&0(9^42Y574&W!2].B;K$D1QMYGX@-81V/#9_D:4\ADJG8>*X% M1ODP+]7?<5,J;`>I$1A%%_E*A0VH)FBWDFBW?:-BSMO>*N1*53;B.Z#;3:+; M"XP^+',?M`=)M(>^T9_+/`+=<1+=26#T89FGH#U+HCWWC8(R*W?Y(ELS+$!W MF41W%1A]6.8U:&^2:&]]HS^76=.BPK'A)(XF/C&>///X@`I048P57]H_Q/(W M>L^&_6+4C-/)2>VL5W%`1;OXC_8.-\2?O6$TH\P=Y.F][UZ-`#[S/ M)N:A%=7@@(X]>*(']"'WSCM*],`[2V,>];)*2U!T&)=56J\AKU=46OL@;U54 M6LH@[U946ID@'U146FD@'U=46C@@GU546@<@7U94FM:1;RHJ3=/$LV&%Z0CQ MJK\8`]U^,2].ZF0*[1]"^G]&ULC%3;;IPP$'VOU'^P_!Z\ MP-Z"EHTVC=)6:J6JZN79:P:P@C&RO=GD[SO&"8%LE.X+PL/Q.3-G9MA1[J#%+Z4VBCL\FHK9S@`O^DNJ8*@H'6!Q$##'>9O:]G99S8ESJ%3W-P=N@NA58<4>]E(]]B34J)$ M]K5JM>'[!NM^B.=%9_*=0B,95X2FHJM>[]0?PEQXR+6Z5!&R"!@ MYKV[X[KFIX+)TG?T/YK^'G9A.1&=OQ(-H!3)7NQ=+P;0I'($G6^P!_?J@\-/ MD?2D0,QPS.L=3>;HQON6^EM3@:?(U.7EV[7@S(TUWY?RX*E4B(QZ%98T;((" M4\$G:!I+A#[X!4QPMH?H\&_8)=Z*U_%YMNO'D@T?<&<[7L%W;BK96M)`B92S M:(6&FK#UX>!TAUGBYFJ'V]J_UOAS!ASO683@4FOW?$!A-OSNM_\```#__P,` M4$L#!!0`!@`(````(0#0!-#&I`T``#E'```9````>&PO=V]R:W-H965T"P?:*-]G5BXLS,-8VQ3;0Q M#J"WMS]9JDK5\NLPQM%]T;:_RDR5,K.6+`EN_OBY>^E]WQR.V_WK;=\;C/J] MS>MZ_[!]?;KM_^?/Z-.\WSN>5J\/JY?]Z^:V_VMS[/]Q]\]_W/S8'[X>GS>; M4X\LO!YO^\^GT]OU<'AVP63TT2KN7 MH3\:S8:[U?:U+RU<']YC8__XN%UO@OWZVV[S>I)&#IN7U8GZ?WS>OAW9VF[] M'G.[U>'KM[=/Z_WNC4Q\V;YL3[\:H_W>;GV=/KWN#ZLO+W3?/[W):LVVFS_` M_&Z[/NR/^\?3@,P-94?QGA?#Q9`LW=T\;.D.A-M[A\WC;?^S=UU/_/[P[J9Q MT'^WFQ]'X_?>\7G_(SYL'XKMZX:\37$2$?BRWW\5HNF#0*0\!.VHB<"_#KV' MS>/JV\OIW_L?R6;[]'RB<$_ICL2-73_\"C;'-7F4S`S\J;"TWK]0!^C_WFXK M4H,\LOK9_/RQ?3@]W_;'L\'T:C3V2+SW97,\15MALM];?SN>]KO_22%/F9)& M?&6$?G88.:,X5HJ35M&?#^;3Z60VOZ++G]&DUJ;?]%-=TK_2_3ZC.%.*]),5 MWWG)*Z5)/Y7F]'U]I;'6])5^*D5O,9CXTZMYX^0SG5TH34_DA?3\>QWDM9&E M7UAW\K[+>AQ0\0OKOM-+'L=4_*)TW^DGC])`)J/.!V\Z\.=3;SH3Z7C&4R+G MI:Z1$>>[/)1#H1E9P>JTNKLY['_T:+HBAQW?5F+R\ZZ%71Y3\O+M*/N[04:C M2UCY+,S<]BE;:/P<:6;X?N&"T@65"VH##,G7K<,IRWZ'PX49X7!VU3T#'0'?\2Y+L$K@ M@M`%D0MB%R0N2%V0N2!W0>&"T@65"VH#6-ZE<0C>G5!:=R\1G+U"BQ8#*WLG MMO?NE8Q<#$1R+H$$0$(@$9`82`(D!9(!R8$40$H@%9#:))9S:::RG'O>J4*: M9A5:>XPY8>IX50J-*9R&T,P66K9";>8""8%$0&(@"9`42`8D!U(`*8%40&J3 M6(ZFA+W`T4*Z<32[YUZ2\;B='99``B`AD`A(#"0!D@+)@.1`"B`ED`I(;1++ MA91VE@O%NC:>BWVA6EG?O;0)2[9[)9F2*2-IKYRD;84X*@&0$$@$)`:2`$F! M9$!R(`60$D@%I#:)Y7%:_"V/GY\=A+3M54F+45:KT*)`02`8F!)$!2 M(!F0'$@!I`12`:E-8GE5U*[N_LR?#BY/8V'(=K@D-$N8:;QP'-X*M0X'$@*) M@,1`$B`ID`Q(#J0`4@*I@-0FL1Q.98CE\/-I+*1MKTIBSKU``B`AD`A(#"0! MD@+)@.1`"B`ED`I(;1++A:*"N\"'C;CM1(6LW*3#%B MHVA[6108%WA9UB.6EQ72;EB*$QCA>-W/0"'+RU+*0)&2LKPLI<9GG96PHG9# MRDAW(F-DVW)*\UQ+:<>K3FA;)4I5B&J%NAPO"HX+'"_$G7E9(=/Q"NE^!N)L MBQ0=_SG'0:&6XGN.&&E;,2,R:22NX[]$2[&ME)&VE3&R;3F%?JZEV%;!2-LJ M&=FVG/*VTE)LJU:H*SRBF+D@/$+<"8]"9G@4TET/Q#$?ALH*CZA\ MS/#(H]*!.+P_/6_77^_WE*&TRG:LPV,Z$E4'I;)^LF8SA!0RPZ.07H9#I>@W M#[6:Z$=L2RO&C+1B@HHI2VG%C)%6S!$5C+1BR4@K5@H97:U9JE&TUV]1.UW@ M4EEJ62Z5R*?!HB=USYF(EQ1-X7B_>:*HG@>TBAR>4$E-1LU3!W\VFLT7$V<" MBM!4S,CL@W<%8T!=4`S@[W?SP7AA_9N&GYSL3-FN[G7&2)\=YQJ9'G"6CX*E MM*V2T=EN5RQ%>XC6P=Z5,Y76+-68MT,L:KL+0BQ+02O$$DW,?OJ>L\@L/2E% M`Y#C&3#2VZI0(7JT+((P'LE_]MXU8CUM*F:D326,9HTI;^`I8^J'UQ%/Z&+& M1K3='%'!2'>H9*05*T9ZPJD9-8I66&A\7A*61MS>(2@T,1/#]YSALE12YLAC MI',X9&3:@B2+6$KG<,Q(VTH8G;65LI2VE3'2MG)$!2.M6#+2BA4C79;5C'"( MB,G+&B(?V@XT5IP0"<.W?6?D.&-WJ13-D:/01&=7R$@L<-_O/DUGL\5DXLRS M$9J*&6E3"2,Y(6-,+!$%"DVT8LA([Q\B5(P1):RHE^X4I3)$.:("48FH4FBB MKUA;4O9D1&/U-PP`8<49`!+Y]D[7V;LO?26EDR10:*(W-J%"4[D[F(YH_:;_ MG*4#3<6,S#[@[H"EY)B8#.S%9-2QFK"&[G7&2*=VKI%>OGW?V>L7+*5ME8S. M=KM24L9Z:CND9C,=XX@LGPWZG_NWORN"C&VVB*T;=8DHWW@KL%12!@H4FNI9 M.V2D%2-4C!$E"AG9GJ)4ABA'5"`J$54*&5>L+2E[?(DRW=R#?6R!4?6_GI#N M*0["^>+*[>;0]YV=[Y*E='8%"EGC2]I2X\M;C+RKZ=09JA&:BAF9?>@87ZJG MO.;,.A89):*[F6G;G$FY1N8M.T5JP5+:5LGH;#\KEJ*RNO4H[(1JENH85:(> M/Q?J=XXJ6=:;VW!?(O.('U&`*$04(8H1)8A21!FB'%&!J$14(:HM9(\J4:>[ MKIXO/O)B@*]*?G-H260_M_*=]6:I%(V@!(A"1!&B&%&"*$64(3A$J0A1C"A!E"+* M$.6("D0EH@I1;2$K`./+"O-&W-[T*N1XV3D06FHI=FF`*$04(8H1)8A21!FB M'%&!J$14(:HM9'NYJ^2FK>"E;W2-985M)KE"COO=XRHMI=TO;1EY'Z)4A"A& ME"!*$66(:;M>EH@NP7/"4DD9*$`4(HH0Q8@21"FB M#%&.J$!4(JH0U1:R72HJ,M.E8C/RD5E:5G;6+"V1"&=;9_F^>S0Z;J4X(@&B M$%&$*$:4($H198AR1`6B$E&%J+:0[7ZWEOP_&8TUXQAK1D0!HA!1A"A&E"!* M$66(P`7%8RTJL.,$MCR:BDK%D:I$*4BA#%B!)$*:(,48ZH M0%0BJA#5%K)=^MM*QC&6C`K9\_38.;]>:BE.X`!1B"A"%"-*$*6(,D0YH@)1 MB:A"5%O("@"]L&`OD^?GZ4;<+AD5,A)XB2A`%"**$,6($D0IH@Q1CJA`5"*J M$-46LEW:51]^:)X6#U^=?9Y"3DZ[I^9:JLUI1"&B"%&,*$&4(LH0Y8@*1"6B M"E%M(3L`EU6(]``*O"Q1\RQ,FI;?!B`_L[S;')XVR\W+R[&WWG\3G_2G1REW M-RV67T-P/[ZZ%HL)10!:YM32/-V$E@6U-`\.W9;)B+[5H'F'"UK$]QTT3Z+< MEC&U4"'=U0.?6II'5:`SII:FBH"6";4T+H&6*;4TSQ.@948MS11.M'M:B&/TL%D5PMYE$[,.EK&Y%$ZY>EHH=OIO!OJ6&>_ MJ%N=O:).=?:)NM39(X]Z1)^TP![1:Y?7XJ5*;(FI1;PBB2WT2N2U>.$16^@% MQVOQ^B*VT%=G?.[,"A&L#OE[2J-.>9%$'?*?)]>?:;CAA>\IM[I2BU[BIAOO M:J%7LNG&NUKH!6NZ\:X6>EV:;KRKA=Y&INMT!9W>+:;K=+70F\)TG:X6>N^7 MKM/50I^YH.MT>8`^&T'6NEKHDPYDK:N%/EM`UKH<'5.+^&@`>IH^"D#7Z6JA M%_OI.DW+L!VM],4E;ZNG3;DZ/&U?C[V7S2--=Z/F;>.#_.H3^<=)/7#_LC_1 M5Y8TS]Z?Z2MJ-O0)]9'XF.#C?G_B/ZA3P_9+;^[^`@``__\#`%!+`P04``8` M"````"$`,4BI>B\(``!C(0``&0```'AL+W=O7S/2W/Z@S[-//SR_7CH?,LO55&>'KM6;]#MY*=MN2M.;X_= M/WX/ODRZG:K>G':;0WG*'[L_\JK[R]///SU\E)>OU3[/ZPXXG*K'[KZNSUZ_ M7VWW^7%3]W?G6^Y)M=$W0\].W!8-P_;HI3ESMXE\]X ME*^OQ3;WR^W[,3_5W.22'S8UM+_:%^<*W8[;S]@=-Y>O[^X]:*W4WG9O!S@OK];SF:+WLT?Q/Y8;"]E5;[6/;#K\X;2>Y[VIWUP M>GK8%7`'+.V=2_[ZV'VVO,R:=/M/#TV"_BSRCTK[O5/MRX_P4NS6Q2F';$,_ ML1YX*;6%C()-SQXQIVUY@`;`OYUCP88&9&3SO?G\*';U_K$['/=&[F!H@;SSDE=U M4##+;F?[7M7E\2\NLH05-[&%"7P*$]OMN=9@.G0_;P+*IB7P*4SN9,F#S<"+9E!^$4V_-Z;MX;B^NP7 MX>)\KN66@Z'PBPRUG,&8]2!M>9^/@&9`^9MZ\_1P*3\Z,$NA_=5YP^:\Y;$A MA$.)6\C!]4]C"P85 M7QEQ]+(H6`/UT3L3RM2PJHSUK$X'1E:Y:`B75`O'<-(6S:5(CEQ"%H0$A(2$ M+`F)"(D)61&R)B0A)"4DTTDKT;`.WY%HIFX2C>F9<0)913(GQ"=D04A`2$C( MDI"(D)B0%2%K0A)"4D(RG;12",/NCA0R=3N%@J@%=BY(LZWC3R=.AHY,\X*0 M0!`5%1+-DI"(1,52HTV4@?'\7$D1]ON:&"5$DQ*2<<)WL*VLP@/^CJPR=3NK M@FA9%43EQ^=$SRHA@2`J*I2:&_E92A'F)R)&L=3H1G9[15I)$1JMB5%"-"DA M&2=7$LTJ-7U;=GNI9>IVH@71$BV(2IG/"21:OU/CL;>0(KS30!!E%$J-;F2D M;"E%:!01HUAJ="/'R+T4H=&:&"52HQN-VD:I%*%1QLF5[IC>U1U,W>X.0;3N M$$1ET>?$Z(YQN\T+*<(V!X(HHU!J])MWVT9+*4*CB!C%4J,;&0_GE12AT9H8 M)5*C&QGE02I%:)1QN5:3.$ZD34+,RE MW4^-,2"MHQ"I!/L"C5HS9VC6L;`OE0J](NH5*Y7N M94S$E5*AUYIZ)4JE>QFK0ZI4Z)4)=*W76$GT^46-U=AF]PBD=X]`*J4^!D[5 MD"J*%0,Z@.0"8VBZ< M*!D;_@##E%.(2&^"Y9(IP-MNL_G[[6D`I?\MWT`+R);/<61,6N,5,S9>:DY:T2@ M&F0+H7)&S<+U93AFN6WOQ@+J%")23DM$8[$$DB6/M"?&$.6RHFB-2)\MPDL% MIJC29XM^Q7;7L!I2[YHK6S%8;N1>3)2(+Y*CMRT*@$=\#N%/7N;('$-=33B&:ZTVXL@<0@3@!7'LT MT+8`4V,IC=!572A&I,;U2B'M]AVR!R"-3JX%DD:GJ+KYI,M0U32UW>VL*KW5 M[;^79RA9_NV,&S;DK)-A>*F]'T=-*O@E^1M'_H+HF%_>\GE^.%2=;?G.WB;: M+LQ7B?FKSMG(@T,XL#0X%$D>*X'H-U#R>*R@H=]``>.Q\H1^`^6(QXH-^@V\ M:GUN'@S&]6?L%>P5_P/'@`)<&^!,/#DTH M#R<>G(%0'D^\U36>3#PXH:!Z?^K!*0#EX=2#HI[R>.I!C4YY,O6@Y*;<'WMP MC$EY./;@H)+R>.S!N2/ER=B#DT7*?==;-"NSD<_0]>!\CNICUX/C-LH3UX,# M->!]:02ON,^;MSS97-Z*4]4YY*\P:%FET.U<^$MR_D12CT M_`@``+$E```9````>&PO=V]R:W-H965TZW3X]F6G-I0G`J?C#P MH_NO4??TW-##;S].Q][W\E(?JO-CWQJ,^KWRO*UVA_/K8_]_OX=?YOU>W6S. MN\VQ.I>/_9]EW?_MZ==?'CZJR[=Z7Y9-#Q3.]6-_WS1OWG!8;_?E:5,/JK?R M#-^\5)?3IH&/E]=A_78I-[O6Z70*M1[;2]1^ZTN7Q[?_NRK4YO(/%\.!Z:GZUHOW?:>NO7 MW:'[A"4GAYV![@#%O;> MI7QY['^UO,(>]8=/#VV`_G\H/VKE?:_>5Q_1Y;!+#^<2H@UY8AEXKJIOS'2] M8PB0[@G<$;LQ;_?3+^LM1!1D!O:$ M*6VK(S0`_O=.!]8U("*;'^WKQV'7[!_[X^E@,AN-+3#O/9=U$QZ89+^W?:^; MZO0'-[*$%!>QA0B\"A';E2(W',?"T>DI<(37SO&>"\Z$'[P*/VLPGTR0]ORTD?]-LGAXNU4(4_VV86.=Y3%5+"&>G:ZH M_JJFH)B8REAM^A>+?"9D%M+-UBB1:L4IFL;X+` M!*$)(A.L3+`V06R"Q`2I"3(3Y"8H%#"$6', M_4KOM5Q'C]Y"V/"QGW7.)2$^(0$A(2$1(2M"UH3$A"2$I(1DA.2$%"K1@@NC ME!;X3(636>@@%D0/L4I!Y%U2?DXD,D6"2.65 M(&ZGO"9>L2#0991",>;/I#/"O*=$*",V.2$%)U;;:"VJ,,%_(JK,6H^J(/+> MEX+(^/BCH$4=(A MB(RBSXF1CJG>YJ`SPC:'@DBAJ+-1;]Y8C*\Z(Q1:$Z&XLU&%C!D\Z8Q0*"5" M66>C"KGZK>6=$0H5G%Q)!]L7:OG@NY8!VXXV^\/VVZ*"41)6X%?*9@R[$[%G M82IZGEIA0$JB$,D`^P)-M,JQC%5+(*WPAD*!U'%+6BFQL8R!?26M4&M-M6)I MI6J98Y>T0JV4:F722M4R1H=<6J%6(="UK+$MT?V#&MO+F^D12$V/0&IZ!)+S M:2"T^%E4F_T0Y:5CA$@ZKJCC&JVD8XQ(.B84I8BD8X9(.N8"*4TMT*IUU.9C M=EKQF9#R;1.LR3%=BU;AL6]#S.3"PC+&W"5:V9VCCTANB`*!G!$_`)B.IG/7 M,0:>$/VD5(1(;8,U(S7`&V^S`O[^-!^,7>UO$GPQ>N<:=>6E8D2RU8E$:@2, MR2)%*ZF5(;K9[!RMU"V.-3-&T0*M6GD]Q6P[]HFJX;LW+<4<.6H[;,1_]-'\I!*18BDU`K1M)6R!I80$R_6E7R2 M)L8H(G43BE)$_`R8W5N&2#KFB&1U%(A:1STM,/A_)BW,W)AK.'+@II3*,\IE MR2E<'R42*1&PC;5^BE:RV1FBF\W.A94RG^H!*5"F5=:3SG:K MMY+^>_7V5YL@M;[$IE?-.D?*G+.$Y;Q1:[41OA?J^_:;8SZJ1YLA6.XEM&RO?I26L9._R M!=+JBUN)^K+SK:- M36J*CO*6,T2J(VEGCE8P170C%ED)%6A%JPKV7;=3?5]5M3+Z>D^@=MKDO8L_ MU\!_CCV5E]=R61Z/=6];O;-G%FP6Z@[S!RH6$P^.O"&6!H-"C'0=,;L,#(%=T%F,/?F:Z MHN^`_K4++QP/?BZA#O[<@R-*RJ.Y!R>.E,=S#PX0*<_F'IP'4NZ['IRY41ZY M'ARA41Z['IR(49ZY'AQP4>Y//?C1@/)XZL%I/N79U(/S>LK]F1>TJQHC`=', M@U-O:A_//#C$ICR;>7!,#7S8"<$#,V^;US+;7%X/Y[IW+%^@&PO=V]R:W-H965T':W;;1AFQKR?HJGC!^YN\4)O9+< M:*M+%P!=Z(V>YIR&:0A,JV4A(0,L.S&BS.DZSJY3&JZ677W^2+&W@__$5GK_ MUH!C]@KCT&GB^8'A&"F]X2V!A:>KL\1V4$ MHS*6"ZU<^\!0)GE;9O(_,@B&>@_-+Q8]KU?VF&E7[F$^T[$0ECB988O?Z?PQ M-=P';9F-1--7H@<09/U2UC3J0:/"@N+'"XO@3KVO["$R.4D0'`YY,<%IE`80 M/M\[W#>6\)$)_`RRB=_.!D[;4/6\%(+'4H?(:38X;5_?B"FYG@=9S=QC,EJZ0OT1_"=&=PC4ZO=9RV*;Z+E4&WHD^O`1JE[!_U: MN!`<)F>G[WP'?FA4\))N&_M3[;YP4=46VGT)&;G$LN+IEAL&%06:27+IF)AJ MP`!3RZLHC0&.-MS8.^$H,6);8Y7\&T`^(Q*X MO+5;:NEJJ=4.0;\!;3KJIB?.@-AY2B&SP-"[?,DDN',D:\>2XRN,X+B!RCZL MDGF\)`]0#;;'W`0,7'O,$4'`36\);`PM/5^>@[(#.V57+F?E)@2&,DEO9"23 MOD?&@:$R0_-IVO,&Y8"9^AD8YC-]CY`#0R]F`Z5D?LP@*.U!T/5C+=-%;V>4 M)H#>7DT']NI].?<1/X\C7G`XY/6#,T_=Y+XPT(>.N8-CC7UD5-UI]'PZ,&-# MV=>'PX''4B%RWB.W8P>?P>NT#GS6H]-IV(.@',<>35^8^,5[U!UXG-0^?:(6ML6@46&MAMTE MN:[X)]XT!C&U=2LSA:731_MUOD[`!'I/]U MK_X!``#__P,`4$L#!!0`!@`(````(0#0:>(07`@``&8D```9````>&PO=V]R M:W-H965T[]=S M>29*(K4J%I!D]]N?'H:>8;I=CE:=?5C,C^Y_,W1/`P./?_PX'4N??A0'X?FI M;%5JY9)_WH7[X/S^5/[KS\&W=KD4)]YY[QW#L_]4_NG'Y3^>?__M\2N,OL<' MWT]*H'".G\J')+FXU6J\._@G+ZZ$%_\,>]["Z.0E\&?T7HTOD>_M4Z?3L6K7 M:D[UY`7GLE1PHULTPK>W8.?WPMW'R3\G4B3RCUX"QQ\?@DN,:J?=+7(G+_K^ M5!\K'_%!]J(+2\^,^@!&(TUZ*_+>G\HOE;JUFN?K\F)Z@OP/_*\[]+L6' M\&L8!?M91`9>P_"[,!WO!0+G*O,>I!E81:6]_^9]')--^#7R@_=# M`NENPHC$P-S]SYX?[^",@DS%3@]C%Q[A`.#_TBD0I0%GQ/N1;K^"?7)X*M>= M2K-5JUM@7GKUXV00",ER:?<1)^'I'VEDB8-2(G8F`MLK(@6.]V&+$1J7=;#:<]G]X.IDG;#// M9L5JU!QQG@H"MC(WV&+`&X<(4S0]5-C>-<2'S`^V&/'&(5I0?K(:1!W*3-\T M2$N5$?S`H#<.T\+J$3_N&JB%Y2-^8-1;AXH%9.D*NFVH6$%BEF'06X>*-63I M(JK?5+86EI'X@5%O'2H6DJ4KZ;:A8B59N5(J'FI5MI>T6_6\Q'M^C,*O$EP" MH"[BBRO&ARG`.H"?%T&T_G^UVX['Z"1UR ME]ETN(UE6G310O0P(=NCH$_!@((A!2,*QA1,*)A2,*-@3L&"@B4%*PK6%&PH MV.9`%?*ED@83\O](FI`12<*'/S2*K^6!FH)/9 MR`N]F"1=1GJ,]!D9,#)D9,3(F)$)(U-&9HS,&5DPLF1DQ<"DATQZI+ST/+6LJD9\HK+]TVI>?*"*473'K)I%?**R]-KAUK9832&R:]S4L;:86;.R.M\DZQ M(I[.DD.P^]X)Y?/HE9E7ASM">9\H1,QL2Y+/=D9RV98$KI_IC67-JINGK*_V MX[@&3'7(5$?*Z[KJ6.U'U0E3G3+5F?*ZKCI7^U%UP5273'6EO#)5VSP#:[4? M53=,=9M7-3(+CQ]&9J]D$!ZF,87"VDQA1G(3-B.Y%&;D04WAOB1VNHR2%L>` MZ0R9SHCIC)G.A.E,F'-1-AM6JF<72S8QLE8O>53?R=-;/C,1D_GRV*M:#^:__C4S+@5+%HARR MR"-EDS]@$GE,(C=8J(F2P5!3%FJF;`I"S8U0]4J;A5HH&0RU9*%6RJ8@U-H( M955L\W0^L,@;I8J1M_G(1AV)%:,["BDU-RLI0S;<<>5*B?2=+EK))4SYS"Y" M/Y6)(TEI'QV=K)IL2"H1'Z!-0Q7J$)&.-T)D'BB)-T8KC->T:OE_%HL^00\= M?8I(1Y\A*HP^1RN,#LDE@UV@B0ZW1*3#K1`5AENCE0QGPW*H45M0U"3Z!CUT M]"VB-+I97&)=(K]H5'S!$(N0I$UEB/0ITC^Z:)5K5(CTXV\?D>Q+=J5%;J@& M:&`V1;(Z-40K'6R$2`<;(\)@%KGGG*!!8;`I6NE@,T0ZV!P1=MPVN9];H$%A ML"5:Z6`K1#K8&A$&-0$;$$A^BHY4>(M/P84:'\!*VTXQ21 MEI\ATE9S1(7R"[32CDM$6GZ%2%NM$17*;]!*.VX1I?)F]N%Z=4_VA3FY'9&( MW%60AM@5+XU$]G5Y]Q#I*NTCRJ[ WJ[%(IQNBBHXU0J1CC1'](M8$]T/( M7"626%.TTK%FB'2L.2*,1>;&`O<7QEJBE8ZU0J1CK1%A+'*_M<']A;&V:)7& M,BM&+"_=T2_D:I31+R1*CUE*RY?U\O77R8_>_:Y_/,:E7?@A7L2GC[@*JZ\$ M7M)J)KPCOAX0%R;*;1=>"5SA=1>6H3E_:;@O\BL$*M1P8:V3.W2:+BR\<;YP M7%A'X'SIN+":P/G*<6$UZ`ION;"6P/G&<6%%@?.MX\*Z`N."RM/P*LJP?"5Q\5[]^=>]!Z8P/<=Z<\#?,_CPRN?FGA'\1:&"?XA`GSA%T+/_P(``/__`P!0 M2P,$%``&``@````A`)-3-/)@"@``@C8``!D```!X;"]W;W)K&ULK-M;<]I($P;@^ZW:_T!QOX#`8)NRO84!@3B?3W<$RS850"Z$ MX^3??ST:-7-X"3:;[R8FCWJ:D:89:22X^_?G=I/XX>_#=;"[3SJI3#+A[U;! MTWKW6'<5]ODW?IBG3P]W3FO9`'/;$WG^^3Y:<8JF4S2;3#W?1$9JL_8]0>YT( M7X./VG[]U%KO?#K<-%!B"+X%P7<1ZCT)HL9I:.U&0]#;)Y[\Y^7[YC`(/NK^ M^N7U0..=IUT2>U9\^E7QPQ4=4DJ3RN9%IE6PH0[0OXGM6M0&'9+ES^COQ_KI M\'J?S#FIFWS^JG!S36F^^>'!78N2=?$,?DS'`ZQZJ@%W'3 MK#8FYYKR:#I_-)P.CZ=X\=\/08$/`;VX\!#P.#IJ(+]Z"&[Y7>E%_*[_Y3/% MXY=5XW=Y%=#<(ZM`O+CL$&1Y*,6+N.D7#X&HKZCVQ(L_.`0\?EDU?E\^!&DY MTT439V5Y6#[<[8./!)V.J*;#MZ4XN3G%+(TN3YFRJH^3Z._F4)H\19:22'.? MI/8T.X8T\_]XR.:O[M(_:+)>Q3&/&..8$66.$#.S2%NQH6J#:T/-AKH-G@T- M&YHVM&QHV]"QH6M#SX:^#0,;AC:,;!C;,+%A:L/,AKD-"QM*Q^$5)U\JG&/U MT,?H_U$](HVH'A[W1P:MG*Q2X0AN4K&A:H-K0\V&N@V>#0T;FC:T;&C;T+&A M:T//AKX-`QN&-HQL&-LPL6%JP\R&N0T+&^CZ3HVE42HT;1JEC-FBBN*`V1+19&U*H-O2I MY,::2HY!7%(5D"J("U(#J8-X(`V0)D@+I`W2`>F"]$#Z(`.0(<@(9`PR`9F" MS$#F(`N04DDGHUQH67-!N8AHLURDZ%,)2`6D"N*"U$#J(!Y(`Z0)T@)I@W1` MNB`]D#[(`&0(,@(9@TQ`IB`SD#G(`J14TLFH#7'OV%X_9_,IFGK.7^"*=F:5 M2"EH)YQ8Z!2G7;'6L[A.9718W*O0/W_EZ M%C=RK8*.2:]HI`I2%IA]1'&B`-D49(8Z0)TA1IAC1'6B!1J>MC:Y:Z6!_KI?Y) MW8AP:RJ79"YV"KECF48WZLOBR10U-$H)J(I1+E(-J8[D(360FD@MI#92!ZF+ MU$/J(PV0AD@CI#'2!&F*-$.:(RV0J)3T43-+B2:J2TI)A%NE)$DKDK)X,F[7 M#5`5HURD&E(=R4-J(#616DAMI`Y2%ZF'U$<:(`V11DACI`G2%&F&-$=:(%'= MZ*-FUHU85^M3D'S$&)UM#Z_KU??'@$Z_=+(^,37EZ%%B_(!1KLZ-,UI,ZKE1 MF39'17=S/#]78LK1Y:VV0+*>3595%)_87:0:4AW)0VH@-9%:2&VD#E(W)D?M M=D]%Z;MM/4+IJRC>[0'2$&F$-$::($V19DASI`42%9T^W&;1B07[GQ>=7/;3 MV_#A>13?@!#3FEYT,:FC7XFC"K0XUXK.>B)155&4PJ5X/)S&7=N6RJ*,[58E*YVDQZKAOK[D1'!7&J;DQ&L/YP]3'7@$EU M:\BD=RM;L`[72$5QO\9,*M>$RQ:\KZ`O*#W='EK_]>'3$CS_HGCSE@$TYL2FZ"PV;KL2F MZ)UA4UYLBG[&86_*9F@3?;A.O%!?@#TMGSQV\O]RWH7)C;^,Y5P M)KH]M9<_(9+_.01O-,/2SV>"`_WR)WKY2K_U\NF+IQGQO/\Y"`[\'WKK]/'7 M8P__`P``__\#`%!+`P04``8`"````"$`--(P.J<)``!.*P``&0```'AL+W=O M!_`QD!`"4<#OE]7 MJ[.[SX0X"1K`$2;)S+<_U787U=WE0>%HYV$@OZ[Z=[NJ[_C^CY^'?>^C/-6[ MZOC0MP:C?J\\;JNGW?'EH?^?/_UO=_U>?=XRB.4/%>GP^8,?YY>AO7;J=P\ M-4Z'_=`>C:;#PV9W[+<*B]-7-*KGY]VV=*OM^Z$\GEN14[G?G*']]>ONK4:U MP_8KX?M(GHY5J?-XQZ>^Z?E;+:HW?S! MY`^[[:FJJ^?S`.2&;4/Y,\^'\R$H+>^?=O`$(NR]4_G\T/]N+0K;Z0^7]TV` M_KLK/VOE>Z]^K3Z#T^XIW1U+B#;D263@L:I^"-/H22!P'C)OO\G`OTZ]I_)Y M\[X__[OZ#,O=R^L9TCV!)Q(/MGCZY9;U%B(*,@-[(I2VU1X:`/_W#CO1-2`B MFY_-Y^?NZ?SZT!]/!Y/9:&R!>>^QK,_^3DCV>]OW^EP=_M<:65*J%;&E"'QV MB%QQ'$M'Y^)H3P=WDXDSO9M!]5<\H;1I-WS**FT0N^(PE0[PB0Y?K&HF/>%3 M>DX&EC.:B@!=J1!&6--"^)1N%GR]XC"7#I;H!&V8OQH-ZY)&^(*^]L"Q)[.[ M)I%7JK4P>^(+^GXQ-!8F4'R1OE\*C@49;_L=I=[Y8GLQ]:*;?ZV]P[;3-V/( MW9PWR_M3]=F#B0FB5;]MQ#1G+80*[Q@VM=Z[UB/WDK:M-.^Z)QK1EQ& M/$9\1@)&0D8B1F)&$D921C)&(:FLT MAG0J1A/=:'TQNO1<1CQ&?$8"1D)&(D9B1A)&4D8R1G)&"I5H@89Y^(9`"^LF MT!B>54L@JDC6C+B,>(SXC`2,A(Q$C,2,)(RDC&2,Y(P4*M%""-WNAA`*:SV$ M+1G#6%`ZYM3HF!(STC`2,A(Q$C,2,)(RDC&2,Y(H1(MJK#`WQ!5 M8:U'M24050S8FA&7$8\1GY&`D9"1B)&8D821E)&,D9R10B5:",6QT]QP36"S M<..&2\CHL6V)T6-G1H^]&&$"7$8\1GQ&`D9"1B)&8D821E)&,D9R1@J5:.&& M(X46[NMKEK#6H]H2M<(S$C`2,A(Q$C.2,)(RDC&2,U*H1`NA.(W= M$,/&7`^B1$;?O#/Z)EE=.B=''D<^1P%'(4<11S%'"4%AO0HBP.# M.C%<[ZGBO&MT58G4OLJ1RY''D<]1P%'(4<11S%'"4Q8L?^MQ(6`B#*=L]:([BY6KD3CYI*K.;AZ'/F(R#%`1(XA1Q$B(FJG*VZJVL"KG]^1R(6_?SZV[[8U5!#X55MF,= M'L,-I[SW;(]*6M8D4K,F$3V1"QXB:Q/MB<;&$WEDA4_D2S0FK8"LE$%E&:M! M2%:H%7&MF*Q4+6.`)F2%6BG7RLA*U3(FCIRL4*N0J"MKXERE9JTC._"KQ"4] M[3$,]%![!6MY,PVJZ9&(0NJBU?SBZ$ED-[]&-=GWT8H<`T3D&'+'"*W(,49$ MC@E'*2)RS!"18RZ1TM0"K1I'??T69Z<;0MH>M;20MLB&P4*3NF5,Q&O(I@B\ M3;=2+B*Z5/4DP8_Q(WT<>ZC&RD%B-0F6#,V!&03Q/C]6(Y@K(^= MN?+/F.\C5*6*8D34Y(20\OBV,612M"*M#-'51N=H!5N#2W2MF3&/%FC5R.OY M%0>[&_+;G@.U_+;(4=MI.T96UE9K!:,/QYJ+B'8X'B*8_G[_-#Y:D5:`B+1" M1%>U(K0BK1@1:24,!2(^/,2LI0V/O[4/:%2,3`GAA[XQ:HQ0K*6C M.FHD8C$RO:Q_#:>BM@:LR)7"A"14HAH*J=`<\K#2:2,@S5'KD0..7J(:)?@<\>`HQ`=:8&. MN%7,4<)1RE'&42Z10S46FI4^`8D#IKH8_+W>WAY3U35"O'LB5G=M/VL9^]DU M6E$G<25R:/OB231IYZ79?.;P/0!7"A"I3>![`+3"`3"S)R-E"S`WIM(([:G) M,2+JUPDA6M9LQ]P#H!5I98BN-CI'JZLK78%6'2,)Y*^F_<_J[7>''64[+;(+ M2=;RWJ(F%&U/:U_4:E\R.92GEW)=[O=U;UN]BY>PX'9R>7_![1MB*PM>$8-K M/-@WF"63!?S$U\&G"_B1JH//%O#+2P>_6\!/!!U\OH![[PYNC:!%S4[?:!$< MW!;B6,9]X!BV$(/"N$KC4@0?O*H$K&GCPKA*X<($' M[RJ!^PRHIROI<#L!]725P%T#U--5`C<'4$]7"=S:0CU=(8-K6:BGJP3N7:&> MKA*X185ZNDK@WA+JZ4H!7$Q"/5TE<,T(]725P*4AU-.4#"^)@[<9WS8O9;8Y MO>R.=6]?/L-`$Z>;?N_4O@_9_G&6@_RQ.L-[C,UX?X7W5DMXF64T`./GJCKC M']`!AI4L;6O17.ONT%Y?MM9?7[)/&VLQC-7U4)V[:[.UOC>#]?GQUU\> MWKO^=3@US;@`A>NPM4[C>(M7JZ$^-9=J6':WY@J_'+O^4HWPM7]9#;>^J0[4 MZ7)>N;8=KBY5>[680MS/T>B.Q[9NDJY^NS37D8GTS;D:X?Z'4WL;A-JEGB-W MJ?K7M]NGNKO<0.*Y/;?C=RIJ+2YU7+YN^Z5F)8'@L!YA;PS6H$_^L6A.59OY_'/[KUHVI?3 M".4.("(26'SXGC1##1D%F:4;$*6Z.\,-P-_%I26M`1FIOM'/]_8PGK:6NUFN M'3ORUJ#RW`QCUA)):U&_#6-W^8<9T8@F$9>+P"<7\<)EL+8]!Z[YD:/''?W) MT=G,<@19>MOP*6X;+O[!+8;<83TYS+P2+!1Z)?B<=Z6(.\`G=_CX2BM6$5K@ MI!JKQX>^>U_`JH&<#[>*K$$G!C%161;D5.L?E1IJ3$2>B,K6@K"AB@/TY]=' MU_<>5E^AIVINL\,VCFZQ%Q:D@8AL8H+4!)D)IE`LDE0I=*8I"#RF5PHTJZ4DAT\C\I+#914L*0RYL]C(I/DH*MV*O7FQR MGAQ%`Z4.0[Y+ET5@>U$$?\RL(*F<^\$]"*E"EW)])]Q$OK&1E,*/WI6>%C*[ MS$\+FW2TM#"D]TI@5'CO<"M9X40@6>&4(]XK[GICAWY@+/5,^$FI7"`I5>A2 M_MKVHW5D9+@4?G>ZA4PZ\]/"YB(M+0SIW1*@MRQNI7;+Y"A*G)+7>WCZNC"G M3)WGK(W=)A-64BL72&T7IL4[SW4C+[2-8I7"[4ZWD%%)2@:J<^P6"X\I5@A$!,+[2`('"?8 MH$92[TQ?7V2N4C)V9YN%>7+:9]D4!E<5Q=_!!DN#EF7=8Y1P%,A=)!5([B(9 M=LR%E70L!)*.I>:HQT@,6US1!_D3)D=$+/S MPTO3OS3[YGP>%G7W1@Y_X1'^^#!A=C*]6\?PE@?),/DFAO>D.SR*X;7B#G?@ M!RC]G5]<&PZ_Z?HQK@$O`C&9];$/S/8Q&=_Q+W"2_D37NJ&U@Q-V^E@PN0L7 MOZ.S\V(XBKJC[X/^72$_AB,=[+`+8C@!N]2_M M=5B_9EY.O_N1OAK)T^"D[P?RL-'-792]BJCUTWBB_D`M/_ MUCS^"P``__\#`%!+`P04``8`"````"$`?M2%LXSDXJ+*B:!ZQ.' M58E(>;6-R9_?#S66*W*X^?UKNA7Q2.6/:`81*Q237NEYX MGDIR5E+EBII5\"43LJ0:7N764[5D-#6+RL(+?7_BE917Q"(LY"48(LMXPNY% MLBM9I2V(9`75$+_*>:T.:&5R"5Q)Y=.NODE$60/$AA=A^"48T.6";ER/XDB=2*)%I%^`\&^BQYKDW]P!IM4PY*,"T.Y)E,5D'B[M@ M0KS5TB3H+V=[U7EV5"[V7R5/O_.*0;9AGW`'-D(\H>MCBB98[!VM?C`[\%,Z M*'I"VS,!V.3,Z(S/F%D.YLX8N3=@&TJ.)KJ%!YYC` MM0T^G+[A6F;K,S(%T]4SNH8(G2'EDQY3U"JP3(T32.V$,VJ=>C*AC"[/)CH; M]C:=C24\4@41=G&Q\L,)5OF94L%U?0IKF<+AZZ@9GU8#)=9E_;@JT;E/U5BB M(S78D#O5;M3X(W=Z5@XN[',TEGZM3$[+F?=I/Y:#SGTJ:QED;GJ:*H#\=B5^ MS&6\^V0'TW'R`CS:@^Q%P=P]FSRS<,!BVT34/P"S=S1=U2J"IC68>6`/TL%T M0A.>YH&FB^H[L&W`3IV&Q9H&^S1_1]-5[2)H^T5[8@^F$YKP,`\T1;/H@D.+ M,VU0>P=3K\YG_CNB!MWB3/$=]PALB!!`I[G:F6Q'5LGDEGUA1:&<1.QPWH8P MA%IK^R^P-FUL:!\MUG:WO/8+S.B:;MD/*K>\4D[!,L#T33N0=LK;%RUJ*%\8 MU$+#<#:/.?R-,1A$/I9_)H0^O,`&>>W_W>H_````__\#`%!+`P04``8`"``` M`"$`0^T4W#(!``!``@``$0`(`61O8U!R;W!S+V-O&UL(*($`2B@``$` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````````G)%!3\,@&(;O)OZ'AGM+ M:3,UI&6)FIU<8N*,BS>$;RNQ4`)HMW\OZ[HZHR>/Y'UY>+Z/:K[3;?()SJO. MU(AD.4K`B$XJLZW1\VJ1WJ#$!VXD;SL#-=J#1W-V>5$)2T7GX-%U%EQ0X)-( M,IX*6Z,F!$LQ]J(!S7T6&R:&F\YI'N+1;;'EXIUO`1=Y?H4U!"YYX/@`3.U$ M1"-2B@EI/UP[`*3`T((&$SPF&<'?W0!.^S\O#,E94ZNPMW&F4?><+<4QG-H[ MKZ9BW_=97PX:T9_@]?+A:1@U5>:P*P&('?;3&PO8V%L8T-H86EN+GAM;#R.00H",1`$[X)_"'-W9_6PB"194/`% M^H"0'4T@F2R9(/I[X\5+0]%0W7I^YZ1>5"46-K`?1E#$OBR1GP;NM^ON"$J: MX\6EPF3@0P*SW6ZT=\E?@HNLNH'%0&AM/2&*#Y2=#&4E[LVCU.Q:Q_I$62NY M10)1RPD/XSAA[@*PVJMJX#R!BOT#J/1+M!K_(_8+``#__P,`4$L#!!0`!@`( M````(0!B(%<'!P,``'0*```0``@!9&]C4')O<',O87!P+GAM;""B!`$HH``! M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````````````````)Q636^C,!"]K[3_(>+> MDK;1:E41*BSBIS80DJ412[*4C[4W+K0[\_LW MPRNRG!Z+L(MWS%Q">84+)NLV#$)T^))SS:;..16%K[L M>"KUZ^'PA\Y?)4\C'EWDAX!:'?%V+\\-&F5AR4^L@[<<")L&RO,D#IF$79K+ M."PRD6WD`+^&/#'TMM$`=H2'+T4LW\RAH;>G!@E9PJ<0V-RP1'!#/RX8]YR5 MHGDL+H1I[.7MGHL[5D1LU0"K=*MGE3C)!>R,!^R MXEEL.9?"T,&A7JR&;=_V.!Z9(^`*SC#J>I:+-1,P=#D&L4RX<#<>*Z2"\@A: MXA%[;2N=IRUF1_V,'4="SL$6Q1&Q%W8%@I@,D$+ MY$SQ&9"KKV!(`-F67TKS#CDGS?49U&[.P(R4&->?(\?^@P+;=2AR+.J@8.5C MZLZHZZDEF+NV,R\+,\6^HPP*MC7V`WNRP-3"$^R4(8G2E6#?QH1.RG@'C.?C M&?9];/5!["]`%O:T;">*YCZ&RCH!J?9JU6G460)W^@M2+#U`UO)XT'TG=E$Y M/R#?1Q!;&6_A$D(][%-RCWRUL#-D^W2-%BM,EQ@1T*RBJ@Q'5A."?Z]@*Q2O MRPTIO?JKJ^[6_HJ%*:J0C6>THE)Y=Y?H\3PC8!^E72'TV.P>` M6ERR.!$T@/?IA<$C<;C%RDN[O@+;S7T\$`U4">DO@YI8/^:F+\^)TZ0N=_]Q M4F/J>G\^3[4(:FJGNJJ2O"]-YVX/_4\4,KOD.4Y-6NO5URJGWK-,HL MGZZ!9L=5HC:D\[Q_>-`7\L1\7C'OXK!1) M&62Z9>D3CQJ?SX;R?[6N/Y'FU>AR>#.$[TAKS="/WT7S'P```/__`P!02P$" M+0`4``8`"````"$`;NOT>_\!``#G&0``$P``````````````````````6T-O M;G1E;G1?5'EP97-=+GAM;%!+`0(M`!0`!@`(````(0"U53`C]0```$P"```+ M`````````````````#@$``!?&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`!6=C8%Z#P``>U8``!D````````````` M````>!0``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`"3IK1D+`P``ZP@``!D`````````````````4"P``'AL+W=O M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`+"2 M]X9T!@``$AL``!D`````````````````DCH``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`*+8U>&3`P``[PH``!D` M````````````````F$@``'AL+W=O&PO M=V]R:W-H965T&PA;H#``"8#@``&`````````````````"* M5@``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`(7Q M[ODV2```9OP``!0`````````````````>EH``'AL+W-H87)E9%-T&UL4$L!`BT`%``&``@````A`-)W,S<)#```KW(```T````````````````` MXJ(``'AL+W-T>6QE&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0` M!@`(````(0"^@7BM%`,``#`)```9`````````````````-NU``!X;"]W;W)K M&UL4$L!`BT`%``&``@````A`,ID7I.N`@``T`<` M`!D`````````````````)KD``'AL+W=O&PO=V]R:W-H965T&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`.0UJ;9H"P``%CH``!D````` M````````````N&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`%?J+^%U`P``?@L``!@`````````````````;=P` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`.JR!"IJ`@``:P4``!@`````````````````/^@``'AL+W=OP0C0L,&``#$'@``&0````````````````#5\0``>&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A`-`$T,:D#0``.4<``!D`````````````````B_L``'AL M+W=OB\( M``!C(0``&0````````````````!F"0$`>&PO=V]R:W-H965T12CT_`@``+$E```9```````````````` M`,P1`0!X;"]W;W)K&UL4$L!`BT`%``&``@````A M`'S&5NVU`@``$@<``!D`````````````````_QH!`'AL+W=O&PO=V]R:W-H965T(07`@``&8D```9``````````````````4A`0!X;"]W;W)K M&UL4$L!`BT`%``&``@````A`)-3-/)@"@``@C8` M`!D`````````````````F"D!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`');%:XX`P``)`H``!D````````````` M````XD0!`'AL+W=O&PO8V%L8T-H86EN+GAM;%!+`0(M`!0`!@`(````(0!B(%<'!P,` M`'0*```0`````````````````'U+`0!D;V-0&UL4$L%!@`` 0```R`#(`APT``+I/`0`````` ` end XML 13 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
3 Months Ended 9 Months Ended

Aug. 31, 2013

Aug. 31, 2012

Aug. 31, 2013

Aug. 31, 2012

Revenue $ 12,329 $ 12,329 $ 36,988 $ 36,988

Operating expenses

Selling, general and administrative 207,753 231,953 626,092 649,454

Research and development 95,418 53,694 216,590 276,324

Stock-based compensation 52,945 105,446 175,866 226,162

Total operating expenses 356,116 391,093 1,018,548 1,151,940

Loss from operations (343,787) (378,764) (981,560) (1,114,952)

Other income (expense)

Interest expense (707) (762) (2,058) (7,424)

Change in fair value of derivative liability (902) 60,562 (11,342) 104,526

Gain on disposition of equipment 0 1,500 0 1,500

Interest income 36 106 171 593

Total other income (expense) (1,573) 61,406 (13,229) 99,195

Net loss (345,360) (317,358) (994,789) (1,015,757)

Less net loss attributable to the noncontrolling interests (42,264) (22,771) (91,211) (71,841)

Net loss attributable to MultiCell Technologies, Inc. $ (303,096) $ (294,587) $ (903,578) $ (943,916)

Basic and Diluted Loss Per Common Share (in dollars per share) $ (0.00014) $ (0.00028) $ (0.00052) $ (0.00099)

Basic and Diluted Weighted-Average Common Shares Outstanding (in shares) 2,105,332,608 1,065,058,664 1,730,465,999 957,413,780

XML 14 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

GOING CONCERN
9 Months Ended

Aug. 31, 2013

Going Concern [Abstract]

Going Concern [Text Block]

NOTE 2. GOING CONCERN

These condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As of August 31, 2013, the Company has operating and liquidity concerns and, as a result of recurring losses, has incurred an accumulated deficit of $43,158,172. The Company will have to raise additional capital in order to initiate Phase IIb clinical trials for MCT-125, its therapeutic product for the treatment of fatigue in multiple sclerosis patients, conduct further research on MCT-465 and MCT-485 for the treatment of primary liver cancer, and initiate clinical trials for Xenogenic’s bioabsorbable, drug eluting stent, the Ideal BioStent™. The Company’s management is evaluating several sources of financing for the Company’s clinical trial program. Additionally, with its strategic shift in focus to therapeutic programs and technologies, management expects the Company’s future cash requirements to increase significantly as it advances the Company’s therapeutic programs into clinical trials. Until the Company is successful in raising additional funds, it may have to prioritize its therapeutic programs and delays may be necessary in some of the Company’s development programs.

Since March 2008, the Company has operated on working capital provided by La Jolla Cove Investors, Inc. (“LJCI”). As further described in Note 3 to these condensed consolidated financial statements, under the terms of the LJCI Agreement (as defined below), LJCI can convert a portion of the convertible debenture by simultaneously exercising a warrant at $1.09 per share. As of August 31, 2013, there are 4,659,629 shares remaining on the stock purchase warrant and a balance of $46,596 remaining on the convertible debenture. Should LJCI continue to exercise all of its remaining warrants, approximately $5.1 million of cash would be provided to the Company. The LJCI Agreement limits LJCI’s investment to an aggregate ownership that does not exceed 9.99% of the outstanding shares of the Company. The Company expects that LJCI will continue to exercise the warrants and convert the debenture through February 28, 2014, the date that the debenture is due and the warrants expire, subject to the limitations of the LCJI Agreement and the availability of authorized common stock of the Company.

These factors, among others, create an uncertainty about the Company’s ability to continue as a going concern. There can be no assurance that LJCI will continue to exercise its warrant to purchase the Company’s common stock, or that the Company will be able to successfully acquire the necessary capital to continue its on-going research efforts and bring its products to the commercial market. Management’s plans to acquire future funding include the potential sale of shares of the Company’s common and/or preferred stock, the sale of warrants, and continued sales of the Company’s proprietary media, immortalized cells and primary cells to the pharmaceutical industry. Additionally, the Company continues to pursue research projects, government grants and capital investment. The accompanying condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

X

- Details

Name: mcet_GoingConcernAbstract

Namespace Prefix: mcet_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure relating to going concern.

+ References

No definition available.

+ Details

Name: mcet_GoingConcernTextBlock

Namespace Prefix: mcet_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 15 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 16 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

LOSS PER SHARE (Tables)
9 Months Ended

Aug. 31, 2013

Earnings Per Share [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

The potential shares of the Company’s common stock issuable upon exercise of options or warrants, or upon conversion of other convertible securities issued by the Company, as of August 31, 2013 and 2012, are as follows:

2013

2012

Warrants

7,974,030

9,963,030

Stock options

50,399,503

24,168,947

Series B Convertible Preferred Stock

27,806,452

47,049,793

Series I Convertible Preferred Stock

-

2,293,600

LJCI Debenture

5,819,876,621

6,055,511,583

5,906,056,606

6,138,986,953

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 17 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

FAIR VALUE MEASUREMENTS
9 Months Ended

Aug. 31, 2013

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

NOTE 10. FAIR VALUE MEASUREMENTS

For assets and liabilities measured at fair value, the Company uses the following hierarchy of inputs:

•

Level one — Quoted market prices in active markets for identical assets or liabilities;

•

Level two — Inputs other than level one inputs that are either directly or indirectly observable; and

•

Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the Company and reflect those assumptions that a market participant would use.

Liabilities measured at fair value on a recurring basis at August 31, 2013 and November 30, 2012, are summarized as follows:

August 31, 2013

November 30, 2012

Level 1

Level 2

Level 3

Total

Level 1

Level 2

Level 3

Total

Derivative liability

$

-

$

30,587

$

-

$

30,587

$

-

$

19,245

$

-

$

19,245

As further described in Note 4, the fair value of the derivative liability is determined using the Black-Scholes pricing model.

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13537-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13504-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 18 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8

LOSS PER SHARE (Details Textual) (USD $)

Aug. 31, 2013

Nov. 30, 2012

Convertible Debentures $ 46,596 $ 0

La Jolla Cove Investors [Member]

Remaining Number of Warrants Outstanding 4,659,629

Debt Instrument, Convertible Percentage of Equity Instruments, Maximum 9.99%

X

- Definition

This element represents that, the maximum percentage of outstanding shares of the entity's that the holder of the debt instrument would receive if the debt was converted to equity.

+ References

No definition available.

+ Details

Name: mcet_DebtInstrumentConvertiblePercentageOfEquityInstrumentsMaximum

Namespace Prefix: mcet_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Remaining number of total Warrants outstanding as on the date.

+ References

No definition available.

+ Details

Name: mcet_RemainingNumberOfWarrantsOutstanding

Namespace Prefix: mcet_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20

-Article 5

+ Details

Name: us-gaap_ConvertibleDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 19 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

GOING CONCERN (Details Textual) (USD $)
9 Months Ended

Aug. 31, 2013

Nov. 30, 2012

Accumulated Deficit $ 43,158,172 $ 42,254,594

Investment Warrants, Exercise Price $ 1.09

La Jolla Cove Investors [Member]

Shares Remaining under Stock Warrant 4,659,629

Convertible Debt 46,596

Potential Proceeds from Warrant Exercises $ 5,100,000

Debt Instrument, Convertible Percentage of Equity Instruments, Maximum 9.99%

Investment Warrants Expiration Date Feb. 28, 2014

X

- Definition

Exercise price of the warrants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 12

-Section 13

-Sentence Column A

+ Details

Name: invest_InvestmentWarrantsExercisePrice

Namespace Prefix: invest_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Expiration date of warrants held.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 12

-Section 13

-Sentence Column A

+ Details

Name: invest_InvestmentWarrantsExpirationDate

Namespace Prefix: invest_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents that, the maximum percentage of outstanding shares of the entity's that the holder of the debt instrument would receive if the debt was converted to equity.

+ References

No definition available.

+ Details

Name: mcet_DebtInstrumentConvertiblePercentageOfEquityInstrumentsMaximum

Namespace Prefix: mcet_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

The cash inflow associated with the potential amount received from holders exercising their stock warrants.

+ References

No definition available.

+ Details

Name: mcet_PotentialProceedsFromWarrantExercises

Namespace Prefix: mcet_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Number of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 9

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16(a)(2))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_ConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 20 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

ORGANIZATION AND NATURE OF OPERATIONS, BASIS OF PRESENTATION, AND RECLASSIFICATIONS (Details Textual)

Aug. 31, 2013

Xenogenics Corporation [Member]

Equity Method Investment, Ownership Percentage 95.30%

Multicell Immunotherapeutics [Member]

Equity Method Investment, Ownership Percentage 67.00%

X

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-Section 50

-Paragraph 3

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571

+ Details

Name: us-gaap_EquityMethodInvestmentOwnershipPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

XML 21 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCK COMPENSATION PLANS (Details Textual) (USD $)
3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 1 Months Ended 3 Months Ended

Aug. 31, 2013

Feb. 28, 2013

Aug. 31, 2012

May 31, 2013

Aug. 31, 2013

Aug. 31, 2012

Nov. 30, 2012

Aug. 31, 2013

Xenogenics Corporation [Member]

Aug. 31, 2012

Xenogenics Corporation [Member]

Aug. 31, 2013

Xenogenics Corporation [Member]

Aug. 31, 2012

Xenogenics Corporation [Member]

Feb. 03, 2011

Xenogenics Corporation [Member]

Oct. 31, 2010

Xenogenics Corporation [Member]

Nov. 30, 2010

Executive Officer [Member]

Xenogenics Corporation [Member]

Mar. 31, 2011

Officers and Members of Scientific Advisory Board [Member]

Xenogenics Corporation [Member]

Feb. 29, 2012

Officers and Members of Scientific Advisory Board [Member]

Xenogenics Corporation [Member]

Aug. 31, 2013

Director [Member]

Aug. 31, 2012

Director [Member]

Aug. 31, 2013

Employee [Member]

Aug. 31, 2012

Employee [Member]

Jul. 28, 2013

Consultant [Member]

Feb. 29, 2012

Replacement Options [Member]

Aug. 31, 2013

Equity Incentive Plan 2004 [Member]

Dec. 02, 2012

Equity Incentive Plan 2004 [Member]

Dec. 02, 2011

Equity Incentive Plan 2004 [Member]

Jul. 11, 2011

Equity Incentive Plan 2004 [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 8,000,000 5,000,000 1,500,000 1,500,000 70,974,213

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant 22,074,710

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 30,000,000 2,500,000 3,000,000 5,000,000 1,000,000 5,000,000 1,000,000 500,000 1,250,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price $ 0.0011 $ 0.246 $ 0.246 $ 0.0011 $ 0.0032 $ 0.0011 $ 0.0032 $ 0.246 $ 0.253

Share-based Compensation Arrangement by Share-based Payment Award, Award Term 5 years 5 years 5 years 5 years 5 years 5 years 5 years

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date Nov. 30, 2015

Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period Fair Value $ 576,250 $ 692,700 $ 117,000 $ 298,500

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value $ 0.0011 $ 0.0030 $ 0.2305 $ 0.2309 $ 0.234 $ 0.2338

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 1.89% 2.16% 2.78% 1.62% 1.23% 2.20% 1.60% 0.62% 1.37% 0.84%

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate 147.00% 148.00% 148.00% 141.00% 165.00% 165.00% 175.00% 170.00% 175.00% 170.00%

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Term 10 years 10 years 10 years 10 years 5 years 5 years 5 years 5 years 5 years 5 years

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Share-based Compensation, Total 52,945 105,446 175,866 226,162 251,128

Reversal Allocated Share-based Compensation Expense 57,725 57,725

Allocated Share-based Compensation Expense 1,893 9,521 10,705 32,759 51,052 95,925 165,161 193,403

Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options 35,000 35,000 83,000 83,000

Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition 1 year 4 months 24 days 6 months

Closing Price Share $ 0.0012 $ 0.0012

Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Number 500,000

Share Based Compensation Arrangement By Share Based Payment Award Option Vested And Expected To Vest Outstanding Number 2,000,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Percentage 50.00%

Stock Issuance Qualified Financing Milestone for Proceeds $ 5,000,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 1,500,000

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent 100.00%

Share-based Compensation Arrangement by Share-based Payment Award, Original Terms of Plan 10% stockholder shall not be granted an ISO unless the exercise price of such option is at least 110% of the fair market value of Xenogenics’ common stock on the date of the grants and the option is not exercisable after the expiration of five years from the date of the grant.

Share-based Compensation Arrangement by Share-based Payment Award, Option, Maximum Term 10 years

X

- Definition

Represents the reversal portion of stock based compensation expense.

+ References

No definition available.

+ Details

Name: mcet_ReversalAllocatedShareBasedCompensationExpense

Namespace Prefix: mcet_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The maximum term of the option.

+ References

No definition available.

+ Details

Name: mcet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionMaximumTerm

Namespace Prefix: mcet_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Fair value of options granted. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.

+ References

No definition available.

+ Details

Name: mcet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue

Namespace Prefix: mcet_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of options vested.

+ References

No definition available.

+ Details

Name: mcet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodNumber

Namespace Prefix: mcet_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Percentage of Number of Options Vested to the total options granted.

+ References

No definition available.

+ Details

Name: mcet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodPercentage

Namespace Prefix: mcet_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.

+ References

No definition available.

+ Details

Name: mcet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: mcet_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Description of share based compensation arrangement by share based payment award original terms of plan.

+ References

No definition available.

+ Details

Name: mcet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOriginalTermsOfPlan

Namespace Prefix: mcet_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents that, the amount of milestone for proceeds from issuance of stock under qualified financing.

+ References

No definition available.

+ Details

Name: mcet_StockIssuanceQualifiedFinancingMilestoneForProceeds

Namespace Prefix: mcet_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Unrecognized cost of unvested options awarded to employees as compensation.

+ References

No definition available.

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Date the equity-based award expires, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Purchase price of common stock expressed as a percentage of its fair value.

+ References

No definition available.

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

XML 22 R40.htm IDEA: XBRL DOCUMENT v2.4.0.8

SUBSEQUENT EVENTS (Details Textual) (USD $)
9 Months Ended

Aug. 31, 2013

Proceeds from Warrant Exercises $ 130,800

Subsequent Event [Member]

Debt Conversion, Original Debt, Amount 1,000

Debt Conversion, Converted Instrument, Shares Issued 122,122,222

Warrant Exercised To Purchase Common Stock Shares 100,000

Warrants Exercise Price $ 1.09

Proceeds from Warrant Exercises 109,000

Subsequent Event [Member] | Xenogenics Corporation [Member]

Required Payments Under Agreement 4,300,000

Contingent Liability Under Agreement $ 4,300,000

X

- Definition

Failure to achieve the milestones could result in all milestone payments, becoming immediately due and payable or contingent liability under Foreclosure Sale Agreement.

+ References

No definition available.

+ Details

Name: mcet_ContingentLiabilityUnderAgreement

Namespace Prefix: mcet_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Required to make cash payments to the sellers based on the achievement of certain milestones at certain dates under Foreclosure Sale Agreement.

+ References

No definition available.

+ Details

Name: mcet_RequiredPaymentsUnderAgreement

Namespace Prefix: mcet_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of warrants exercised to purchase common stock.

+ References

No definition available.

+ Details

Name: mcet_WarrantExercisedToPurchaseCommonStockShares

Namespace Prefix: mcet_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Exercise price of the warrants.

+ References

No definition available.

+ Details

Name: mcet_WarrantsExercisePrice

Namespace Prefix: mcet_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionOriginalDebtAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock warrants.

+ References

No definition available.

+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 23 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8

SERIES I CONVERTIBLE PREFERRED STOCK (Details Textual)

Aug. 31, 2013

Nov. 30, 2012

Jul. 13, 2004

Accredited Investors [Member]

Aug. 31, 2013

Series I Convertible Preferred Stock [Member]

Nov. 30, 2012

Series I Convertible Preferred Stock [Member]

Aug. 31, 2013

Board of Directors Chairman [Member]

Preferred Stock, Shares Designated 963,000 963,000 20,000 20,000 1,000,000

Preferred Stock, Shares Issued 0 0 20,000 0 0

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 24 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

FAIR VALUE MEASUREMENTS (Tables)
9 Months Ended

Aug. 31, 2013

Fair Value Disclosures [Abstract]

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]

Liabilities measured at fair value on a recurring basis at August 31, 2013 and November 30, 2012, are summarized as follows:

August 31, 2013

November 30, 2012

Level 1

Level 2

Level 3

Total

Level 1

Level 2

Level 3

Total

Derivative liability

$

-

$

30,587

$

-

$

30,587

$

-

$

19,245

$

-

$

19,245

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19190-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

ZIP 25 0001144204-13-055158-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-13-055158-xbrl.zip M4$L#!!0````(`.IJ3T.B+G%]/9D``'6V"``1`!P`;6-E="TR,#$S,#@S,2YX M;6Q55`D``P=Z75('>EU2=7@+``$$)0X```0Y`0``[%U; M+$O<<535A,OEZO%.5=EC>[9[8V/#@4&VV2'!`Z3;[HW][RM!I@TD2`)$)DK3 M,1=W!+,G%"=^%'XZ@!_`P0R%;N3YX?VG@[]??YM;![,_ M?_[7?_GXI_E\]@L*4>RDR)O=OLR^.JES'3ON/Y+U\S/\^`=S1O[0Y^=N.E<` M5&?_!94CH!]I^G_/_O?XQ__-3J^N9_/9[[___L'#;TBS-WQPH\5L/E_3^>(D MF`9^SV]?+K_/E`]P=>WY-@[$_*_,\QVF!PM7)1^.GA(T\>CPT/RRL4R2'T7 M!4&*W`?RUD/"`[!4>+!Z)/##?Y0>(:_[$,7W^$Z@'I++MYC\^G9RU?-?'RC> M;!SF%U]OW7CU[VIV+[1M^S"[^GIKXM?=B%\*#W_[\?W*?4`+9^Z'2>J$;HD7 MG$[]7X_B30%FK0G\CO6#WCH,48N&>#&9^Q#)W;C*$"'=PX>8?3\&#BADT;Q MRS?\[^L7N=$R3..7LMH2Y'ZXCYX.5Q>SD9D#.'\;&W<9QQA]3<^MKI('E?*# M'O+KG\$7:NB@9_>A_GYRI>8!/WQ"25K_2'ZMYJ'0\=VD_IGL$GD$EA])?+?^ M`7RA[O;T,6ZX'U^I>6"9S.\=Y_'UF3LGNS[,,X2E\>T:>#Q%\\!@2_V6\/,;K[=$"^\?GZ M*_[PG'@'LT/\HMQ4G$1ABI[3V15R4VR!,C.!2>2&PEU=]#&<+X!Q`^`-@`SP/]8$)JF M_?&P^O":U&&%5HF#1Q3[D5?E`'_7<8H-+OJ<8]_`8[1^S]NU]:L*XGB%ARP\ MJF_$O=4C198*Q-<_K72X>C=5L6I!L:J,BE6[*%8=3+''R7DHG4)S'Y36:&9] M19!F(+C!RI%5,Q!@Y0RE&7BC`IFL6T$SRAR[+!4,H!FHK,P4E-W^PWD6_HS% M_A<5*QWT1"BVA-@A%$LB%N5&D+[@E3K_16%SS,R/-CX+M^F@LQ\]9J^G2P*GD<440B MI8?Y M)/]U@@O']\["$^?13YV@%@>G_UQB6;""'J,0_VNR)UBH%VM]&U5!^XV-2Y0Z M?HB\4R<._?`^F4"QOJU>,_N-AI]12"['41!@D<_PC3%*T@D3Z]MH^MEG9"A3 M_#"^^&%+&:@RQ0_RQ0];P\84/T@0/VP-#5/\(%G\L.W%95,U4ZYJIBRK[#80 M-A5#)2F&2HBP*1<:1RXD(72F5$J.5$I":$V9V%@S,0G!-"5R,B1R4@"KM/!] MRO\DSO]&M@.`BK`I_Y,Q_Y,#85/^-\+\3P[H3/F?A/F?'-":\C\I\C\YP#3E M?]+E?R,#5GD7ZI3WR97W"=Z.VP(B4^(F2>*V"XA,F=9"'+B`,MPM"%$5GRB M"+[?(_YC?7K&V6*Q#*/T`<7.(UKBWY+W,.Y,\?=[]+\[_XZ-G',2/:&S[$R+ M*"[%!IBE?D!,5;!,`O8X:99J7M&5@:YDXG MT$@*FC%/IZZQ!HRWEO+`G+"V#U@#1@>L`7.P+OO8EA7W!$`C;PXS86T/L$:. MO[):V[7L(6AL;_T1JU#[+O/N::DM'4+M=NE.$)HV*W6<)IJ@L\_97.G0IFG* M<"08$&$^A@J8*^;C2^3$WOG=5S]&+HGW3AXAR&95D!+M0)ZS/:F(6GZX3S[B^6BE),[X3TB6I[@-RS\ M.A43UH/S9BA+0SBE=Z_.U;S!^%8`T&Z.71>/B9\B;RI"\1:A&G6V"\\+M#FI M7:H#>-[Z<[=O+N[\/U"J>L"1YRY61;*B'GM=2ST"7R/:&+ MP`E)Z%,,5$&1.([_+D9^B]@QY[Y#C#-"K=>;F)ECB5`.["XH!X.NT9K0/:%;5+PV MT+%Y.%![R^74E?>&-RMM)\>AE\M'EK"X?@X!]]A[\I,H?LF6V4U(YD@.6^OS M72"\NE%([;)12-U"D4.Y4>R\R#%]&-.'(4E-1YDK]O8^C$OT&#AN-F][_I@M M#ROB__AW/(#7+X^23SY6Q,@`TR3XA!;*$KD]MWPRF9>1+9IK6!4U`68T@)%C MG=0$F-$`9F234L`LN"3S1K'6FW##9!F0O/J=3F!6%;`[?V1V\4?F7+$&JN.1 M[2"KPLBTSFY,Z^Q@MK5CJ'E,XEF4:=C'..Q9QC+TL"O3L(]JV)7!AKUU9[W] M#B%'UT1JI#/8E91C@LM(X#*RA*/!NOSJQ'$EVSC&$GM^D$UX7B%W&?NICY+3 M9S=8>LC[%D<+TBUGF68YW?G=NDGZ!8JO'IP8?7FI?X&<@'LMN@ZIE#61TF!, M5HYC]T#6IB"O>$\0'@.$&P=F@G/+&.\KNL52+^/24O9WV*2$0S<3MB@!X>3A M1V0>Q^#AQQJ8UF_DF3S\R"`\-@\O!YPG#R^CAQ\9MBKM%KXY?OP?3K#$6L,? M=?(=/:$`%K'T>L.7E]<__X*'UXG=AY?L=KF!Q2O?QOV;"MM)+7EK1_K4":Y, M2&F'%.6](D6=D-(.*>K>(J70VG?R/I)['V6P_3P<2)F\CT3>9Z=(F;R/1-YG M.*0T5,ZOEK<)^N<2LWOZA,I5SLHE^3=^-`K4<,-4'!\`/ON^IGLHL+7A0:9U MY2/#>26=F_`]X7LTV>0R]'.4)F2VH8J=!7*298P^KZ3(;EF_;GVM2(*\K>'] M?[_ZVO!R/XDT!9I'^([N[[[!`M]D,R85*ME^!E15)WGTYW*!@[@TBJM8Y6:M MJ/#J&VL(?L5`6O@AG21+U56:FR]=7RU(SJ'#Q^6&ZLHLD1NXQN?CG^;STR"; M7)A=H>Q$B/D\OY5\9%\C=[E8?=VS%28OT5UC/'"0L?>-'"WAW<"#SQ#,__;Q ML/JFM53D]V/\HT-LG[P^6^U=`LO+5*^ MCAW/#^^O7A:W4=":FG'P^L\6FOLGK);KW MDY0L72`+]%NKQ<)J60:I?X*"8':-W(A=[P@[_XC^_TBCK"G3%_(KHT47R.;.1XS4[V![B:VE0*\ MB51[6<%IO6B$?RRU MLE"%**H@'O:(X`,H2,?'A2C>FP9$WQGON7$^7J8/4>S_@3Q^?1MLUV`;*K:% M30Q72?=EM$FY'#Y,/*-G2;)LHTV+S22#OYQB']Z:%&AOD3=JD-(4YH+>#-9$ M)YVY;%"C`H?DLA!O]3:EBM+)''&P((3K)OVJ.^"ZL_E4-#8:B$W*_ZEEEV66 M6K'9I%1]^VRV-)T*AR-25!OB_QHD1630[DP8YW`].H&P+J(!TI^K+7B<# MRN%]N%3(9Z!ZV%`.5\2E3&Y[_]W'\:NWBFS)!12Z*+,.-.T*.AFX5%X!]*#= M!"HTFMQ'LQ3BI!=^+'=)>K@#Z=L8]R%D5CC`;NXDP!Y"6G4'TK)=S1"2\KA^ M3;.V'%(/(2E/],"4=)C8?`AQ.2(1X>*RPY$A).4(:D1"N)4-/A,I*$]D!'9I M@X5*RQ%>"9>6VP:+E%3K7S(066\90L+^Y8:A7(Q0,3F"I)W4?H:0E2-$ZE%! M$A+HCCAMQ2 MT^D^&\.-C-D@EIUXUQZ/+==V[](&LR MT-:ZZ`QS"RS=T`H5QA8\"&6_2:\L$PVPNS"%L/]UB:ZC2Y0M$+APXD[*IIMR MO9QR-!/LPUJ3(NDVOC5KV3+<8^_)"5U$.F:\-B+X2Q1X*&ZK.8-I\?D(]F6O M07L&W>JOM->.Q;>:_FM@C1](6VN.L?;'T&VC.(%01ZPK2TW:HCL`T):=KZOX M_Q(]H7")6FN([@\T6RVZ@WIB75EJTA#=771BJ8>3,!A.0E&A;A1"8;8Q[6'R M#8;)5W1=L_4VS%10UB'",NB&O1G1S4%-"Z::%,4PZ090FK_\9L8J:.N@+9,Q MQ8==MJXVPEL(9PTJ,QG3;[9E:K`39S'.G$D[J`(:NVB.;LQ5H%MFD3TJU=Y, M-BF1;MZAK11#W99,]M0?R]0KJ@9J34=OCIJ41;?TNJGA)[ISQ*\9AHDW%=4& M]2:^%?DF-3",NJ78.C"YR),U$'ZZR*I4H8?-&EFCC4*WE38V[/ESXA^%?O#I M(,79PL'LL!?5)B5L&&P6U7+ILUWETFI11-F@THF1!K&M%B43,8P,.AELL0+N M?`O)<,H=0B;&2OJ!9!IT1L6B^X)!\3^$.'1'TDZ.(\^JD3\*N&GB-`"^*L%9NX M"'8;-&K3'=I<4Q1=TVVM#[L93A^RNE&2G^[#KTVZ@YHK.-;2"I_H)JDNS#3I MBNY9YCJV&*K6AID??AC%V6E'*8I1T@)E=( M8`XULG54IXUJ%_ZV)773J-$]SASB*$DSE*&E+J1&.!/I8R>8$\^E>3(6W?Y\ M-NF=-3U=GEMKR^UV`]QI M%R='5TZ`DG4IK#IE7G]V>(4CNF/"D6-QKT.%7#=NBEN]J_IAE+'$<<.UXYTQ M:6W8EB68&TC1#=U!M>0&9?;L%Q2BV`G(E*RW\,.L>P$I"YX^/Z(P01W@Q,A% M@%DJ,_.Q(91Y&OKHSD11H;T;YKG`2O<H0[J+P?%\T5-3B8O@E()KR)@IQZ9#&YY3KE8?C%53 MT-!ML$56*9!E-+I03$-5NFHU/]+$29!'VIS@.[+]91T@2G=@NF(7@[1ZJKUX MHX&2L206Z%HI(1;&'!<.63,SNF4,RQP->0PWI1BPE/%P,7?^2%JR8:.Z@F32 M`6V,W$4W8'$?Y0;%KBS10$;W*ZJ-/8\JCB4>:"F,S`1`2R]N;A+&$P51"MU! MX&\5VL4Y6GZ><'(=+=#W*.F`IVJKB&INKVJJ69QZKR':G2\*J*K-(#;XPEP9 MFEB^N)#%J*79%M2-NE$4P1<-7:S*&O93MJZT8FQ=B.DAQI%2,L!C._.'Y(D'0>OJU^.0MQ MRI#U54QPCGP1H]1Y;@\E1O>$N0T*X\?+AF#V*>ACM#\P@&[LC'\>Q*H,-X$C M=6WW`E!0KC**7D#3BXL&!0C@)X]1XNS-'P2/=H M$`S&'0\(-49N8L+!N:.`3V.4L8J9'(N[;%O(SRB,RJ'F*G9XG1+L'69J+.>D MF^IJDTIK;@:1A8)=C>ZG#`P?8PRR<"&=M>Y`5HG MR]M"MNC.3[LE](QMYCBAUU6CO%MW1:LU%S08,Y8,J-!4=:L/%UP`I'NI.>D( M8-E"N*`AA^Z.YA!@`Z6;/&S@N/,M76^_QH,'/XPMZ&2-5['NTIJCH42B@)&Q M=7VN*&;1Z>Y:)!YD,W:^SVVHP#&*1/E,&+OGYR:TM,%$ZO"=,)R;"E107`]< M(M>%%QK`&<4_,@55+.)VY84+F0S_8P-5-RV!O-`@Q?!"MJ;:D'>,UDM8UTV% MOSB)[Y*91C]8IM7N4%P(JGBG^G['.N83?```P(+59?`BAG4:X.Q6K!=7=`[) M.@\^JQON&:P72^9;89T"Y^IF?`;KMMV9]5^1?_^`?S]^PF'L/?JY))LVSN^R M1PL=J'I_`J4]_$W]ZB#0554Q0`%$W?@;5$K*UU)J"]#4&148.B`3WMH8I>3Z ML#BZHN*H'Y#&#$5HCE!*VC?(T1'5UDT-JF:QW8\8(;-6$=G.*G).X'GLW_NA M$Y!?UT'.I9.B\SOR2XH*VR6[:(E>:[`45;6,?5!3PV;)6I7E+)"5<5&8-1+85!NK_P!M!H3ZC@9794V MM^X/I+86+?P'22$MCF,9(%2+[128G?N[""74/5D<=5B2X`TF4S_G87$46+/, M2[>MZHXB43(,$G%9K4^:&D0FL5CCJ*""P03J"32.`Z+JCB]D"T'HY<>U?%W& MQ$1BQ4?Y*::%RN1=82"ND(OOW&Q&R%,@9?20,A6[&FEUY6T;@E)JVHS>5+:V M$5*.6=#2B`YB;^C!D>RZ$FK'&+V[Y-55/Q/)Z!&F*JJM&M4F7/(H1VSVQNI8 MAK6E`%->;0G*V1B]U.3]U(1F:(PV;S)IJ>31AW!TC$9TLNM*K*-K5[N41U<] M'1VC8@DTH-FJ3+:[K!W!GHZU;`&HMJX#>=4ERM7M3P1>UH](5Z*K/*>GD^!7"46_,\3R_NJY%`2T/'G0K@ M*.C*!:RAPT\%M*P7RZ:RGM\B3T4Z#T5UJSJIV5M-V797FHL]?4:QZR?H_.Y7 M)\ZZ[;8N5BN,CJ&FK1EP?0AA.U[$B]%.10.#!\6,+K5CUH-87\`LM(Y0#SU]`3VVR^?G1RBU8%_`"@VAI6GC5(0H M9R!'.#A@29/1LG@X#>0IWW@R`X6O7-E%I"VI0ZA34/A*D:-41S_?H'"4&4FR M`,8C_N"ADL)7/QRQ.L1^''RUP5&JH^?'P5'W(]%3WX]C72\\]OYGF?=Z3*ZC MAN@G>]=M]1"$2X1]7^*G"(__D^^BG.XEB<*&CV>X9_3?L<:%>@5&K_CWKO%^CH?1R?Z]*U=L88#1 M=O^=^KA!RM&,`P+>.ZZ%UCKXCS5X)[H>/&]D'-$P:5Q\$,*]:OI=:KQG$$+/ M_=Z[<@4'(5/>N*UI$,;))>\=UT*#$,8Y+#O4=;O#!H8(%QBGP/0Z/F)[=0#& MN3!#2-'/K3$.?QF"8;&N@G'BRQ`""+*\C.-=-EK%"^-?K$UC--^OG*$@ZM25 M04P0=X@G6`JQ)H@>.PTA14\3Q!V!"&-8K`EBG%\SA`""3!#KF)KJR1G"^!=J M@EJ>3-,L1`;0`1JD-5NX#YOM5$^EVJO6VL.F6-53L?:EM;:PE,Y@+")0<4BNVO)[ M3M&9I$%/"*"EZYHJ;VMM\0FLP3A;05.A;D%3V0.-"?6-_3][3__1.G[8T?OK;W;O;,VT\.`^M%D2M;HO+83;O? M/REEJN/@=JFTWU@\B."0#J=]=]1T3@;]TC4J0'`LD$LHW]^3]'LNR##Q MXBX*'SQ7N.?KK[%PS4T%8#PU)]_9-^MVWD^JK#@,[="4^F`Q7A*Z4U5,(Z/ M0=E"E"OB5J]Y'"1V+.`(S/#XV5NBC0$:4N71Y MXS%Y!8>?KK?GHA?[=+T*$!P)XC)2E^MCI= M]]QRTNHW^UF+^:Y9GP-:"0'WW332;`TZ54';P]*?O`!>?Z9LV'/91[][VCS= MO[NV@')T),J(7JXMNX/V2?\H2.!K(,7Q'Y3D#R#CT<"D`NJB%73`6NP)5;=; MG9YAN3P%F!=`I&P]]L6.X>U>_R4Q&<(*1]$:%G-+(;]]S5\!]')=V6WV.NW3 M?9`79C\2R#NI7:X>.\UNZV3P3)!UJ`936`8\\/Z@;HJ+,(A#WW/IPSF/O1BM/A$#4>57:>P%(HXO1>Q$WHKR M(.2)HF]*N1'?+WHS^,9R,;F_8\.:2W0PG7\=7[/83N[V[ M&M/W]S5V/KP?W>.7[&Y\=7]U,Z$?:O3&^.KB>GA_/_HTNI"/EY+LYR>26&YA M"/7ECT=E"O8LPVH'SZF.5J55_@F0^S^T3I51^9+ZB7_@, M6&D-]EZBUV^WFV?9@]EWK;,/-;;@,4L>0\;B=!I[KLOWO(@CG(O"@U.K1X^"1^\6<6SAA,SEAH9"=EVI"]!X0X_#>N>[.Z(_.K MPF5)"`H?4Y0P%6K_*9H0'W`@@RHFA!)`OEI%X3W*Z'=C=L#X! M6*1I@PUCEH(OQ8#^P@,.(EH8E,>"$QZL#>(SRB['.'*&(KP'>.,BLDM-<[VF75/8]J\$Z@DL7F'!6J=G,3-V%QC0#\(/96QUY?-D%D9+YE'=#XS/ M8O@YXCY;`9L&Q$`H-;S_285BE"3\R-Y['Y@'-C0\4V,.,""8M0#&'T)N;M>; M`8?`ZQX\`(022["Q?#]FLRAT";Z[T'0ZFB(N(]#\4!L"#P]`KL M=!@Q84G$@\P4!]AP$OK.Y^H;'Y%"/*,PG2\`@C"=^J(>XU,N`#V^&;+W;@S_ M?*B#G1_CQEF&OG!2'_"*4V?!.)&)34+?K_O>[P`"IF-720BL_GYR/8Y!%HY' MG^LC^6ND?F3OQ]=C^(FX7/@\@,5A[-*@`$!8'\9QZ"`U7`9"((&=QGKL_9?+ M8;WW@<7>''``D(@<0`\&6P>S`$"[%;@[,U@U''X5XI)("GG)FO$Y]X(X8;^+ M-4O2)<"2\&B.N=6,$)P%(5!&OA/._7":PD3YNB=:)0#SX13OO0>8?AFZ*:XM M$20`T>X"*@BAJ.=_LD"D@`HNP])+8/F191:/?-T@-MS*ATOA>@XL%_"@YX@= MK!@SZG]G(+)(&`%;`H%`8N5[$M`"=ZNNR(1Z9^J%?!J'T922]S$22LJRD2M@ M0G;NA??XI1JCUSFK,9@.&!\@?\"%(CYR>.1Z1`])<6#JU8+V`WL`CQ`H"5(< M3".:-'Z3:$6%]1,0Y"`#-O,_3/?CM2+S>G47=QPI-5`^IP%/70]%)N@'%\N- MZ"\5NH$/,QG]Q.+,>C@RL,4`>QC)6R&F4KCZ/CT`J@X> M]J1$_AK0JE`]'E%@N`28'5![ILG^>3B\V\`/E]<7H%FVXS=2(C]<>0&"#6,# MN_`Y_5XC['A^B`IQ@T64,J/7AA&@-7S#P?'LJ@!FZ6BA_H M")N-^(*%*Z6?XVP"L$R$J(,_`N\1&FA5R(\KRA[$:OIA.H?%8ZS3HLD[L/R1 M(&;7Z^(H#-E99OLL,\-^3<'NGV0A;'SZ*[?QH5]_H(LA%[ MEI&J[<%3(XKU>N.HV]#=':U[G7A>B`A;JAA?4ETDBIM%/D?X58VV.#HGX*:X$/H**+@O*8?2N?!T(P=)U^'Y:H3B1 MGHP:Q,!;B4#?86:6Z:D?/3=9?&PUFW\^8_10W>?K,$T^SKQOPCU[)P-#*XY% M'/0B?EYQUU6?-0A)E/WE9F"9?T;YGS@-?LHSPR^:_2VFFM68A3?6\O^?DS-N MO>6,W[S\-R__STW.^HMP/`68'@+,+P%&`X+,+Q2A?14U5)43?*(G"\B66"/`S:GX0NW MCV!!QPMO!2-C)3'8L:6G6^2E44;=G#SGPA7>M9AS_PK49;+>.-JBTS2;9L!S M$68Y?.?=+\W&H&><:%$9WI=!E+PQ7,C-"K^*Z'9+T&TCNB>GS\"6&KH^A\!B M%R%8>U'PG-A,[\VF>&8XHU`/*0&8_'8-$$B?[UU65]YNL,^WHYO/[.+VYN)J M?&,52;XF[?MJ8SB6-[S?D\VU>!YY`?&;+E'G:0];.TW@;?H^;4$/CT(`)XNS M>4C*VI$;E:I6,2)A::E.S1H%O;-O?FG2E6]W4ZMU>O76J=MBW$;9OFF M)`+1#6P8%G$/2R&S/#E^@-LR2" M-9%6SI>+2;W5[M4H0F:6AJZBT$W!3LFLA4CP1%MU;`:4G*<8<6)+%.TK++0# MQHQ"\/.P^,_#M:X18]`H:40%P6A[\KHHN-[M][9/MXI`T$=K M62<*Z.)ZR2K+',\,.P.Y3+U:OK=5'EAC;I2BZ0<6$U50%ZL%-XL%&SM+:XW0 M%0:.Q`/W4\ERNI(V#E-0/<2P,]VOFN&\=4P;+UR6><27P/79^F-DD((RN(0, MRUP3,8<5!$TWPS@AC.^DL3)_S?7%@93E9W4#F&B@$>I(UM@*WBQ-0!G#FL0+ M'6*4VQPYU5/-GU352O95D&!T,090@8&I?7KWT-O!]0(TZ>W%;K"O("!\:\M[ M2(O4P;C1+*6]@?M&Q@BSG3-+`S=&W@>4U]D.6Z%M"(_\`4NR95OD9',%F*XQ MO3L51I`1)HO#91:?VHJ=5>^J!GVK(7UQJ.\]#.9](1G4;C;[N_2$K#E^#*/? MZ80Z)6%QI:CI'*/HUYS]&OH^A[>!;Z29&4;;.E:N?[TH=*P,,4:I9*)+7L94 M>K(W(HP9#314@(L"% MCQ]J\AG8H$RUBX`67,ES/_4H3GZH(+X^A:%PZP,E8@^5``^$C!,+>9H$[37V M*(]&P-+]:AJQU6@.+%U('BRYKCMUO0R*4[BXFM:MG?0&M9-V82+5/@.";,F] M@)(,TK>6[3+@=CBD33.<0`;P+$)LZ?SRZ4]JO<&)/??&G-O)W6#WBS`%FUJN MES:,@%\4U65&"&!!R94/JF$&)K%[CZHM2J_1LL%E2[!)%'.0\'\DJ*8BWR(J MWJ+VEM2:!+7!BKZW1#C-#4+2T".(>O=E4 M4[IEHQ(NG\0T2E'MM/LR!M6U,),2SI4M',JZSF<"->FF(@O_9,`A7J#+:Y@U M_1?&J]1JTH+9F=#KBU]-Z9)%]/@#]WQY5-L:G^4IN./8&.3:76@%ZKY.O?(Z MH9;>VXP[4G%Q6!20/RA,T79'$QQ9`]2*(T/#V&@TA0U2DG!4ZRWCKAM>6^:T M34A@H[XATRDD%S`B.4IEK;.&<&).,*@ MX/+\+I(&&"O:&KX3ZIJJVBS[6]% M,X#XKR&ER^6I@)J(I!C5:(9VD5*-:`%V"CY0.@M0`.QMD2`YL26,U[!!#4C% M?2DJJ%E0=F`I-U!^I2.V2=DP_LPN:(UD4'R638##X:A*H^1+Y0`!`* M/$!E#G9=%)!0FRNI2-AE[K;648W-4I:GV&T;)1T`HEG(H&M;-(]$PD'(]%8C MF*P(-DE;>;*J.@3]H82V^^2&RG)I9VAT5(>"`-]'XIV^^O M.F>P.SBLP\>2%3[FH69]@IH^6.TNPA['IX>2"\<9_1-,X7_2X=2%\#<:S?_^ MUVI@;)QG)(_05L_>1F-<^ZKG)>L)]H=RJGV) MS]?F+UOB_16.N.^"$0\VO'$VTAY,-C#/3>S-\[*_%Z+EARL1C@:&-L3VB8): MQILG^RE::`:H=GGCB^%:7GFG;(-,Q=E-W[-DTFHCY9KGKX&([7#*Z!1Q!B_DX]@<>UMY,W!EO+QV\M4((EN M9_2!K[]@^<(P<'_#LK\?2HPN,7);+_3S4-E&D'RC?^$)\L]ZD[MAQYJ'Z[5. MZ.^70[IG[][]X%H;5^_M$3B$PKU)J=#RARYB^15"]1/-U9GFVH;"U@NEY`.7 M*?J#LAA%WCQB\,;,V!5&R7D5\;SO[I2]MTAU6A6LL%:SV^P..KU^\2K>@Y'[ M+J2R#IH\!JDJ7&K4:7<&G9/>:>O8E)(*I&RH_(3GIYR'?0RZ5+@2:=#MY)OG MB6B\``F.S1KM"C*I;B/LZ;PJW/9`6 M-_MU&,PG(EHBQL\H6FR_%2T>YYS;3@,K$?_K:CP9G5]?LUJVWD+ZF4BN00UJ@]/0.+HL+.E5,;*"O4@^0S MVD>LFDVHCPL/)+#1R8JON(PD*WVVB@2,]'$H$5"=$;G0-OH,*A9C2$%MXX-) MA%#YK"#56>PLA)OZ4N0O.8$`M#LL>=W>0CN#=)<:2;N>YC;012&M$RH*P78, MNP68*,*7LJO M!@9M5VD>QKJ-TUZA>`$U)#8Y`O_(Z]*HUQ3K,L*\^X.R[2KKR<*53OX@8:@1 M%Y@I$(76U`S@FD%.CZPM5>W`S41LIN'3567",?C37G1=6[(_1VFAMGV?*45J M'SN,90IY-GE%V1FLW\G,#3EW33]#),6DFTH`?TO8##M0D>8Q9?ZH29O2L=E^ M8'9I%V>^H+,Q>29K9%)P0WR8_&PP]!Y^MFPGFZ5E-8=,]VFFWN#7!DI#JP'> M*B*SQJ_!`EMU2K%..P;K8MU8+GX,^5/@+2FNXC+CT2AP"EPSX0^+&0,=<-ET M*XJ:0#.FKNN"P66RGL#:>-Q%ZR[:!238MKKN7!J^JHAA%B("F/-$CN+8[2Z/ M$]U@?N)V,JJ?9U4_WZS>L*OMKHE7J>YSJ%^IO6+K!R^VE+L2V[;4EG)LS1(8 M#"5NIG]1>Y&Q0])*AE#SF@]7X,:6U9]KD_/WL'Y^D+BJ^??D"*U6LP8R.TAE MS7;6.I#)[4Q`R#0XUI_:Y:?F@#0B,'%")*N\+XV=DVLOS!]&^H`"!@NO:W>W MP=7(=VRIOIK8%DEQ&/-T=*\H='P\.#C2JJ:)VKG?S(YRYUC5D!26WL/%$/D_+"*KY(-M#`>X\"*[62B)-.`HF_CF51NP9#^$K/ MR[(-))PM`K+R4K7@%0M;![5N9XNQ6,W6/*VU!X67-]::F+J:Y5IK=INU[J!3 MZ_6[FR!5&J/3[M0&G9-:[[10_2HW4HT.)D=*/@BL,2HK][<,%6.M=C849]7- M!*YL@#:G:[![6PMHIH\%,W1RK!1)'O'*2CQ-L5JQJL]4:[9/:_W3PS?"H%L[*=K$ MNDGH&0PS3*1052RQY+_CPF5M.*'I,=GBPB"+)@D-MXW4VTY'H?FP_UW-5I42 M!Y.PM^FV%G>K>64%FN<:-JU<+?:K3`'SI@_$E^X&4-?($YO)R$+5]L`6T+!? MW"TSJL8T>7<#WJT`(Y98)!_33LL6WCCA1P*+IBU8(V2.9\`_ITF8DFKJVSU<*5Q452:YO$13^A-W=*FXI!#8O3PYC8" MMD3)J!-ZP4^_X*;7Z-MS32N'`0KEW3)N)GTGY3A)T#:]RFR?V%ZEZJ')"8OJ MIFIXIK2YJ&HP0SIOVY,BS^BCLANIMHAJ>91(UM%D=O-BET7>;(..P@HO6TFDYLIPL_N5 MMH9Z;82QT'PM$GO?YJ1EJL'6VD\6EEN0E.UWX2LO\R[-J)65WQU28UO(OI5? M6PM60']7T5QI0:RJ_YKF\USUBPF M-4F)JJ?DHB@L7Q:?*'3!D>,8@D<.$F89@GJ-23;()MB0@=Z2-B0*KKBFWA;H M=N$'[\'SQ5RHOC+4I"#0S-Y:/#ICU]2RZ2RCFT$X(SPR?)]>9/?I?=F*V37N5(%#,/68Z!;$/; MD=GOR>``INTLLZUV$D+&YK46S]PP^6B6IGI"W*3(PDI"%,%0O+H!'3HZQC:J M&*UJ=-J;'I=RN+[J?&GHR(,JI7^%#=#B09USY(H9QT2%F2#1SKN\:A`79.O& MVMA9N2NKL\W_R]ZU_K:-(_'O"^S_0.1:H`6<5)*?2;8%\G"ZV4OC(/&VV$\! M+=&QKK+DTR.)[Z^_&5(/2G[$3N-8=EALL+9,B?/Z#8?4J8NRNQ,HT6/M42),1)$Q.M>%'NM"P!3O#% ME"+;-)L6!4UEBS8L)!-`]^B,8P_$7PKQ,D#@/\76WOATB'B[K"A[\)/Q'(FD M>-`,6>8I2P/6-&*%2-W>Y>4Y>8UV:9-O3+"@5]Z7'H@-T/F2";[8I0\_RFGN MJ35PG$(C.7LAJ<9>`&8&+LY!92(KPI>YC"]B7,ZWT$^D`(C?4<]\M5'4.L7D M!^!$G-,:#]D?!`/\&?9D[@FOJP:*#6QYWB[Q6Y%V./?B8SJ$GL6#X[W8T(S\ MQP-YD/MX`ISL9\?G87R0K'2PXM`:B5H]<$2ZW`1H?D"\48H?% MA9R1Y\H2PK%Z:MJ6,+4H1,;T+N0RQ=]\2E19D"\3Q M>43'B7=.'Y9A!]>#J7@K`=Z2'RLMG)@=F%$02&6&"E0N0&;1L:65UA.WA.0N MZJ!A\E6;X:+CVNY3WVDLTX.AU^?W,+'H!FZNF'GSE+LO"F6*NPXO>X$H$C^Q:!06 MS<968HC'7,@XQ,9S0?)5]3"8EO/71MP3"?9S`+-,I3@#B0OB'>8?27X[62&':$[X.3SS'J_\P`CY)O3Q M:)"_O,C'FI)7/LZ4KK$OL7"NO^<%A_CI]OOO>12)9>!YH/<0KW&D!/MQ=B:$ MW>2.%V"*A_?%ICU&P24B#\C],`ZETWZPXR15.!FW,4P#^6)&:YH]+$S9H0$F MJX[YRT.N-W%^2^YP]HD\LUDCR80F92.@J>GV;3_NE5_`JC38*1?@C%C9LJTD M6ED(:ED`\X`1*\0^\^=(6>@CL2"8%4:>3I1:]6P\PGCT@2>N9J/ZC)GH+$92 M^"2ZRDB9QDT/G(*;%!,LQ!M:(WY!6L%W/="##Z&"2:,@3B.>#.8]:1*X1VZB M7@#4Q*7Y)J(9+8_])*,`82B=\80:!UI1#)$+,YRX:J!<#==G0^^>2J]AX]6Q M>WR3<(2F,TRS`*1&+#Z*L$G_SEM6N%36U\&57W'%U&8O%>;IE(L^N1+QSWEJDW-*C>5 M.[PHB+$UD3[`RU@&9,8+872`BP6_B^4(&OM:I5F(PB>R_H2R%LPZ7-`UUBMU MO3&G6\HS13,I@^^$P1X-0BPQC*6CKQ:RN'RZT@NPT*A7#*VU*`N\#%=R*$I: MXDNX>7$.4S8$\@UPA<=NW6%ML:P"58%B]O[]OW/,9*,DBF3I>GIY4@8VS1"KW52JU62`=: M-JK@(0/O<6)I;"$2,(D3!LM:O;"HNW"JJ]ZH:-4F0'9F)M"T.6FBE&+V)MH* M/[<0J\JG$@*&PP]"P*@K#%$0([C/8A@.(B&8B'R8)/\VJJ]\R_U+=XZ3/9^W+D^;5_O'G>ZW. M`G9(.M_;UV<7G1\'Y-X.T/.EK;N=JWDT79]__7,:43N@O2?RKPAU[#OW\XX# M4I3%Y"Y@94TD*W1X;H0RI+/_LDKMVB/AT57<$AX\L?)T47R M8-!1Z`WCAC]BDFH:)J(1GH+V><=HOL_;V+Q]<5)ZV5KX&=J6A?J=PX_^,NP4 M#5M4:R%Z9D335@S7HT(=>$8\@+VZ6"-U@G_AZS,I@-/G:Y/^I]A9X0A0+DTO MPK8RW&TWW&]TK*Q66>V&66U2;R"3@]%2IJM,=P-,-YD!2EY7FS1=HURZ5J:[ M%#OQII!TCXJ:LVRT.M>DGMP4>]+GO2ZW?/6WK.QJ&ZC=+3%6A3V%O8W3[I88 MJ\*>PM[&:7=+C%5A3V%OX[2[)<:ZW=/WXZ.3?W^][OQ]>0HV:9K]OFFN<$Y_ MELL"D9,87E7GSV-ZLYSPRA0[C<=W+^UQKXY.3\\OOR:O].M))LZ4$ MG:U4Z$89K0*F`F8.F+7M5>A&&:T"I@*F#,QJ:WL5NE%&JX"I@)D;,5\W>44! M4RTV_*O/_ZUPL>%DRE;8PDZ;]5G$PMQOL*M^20UO@JM^47YGN.JD"LQ6*G2C MC%8!4P%3!F9=WUZ%;I31*F`J8,K`C(]FVDJ%;I31*F`J8$K`3,H-;J5"-\IH MW]"JP\I3'*[MX"?IXQ$0Z1DC6!E-K3V5@L?UH'F#5X>-O>86O[1YOP&L*5BN M'Y:-\L$R+@BWE7I5L"P'CV6'9>E&2WVOM;^]>E6P+`>/"I9+P[*QQ;FZ"I:E M6F%8>5Y#^W$D#GIU[/X:UQ5*L[I4!A[+[I*7G<"L?/U7U\@_6*]?Z;84/"J, M*HPJC):;1X51A5&%T7+SJ#"J,*HP6FX>W]!:Q,JS'4Z34]G&-G,LM1!5"A[+ M[J!+MSZ\JY1:"AX5.!4X%3A+RJ,"IP*G`F=)>53@5.!4X"PICV]HP6'ER0_? M/8>&_#1@M=)4"AZWS2NO?C6XML8-%:M6ZQIST10J%2H5*A4J2\RC0N72J&QN MKUH5*LO!HT+ETJC>.XPCABIG5S.PS&D8^EK$P?48#9I'>F+S;UPQ"7?Z9O-/U M2K5F$"OR;?>.WQ\.L/+%T'/#0<#;X477=M-KS+7@2>(`>T*J>H4?G5PA/@MP M5XM]SYQQA3P,;'-`!C0@/<9<^-'T?+P/+E#B>$%`^KXWY`\GYH"Z=T@F_SK) MD@5,WU-\,G%LVN-K1WL9^T_R;S&9?U1I'UA)=%H$*Y=N0ZO4XQUGV)8+/!;: M8@_0M5JE;C3R3Y@G9B[BJ3*.16PL*F(AXSL*\DQEO(2()1EO$AHV$\/G0B'L MGH$]@2ZH.R:6'02>$X5HPIX/PX%KH=5$HT19)]YP!`TK,%0,&%P`74)[-Z3^ M&&^PW?1KA0P\!W0;X*V,@KEX41B$5#PQ&%!`!_Z$)`&MQS%Z0AO&BV*E76SN M.&!K8)VA'3IP/?3P*QE1VR)]VP=;M7FE7L\'Z\&N$HII$+`P*-!/Z#VU'1R: M".D#WE0_!%Z)B1R.3=6G!47[)&C?HA=1""\$1T/45$IYH;4XJ#J1XY3$6UD MB3]3K,B;Z\%#?:[<$84[37M$N6!B".>$-2%E60<# MD1@O/!PY`%&_/R2\T:Y#QZ#;@[[]R*S#'6(R!X\O-\&D^(WX?40M*_Z>!`HB M(A$!6!H\R!_][&,2K_SQ:6BR\$#(\?@DD^)5(L0;E&&7/8;'#GSX\OMOO_]& MR!]1L'M'Z>@`3ZOZCG[N>'Q,'>J:[&;`6/C5]Z(1D)?>APH*XN=*- M6TV_19?;];36;95_KNX0V_J\P(H9 M^+$AQ:VH-)1&MKE#6Q7&QE8S/[)]6&Q4Y)7J]?RM&8`+!XI]Y./BHN/M?L6H MU9]/E+$X42">_,A>O=LV(/[0#Y3QVMLE'H.2?)1D`0%QPXU?^[>F.!" M0,_>",&]BY7/L<'0LY@C-0:?Z3C>`WX%X$=#WCHXV*31;]5C=GX"]8(BN."3 M17[A_/*TC4QK-DP&?YR?=O_$YKE)MW"MD[W'ITD>=[K=SC>8/>ZS7L-D*,GD M0,FXQ47[K#OU]U0!,"JD?WMUB906NNWX,2>=BXNCJQO@QP33H:,`)J`=F)F> M771^')![.T#/6CCDMVWWBM[P?U6 MC\',V"D:]N1)J3+#)L,RB^M2H0X$Q[`7L$DC4G^A:_/I`!.'W_M^9]B9V6\ M]N$K)5T/589;+L/]1L?*:I75;IC5GK&>'U%?,EVCI4Q7F>X&F&XR`Y2\KC9I MNJ];QTR9[C9EZJHYRV9;9Z*>W!1[TN>5)H]A_>Q.RUXHNW:WQ%@5]A3V-DZ[ M6V*L"GL*>QNGW2TQ5H4]A;V-T^Z6&.MV3]]?M[+762X)1$YB>%6=EW/'=1EX MW)*3)E=>!4%*T-E*A6Z4T2I@*F#F@%G;7H5NE-$J8"I@RL"L;O&IGQMEM`J8 M"IBY$?-UDU<4,-5BP^JK>IUD^TMPPP)?-P25[WR&@G@ MJG5CC9.;DE>_4,`LB1[?)##K6UR_9*.,5@%3`5,&YKZVO0K=**-5P%3`E(!I MZ/7M5>A&&>T;6G58>8K#M1W$'VLI&3CSB`6A,2GX1J/5"_-VE,9>-RVLHPK M7QTV]II;_-)FC749%2PW");+GO[Z"K#4&]NK5P7+XKE":U:4R\%AVE[SL M!&;UQSUHY!]&_4#IMA0\*HPJC"J,EIM'A5&%487153@5.!4X"PI MCPJ<"IP*G"7E\0TM.*P\^>&[Y]"0'P6M5II*P>.V>>75KP;7UKBA8M5J76,N MFD*E0J5"I4)EB7E4J%P:EDW\8^+"&\`^?L6\S_O(%6QQ#AM![JFO3\DO-&N0\=>%![T[4=F'>X0DSEX MEJEINW?\1OP^HI85?^=,\!6.]).5?/HD?_2SCPGQ?WR*@MT[2D<'>`C%=SR# MXGA\3!WJFNQFP%CXU?>B$73498_AL>.9/[_\_MOOOQ'RQ]!DX<%54CCR!NM& M9J4EKWAE2=-S0[CMFO4_[USIQJVFW^*QJEU/:]U6^>?J#K&MSSMGU`QMZ[9: M!>8BUQ9W_'US>CMB_NW-@/ILAUC,M,%T`CS0]8NV5S7^^/0T"0FQ"9-)8D9P M1<Z]%Q3?,F3?11TW)GDZGER92*UG2_&OM8T:IF$%^F\2/"1 M:7J1&R:W0%NXXD?,NK!I#Q=\;!;\(A/&7";T1MW06AD3SR4H9S:9ECI]\3FT MX6%Y57:B,`BIBU8^PY+TKJ?KMU6-6]7M"3\WA=_ZC9_N&P5(\4U(0S8$"DX< M&@2=/F]P]&@'!3%4)3$$:'*!+(GSRS.4A59M&MI^;'G+(3VVG=PN-VZO@OR:/_J-HRJ#?2C#X%`MS]#W]UK7QK"^.:QV#B84Y M>BD1Y`?958C`6%P$AEY_K@CDT3I_\X4]M$-F=3TI@I"&[26!\8T^VL-H*`OB MFKIW#!E?B?BJ:805A'(Y27X:X%(I#+ MMTIB?`B/D=1K('GY:5"MOO,%A#"B[I@\T(#X[+^1C=7Y0X^,Z)AX+F'4'!!/ M$BSG%&OY"Q,CQ]AMPDFQP#^A\14@T:8.,:-AA"^0[QFQDM1U&A+JPG\NC-&\ M5A\!*N`CT!`.\(D>0"[$'N'>T!XY8R3C'8Q-!``X'F'W M.+U!L>!S4G(YA4!;CY$['R(;Z"X<``.Z\9[3@XP,]Z8ZCRDZFQ\4)3=@R^6\ M0T'/C:<&/(SDEJ'A9>:[LX+06G-E\UVNEN(-7>\I?[D$[:WY`;Y1K^N-V#R6 MIV-UT_:9_.R__K3])?0S"PMU[37UP\.+8PB5+?2SS`W`^7GND>_C2(U.X'B< M-8G]PM$#SFY&V##X"@W#X-P%Y-F>Q;^=`A#/W="WW<`VI\P?%G$(]26B04WV M#:_"3]F$6)\AQ"7B24VOO7$A&K=&:YH0JTL(L=IZPT+,S8\*0JPM8XG5-0F1 MN]1G]UB8W7$BS?-@2:Z;ZOK;% M0IKGHUK/67U9M9!^V1&F*]]'01`-A5?$&O1G,.,\CRO0/V]R7M]_Q\T?=JJYJK36>A7%*;X<2:\^)H);49 MOJPY+Q-#2*WY1J4VSZ75GI2:OA:IB84N_F+Q?.:+Q30M_AFN">)MDOL7;TI( M]@68#J/^0<\+!_G]$L7M$L6-$=^.KK^>7QX0^`Q_\2X9\5MQJT5%7*CPK)$^ MVG>A%[RH0]B(B2P_\=0NWCUDN](P.OI]H3>]-ODNSK=-JGOD9OV M]7G[AIR3D\XEWP]R?-$FY.JZ?=:^OFZ?DIMNY^3?,Q(E,@H&6H3*G-UP M7"$/-GR,P%KZD1]B_A`"QW.3I"*>R33P'(OYT&WH$1N0S4@TPL^9S0BQ%'7M<(?)MSA#O"FX,V.RN][@L4[E)@@-AW=DN=9PQ^,W` MOG,I'H*R$/^$&+/9!WW$J63G\U+)]D@'A/)7!-WKU0H\4*M5N!22!#83_N\P MI(ER(8CT+FIR;RTEK,WOALN,@I1#ZN!-"_$WA[L'AMERF>@"L"/4(=B8"9UB M*B1H^QZ4!#+>(T=<)T?1'2"#5'7D4Z]RFBZ]>YZC2*H:OVI4X!F.$ZM44N@B MP@04W#/28PQ$&C?C=`!AV8/PL29/D8QOBJ\E`D>J7.`D?\R1B_.3]N5-FQQ]O6ZWO[4ONS?DZ/*4G":!SG7[>_OR[[:*;EY7 M1_(8=-*YZ%P?D!X,;C]%C.J2#@S2.#KL\Z&Q62'?,%GZ!%P:88_,C-"_8YXU M>S2=*,`$;$=@C[OQ4;RAA]`$B>0#.G.2N'%#.TQ!FE[3#S_RV`E\ON]B4O:Y M:WK^R/-Y9$`^2#?'+7*WPH`17ZYP`?SC^3_W\H/HWZ[%\ZN!DI#YPW2026FI MI'TG<1T/BG"$M=@]<[Q1A40!@[$2A!OUP57`Q*_">0Y0-JF4CT6_M3UWLD\96/>Y*5^?`D$)7%;WVP44*@1=N->+9\$(W` M+D)BAQ"`,1AA0A1!;(*@D*L^3+G\"EK07LYPQ`^RW)= MG[_^[9X!!`A)2$8"Y-FJG&-),#/=_>O;]%QB8G0C"4%HK4ZG9L!L&(UE>Y%D M$39)X<%;$=FP0"9IRZ?P&0!-"4 M>^T3>/P9TQ/7!0;BD\`_GI%P!+T0/GQ/=4;4:G7(%SKY,1.1L\*'6!*">I$:')&N%" M0ZHWXWD?9&5`E&:/+.._."#V`FB;/:&X9P,B,Q`FXU[.G*V7'!5Y`8^`FF78 MJ8[#7H&;^:C.US\DC4I_?D8A&A`*M\#^6JV&='2TN+\&9I(XC040-"%I!BD% MW&7BX?N$N'7VQF"=(7&UO#''("`D^DS!I.MS&0Y[#..[YKQTV/"0X4_\N`AF M#,/V0NJ`YM5FN#N%T1HD::@T4K9R.U:@D9_:7>A M-9Y3<\:>>5T/34.6`O*)C+AE:7(YY]#U!0)'X9*?%*6!.P3G];X18&&!ZH=] M1*K_.\2-*@0"\.[1'DQ)+,ZXTW,0X9.6_D7%2,!">=P%[%D_.U^^+0X"@<3\ MP;+.$S,(E\P'W7&%Q6"!;T788(!]7(W3^RO@TX)VY_8]!M@,AA;]7V0_$N.0 MNL$X6HO'<;1B?YH,44%LZ^.*_E\WWCQ\.UI^-E&K!5'%KL8;\3<^WE09\&C% M,42E\%=>,MY6!?F;P.\CM[M\IA&5)VUCYF<4CY8?*"2WXK:@#(QO0E-GN:#Z MNZ,I6P\VH6G%:45ER$E^+4W+-Y=O)J>$;[7T$"<:!AGU-4<@\W!;&!BCPX^ MYISB6WN&[Q43?!O-[Z7"D.6L6H&8US$5_'W^I/+U.>72E'(AX+;&C`T4IR_E MYMB2T/S5D7EF8+X1`PU7,VW7=RB>QC);Y!,4PTYMUW/GUOB\ID+5ET6%:K/J MA^LY-EB7L$S5:_+U-N3TYLOM^?7]X.'RYIK<7@VN[UG2,WN\`M,;AJ>"]=B\ MVK/P5-OPY%G^9?;,3B*#K\DT3YYR%U\'P@T'_"\8DT5K#\B`GRSTA5)6<\`5 M$LD%/:DE/CA/[MC/W)F"$:*6SNP83K-;FD/58&[?\MER#&@O6``!_U$'W_.C MJA56Y0DY_\?',@HX3YRE!\=\"P9TSOVR9_&7A!.%7F.K4?)-7?@E76#$?D^X&5]/@=+XQ-'#2[H(737"-5&-V6M60G%&-+Y8)$,++ M+M;L^^`'I;&>*&]#6B.*=%PEAAR,6)I/1K$EBJ^=KT-B.AGKRY9,X05D0E"( M?/9B9VT]&VZX4BQ)=JHRBX$`O#ZU71I.^\\X9+"2%FM-!S].R(2JT"9PBGMX M:AHCM@;(@ M7]S<\-L+O6H>NI MGN_9$(8$2Z3X(XW@XRSJ9D0U2/#]DVWY;O1E0#>H#["#5[S"I7W$Z0YY$NL M@ACG%ULZQHP5U1FH05%P056^]6M*0P*#T9-3`(I\R6R)5X)K1'U6#9/-=J+6 M#GU6$0\&FJ4ZR:"/17W-NKFF6'"1]+6S'VI:7_D\&-P2#P^U8PX/19I`=7@^ M8%!NG\V-1GJF0L!4?$M7&U* MN:V-1%N/;S%U)CHN M!1VJAI.T"JS;1K!(-D98@FBVK#3,#&#D4Y8&\O/_8F4B5ED.EE[@]#/1?0?- M"!\@9N4A1XS4,8N!D0P8E6!/5&GA#&(!`R[K8_5VU@]:(EZV`@78]1]?'_&U-<%Z8S8&R'38FA/-8^="!.K6R]QMV8P=;"\U$4WO!"$# M4.3)!*=APG7H&!#%HKG0=01+=C`&C"V?@O!W;A*(90_,`+JA%64Q>JRN#)^M MH+B,Q=XIANN6-U/`H6V:]C?V)@8GQW7BZ$YT;ALLN&)W\+`O+J_/SI%HR;!. MR-?+LX??\/'$74:\1C[?^Z>;N[/SN\-/-P\/-U^.R?_TZ5,7K"=PDC";>D*" M)Z[.+QXR?X\$`&"(_FMV8D/I]9O==U%#IS=75X/;>Z!(`]BH4Y>>D)L_S^\N MKFZ^'A/,AY[PLI_@Z8>;VV6C"NZ,FGL`KP9:4=PGX$1&UH<#O,LHSJC=7B=< MQ+U.K6YU[B0K_3*G*HBGER0'Z$&L`Q:M<)=C+6C+%%5OKT6UTXOO=D!/UGUV M595/.7##.2?JE"6@S@K3\)4B?*@N)%6VI/;+BF_C]D01/^V#.*L@GGW6O+=N M)H5'JXJH5L4>@V?JJ",J!%6VH/;+`(K00X0>>Z1[_*R-&@CJK1M)XNHD\_TX=S7#K M8"'W7%2K`H]3V_((O1814YZ)9;$_A%YMN:I M1LK)[RNM@2BW8D7W2I3L/DI+5&LFNNZB!)$74(Z*> M2I`3BB>QIGS>!.R6VNTO#'T%N;5?-RK`*L!:1>D*L+YI:MLUHE9`5=C5VDAW MOQ.03X/3?WV^N_GC^@R$J&G#H:9M,2NYF5T*A5N&YV["VJGD-R.]7K9K:^+= MK<6Z'9R=75Y_#C?E=L+=V&40GF6[E&Y#ZAXU^NU>#:0K$+R0QI_>&G"EIB0= MM6L@4`':-T-C5B;3:LKLVI[=+H<64!7V]77V];`&LJQ[@A-B@)\C(TMK8F#( M_FTQZ?G,#TPJ#PFY*:RQY2I2BK7*;0HE/,N$M:3$G>?5EJY`L$!P9I(CRS60 MK$#OFZ&Q0N4:@=5J877CRLUNK6JM)+EG.8Y<8IZ;F>.$6Y%*S'(JD^]6@<;* M62XQ42.`*X`K@"N`N]\T5C6O$5@M':O%Y#5;-ZBUDN2>Y35*U6HWY]^G['X? MO!.+W[8C"CD)&M?;_K:OTS?K<:$F$SSO.XUNM]]HM]L_"\A7@L;*^>TZ5'[Z MHFY9#1IKG"&)RH_`:FTR)%'YV:<,J:2LL4J'"E0S-:X2C?NQ\[`T'E35R`FL METYC26`6:!4T[@.-54UVA!Q+IU%8UOI)LD+)SM9+/ZFS"E*WFXO,=W7YHP71 MMV[[[-+M2LN_'#;4>%Z](S5:_7ZC(PD]J`:->[(?=R<%H;8H"%6#1E$06G+> M0;_L\PX$5(5]7=N^ML0^X:HE2J(JM"?&JI"*2#P9>1/S/:]A@I@/$C16"\T" MK8+&?:!1U(4$C<*R5HK(/4EW=K`EB!UUH$+T*.I"HBXDZD(QYLC]AB3W&IU. M7^A!)6@4\Y9KG(/=K8%`!6C?#(U9.9+25$1=J$(T"OM:^5-J*H/7*$GB'S"! MB"=-\&+(`\T$%3\&7H^3E*8)39'$QI8<1#V;7O:I!A2=Q#'\'\@.C>'+"?DR MN/M\"5_``R0ZHYR_D$9P@W_1(/?4,88AY!;@K-JCOK'"#%GN\@RY0;PQ)5]\ MTS-.J6F23[;JZ,0>DC/#H9IG.RX9\1/3B6H18K/[WHEG$ZIJ8WP.7Q\:SY1, MV.51+GYG>&Y60_`6F?J.-E9=RM@TM"TOY%/:(K`1=Q*'7>/CC`YWK#J4]<2Z M/[4G4]5ZX2(Y4N3>B4LT>S*!@;J>K?V-$P,_Y>HO=C9QU-F4.KS#)GF`SC@' M7/),@8OD'U]U/.J8+\1^AN=LB[*`H$%<_^D_0#;2K$%+AN7CRE67.L^&1HGJ M$I40/>`,O,;9Z?KP/]@P/JNK'FT`TW5"V;$G^3B&HDB.GP4H1!W",+DHFV2@ MZP92H9KF"P?`"KG/Q`X?Z&1JVB^4XL=(G`7),Q!;P7(#P1EN2`3RUR70BS<. MQ>:-'BU"@25AL$]8P"=DV(=?H"%F)D6*A$-GRM$E8VR8D3<+F-N'5)@%!.%0- MASRKIL_0&8*6T\<>[S>*>1#5#U7@FCI*#`0;C@]D!B#==\*>+`-4A+$>AF?I\&-L$I_% M*.0;<+@H1Y`Q8M5U_4DP0-^%`0Q1`[-'O'K(?,04M-,QW+\/AP@C`YIPT#HX MR&YD2S[KV>PFE>)=@SS;INH9IN&]))I9WDZODVX&0`B`AI&;QI#F'E"G*66` MD<,:8EY#!VZ0%X.:>O[!_9 M\EPS?9WRN,DV3?L;_'A,WAL_LZ_F-"N)5.+0*4B,HD'&QP%%ALV(`LN,C8*# MP^^S\0U@([,>P!T]01>QK7$P5,`81G?!$?`G,*[TP.*B!I_PI+HS?P!>$3R] MH:EF$!\E8<%09&?V!QJ5B;SV1BHR5Q>@J4G#%OOC>>?N4U/@2PV/.@0Y#]E36BJ M.XX>=0,!3%4#F!I$#0O&D.B[6:V$">&)6!@Y&G4^21\C?@^&;O4V)@^950LV'Q`:FUZGMCB%7^&[3*8B3$U"S_5;^I#G?3LY'$ M(HHH907E_$U=)2"`MVSJ$\-SS08M>DF\V@H]/MN6[`97A=^B, M@!7<]?&J>J"#_&\VQ:C]X^-\)^8/X#"BN*Q)8L-@*4+`NBAALBV3L2S2="Z_ M,#V:^1\V8P>MS1)S'W#,0Z4I"G:"_HS^XT-FE'=B,X6H=R%:)JKS-_5F?6?+ M*7O>.;)T8)5RNF[I'6\+DEH]F+.`J`&UY(G&IW21>M^"Q-<-\I@TCYA.AUFQ MP?P\N!^L)F(?83$0YVD""F?SD3F@F)J1C`AU&1@8$V9=0;#B_GL(VQ&S^A&#CR(.%,=C1PZ6F?B3VETEGLZQ'-<*1LDJ67Y MBR]*N[MHNG2^I@/Z/5:?V=E.5ER!F:*"FN7J,\[M9)88+]/%W4G.0"F+9>&T M#N<<%GG0900FC!=3V.!#T^70B6I82&%.YZ$L#4I8J3%P]T/?\X$8?QKT#L;% MH,`*<.$\X`)$&4,#QCP$M;@Z]3B:XMH[CBPI6/DBQ,KQ&J*.@E#9.327]1N`M@K#)YA%G M#6:M\2I7X/+&W\%D$.W,3!GX("\AQ:2Z2DD7`9X*$R3?T:'Q[-HYN8B M9(X`_2[J`*;\D*4^T:$-C,%I5))C#8^D=JI43 MSB#D]7F9F,]9&HN@POFOJCC',)SFLR'HFJ:[6!-&)=SQ1Q& M%/SF+$:M2!CB&I307&:;HEOZV!2J3B%1-IYFU?99^9Q,54<%]S8=9SH\ATX! M=D%(.Z-E:/L.B;+\*(0U+"8'8!^HU]B.*1L-+Q"TDFP++.`#"]1C725->>!+ M6:^)/D`FQ',H4Q6VC@_T`)TK3V+X/-+GP>`V,`><*;Y#DQV0J`-CZ(UC/>"T MEV]Z,[XY$-X[8%3SUTTZO49/2874\/(46C)LWS5?#F,5I-65O6`<&<75:(J8 M*'V^9D5$C+M8UA_Q73EJ!#7;_'K$(9W0(WMM/8K;GPQ=#Z$VT_1Y?8N/:=UU MQI!PSMNI]8H-N'(AV6HL"4;3&+$(+UYXW;^;0R;#X*1.=-GW1T8,L MCWZR'9TZ'P[P[(Z@*W:"Q[$L2>]."'OHT%1?;-\['AK?J7YR0#1JFNY41O`B?[2P[]^B?_IS/X,C_CX]1??/1RIZO3XS'`Q=?4=>C,\ MC0GBCHO@%`L(]Q@1?$(1W`82>*#?O4\F2.;CCS_\^`,AOX;-05Q`==^$QF8O MQ9ME*UYON)(.T)"!&W_`444MLB`./MS1X8>#6UEYE.1'M`H/MG3TV&)_MPZ( MH7\XN%"A`?VQU5<./I+$OX+AB0/97GE./;F%)5JQP,#2`HF$\PVHOU* MJN?'5J:F-Z(]O<3VA*!!FC.>K.XV5JT1=+Y@CR-\M@(_B$8VV'$UFS.8 M\A[7B:/;C@L+U;(X"Z[8,4_LB\OKLW,D6C*L$_+U\NSA-WP\<:(4M_#SO:=/ MV>S3IRXDI-+L"NC@B:OSBX?,WR,!`!BB_YJ=V%!Z_6;W7=30Z#V'BC2 M`#;J%/<^WOQY?G=Q=?/UF#P;KO$T=P/!PE$%)W?-/8"G3ZUP340UC9'UX0"/ MRXHS:K>G\*8%7-B!NR4="+>2GGJ=;[>9>'I)Q#I@$>"FU(>V3%'U]EI4 M%3J8O1!Z*G0&>T7AACMHJ%.6@#HK3,/7($D4DBI;4OMEQ??F%@,1/XGXJ:JT M"3,I/%J%1;4J]ACP>6DAJ+(%M5\&4(0>(O38(]UC):3=7BPAC.0F@A+NK"*2 M6A5WW(6[[82HRA;5:J4*-_?50%8B\!"!QQZIWA^X7:T&S!I(448^(>BI! M3BB>Q)KR>1.P6VJWOS#T%>36?MVH`*L`:Q6E*\#ZIJEMUXA:`55A5VLCW?U. M0#X-3O_U^>[FC^LS$**F#8>:ML6LY"9V4:7JS6Y':$G\[(N=2GXSTNMEN[8F MWMU:K-O!V=GE]>=P4VXGW(U=!N%9MDOI-J3N4:/?[M5`N@+!"VG\Z:T!%V]3 M#,Z%K+9`!6C?#(U9F4RK*?-CAVI`HH"JL*\AP84C(36&-+5>14JQ5;E,HX5DFK"4E+K:IMG0%@@6",Y,<6:Z! M9`5ZWPR-%2K7"*Q6"ZL;5VYV:U5K)NDTE@1F M@59!XS[06-5D1\BQ=!J%9:V?)"N4[&R]]),ZJR!UN[G(?%>7/UH0?>NVSR[= MKK3\RV%#C>?5.U*CU>\W.I+0@VK0N"?[<7=2$&J+@E`U:!0%H27G'?3+/N]` M0%78U[7M:TOL$ZY:HB2J0GMBK`JIB,23D35()& M,6^YQCG8W1H(5(#VS="8E2,I3474A2I$H["OE3^EIC)XC9(D_@$3B'C2!"^& M/-!,4/%CX/4X26F:T!1);&S)0=2SZ?R?^#^&():0/=F.3IT/!RBT8%A,=,>R M)+T[(>RA0U-]L7WO>&A\I_K)`=&HB3?B:H8U8B_BYZFJZ\'G<'A<>ARLT9#C M?SJS/T/9_OJ+[QZ.5'5Z?*^-J>Z;]&9X/U8=^DEUJ7YJ3Z;4L[6_ M^=WF[D#SC&?#>WG`9A[H=^^3"3]^_/&''W\@Y->HQD>''PYN!^Z-)1T] MMN1'S&X?S__Q86"7%MYC;#S36U.U%$EJ?V'7./DN#@R_NU8G=/#=<`^(H7\X MN%"!(/VQU6\=$-\R>,LNZ_V`Z%0S0*7=#P>7UQ<''Q5%ZK5[LA3CW);H+(R? M@=18H^ZE=4L=P]8_.[;K)EDI*X\28Z/R8,=8>F8X5/-L)\[#!\-#J%Q:`'1# M]U4S@YGMUWO( M^L*,AQQCL;(QNH]6&P_Y31J/8MC;7P/!+>5-(W@S(\&R&X'@[;%7?D,(9O_S M)W4]2)QXM_(60XNVI!Q\O.W\50`L,P9>.E,V!5QKOYA2A!]I2^U]9LJF2.G4 M@2EYK!G[\4SUZ(5J.'^JII\KK$YQ8VMY2K&459.Q"4"F&+M.%M+:6I"Q.\9& M+0YETS]+%[+W2)XG9?8JG"W&'?2 M7\E=J;M.+%F:6OPO9[=\_EW_#/%(JD;L*BUV$C*4E*7XW1+D"<<]5LS MJO,-HM"A*XO-D"PO'7J_H\AE##V/:T)2EG%=ZDF=4L>^Q/K+K:5C;RF]3O^U M8P_CGWOJ/$,ZD_WNM6T]@[90'JRX#[:GFO'?3VW7N[:]OR@,5;-'EO%?&$6L M)+.L*)(BN;VYK+VPG^`J?RY7NI%B(H:G\5_N+TC[;`:LR M1YWIL3+F"Y9"8:V@,NTQBDW.4\4PWQO;#A(_3XTL!=1(C_^FECVBEJ&YI[8S MM1W6&?>6.C6NZ$@USRW/\%[FG:3:=(:(ZEOW[]I>"!ES9W+O4?;-#/EL3-W/EWJOFX MG.%F.`31K3.H2P?%C+! MD"2X2*5V_V2Q2R@G;I8KR-$6\]T-!M&MT5TD8WG[`PME!RD_U1]L_"IVQ%L6 MKUDT5!:/6IG6=7A>,=D':L(@K6YU% M"\7^IVU",R8P8?$\6JF"Z"Z)Y,#4R\UN9TMS;]DL*BQ(7M8EADL+,NE2A='+ M*B)MA?B=@/\,^4(MO:+07S:M#T9H6S/Z6=S9>>P.2?5LNK$5Y#7R8\!W%QP7 M9Z(+::QF0.L&_##0GPW7=EX^V=#3=F737^VO6SM<2,,=$2:?ER!(U=+H_P&5 MP!.J7Q@6?`:'_L4PP'.5J979^PJ=_/"S%'#3B\FK+#K&NGDZ*%L;*_U$DJ_:/._D?V13.U+2U7<;G9*S\2 MW^%<96%\E=]*A%$XYY8EAR7/(1:W;O4U;KF]?,UB1Y8Z2G76BKZ*TN5YD=SM MR-U2EL5FK^A]%:G+RW?]3E_9>!%ML>ES,>1V=Y3QEK[X]E5?4>U2..`=/X5W?].#E-7>>M',4F:JX=&Q;F[6+ MYF]'RK-@NX6IN=+NEKI;>YW`. M0,7K+)W\1Q"`3/M"IMN8=^PHQRHS&N.5VUWO:KSX`I[LLL7NK5>W7<_7-K)HK6(\KN,BM;,86`\AEZ]/VB;&K#Q"K M>(;;77W>FZ*\P?/>RIQ)ZJX^)4Y6BLC#:B*3HN=%>\N6U@7\;6TK#JD@?XN> ML.G)*_DK';5K=LIA\2MM>BM.Y^NWVM*K3T7,?GCKI"U?"*=T9%E9.5%7G;4" MU7;AO79MEAY48GZZ<'?2R<__5A%F;T?3T]N^)Z',$*N7JUBW'SJSLNY7XBIO]HRIQ>2>7JA2!S5P7`W'%[ZR38U5NG9YCC`Q+-7'6#A"* MA9=MK]$]8F=*OR,NKDH>VZ9.'>*.5=,DENV1)TI&?$D=@:%$<,EZ@>,:GJ>D3&'N!W?&L(OHU,5.=OZI%GYNCA MAQD!_'K5(T7NG0#I>*0F'QJ!/_!U'3.AH"DV-.C&TMG'6<M&`*W*O9(HWRFK>!*?\['@)=GBX#=7/?"=R`;PR&M]@$!HI?0/BIS/G,?:'.GF6!/1E^1>IU/@VK.Y`6\1(Y>6!_KM&EI&GK[4TRS? M?U6@!5TXV!*YLA`O1TNYTBK4M:S'F$V*T?-X3'8DK\&9Y4<4I-FRE=%N$3#Y M\ZEE2M7/M8>IR`G\]2BI7E*ZQ-WWU[F_LRYW**_J.FQ]6SQ5\O!T3?M?*$T[ MCT,+9G!K#=#VMW/$W/IT5L:P+F1KK@I-P-;V=GST+AD8\X$%,3!7B27T3.O, MUQ=#2=$ASV*YW=&):ECP_2GPS@'V^'PR2%D\;;K0W7MC\4+Y2_DB*P5R;X.A)R;;OZH. MBYW.#%\T0-0]/U2>P??"2)?_]K>B>Z\4Q<[\6D'PXTDZK.\9/M MC4_(Q7U,X&_X[SM_F?]&4N\V^!<-<@].=$@._G?DG10VCH?S?S\<#JXN/\-8_N.[ MGC%\.2$+!O=DFWJ.$08#O+YY."='37+_<'/Z+_)U<' M(-_&AC8FT,,S/NI1"[LV?9WJ<\U\"]26>#:9!C>I$3Y=AC\OI"5>$VK6243U M!-8`L.([(`P'!.]JCO&$H+'(M>U1TD+AP6]\V9V.2]G8'+MKFP:6T702`,U0 M3:`.O@EP\L4W/>.4FB:A;,4?-LF;(E>_GUZ2P-@5A]?L914? MT_$7%S_BZV?T"5X#)X"#Q"\0T3"`*8Q`G=@^-`3H^@E9/@3G$/*P>@@G2@TQ3Q*8]Z?X,>>`$F,A M$\,T<0PQO.E4US78P M^D%"@$Q7&U/=AS<2B%&)23TLPZJ1<#E&B'+4((HD]5)2N8W! M!,?H8:V5A!QA_`\"A09P/*@E:WC2E.,&Q6!@&9G:3E@;7@B>E+!9VX9+'#2( M#H2],0C"52<4.1Z>:!SV'&(E$"TT#H,(B)M_ M7+=-4W52@XPIPQ-%\7!Z@>=-\@`:382#XDDGJ`OI`QP+L47%.0 MX%5(CEC#H@3P[XVA*6JA/QKX(["1I"4CG.16($<:E4LS_5/$FZ58[;=;AA3'=>+;3C1K&RRXHD-HF'UQ>7UVCD1+AG5"OEZ>/?R&CTOO8GTSP63T M_NGF[NS\[O#3SZ!(P^AFZM(39V MV:CN+C__EC6L`Y"?!I&Z.U7Q5C`L1+'/4U77P\^J:8RL#PZL3`IQXN#P=7(4- M@Y0\>Q(\^#484EN2D,)OANZ-/QRTY'=)E#';M0#7[).GET;/Q-!UE.\2>K9` MCL82TMT)J).5*\.:B4"#Q%X[)'J_8&+ MCVH@I[=N(L/M/4)498MJ5>`1V]$AA%6VL%;J5;0GO@:R$J&'"#U6D9->R\0/ M<"+R;-50C90SW/]6`V%NQ8[NE3#9QF0AR>I+5&LF.`:J! M)$7<(^*>2I`3BB>Q+GO>!.R66@=70E257*E&TA5@%6"MC70%6-\TM>T:42N@ M*NQJ;:2[WPG(I\'IOS[?W?QQ?09"U+3A4-.VF)7$#@_#;;?7]C.[MH&T)+[E M?J>2WXST>MFNK8EWMQ;K=G!V=GG].=S8V@EW-)=!>);MZC>47J\AM:0:"%<` M>"&-/[TUW$K-7J?5J8%`!6C?#(U9B8S25/CQ6S4@44!5V->0X,,:R++N^4V( M`7X4BRRMB8$A^[?%G(??$E4>$'(36&/#5:00:Y79%$IXQ2R8`*X`K@"N`.Y> MT%BA\HS`:K6PNG&E9K<&M5:2W+.D1BXQL%FDSFO&]UI9)3H@H"_BW`>4_*.U*S(Y69$@GT MEH[>RM%8U91(8+5TK-8D+*B5).N>$I64)E;IN(!JYL)5HG$_]A26QH.J&CF! M]=)I+`G,`JV"QGV@L:K)CI!CZ30*RUH_258HV=EZK2=U"D'J\F^1^:XN?K0@ M^M9MGUU)76GYE\.&&L^K]QK]7KO1FK^R3#`14A7U=V[Z*[92Q'(E_4"'NB^=,\&+(`\T$%3\&7H^3E*8) M39'$QI8<1#V;7O9I9]WR?PR<*"J`OJ-3Y\,!XB'HFJ'B6):D=R>$/71HJB^V M[QT/C>]4/SD@&C7QM'0-4D7V(GZ>JKH>?`Z'P('!]2`:5OQ/9_9G")M??YEH MU#L.;[0X,US-M%W?H0_TN_?)M+6_/_[XPX\_$/*K[QZ.5'5Z?*^-J>Z;]&9X M[\'/8]L$>MSS?WS#>[FV/1HV=>/?+BCPP\'M[+R*,F/>-S> M@RT=/;;8WZT#8N@?#BY4S3/TQPXHS4>2^%>,T$Z^#.X^7X*NPM\D.JJ#_Y8V M`PW^18/<4\<8DJ3BUDH=:M#T2=QL_\=W/6/X MF,(@5<]W\=.W`*P9,S`-HEHZT<:J-8(>B.X[.%.#KUN&1Y9A_7B6^+7%*A0-H&"ZZ8PV=?7%Z?G2/1 MD@$._>OEV<-O^'@BMN!V>;[W]'1+GSYU-8J<#&N^P1-\-7G&[Y$```W1?\U. M;"B]=K/[+FKH].;J:G![#Q1I@!MUZD(8<0/QQ<75S==C\FRXQM-<)7KAJ((8 M;NX!C$-6.!2BFL;(^G"`@5.<4>)6BJW2(RX"S;@,IE;">NNW%@IA54=8JZ[+ M^DHQ/-_Q9B,AJ;U7J[TI!XOX0\0?-1/66S>4PJ=5152KHH_!,W7441UN>=QS M0>V7`13!AP@^]DCW[L>J0]_L->,U$I1P9Q61U*JXXXY.5,,RK)$05=FB6JU4 MHY%#1ZI7![42@8<(//9(]?ZP=.K40$YOW42&)R`+494MJE6!QZEM>8ZJ>;YJ M"F&5+:R5>G4)PC(LU]!J("L1>HC08Q4YZQT?6''E#%>8UD"86[&C>R7,6\?0 MWFSX4B=)K@IPKHRAD&,-Y+A2(_]43;\.DA1QCXA[*D%.*)[]."5M%^16Z"`4 M`58!5@'6BI)32;!6F-H*'8YU6IP8" M%:!],S1F)3)*4RG[T#(!56%?U[:O)1Y:5AF\[OAB3ZEJ%WM>NJXO[O6L"(W[ MEMF(8Q<%<`5P!7"K2V.-LQIQ-:?`:I4K->)JSK>2U,@E)K:924VX^:C$O*8R M"6X5:*RSY=KZ+,S[?KO5D"3IYQH(4H"U?KG,U@$L-Z6^)&J+U:"QQ@G-MLLT MM:)18/6-AP6UDN0;3VBV7J4Y_SXU'%&F2="XWM:V?9VJ68\+-9G,>=_J2B6G M1!4$_%N`\YZ4=Z1F1RHS)1+H+1V]E:.QJBF1P&KI6*U)6%`K2=8])2HI3:S2 M<0'5S(6K1.-^["DLC0=5-7("ZZ736!*8!5H%C?M`8U63'2''TFD4EK5^DJQ0 MLK/U6D_J%(+4Y=\B\UU=_&A!]*W;/KN2NM+R+X<--9Y7[S7ZO7:Y)QE44`UJ MA_&J[;3=03VHIW3D&@A4@/;-T)B5(LG-7MDG&0BH"ONZMGT5VREC.1+_H$+< M%\^9X,60!YH)*GX,O!XG*4T3FB*)C2TYB'HVG?\3_\<0A/P$?#HZ=3XL[6_Q[8)XW3/__$-[^7: M]FAX,\6-.K5&JNQ>./3FUK6?J>`;T M=D:?/*+9E@?OW='AAX-;67F4Y$<\%N_!EHX>6^SOUN.5^KMMFNJI_4POX6W7 MLQWW"SM&3Z?&%1VIYKGEP:`&WPWW@!CZAX,+5?,,_;$CR0?$MPS>_!_W_[^] M:VUN&T>V?P77-5LU6T4K(O5D,ILJQX^)IQS+:SLS.Y]2%`59V%"$+D':T?WU MMQO@4V_;DD4JF-IU111$H+L/NAL`>?KLB`RHRV`Z"E331U,N:C*)5PPTD6GL MTO!]++GBN=BU"%9.!"%+I.:E.&XG8J`@\Z,KC/N.NE'`0D;%312X(T?0DX>` MTC'UPS,GI+N6I''TT:K7.\=UZ]CJQH-=,Z3"\)-7\'K#6,2O$^XK.PG&_=[P M+1#5//HXY`&ACCLBOYCX1"'A0Q*.*)D$S'?9Q/&2"S`<$",*I&(13'1@D*L_ M3B_)$X^\`>E3$E"83@&`*.1$L''DA8Y/>22\*9G$^@"/(Q]<),KX``:8AO+^ M3TH+N*/S"[XP0R;PA6P5*WR.MW.$ADMV M+'M?EMR:F-V5ENS8S;;Y$D.>>HX0Z0R.VV"TOJ$!XQN%GYF!VD M<_MB_$"=?P([#,`0$^H+)P0WTAO[D76*J)]@;YB]UI5L<++/?) M"1IEH<)G.,I.,??Y!BN1;W(,>4W!TDG1+^\^MA3DV($+I8/-%;?1;.MNHL#Z MMOWJ:C&V[9%B1[=ES=D;0D]12FS/66T@S4Y=^G;5:-4WGL&MW?G\MU/FBUW@ M4@6:F[M`JV56V@7F.DUKA\M"FIM'#,M:N5K>120M#G5O&ED*H$9)-)+L4)P[ M`:[.!$Q-><=T?_\%W@5P3PK_;><@YL.7D]O?+Z_?$_@W27FPU7>S9VR&NF"0 M.W`U0U(\%7OM./)'@/^-1,B&TP_DQ8,[RDZ*=C"^I"+O:X>'0Q-AP/V'Y!0I M]ZEXPEAL-OMQZ4%9F8U3E/>Z=W].[!JYZMW=D9OS6W+W^>3V?*6P>Q&OS[T! M8:'C,?<9HBXY+BZW@<`!@I`>[G"DYR*$X7;'>!)!F"3XD8C7#=$-4(8''$\CPQP*.P1QL9#<`X,KDT)C$1$\H1Z M8\'GYT,7Y M#Y&:42.;8*P4\B?J2GR$)L@(M$E\'I(^I3YAONM%`[@=4P:8-1*>`.+UFJ%5IJNW:0>SP M48[=*.1^E)M+SYT_*>(5Y%,#?\_B3>+]#<^_"P%?RX2QYX?+Z[!Q-6F?^ M!_+7Y=G]9VQ>>`Y,/9XSW_OLH_$V[;=AI5C/WL^-6RCFKP7?I_`"]Y+^O];* M#:7=^D=ZF]/>U=7)S1W(X^+1Y$30#Z3WY_GMQ57OK_?DD0G6GWMG>.F8XJ?M MYAK@$V-KGBJ"4,$>_'\=X2-N>36][8LS6WE,M40O1^W]&;^7\GXERXC]F-`$ MF7$^`%X!DM:"`FIO_6*3-N3.#/FV57+W;LC]OIFH'6RI'_K?V#R'P:/R%N)J ML&JP:K!6$*PE>H5_JT3SBVR<'-_L[ZVDTC`WE$'&TI$JEKVB1PE>L]<`U@!^ M.8!MPVXW-(#+%GBW^OKZ(KO?Y8^.]F?[TKP37`89#\UY[?QE]E;=:-BVT:IK MLJ=RR*@1_$P$6TW#;'<-N]FI@'5_HOB[\X4OGJM#_Y]([HU\-9NMM3[@T@C6"MX3@9L>H-VVC8^\QL2P-@DL4EG>_ M+%9A^;*<8;DTF5H99#PTIZ:IWS1P-7`7YI.&93>,MBX36*Y@O/,ULB052^G& M=":VWY*^)5QM;*VD;]G7(RVC:]I&M],VVM8>R;'U1-`38;\3H6W46RVC99I& MJZO7YJ5*![:9(I7I2>MRYH%EDO$P'G/=FPXTUBLDH\:ZQOI/$M!WOKXO@^%+ MD\GMMU9;==8T;U^K[0U6]W8=%S:PNJ^W]5304^'GG0IMPVQT#;O;-NR67M_G MT@'U(2M5M.!WZ:>TJY^-H*::E%Y?(B]DIQ09JS@T]GE(W"@(J!]Z4\7@)*+A MD+F,8E64*!SQ@/T?DD)EO%@LG&';"3D94QI*'AS\@H7(F(C,32$-)`,4M,AJ MKN2*NB1\3P'U'"3KDH0W0T8)9":;&WXZ^I6#-]HM MVVA;=G'\2;6;V)@P0A`%QB=EF.]T@%PYP8RLF?'Z%,>3UN6I*TDZ(P&4J7F@ZU.*5A9KR$QBH>B9RQ M!5489.)%@CBN&R#K%0XJ\B<.D[,;9KF0D@24^[75T2)=;):[L MQ-N)'[*$>RZKR77^0_'@J8)H2$HHV69[PVURP[8T-ZQFF-,,> MO>]25):83#/,'8@A-<.<=K#5-:#5#'.'X[STJ\>[!JX&K&>8J M$XPUPUQ5GH4LG;DUL=8S-[HUPYR>"'HB:(:Y$J<#FF'N9UO(:-8MS;JEL:ZQ MKK%^D`%=,\R5:DFC:;4.E59+,\SIJ:"G0KR^UPQSKV:8*WZJ#(/0]HF!$NJA ML4O#][<)(]AU-.[3H#=,WCWKY:B@"DQ")Z+G9PQ"WZZ?IOEO3GXP,4-&U#XBD<]4IXI5YX@, MJ,L`M>)?1Y?7%TS[3462]<"\(?1#\( M?AD8MC+>(T1O*!LLT*.Y7H]6IUMO-UO6@>GQVTVY998346`OA>@U>CN5[EMMUN5#MX%?5= MFN#5VL#I-LUVUVYV#D;YNPA>FRQJ.O6FW;&KG`0LTN-V@]<&ZR?+LAOM^N'X M@JV'L$W67_56JV6:K>ZNT7CAL.!/QXOH&1.NQP6()%[!9-RP-9/Q"TH1P-A$ M&'#_`3]?]^[/X;4O^/+GZ>DZ^G)_LUJ,?]H9F-Z?>/BSGW!'918R6!4_"TT?J$>[3!`\^$3SV/^4GKNN`Q`.')\XJ53 M0WEU520$&?T)97$EG("Z6*V'8YV.[%-?T.#1D:>G$&7T#-`SH)PS8!30@M__ MZF?034`_P*9\`N$@$ICN$%@UP?(FI"J#`J1LP=R1F2_:I8,D/^ MAL#25=76&7$LO93=(IYB:>1Q8*V+]7-@>??$(P]^"AG8HJHV>YQ0%<[*JJ20 MJ[6I.KAJ@$Z`R^D`D=IW!!/8)*[/DA5H01!>\T>YWB>-NI$KU@)0!/#).FL[ MK]M28>3L0@5)7875]69`CKBNBFK_M@5H)C_>.U'(TR'9]?+6G9G73_4*(UBM M\CS=N_='MJI9L*11*%ABFO,*4/XY4P/XZ>R#KDMS*&9.(F[.T/6BH77=&NV> MJVO.$L_;E[]7U5E3;4JN)#,5O2V%0'7>K?MY$5%2GZX1L3=$E#2=TXAX.T3< M\]#QR@D#;6>='>B9K[,#C0B='6A$Z.Q`;P5M)K[>"MJ_.'MW4F]3%?;UXK8K M:%R-58W5JAA78U5CM2K&U5C56*V*<356-5:K8ER-58W5JAA78U5CM2K&U5C5 M6*V*<0]SNWQGQ*4+]]#/:,`>'?GB;?)>[?1-K5U._M(RR/A"GMY?MNV;2L2] MN\A+[;$\I(:KANMSX=JH&ZUNIP+VU)C5F-4NME0R:KAJ%ZLQ>Y"8U2ZV'#)J MN&X$5],VK&:K`O;4F-68U2ZV5#)JN&H7^Z+M>/5ALUI2:5<_&Y-5-9ES3P09 M1H&B/:3"#5B?#I`3])J'E#0536Z>BVLHKPRRPXOL]((PI)4+:3!F?LHKAZT_ M>8[[_?C.'7$/QH.\HY)Q;LP'U%O$^I9377H45.Y*9"LYNI<2>N>XS[[$U&<] M_S8A.ON$/&>O(/INUC71M^:CJZR[TWQTFH].$QYI2H--3:CYZ+29I:B:CZY4 M3U5I]_SSS%O-.*/9)/:$B)+Z=(V(O2&BI.F<1L3;(>(G9)SY*>VLLP.-")T= M:$3H[$`C0F<'U=T*TGQTE1!G[TY*O]NKL:JQJK&JL:JQ6A7C:JQJK%;%N!JK M&JM5,:[&JL9J58RKL:JQ6A7C:JQJK%;%N(>Y7:[YZ$H`@3+(J-_;U:^9:[@> M&EPU65*)9-28U2Y6P_70X*I=;(EDU)C5+E;#]=#@JLF22B2CQJQVL1JNAP97 M[6)GM^/5A\WXZ(J?JL;&9&U[`B%[1)*]7H4=O;E-=9(]GH4=K=LKWYXROU' M&@C&_1ZD3,QW/+QZ,N:1'YJ;L%!^NXOZ@OYO1/WP_!'^Y&6<^>I^.J$+A+)7 MFZM>+\BU9LBK953_"NG@TA=A$(UA4'=EOKR^ M`*DM"_X'_RT3?9TDB1[&+@W?_^4$@0-C^D$#EPDZN.B??L/]?D#]9DK3GDPX0'X3.ZK'PXHNZ(/CG?NARR<+E#$ MBFSGN'7TL=G(0WBU>`5-P-P.(=F'RXGSGJY2QDS^\\9*6)$8S2MAK62S:)\9 M\6L(DEMM39#\`MY?&!L$&.X_X.?KWOTY,[\WU_/K^_)^9_P]TXN M;+.&L\OPZH@XLSU1*I'ZW!L\3ZX(_RFC(U&)`1GR@&1I!#*\0V(!4RL*J&2P M3IPS?D.2B"1ECTJBA=)P5N^,HG_,P1C#R/.F9,"$&PF18^EOD)`CS[Z0B8Q\ MPM<)T;"0"?LNR4>AX^##R0!/V9P>%.5W^<7DK#,X4/ M]1GO@:!Y4@#`SJ$SG[H8&<@3"T?%.]7(610D!0`@U6%\`+=(G3=V%/.EIW3I MX2C@T8.Z#TJ`@,,Q@!!IX0'L=$!]%'^)K'E1Y=#=)#$FN;W=.4 M&C<-B$\2(-A6VB#N/=,3\T&`#6]G60;^'W+WXDU5GIM*!HGKQ/&G"J-=R^Q\ MP/0-DUFE>O"Q;`RVG]=9+%XRH'7B(8/^+YOU!@ERL2O`E^JN1NY'".(0@#") M\TPRA$23R#'0G"O#SZGL3Q1LNF'O=7M.UMINW$FZE=P/WN6VK\OLJV9"9QIP M)CA9$7JWX*9P1X.D&=Y,*"E5?#WPR#(+^-/>5>\6L@JLUR*;]'QH/PE5!0NK MHQQU/H1(_BH#\"`%QY(.#QW'?R&N9?YU:>_DUZ1_J_[AZ^?K])/Y MX9_2GU*L&(*A[,OI_7&SV\*PZ?BX&E+5;X3,OK"/,*!.*)4"XYH$T"288FT= MZ)BX&`$#\BNVRW68J"PWE7+]UP@8[X\(XD0+=`IV,XV\'R8C9P#]T$>F@DEB M2!G8G$5FF[4;R(OQ`N.S#.=/(^:JJXG4@^6!#70\B$#'+IH%0S@F)JBC=DOF M'K&^#%08PHJ.$5/P@3PRK:1HJQ:0":1FL+;%C(1ZF"8]0OP9#A%8\/O"@&#ZT;$Z5E21"!;+ M/--BC<@EL9*.!F.9,E`'E)VD#O-(2`9""K(5$1#0T&&8,M`?KA<)'*#CNE2( M.)_,3`_9%4X>H=)"0(J'$D4JR$+PA8F!C=$KP!23\;;P>U3:H]HB!\B!I<:` MC?XT%>(LJ.6$P$Y@V`;^?J(TYTUW%&)U-%@;NV>#Q*HG!Q;<]W(`+K.HD`6= MS,>B9W;SB?&[,)V^9JOQ(;%"R\0U%,!_D'B%"W!L<94NEKP0O""@77V^!HP6&3/N-.'X)S/ZY#)=V]$!1:D5^_ M^_S)QYIB.6GD%"3S,Z20KJ#7#:@GPS:$&7?D^0;3EB1";QCK=:J&'(V&SIU:PUBBGFF'D>1N,X7L4*Q(ILT"5>1[5"C&'T MD2:3/]$B_!84RWTJ:[(V984626D2AV3.I2I M=*K2I#,`B%"5X,E+,P95-LJ9:(5>`..!DAP>.!VDN)1SDW/+#'A<.\>+,M:87Y MV")97!YY@SBWDHL'\!?9]^E,,K8UE0S`FLO'>",VABR-`6YPTS%2>\'8(0JZ MLFIG19^X6WJR)(^@?ON?X^,+SD.YXWH7;WO>TN'Q<7)"!=K__GX(37QH<@4? MR`]Y*>`HXR@,)^_?O7MZ>JK]Z`=>C0`L``00E M#@``!#D!``#M7&UOVS80_CY@_T%S/RNVDV9M@F2%FY?.0%H;2;H-&(:"ELXQ M45KT2,JQ,>R_[RB_Q-8K%<Y37/7N=`^?._)XE'3V;C)DSAB$I#PXKS4/ M&C4'`H_[-'@XKWV^OW;?UIQWO_SXP]E/KNM\@``$4>`[O:ES212Y%\3[*A?Z M#JH?O''TCV.WXRGWL-$\8`='/G#6!(7!I(10+O24N;2=-KGIRR"-P-^KR&!B8* MT*2_P*/O\D+A$"43WIYQ;^V63*F MY.)*--9NHSG/VU?SRU]:4D:!.+/,2`]8=+\O<8'%V.S"O8M0""2KT,NEW(JS M*U2VQ+K?1'@+D_@SP>/Z+#B7J,MP.(RLN11#:*'?%WR8/F[S&_)K^_8OB&DAYE5%&0&./1!G/`&0Z9 MU/&NICEQ4ZRZF_A?\RMBW92(>!:LX;"X!EOQLWAQ3Q.VBR,#.JJPU6EY M'@^Q4.R2J:X2,?+PB@C!+T57*2MV\5A0J95"9C'/ER'<\UM@>LWI$F%&:YY2 MI5C,`[*50B[9ZM-7OK3\L5[MKQ'*)?3P]J&`7Z-)/IL,4\5*$&(*QN+-$%9O M8]P64)P-T'M5G$59"I4@K`A$.E&O;2#J$OJ`7OJW,(8@-.CY9"E4BJ@L$.E$ M'=M`U`HXH_UJAKQ=-!G4A\6;5BO:";'4-Z(H1\6@'"@3(/+9?Z@9V!46IKM=+#8'%LT&I7FQ!]W57 M]+YL*A0'@=5K\D<:%+,B#U`%..3U>^FSQG#0/59V>!B&3*FT!(\DH2IP5 MIWEN,2]WA(%<[%YRG[)(2%K`1TY4)=;PN/L6D[*$=349Z07`*%6>9*M%3`J` MX@79W5W"0%1ES-Y_8/J'AD:L(G%>!PFDLL0D\4Y=PL2 M<'ST`ZB7.$LP'CV"54QG@5Z56"R`8O,6=D`$O"=1J3S4[D;CDI>$&0I5HBL+ MPU8Z5AD'S;CUXNM3_=SKY8YMLST"]](*]#;1Y+3<%I\Z-,.Q@A/A^)L``R:O-DJ>\-G-D2+'QQ: MZ^]M>%3W#%L6U$]&'6>]@\+^#%%'M]//R,I[6"Y^6IYN.X7O=I1QH@%V?8<>E.2T1BR MQ=V>BAX'E0S9BIX5[5,W9W/2RK5Y_M]]6$[GQCN/W?438K6X?DK5O`DTD]X+ M"E.1;66?D=%UC2_6[2#Z"L/31QBRNJP&BI5FR!2DQ2\I)+U_PETT?QKH5IK> M$CC3&?[9DGDT[K[)VY^E>#V#D'Q-XS*!4+"=T]I3V!,YWA MMS8P_+T%1"9U^[/.IZ;6XD:H%])4/V;5JW`CF5II1Q=]&F#LP^R9`%D_9 M\M4G)QN;S8]@9H">G0%N.(FF&K&`Z"U.HJF0+3X!7YU1]%/=G7[F%_3RF_OF M5BP(@/)!G]+]-T=L/".G'Z">+;]]'HW`L``00E#@``!#D!``#M?5MSXSBRYOM&['_PJ?-<7=;-MCJF]X3*+M?XK*OL M=;E[9F)C@T%3L,UMBG23E*L\&^>_;X*4+$I$XD("8M(]+S-N%0'FEQ]``(F\ M_.4_?BRB@V>69F$2__)N\-/ANP,6!\D\C!]^>??K[?G[DW<'__$__OM_^\N_ MO7]_\)G%+/5S-C^X>SDX\W/_-O6#W[-U^P-H_M/Q`?]C\OXJR-\/#P>C@_\] M&/Y\./EY//D_!_]O]N6_#CY]NSUX?_#]^_>?YM!#7O3P4Y`L#MZ_Y^^)POCW M.S]C!R!8G/WR[C'/GW[^\($__^,NC7Y*THJ M4LIU@#[!_^O]^K'W_*?W@^'[T>"G']G\52YX9IZ_OJ;:P>1#^8_O0%T'!W]) MDXC=L/N#0M:?\Y;<(6,G(X4GYJG\_3>(YBS,V MAS^R)`KGG-J/?L3U\^V1L3Q[=\![__7F8@OO8AGE8<"B*&?!(Z?N`W_J@TYW M'T#FEE)?I0]^'/ZSH&$6S[_Z^3)E5_=73WQHPF_91S\+LZO[ZY1E+,[7S]VP M(/*S++P/2P:S,Y;[893=LA_YTH^,D+H2P8)V/BI2F;?\N3X/?5*XUDU^[3 MCMX54_3:3T%]CPPD->?`K._]\=%D2)EV;0W-A3LT^EU;0',)8L!PF#VDC"V` M]PR^@&>K=]ZP9Q8O60M`#7JWP1#7U6FR>()W%Y_P:QC>6:-9+^_)M:R-QI!6 MA[8D_YN?IC[PVEBYM0X<2=98E5@_-N9>DF77+/WV"%_<)@H4MGPDBN]+$S7*.W*UGG^##6?YJNJ6M/U:CO5K8UXM[S+V MQQ+Z_O3,6DXM15?[T/JG/Y9A_@++41B$<)I^L:O[>N]=8+*\431XU3[0GOK9 MXWF4?+<\;2K=[A6%0[*P=UC`=Y8$2_X6V-I]BG,8$A?Q?9(NBN^.$0AY1Z^2 M^FFP%G;U9[7_5Q-,&.Q&VE77K84M^GF_8(L[EMJ4=+O?MF(^@D1I ML+QC[U]58%%88>]M18Z3?&9U+JT[?!4,1FP8AWS:7T)W6R^"_0]U\_2HN MD26K9V&GA;='2;#URH@;DY-4"*X`=N]G=P6Z9?;^P?>?/O#/XP<6Y=GZE^*# M^?YPL+(>__OJ9^_U"PTXV07\F:W?$OEW+"K>[>$/>Y/)1FL=27[KWVV(ETE= M/.A-#K)3#\?GF7ITO6.6NGW,)]=5\< M<&<_0JUAM]O&FPP<;:VX`IKJ#WN3H4-^ ML,V`A!RASL4\(6C$!(WZ2Y!7VYRY)&I[D^F0J0TL,6-C<\;JYP[^BZ>R_W_9 MVO]5:#%H[4U&+OD1;53KW"`S8IL44U!B=AIL*J3LX/<9.NRH6GN3HJZ_=+,M@FSR[R[@S2"[YTFT_Z$V.NN?':/,GD%],Q7%G"X^?/<[B.?\_ M;H5[]J/B;BT_]=/T)8P?"FNV;"W2:>]-CKLG3L`%L@YI0Q)S>=(5EY^+VZ4; M%C`0&CX'I\LT+<\-&'M("UBD"_CT/O%U]BN3 M<2)KYAVY-!'9IDB)!&&L,Z-"979_3>+`Y&NV>=X[C?A1%HCG''M.+\]9A$(%167FYK''9T MN_"."!@1C(Y!1L@09CN[GY@%0;*,N3/K"]]<`@#X)5VR>065QMY!OQ?OB(`9 MPH@R9+8:0D:([\Q*<;9DM\D-B_C]WK6?ZO&,-_*.)F^"5@5"A,4&!@[$$CB; M/_.KUG/`]NKZ_]<"`\Z.7D/OB,"IMP5#!B@1ECHS76S'<^3J>29NX!T1,#19 MF&,2=`ASG1DT=GSP-;Z0P@;>$0'#AHVO(XX.N1/NS.QAM'\1K=D$#"`6&$.0 M(6QU9A^IB+DY>IJ=*NKMO&,"%A*['"(@$3J[\\C8_L)K&5#0-MXQ`2.*F@.M MM6X'%<);9W:5G>^[%F]H&^^8@/6E*6]R5`AOG=EGSE@:/OMY^,R$>*7L25MZ MQP2L,"H_*L'3WC$!DXA"Z=A5MA@,XG3=F06$?P*26(N?W4>] M8P+6CT;D")$@S'1F[9C-YV$IS+4?SB_B4_\IS/U(0A#2PCLA8.%HQ),,$$)7 M9]:,&QYS'[/Y)S^-817-9D&P7"R+*Z(RJENV1JD;>R<$[!N-2-3$AO#9F96C MCM5HC^&=$+!K-.(+P8+PTYDUXTL8)VD1UIZSE&6RV;7[J'="P%[1B!LA$H29 M#J-9=Y%=Q$&TY.DUKY.T4'.>I^'=,N<^$;<)/\##T0.4!Z(\:/!IYP7>"0'[ MAZ49VA@_,G8H6$N$=H<6OF/>"0&[2B.^M9`A3*Y.N(#WPW8B`(?I`1RE"NUA M2H%!=Z[)37,*#`Y=&D5,DPH4"L2^@G6YZ:05R%CPTT/R#),N+#F#/W:I@I^\ M2_;@1V6"'B1U@.`I`.O2+M(F6T!!PS9A*``G&0)T%5\*@P::[SX"$CNU=B@3 M`*!:K"N[+K>34'^'FJ81R=]"Y?N+V?\[BY,'%H=!=IJD3TFYPLI#P25-X(/; MH;%(/'BWM:V'P'4L_I?USN=BL5C&"8^)\9_8$G[+Y+I7-@3Y.[3T:#.@B8-8 MU'VY7_["\L=D?A$_PRF(KUQ7WV/82S^&3]>P[/$-Z8-LOZ3=!VB`A)W!9%-E M"$X:R;_7,X7\?SPW=>7<@Y.0'097I0C0[;KP.4!$P.E!,DW$[`@P6#LAV;H^?XVF M?+D%63,_*$W%+]5_42QE^IW`!L'E.=?1NF:*C]CIJRJD\H-9?Q@P.3T9:R]O MIC2HR:P"))8=S0)IM)8XE^RI%KL&GK.(`>K2_\\DBOS3Y)F5Y_0D55B>\!8@ M.0%G%6P^"(Q/*BC$$IZY=@T;#$EX,I@LT#$16$KV&`)*$4X(.=2:(J&566V6474E\E=Z$#X_Y MU3+G=7&YVXQD_JF:`F":81^2V:>'B5JRM9TH61EGVT\"')J!'C**1!#L95A# M=A7720X"AGYTG28!8_.,YU!9#9/U-!<=P/0;`Q`2(1TZ7)BBLI>0#:&'CX2+ M.,O3HK)3->OUZ[W,NI+8YK'LB_\C7"P7&&VM.@7@!.PA!G1:0.LF.YN5/8$0B8J3EKJ0.29Y>;:_WE3K5N_MX<3GN+)*M\<7ER.4M MO?'%Y5A=;J_QZ3UU_1KRM[^/#[MFGY'!*P7V'PP-/V.4*-%]Y4=[3KEC,@ZY>`K MF`8D8O>5EGP\1KUPRAF9NG:,4(M'9W>5U@BCM6S99\[!/66G3CDC`D8HR301 MLR/`0.SBLI(G1_8S-'E)6 M3'O$FJ?3S!N,2>0-T;%SZ..A=KU8O1K0OZ62M`*8!.:.F7E*"8?:?6*15KX0 ME"_#5VGX$()@_->S)>.#[>J^^`__Y4L2Y[P>XC^8+_L$-NL0E$,T3`CGN@U2 M:F6BMF^$OO!D!3S\3?S-53<"D$2]<>1TRM!0JS2%#[]U*+.-`@#6GBF[=?AHLPE[,B:P-B$S!)&)"A!D.MZE)Q1"\_JV>P M7XD?ROE<)'2MCJ+*661SN)2:WEOTZPTF1%UG9'X%K0%3J^N$0/KVZ,.NQ\'@ MT.P8E-4;:XQ-Q/8*26'&,YF0M74&]6`U[`;`]<9*TQR?O;)1F--QQ7"T$:*0 M54681E,`T1OSBADF>W6A]E]F=##IC9'$!!&UDD^V:HH.)KTS?LB04*OGM&VH M64G.YAN37/F%+K_<`PE]9AV!,GIC3&F#T%Y)*.1#69IU-@OG#>/(87W]-6:K M+SAJ;M%I"S#Z97/1!^6F*A2A`,]);XPR)HBH58:R6TMT,.F-\483#+W*4$;Q MA3K-O,%1[TPO:CSR>E%[#5GZ!H=%EGVLQLQM%;E:12_U,FSIJ#.?Q<9A2T>D MPI:.)-4JZG*_A;"E5URK"Z9B#NBZ=>^V`;60#4K"2WPJX!"+0:H*J70-KC\, MF&C$("FTCNP/$#S$0HXL<$34=[L]6?N+,%*M]/)H([W6@(B`\0&;%B+CN0$L M:E%(W";RT89#,3@_OFP>N?9?^$^S[WXZORH@9)]+%Y:X MO"XH_HL[AUW$>1K"/`A4E4/W\G[0/-&CMF1OM#_%6(NMPKX93:%LK'F%?:$H M"U695NA7QM'[0%M$#__U8;0'11"+\&H,]MP/TV(VS+)LN2AGSTV8_7Z>,E;U MAG3Q%=-]MSK>&>A<_AG,7S?7[X1.\&C1-UI-G3AP]7BIL$J,3& MX6])!-U$8?[2Q4C+&+YS[:*>>N=I(??!L_4*T!]1"P*^!;6+G9BA?GN0PU'L M*BVT4X857K.T.)!*7?UT.@#L1$_K..\FR(C9O;=%+UWM9\O\,4G#?PI=W/4: M`E:BX4"Z+(H1$;,ABT0N`R4,F2L;`4:B44%FK%714#.WBN35JUND:`EP";C? MM">O!HE:;KA*/L$&JZ!&:X!--#@(9U(;%K6<<17!#58_22N`2=1K28L],1QJ M*=YJ`BM7/:0%P"-@'FC)5A4*ML M4Y?'9=-;UD*!>K>L4SR9Z)_YEG7J\AS=ZI9UBL:H*."\M5O6J=/3LHU;UBDZ M"S$\;^V6=7K4FUM64[+>VBWKE(#)`IL6+6Y9IZC)HK,]1KL:'H,I`>N$'E$* M$,3N5F_#/&)7]Q=PI'L.Y[!U5NP>A,\#,I?F"$<[!PD48I>8-4G_%N:/1;$Z M[BC[&#[=)I_B/-2HCFC8$^RIG=HLM/<;$JXTR=4!2NR6LU/::6UA]L&_:F_3 MV7WIQX1'VMZ?A2D+>)W)TT<_3!=^K%Q'Y0T!,P'[5:.)*N99C?1/ M:W5J0H1JM>GNEG)5@D%)R=9S`(F`ZU1ML(NI$$A.[0+2E8?;\)"FNXW$>*^# MR'G!J!UGR55-R")AQ=I3!+M7-&H/<`B8I/0(:@#,>;&I;7%V4HOHD;/3"`0G M8'MJS(@0C?,R4S=LO@S8;FH7&!`!0/`?4"94[4!\FHXO&!EZ@)S7E=H>$V*A M]&:'N*TW'-!T;M&;)#)0]NI-8?7Q*L5K=OTS%B'/!I)4;,D5#QSU=++0-2B! M@)7`@%EKF.T5D]*:E.N<&ZN\"$@&"KV&`(!F&)+>=$01V2O@Y&*77LV:(IV; M)LT!.,W((NT=NPR7O:).EBJ@K&3-8.AQN]:J7,LLGFNE\M=I#L`)G)3-"-7' M9:\8E+78T609YVO!>2QC$*1+-K\,_3N>529DF2')3;L$!=&,4Y(0WPZKO3)4 MR`JZ.RYO$Y6'!+:DFO?D34:],:6T@DBM2I6[6+3AH#>,&D%R7G@*J;^Y+9R< MHT;]`+Q^642D\5"A0/>Y'<;R'\ MR([S\'#HTA[2QJFI($I,J00*L9"C#KU(AT[M'2V=APNN-,G5`4HLBJE3VFFY M9^V#?P>!4<2=AX<$;"6-)JJ826PO*7R'0P)F,6Q:",QB)K"(A3`5 M:S*O^9'F+[>I'V=^4"S1'U^J_Z**@]'N!`[C+FUCCA8S4WSD8IDJ4BH_G?6' M`9133S/]N!I#'M1L5@&2BW]JSQJM!<\E?Y_Q M,XE\U4,;@.`$O`&Q^2!8Z!1(J`5,&<9PCEQ:K5TM3=OB4XN6:A!#.'+JA-2#LBZN6$7T/K(+(7[42S5L1P1,#FTYZV*AIY MG-)>W60NX;6;QD;\!39MS9LM[84V;L\@!H["DS M5M?,K,C=K:<,G(\0]]%J"1/0:.:SE,%#"L>;QH*ALU4TF>!DF[/?$I M=*BA\"H0:]XFCE5.XY!G4_?[2X%[?0_[LE1N]*L^`])U>'Y3#EF!ENO2NZX- MNA8PGJ]3E6QD95F0AL6K5>-2AU=QR8XBJJ3><$`U&P>>,'B9BCA2UT[1LS5(W`HQ$L[MH M\U9#(W>+V&_84)F!:_$$'^>RS%+DQ]G*!-)+V\>D?U%"$U)%BB;:44(34D6* M,A;\])`\P]P)2\[@CUVJX"?ODCWX4>ETC=A$!$\!6*JEAPH:M@E#`3B)_-%5 MO"*:8_<1D+C;4D*H%NO*KLOM)-C&H:9IF$%:J)QL?$MQ'_(1CJSSZCH[2U-^ M@\FG\<>7S2.KA&*S[SS6HX!039;Q=:FXJ+7^+M`LT:.F9)ERHP1JL34M47Z& M!_/L8G4<_)PFF72G9?]MH%6B)VEW0PM5`S&C57$L**]PSY9IF7H2!"ZO=LL4 M,"6@3S]@WQ)FTJ.Y>6?>\(CH85VV.6Z&DEAT4=L1?IZD]RSD^4_XU?JG'T]A M6L8Z7N#VMKV]&S1.U)C@[I.CJ11BEL"VJ%>3C!^0G&^::N\"C1+-B.INF"%* M(&:T"6@E%U!%U/FGPT.06F'48CHM;M@[&L6:$H#Z_W1V0B/54(MU+9#=J<'? M&>_C;QCG"GX_3>(\]0,>H''+TL50-4KW*XTW/.Z?^;(K-5&+%&ZK"'SJ8HH8 M.!R]#:0!6OII).U"3=3"JBW:4"X`;QAG88"5#77^3E`Q@;0@G1FQ1,J@%D%N M<>)MP]W31W'GI:#D?II-'6I#'B]/QUNUSP&[T^XNVIHZK1Z[-"(8.ZU.:PD) M97+3<5IMD7<`AOY7?Z%*ZU1]#,"[=.9JY<1ZC&<7J"$@EK]^+:`R-]WV@X#% MJ5U#.\-37<%R(JKB$\LIWX(*&@ZP[3G97_3OIS^68?YR$?-ZJ>$SXZ(,#P_' M\G!@:2-O>$+`<"(:Y]O:UT7B.E98*,+@L`$#ZT8@-X'#?QL&MI$0\ZLL]MVW M\!;%JKWU'"!Q>0QVM&P+(/3-U1&](=U@B^?:2XZ+UX%>G7J::>\A!&S;OI96 M::%O'HS]&%VTMD6=#S/5[JJ!9R.RMM^PI\@/"EE7AAKYLHX]#U)3,&DYF_:" M?8%<%=0\_RS5J#LA&Y^*[Q$D4*AYOG58K>RDVS!8#;(TV=4!2LV%K%/>:2V^ M^Q@`RH35G9F6/OU@P9(?,Z_N[\-`DO5,W@!`$O"^:S0UQ23+8-KS3$(V2:MW M^\KV\4%$0>\R9"`V1E10$@FF\9,.0L.=V48!K`J49. MNBEJSARV/"$[5#6-M;:%SI5+K;T3[]]9G#RP.`RRTR1]2LJ04ODI3-($A._0 M,B@>OH*3EA(!HG:Z;A[8S6.9Q^;JWJ`DF_5W@4H)F*8,/:[=*`$95W0=/#1A M/OMAQ)?P\R0MTH/L87CMOM*;#`GLY[L996)=((.MMXFKNL_V.3HD8&[:#(DFGVHQ&FVK!QFE=)-/25W(?F-9_IJ551E=:NDUH$BB MB:,E1F["[/?SE/'\$@S.W/F-H]53]]V@\C^/5#<:>0VT@0ZY_UPPRO&?(D&2K#0PY:-QP'!PR/QH%A6MV%PL#1](<8;:'<-L$&4)K9\;F=5#(-Y8^AP$3(_B:Q,]P#&.E M#3V[37(_JO[[:9+E7Y/\'RS?5'^OUI23C(J]O!]4W[NO^AX5@XS)[F)974%? M&6.3=/43?TYVM-FO($!&[VY]N]`0,ER[M9YK>0^4M]>C06_N0C#I$0KLI8YK M:^3^K1AO:R,W6F/1V;N\R;`W5Z..E8",%7M^SBU%+R4OZ^Z4UI:$_Z13UWR? MKP=E]N:J:O]Z00:9O3AFN_,#_I=GA?0?G-W$8^^#PV5O[/E[4`0R;AJ84[%Q MLZZ[[<VB]2.)BTJV^C"XN^I0OA4-%;W;+^](&,N0:V'^M[VC2\`$^R$6=J>SJGF>] MM+^+J;\#U-(;KQA'X)$QTE4.G*;F&/DU!K8 M)C%'0<,V82@`)X6-7"6+&+DUES7*RU%HL:[LNMQ.ZA8YU#3=M!R:*M]?6:+& MNX#U\NK>,(V^R1L1=086+#M.5>"ZFPYZSJ2Y4@+7R3GO8-A@FP-CK^T&;-)V@]K'%4"O&=5DG.^L@,\VQ MLK=W@Q9I.E^YW9CH*,5>X2EW*]QJ1>YD=&F]'51)\R;+X6JHK19[1;/VM(?J M:)QIRP!JI7D%LJ^]EUHY]@IV[7]C=L.X_N'WTR3.4S_(E^6=X+"#31HJBS<: M_WEM0F9*LE.K;N_4=NSQKMKKU'0N3U0L!].O6=^ST M^-7LUG%;7SV5[^_6]]+_SR2*_-/DF5T4P9!)JBB8CK<` MR3L\]8F'KF`_I`)@[0[5SDJ\#B M.4LYB%W;'F;PTFL(&(G>$=<9,D'D^LKO-/*S[.I^)<%*`+Y]DU_P*IJ![$3O M:Y'YHH7'^;T8"Y8I*(EEZ_"-V4/*"@1(KFV=9B`[S;PD&!=:>)Q?)*WGXNN@ M^/6))Y'@RQ7?*E[=(XNV?F,`0O06&B'&`)7S6YCMF#I1+K5#K<*%9X MG2X`%-$;7?GZKX_-WA6&_9WR#AB9X4W6#(`2O3;5VRN+\=)=/"WSXKKFZOZ3G_(;O-?9\O%%W`%B!][#6X$:ER?>5G;E M(W1X.5>($SNU[6'WU5\PU,:JVQ3P.CU0*ZW<>^/49"CMZL>)-9WL>*!AB^_! MP'!@\[E@./D\J$Y854AE2MC_6'`Y-0< MI+TW4FA=3!6&Q]I5`QF.:.U7+)*EVE_8O)-(X:/]L7)/>PV/LS1=Y?B6^Q?H MM09$!`QSV+00WE#HPW(?\5((<]&*(55K@$(@!L"8(3U8SN\J1$XJ9^P.O@3+ ME)D[Z.PT!1`$4I89<*.-B=J=1,L#YVR1+*6Y#ZWT[XV.B;JJX%9AB\!I7X?T MV7_]N+OR;TUO18Y=GH+-;T7P-)\"N=_"K<@-BWC%HFL_S5]N4S_._(#CR3Z^ M5/]%<5#6[P041_;DS"D5DV^*C]@51%5(Y3&M_C!@HG&4-J5!3685(+%[`@ND MT3I;NV2OKP[\QP0.U=A\T#P65*$0,]CO>*Z?+N%L*=W=BQL`-@*G-[/MB@R) M:]_]U^CG,E/>JRMB-;`5FRPZ;;W1"=&`BCH?AJ!<)Q?C8^$BSF##61@Y*Z:7 MUWHH<';[8QGF+YO'LE7&:8RS5IT";JIG83&9%M!*K?A[/?^^UGK^POQLF18J MZ'7>[FG__`)/2)V`I]I^@2=OY`3\.@<^OKS^^=>0I:#"QY=+]LPBQ>E7KP-0 M&-F3[PEZ\C7!1NS4*_RVU4$HSU9&_8`F:)R538A34*^/F]@1NK,10.O@W<%0 M(.M<]RKT1?P$F^\"_4#IQ25I!6@)G.$;S%4%TQA28D=\D;S#1GP.7U$2N$9W MRN<64F)N>B)Y1XWX'+VB)&"\<*XD:_I]:`SL9] M8VO`E)8UH);21R8W'6N`XWQN4[(G^6GM)(\"Z%<^MVFWQVI4BW5EU^7N5SZW M*9'C:PN5DSU^?O,CEMW`IBU>LJ],6F1Y^TE`1>!88KA$B"`0.S^N-CCQPZ/@-MK`@ZV<6@]31+)[/Y@O0,)>8 M;[57&&332JL#;WQ(X(9900TRZ0P`$CLKWK",\6,P"'W&S[7)$Q_%:DZE[0`I M@;-C(RHU:-*$*P MV`L"LTS/11PD"W8IKMPI>1I@$8@P;T?1+AI[<6!V2/J:Q,FVK"N8&MM(95N` M3#3Y(+Z=U`1%+6SL(LY9RC*-S<;.DP"'0-9!3:V+*1,BLE>BQ@Y!GT$-_#-P M%6\,ZQ7W.CA>7JDBPL0PIG6<9R MV1HH;>=-!F^(50P?0F5GYI5-_NP2[?I;(_W`BIN`9@A8P%I^:670$.[L^>6C MLL-_1,M5N2G%,MBL(P!(P##6B+LV@!%&.S.P7*?)?9@K3A*;A[SQ@(`5S&S_ MN2L]0D%G%A)8>C=GFEF>I^'=,N=7=[<)##)^00JZB2H#2G:`,.T+5$+`%F9X MH&@&$N&],V/+%@Q=3@$*`3M8"[Y*`,A%6E5J623\+`VYDY>DMA-5F-%L" M7`)&,3.^M"`A#'9F=MDIM[H.JRL`5&+J](EMUB$HAX"%S8SO-DB183#LP'/M MV_(N8W\L^7W(,WL3Q4I M4IJ*6X!*7!ZNV[BT%60AM,K`$(M&$\BJC#M"VP!"I^=I_>2F,@:T2:N"(A9" M9ITV&KYUKOBCZWBW+;4RHD3XO#<>4C"(R">0%FM5/$X\\MPZ8(^'5`N?"%8K M%(`3WSI7;L&3L=.AW\@!N]!B7=EUN9W6576@:1J+1`N5J]8!>\51_\[BY('% M89"=)NE34D8KR1-R29J`[!U:2,6#5W`?H41`S-6L2$&U*4*9A@\AR,5_+?/" M#B0KL;(MC$F:5E+)@503%#6?M&VQ5[F/V'SC6E"6JRQ+6NN3JNH(E$'3KJK- ML!["MU:1=3RD:1X5T-8,FSTW-CEAR@+L^,,@*$TG0@4)(A34G-)<%,`=#PGX M$YI]ZM1X['F8H2DG_UB&*4]B^E)XN/T:PQM>2Y)C$T;>"B`3\!@SF#DZ<.PY MB"%,P$K'O60*@:U/(,W!R&+@Y<^ M7K2-Q[W+$3D>NC3WFUZTC>NG4IG<;^*BS6KUP/'(I2VME?ERJ+Y#%<,A=MW6 MMC+=>.34#F2A>F"A=3%5&!YB=VL6.*)A*'5`UOX*&NRE>N!X1,!$ATT+P=;- M!):U^[,NBP>.1P0L;,8$Z<$BEL.B8DM27D/7G@5$!&QJ>D0I0!#+/O'Z\2[/ M.#Q\/XGYJ4=WFR=J!TBII@K3V>KAD(@EGM@15+F;$#X/R&CD[M;0OY@X"2QB M-X+6"".Z`[3&G&HCV-UEX&P^#TMAKOUP?A&?^D]A[D?*-4W:#B`3,+I*YI&8 M/@U,U%)7W'"/^9C-UP$@2M[$#0`<`:NL,6$R,-224XCCW)1\R9H!4`(!N<:L MJ2%1NR(L=KV/201B9.NB4*N0X>LD+?3=+@C4S@N\<9=^3TUMS?:04TN!43H9 MR.OEH<\")`+6%D,RQ2"HY;,HQESILW.V3/E(8VF8S(N,_!5_KON*76)3+%TU MBYOV"ZHB8+QI,'G;`;:7+\/IV"A'MH/!H=DQ*(N`Q9(+K;3=I:N%-E80Y?EO0Y#%B)_H8%R4/)6C&(I88.MZ\& MA1.PE9A]V?>C$VH91XP3+XT)V%3,B-V57IXRA+97V[7/BZ4_,NBLG[DDQI,. M=\$-7=PF+L\PQBYN$]0&)9+[7RYN-8>7BI2P MX>(V0>M28WC>FHO;9$+T@K,]661S1>#!F6NC\0THX>J>_R*ATZ0;T`?1K3R^ M$)KCDWK*T=H2GOK9XWF4?.]EW*-MW]'ZCU"16XZVS_' M:5>.R*9=.:H=3%$`O:I[.3YR>I77+.W*D3H'2"%WK^I>@L0TMEHM5$YV2_65 MY7Q%O4Z3YQ"6ZX\OOV8\%\)KG9]9D(?/Q>6-3N$'@=AQ+;R>-\F]F:OB]>!7@E[T1"WPPE;1R","1VAWK"''$8DNB,5HN"KK1,#W:=^L:ZB$6+S'3GTE, M\#2H@\"=Z+Z)1A5!+1ADK_7YC@CXKGN(5AJT25UL6=!P-/.9M?^"Q^6LW@.OZ1+-E]G M+I-[J#?K$)1#8._N:B3H:X!:D$L=R]DJM<8->V:QU.=5V18@$S#%NB)=")9: MH(K^OL2*$1Z4\.9,NJ;HJ56"1>0O"Q1;NH^1=.9-B!;.,[^/4:*D5H&VFJWW MFQ^QJWOX!<9M_G(=P=X4UBGN#OV$I&IMT`NH@>[\5]*'7NF8P:<6%J.O#BL3 M'[Z"="]H&HX!4_34@E(0^<_#V(\#2VN`I#-0"H'[&BMK@!*EO?JYB"VF^CW: M1.85#K>J*$:-I@""@.V]J?(%=AEMS/**MQ:(F\V?07I629W_UR*C!<86]CR( M2\`H;I$B.5"$E\XL9OK`K7Q#O?$)7?NV(=M-T2-#H#.C&A<>]GW\__C>[QEV MA=SZ4T2I[AH*)(/`I!M0!`$[N=D2:HX/(;HS\Y@8P0Q&;YJ^P$!5A85KM0?H M!*SD-J@5`D,X[2YJ=?GT5'KG^]$Z].,BOD_21>%/H[$!UNP!X/?.\F$$#6&V M,TO7VH."9QC0\#CACP$0`@8+(ZW+O47P3SV5DPW_["2CQI3H01M?7,SQT9.B24JWMEIHNQ2ZY#HA8$K6U@+_&V1,+POL0#KNJ/%UH&T!( MK&IH7?\(87)(Q+*J62>-QL[/#7N.-X5F^_$;]A!RRU.A2^-AWZ M-S1=ZG`D3K)TF'%Q"F!2/[J`W=Z/_\E>I&3L/.M-!AWZ'[1C0PC%24H.73I. MERFW.)Z'6>!'_V!^^BF>G\$G`&$$>QR0=.@-T)04.1HGJ2K,ILEY&+'T%"1Z M2%+Y)-EZ$N3O\`*_W101`'&22T*7B-O4YR6!OKTL[I((H6#K&8#7X>5,4^4+ M(#C)XF"X3&RJ]^I4I=)K".@Z]"AMN8`H<;E)SF!J4KB%;A5F!/X(B-S##U4= M@9N4![I*GX$P>1CTV+K&1"ZP^#7IFH70'!3+=-TL)=WT_*-D_!9`-&A MG;CM\!=`<9-,P)2/4'@N$D$T(P;OM?69^;U M:0#2H7.<'5YVP,CC[X6W*'_YP%_!:Q05BOC_4$L#!!0````(`.IJ3T-*],/* M8T@``&T(!``5`!P`;6-E="TR,#$S,#@S,5]L86(N>&UL550)``,'>EU2!WI= M4G5X"P`!!"4.```$.0$``.5]:Y/CN)'@]XNX_X`;[VW,1*CZ:7O=8WLW5(]N MEZ^ZJ[:JVMZ)C@T'14(2/!2I(:GJEB_NOQ]>?!,/O@"H_&&F51(20";RA40B M\8?_^+8+P1-,4A1'?_SN]8M7WP$8^7&`HLT?O_O\^/[L=]^!__CW__D__O"_ MSL[`!QC!Q,M@`%9'<.EEWF/B^3^G.3S`X"_^#9`/OSF[];.S-Z]>OP5?7K_Y M\=5O?OSU;_X;_-_EQ_\'KAX>P1GX^O7KBP#WD-$>7OCQ#IR=D7%"%/V\\E(( M\,2B](_?;;-L_^/+EZ3]MU42OHB3S]EE%3*>0%A M"_+76=[LC'QU]OK-V=O7+[ZEP7>8!@#\(8E#>`_7@$[@Q^RXAW_\+D6[?4@F M3K_;)G#=/8LP25X2^)<1W)#%(B.\(R.\_BT9X5?\ZQMO!I:EYWL$$Q<%5-&S"36CS,W_(O"0;,? MI9U3?4Q5).DV]FL=AD0YQTD=WYT/F2%Z]3NF87]%OOG;AQA;N(L86X(D6JY2 M8H:R')!.EW;W-TG;'+LUZ:^3>*>D M(!\Z5J)9)?5$:_Z(N>\<`_^LL^B5QO96O3ICQ;*3IH"V%2S\Z%ECCV\5%TKH MQ"8?Q/YA!Z.,>G)C9_^XA=ACSE`"08!2/XS3`_Z8P!#WCM'*8K"A^/FLJQ<. M26)+!H2B*!``'5GDLZ8S7GOIBD[[D)YM/&__DLCH2QAF:?X-E=JS5Z^Y-_PK M_O7?+N$JNRS(*U'8*@!C\JN<>9.12$-0MG1">>N1/V>;/K0WQSHW<;3!'M.. MS$JF]17MC3..:-Y-OB'MSDA#0#G(OO(?A$#6`P&3G"_EGB;C:[#."/?E`6\' M87J.53)>@`RM0GB'F\,D@7B/B`=2N;'Z\&:=G!YX-5F'@8)S4`$&!32@X$XH MTD$+6#/'PU9O1G93>M`].G"+X63*2H_CK.O@9X.GEJ\^!E&)_X[QQ.Y[RBBQ MPM\%$.X\0@B_0I1]0924C&7;P>\MMKVTS%Q6[7JD5=.!MZ%DM/`2R-[U*5DU M_07LX+>^JSJ7;MORGK(:B_5 M,KTINT$^C%*XW"383\#43U6V2P)@5G?(9M[:KK.VH&SLCBU2KD"-0S3)/R5' M*,V+#,(R3TAC.!U,X8:Y.`$TM*Q!+SRZU?\Z3D#(,?2*?FQK>;6,R(76_ME$ M0>';]46\V^/IT96\9];V(DZS]&'K)9"D^P1WWE%E&Z;JV/Q9QUA*M,Y$2N:- MUZ#:)>!]`MKI`M!NSVB_(._8";LT+9>TCEHF9!$')>:\.FN=PYO1/;LK,T): M2(3F5D=HSAM"8]UN&R'-('WBU-'41%(T6*7HB)`YG?)7+TD\HMNBX!YMMEGZ M*R4I5UK-N*TT%$:Y?7#Q/Q-N\K[\?VYDY#0&J[.VWI,&=8KKPD M0M$FO8,)-7L:ED0,8MQT2&;?Y*:\*-`\LQ"#&I44R^U922-$4L+9.J6'5,C1Y26\-[+&1CNJ5 MP%AG)&EZ49N3G-&V<^-A4R:4"E:3H0Q*1>9E]/CZ=OT>15[D(R^\BU-$8D,Z MBE8+W+RLZ&'58K<STA39QB6MJU!7R1P=I+7#"1>BEZ>V:Y6%_0ZD.4[1A[/%'Q_R;K$*;D*/@ M/*<>-W.)741+(.0<.?W-,5%U'I?QSD.M$X\*NEV-C;--YXQ5_,(:.L`Q8GHW M645%[!EO#'Z$NQ5,.ABA%[1;=P4+G(9=H&/@#EPSF`O#'85VXB*!+F/VNA#7 MQ94S7D_2$2$UM%L7DU0,IKBMXXP(S84A$R';)_G].+/739RA,C2QOWN#(GB- M/VHYNI7&]CSKQP3[;=K-`DV5EZV]P\^6EVV44D'^N?CF@)R^D!P'9 MA9$'^OP-!HL*&/ M?FG%'_HK%W.:\P--/KV'/L03PW[JQ0$[J9',X@LAC&M'\=Q;!3=9^G/9=`%X M8[MJ3Q^#L@T@[)FG.X-M'`8VHPV:?-24"2TF,B<%M]D6)LR540M`5V/CO-\Y MXR;3T$:`M7*$XWO,VV>_`X^VML_B8B9I*0TSOX]0\;9N=51S1X.%Y?=:L M4LU_\(SI!)WC82WV=8)S[Y(8>W_9\0Y3-C\;L M73$64EZ1^#PB1C%8`1UY*Q2B#$%R,9H>N;"-4DID,#MJ!+;UNS!?)UT?NW:Y MIP*T,"Y8,;L2'!^#V?7R_/KF^O'ZZ@$L/UV"J__\?/WX$_C^\NK]]<7UU:>+ MGWZP+U%]^;)5;GT04QK<;OA^?,`;^SOO2';U>([XF^0`@\K$-38C?7HQOU7I MA6-K(\.A`0>G4L@[`)4>#&UU=`^MIL%Y7\'9XSC#;Z3>"G3`W`U@WM;.:2CG M&JQ$=8"/,:]L<^A(I`S)?/TJ&0:O^T0%B`2IJ'?'VC@3#>F&2*XPL+JK: M[C',T;[@J%FJ57%)DY]&Y)4M@R?RZNE[/-M+N,(]'Q+X)VHKQ>RN"V@VFTP' MDY;*93"``($""C`PR]P_&BGM`Y#QD<#*NY,SX<'KO_"EL9G3-P25(I7`VQ'# MA[>N)&J#MX)@Y844R70+808"+.GDEW@5H@V=10H"K)J],`1!P9YL+6WG_6EK MCEK*7T^U83`WIDQ")*\TJ8V]",!\]HMHYBTNK.22%L2?*P5$-Z-ER.2#N2SC)#^G"'*4$@9L7P;D?-1^P%+-1%;"MVK^=R(HI!4',1_>T3K) MUII[_3@[+$'L<[I^>,:=*$QE)N5I2;]3B2XXFWS?B8=4!$H(%P\@M/#!CBH63.YJ)U\#BUD9]+J\I M"M8V.%KR+(&QO7C&R'[TJ'D+<6^QP7I2-"3 MEZ$GV&F,I3*B@+0@*2I79&8$/KEW>*R^25D4E)"\2>F"5&GQ M9%NV>C"DY:U7WRV7*ULM_2V66X$&*08LUA"=U-:JUY;*`=;78WB[;*YB;I<8 M6LC&KK*N!L/:V_'O=BAC[_9%`=[`9"C:P,B7LZT4RL*N7X9#>\]9M&;7]JOM M;6_\QR#BJQ$QNWM6U\;_^ZNV[W^=9Z\LL M2]#JD-&TN,>8)/>Y%$ONA21'Z7N\(468MR+_^`/X>`@S=`'#$#Q"?QO%8;RA M=N\Z\E_0>U0$("@![,M7_XQV]W+8ZY6Z5)5C.EM;N&;8->?V/;Q:F;5%7O_E M.DT/<*XZ(EKQV;[S=V1C+&&5]EU`!9^8=:_B2(N[VTVM.%*-V78Y'7%DDJE[ M^$YZO7J5_P=2\GP5=JP.V39.T#]@\'OP M9O'VW>O%F[?O%K]]_9:Z7*\7;W_];O&[5QCTS;L'N'-H43RA!#F[SL)Y][.:\Y;`M(4H`CPQFY<8AJ" MR!XW/<.(^*RQ?=97L%+K1I(.'YD3A'N8>2B"0?XFW[*\^\\\7]D61@?8N'AH M8=2NYL2`0/':XO<5.,`!?W!";`8AN*S5=*"MIL;B'<,B@ALRRNQ87,JP,*D` M]$6HJ0OZRH_-B$:O2(83$0Q%Y*(S:)'E08N9@]DZ>S`MC%A,6QJ82%OAFA,) M5>B'*&R)R4<48;\_.UY'>$5A*K.5[:;&1:1CMH-#>^3L+(XR/&Y(]BUYEW8M MHP:"C7DCWM*!4+B(EYK<+V^\9=$$LNK`>>ULE&)F4=O.C<:V1QGJV7`^9Q=\;9>?MH.? M74]EC.93>S?CU9X[A;[TTEP$H,X5]I(GQ%0*>CF@:P?@TDJ8*0I&.K=[T.6[ MO@6\+!?NHD(?$C)KO?TB`;)5EJL;`T%%*N;%L-9.O;FK7@Y!Y2GE6IACJ7,O M1>GMNC&Q(_N_SIOHNAT89S5MS-HN!08D%R=*T`5CP"/XPO]UZMGQ?FO8Y,DA M"V@RSP/%R1UU,^^A3]X(1=C`T-HTR^#OAY3F?%W"U$_0OJML3BT/H&]7%C)$ M>F/;\01%#^;LCJ,@0W& M,/TM#`XAO%T_D+0<;!]A:?@=@UHMV>T7U#M>,&?FN5]+T#>NW.:8%X2Q3F)5C.0R&B4;#+9 M:D7()A8L*_JF%6GX%&>0UYY,;Y-[M-EF:4\UT[=/F]JE-_Y2B>DXUR?]+?)J MGGB3EP#6I\OZ9%JB"-0(6'[UDF#!?D_!YP@/5]+)<54R3&PD&F2,S-A0'$N\ M<0]0>""9OP_0/R0T=GGUC1P1P(!4.R5K?6"596_7>6H1WC#1]>ZG4:8;S**J MF9!B,G&K#@/*<4`^$*LN7!F*`!7IAG@T)I`.JZ=G2D@[FFQJ.1:KN'F$V$(@ MI7)6\Q%ZZ2&!P6UT3S!*\(1I<+-75*5??_9"+#WQEH4?JJ>3>5_@-@)%;X"% MQ%U30L9H$0^GA97`S!"9$$9IA@M$7VV00O_%)GYZ&4#$%`'^T)1__-7?;N#& M"Z^P`LN.RV^HJ]I`9RMCLMH]QU9.`&D!6!/PA32RR$(2LN:,H:3I7,O-QKN, M=Q[J.MYI-S&ZT(W9M6Z,\_5E#2RO+W;':*8/$_I[2%V2_U4SB,:@&8Y10>3)K\4,*`-I.":TS:?K/-&5D.@ M1Q_&]SQ]\!-4;&'`H(1>@`(>E!W8W<_8QM/D7J4WSS;W)P,9UN15&"^#9$YL MIB2<$D>T0%7WGD43SL+%%3D>`DXLVUG?W/1:D7;FO?9RF-;XQ5R$>R-%>TN: MO#UO%0\YL'_2(GVWDI+2W1S3\/,KH5LM:&><29KS;#)'_A:C_5V5E+)-7I"0 MU61EC^(UU^,CGD[J^30CXOQ8_45AH?IT8J'21P\,V\FSY0/$]H-RPQ>M75-B MV(K984RE.>MJ;)71A(:LP5#.6#$QN66L,W%D\,;[*H(\, MPFRT1SKW5JC?`[0U(,U!T=Z)",\4B%@.YZCYJ!;'T66BH><9B';*5!_[W%1Z M[-N_E=O6/+7HZAO>MJ(4WB7([XK6Z`(:DP5M3)J<5$(4668+D`,!"F4G&&,> M(Q-RTH_C4 M[XCR=-8%J`!:?=&M/U(\`?4>$E>#Y%L<:"HJ2W+G'=GWGW1YKU7JM!?C67N^ M428ZS9:VGVKL$HS&XX"VZPM/,U^SI7L[^4'Q;.%D.X.[.,/6!GGA71+[$`8I M24CD0I/;GJX(11]@L_L%78Q:U=1S.)`#`@)9J/P"UH::GQJSM4G,M'9'0Y%[ MW$+@>^D6H&@=QE\!UOJQCV@HX"O*MB##O^\+`G@[)-"'Z"G/96-U^]1+6V#QL@IR-4"M%/UU&:)731*XJK/"F\7>>E ME?)FZ4?O&]H==B)5,[)3LRIH+`7:SR:N,E"V7("J&2O[)/<[^7E.I=L%X!W; ML[*E/ M5L;*MDZ=1%?5=.V$BLI*6&R/6/;A)3:A_>)B=4@7`F,-7#3B2*`$`@3*NUZV7PN4F@52S"H1"#\RL#Z+&HA4/*N_Z MY2"@@+$H#=.ALS"#CY8#T!\ANM.)=WLO.A+C#,E]*11A4^J!M,1UGR^=5Z`: MX/YL&UI-H:J9TEX29;)06KF)TH_F2:$LE#^3X=!^:*X:$'$KYC<0DW4')IBO M#@E6$G<)BGRT]T*PI.$"^T%"#99KUVG3Y#=S@D/&9E-)R57G!&U0Y(7DV\L# M)!)]NZ9_>,>/<91MEU'P$_1D^7-#.S0N;H,Q[]SXECTM0-X7E<0%P-U1RT9" M`?9ETSS:L0QMDQ([CM>;PCP%HYN5\W)O^]'+B!4_"GQG'2`K\BK$0!F,RMM; M])F-(6):IN1\U24W.DSE@@W,GPZX+\1YD.7KZL8A>]>)95]UGW<"[D_`U,V` M\0E8.3$WZ]LV%2N/B/'D(23V*O*G@RP5MKNMV6B.8+Z""QLI?^T9L(86PS8N MSELK/*,YVQ'8&0L7PN[J/E]A.#5T[+XX;/' MCDY1D+D/#[95G,LB,JF)._N<[`UA^W_.6` MR.$,I41&3VVJU,AS(FPKD%Y"6E,C`R1T3.$BEAM1]G^#=BB3ZQ`YC.%R1?+Y MMXKZ\#R=B@A1``?4Q%28.*`2>J+R6$F@JDASF*/CBDSKR$J]U)*VH!A^VICM M/BZIU\6\$UHCLZIE*L=:Y5&Q)&@VLE\[#QF/H$/G^\7Y%IOUR!WU15Z4M>Z5 M5,]'RYYM7G.R2Y+8,$ET2X1/3!32%7TB">/KQ[L=QIQEPJ_CI.'+_/K%O_WF M?Q/-Q\[.'7C'?1+ET?DH\#2:P[H:9=?^9M"CVAV[HDCU*=%';;!>K:K2<7K# M&%E,J],Q%F8X449H4_`]BGA6O@-O/$^C3S15ZR!E,B;I5S:-UGY7>".R=S>& MDX)[8SE$Q#MB7I8TG0VDX]F15M\4'8^R5&M5@U]%L%RIJ\QL[,>C7I[I,8Q% M!WK`2X$'<*^'L(@!=%'&=DQ@H&JKIV*/T6MCKJ=7LEC+8>AL5*I8"]3PU70M M;.39UU7E6BO5,=OM;;A&$2(B]^&``J(39D)O74,O-H2>QK7["=!JZH;ZS7*K M]^X'8=>\=4^1%"-(3DV*BRFY.6&W3;T,[!,80+P..Q1A/;LGE8YLZ\P>>J=^ MT[ZOTK&5>7B1W\4MTR.9,F=*_K5D^]^W(\O9AQJ8*K/QBCYJZ;&\@!+KQ^:> MU2S"+B5:6EU<>YF6NM(KS[7L)[HCO#CF49?N85%R['.4VPQAYI<>K%D_3A,? MP<:BLBNN%%^K@%K<*X_#K++U71A%31D],[FDU&)I#6](!12A7[DDQN0^__GQ_+)G?>D7RUQ*HY MN*7)>ND'EL`>L2@5_8M<^KJ.L@1%*?+IP:WLA-/,^.8/0@W1M;/4[!GM%51' M!I6AP?D15-OQX0$=?P'X#!;@`[\I$A4A>/H-N_];S(1E;U@^7[5$;?K*\A/Y ML1F]MZ^AC$IVZZS1O%B/.9(<.MMRAT>KAM^N[_`P,$E@0`-1PK/+V<8S?,@Y M']TZ]1K0U&N@0Z]5TR'HH&1W6`S+(N`VCT[-D;)""!H!)JIK7Q!"HKT,'2N: MH\1]M7IC[?)`01B/1<]M;S?GUE#U(T@CZND$?%QBWJFE6:;I8<Q6>BK(B?;*`S3CX:-SDJ-V$H'L:MO M>^AG,'B$R4YV8#SGH';,S%P4-&A?\J$!&=L!JV**I`7>(5J[HN)F%GEMD35X1_B4/<38BRHPU5V!S]>2C#%DUMJ,-R$L]5(2K)7#9XINJP6WB- M*$29Y(XX%3OW0G('X6$+87:'YQ1E6Y@AWPN7JS1+/%]8$D8#T.PYE0XF38;E M,(`"@1H4^)+#67WE?`A6%[>?+J\^/5Q=`OSIX?;F^G+YB/\X7]XL/UU<@8<_ M75T]/M2QM7WTH(?1R?!OY#VK/6$-B7LPW1#&?8`)J=-D_4K7H-KW`A2] M`P_[[-7^R0L5;`3\*:2U%TF38AB[EMP0L8(:L?:\%TH(F'=![Z0&<1AZB0L7 MZ*<6LJ89GT?"3";Z5L]EL7Z\31XR@@UU,>Y@0IT0:O-WQ%:0`.1N@9`CMQR5?.5CGQT,95=V;@M7]GN*2`U2">DI(Z+KJA4 MH-R3%UV4ZD(3SX[28&,YTQK95@4=8J2C#X0R9$XI7-!+.$/WM5K0QI6#'D[M M/']Z'PH]$YF[]J#,9NBUILKK8A;CRVK%,JF>&GL@.IBY=A.=1`JHCVJ M4S*CNXW39BV+,J+Y_]\M$\[LT(9ATW-O9E5$-/8Q^AQF*[)Q@WXA]4#922+Y`6)BJ`IK MZ'=A.=8AQ4ZYH:Y`@Q)\X4)1BDG0Y,(65M!L;7,\YS&IU;2^1`GT\1#IQ=9#R"C>ATL:X5%3GUU+%Y#=G'(`6)9L, M(""CX;56*L9:*SOK+=0/?,6=L;4=%.U<=;LRSA_\5:Y\HYWQM6_.4_2XM#N6 MH).R30Z0D'74,TFU'&+^T@HM=Y8?Q8HB9K%(,K`9 MDYL8QT4#R46)Y;RA1\V'AB;`DSTK5#PEQ`HB%OD4+`AI^VI@7V%L/"`T1!(G M4QV-6HEZ^J(%9%-)M#%02DVS!JLSRL!=7`9(O!H9C1*P;LFV0%HD`BT5E1%2 M?`^#@P^;I4ZQQO#)(FV$@JR&,RO+&GBT8W`4I%U)N82R*-`GA9"65`_"J%;1 M."$]T$-#%+7+&^^+GFP+NZY0U>2]GT1-9KB[A]6SWR)8FV9FJ;>ZTQ9>+F<3PZ\C8"&50]MLL;WZ#=H@4:(PK!].57"*U MBS!)UV95R334D+BG[4<:`.\9/,:@EL)0Z=T-CV1VXL1BXF1UXM22#A>.^#?S MT.=Q6_5LV+L\58H1O^@!)HC<*FVJ0(!2$)84K#[H4TUT!/A+TDU`'D*J#6!; MATZHG6HJ=G+5-)D[EE>#Y,72!)43=0%M.F+=F"CC$$6QT;PJH;T2@Z>)U`#W M2P^K2YCZ":*U^G+%T]0W08[GGN-)'ERPK42T!4SBA2FERU8R=;5ZK-0EZP=N M.8E:B)6^I!%0`Y[!@)O6DR&7GV2JD+27.2WG3GG6M`YKFI.Z?#8IU@#D2=J+ M0T*J,"ZCX!,F#/M#(G5ZX,:E3A,K44'P%'`XNPEB\V)A4GKZ<%E3>OJSF-$J MH?$ARO*ID7J"OI\<8'"#O!4I]8NW+STE:GB7-JJ`#L6^HY`E[2IG65;BD_4& M*MTMP&.<>:'U@IZF\;8OPF-9O:,VYP1\/F)_VM0KCS$+-YRS372&\'=Z[\0. MZHTA2F\D^DE3FS8[@*\JVU8C7.8]5 M,7(Z=@`P7'!J&]&Q4C/1X8!P-/G%]X']V`O[:^(IC_%+A-S^=?D94(YMH]P[ M0#\09Q*-CPXD!;>J;5JE`\#7+?*W@&065A44BK`EX,%V#$&>NT!/+.Z>VM96 M0V5=&%?O+^@C-%7QGD@Y@_?0RPZ=U=&4$&:UCW3N30:L/,Y3D3_>WJ(^<1X) M+0W1'POFZ=1/Y=8,A/H_YD?P":A1Z`.9H="J&\;U"JA@3N MRT-:L+!/-MKC%O!HIVUN^J*ZE=$WXUJ2=<LY44)*3B#"49!?6BV9I.1^_G-U';'$R&)$3R'OX!"-I MH5DYF/$=@`(+F815``"'L)L/8@(7DWL='0YK;GWTV6N$2;V._'B'>_7C381H MV5F8H+BK0K^\N5FC*9YUDS-82U!I"EA;BT;1W=EK&3W]Z3?N9.]I.[".$Y`P MZ'^08";Y"=$^;1LXA3#4+)J6)!A,.N;'IEP_%/\P,DN?W%"#FD\V5F/3OG+" MC]AYXT7^`91@EG./32)E-!59D_=::ES$D&K0UVCG=OP46\VV/OE#H*RR0A-2>)XW!^+)OP"W#+KZ0, M+9UV]8&13P?%@0T?3?-NG7]N5S7G^>Z_ERJZ]F(X#H/*9!O\*AV'3Z#9,QU6,Q5.P6=;8^H M=?G;)!--XS!P)D):3'1*6E^BPZ;6^TH%9E#SDZ1[]EKFY2%A16R(3T;EA67D MLSE??8.)CU)I7&E(9^;U]A",YU3+^3@5S6Q5)4U&GZ8K70`XH"P&LWU+%XSD M^=-Q\M['R1HBDJN;+J/@ZML>)>REIFOQ$9+!L4_.`=2AYYR6O#(^/4:MS*!J MWF>I%?".D3B"&P][8'-[28,IW?08*2@F:9R0,RW2IQ/*S)1@3^T']93JTU&5 M7->3&]FS1ST[QCHY5=A%+P,N%QDOCWJ>\BY0FWP-CZP"=_I:3"AS4VLMA<"= MCI:JA!__"M%FBXW9\@DFW@;FOJJHW+OQ&9R<1M.G[9QZKA:FS^.RSTEVE=?G!%O@>$S.(P]!+TK*\P`\GH'>GUPR]=>]< M:N&$]&]Q,&%;!?>"SUE4YP MH2@UIYY'1PXVSMEK6YX=324?/ML\'3UO0D=9/PX\3E: M@\IIA"6]KSV#D]/P^K0U=EAI1V,;RN4=3F\Q6>@+L-63SF>KDWMJ@AF/19W5 MLRLU>JO>P?9[2*I6X>\OXBA+/#\[>.$C3'9O5#K7]&SLZ%_C-+=WH%K,"E2F M!BEK]U+);2C.:;6UZ/5QNE$,BJFZ1ICA*(4^;1JO)D$ MQ.:8)Q>MD-'/6`F)8F3VML.S2BI44G6YV23T1DN3#/]$"823$>D9)PMVJ[<9 MTP-ENLW@X_1X)3]Y.RBHO=_=S/QC\_59MJIRX[\`^=UZI7T965NOIPMI:G[Y MA67X10VML8"P^'Z%":P7W9>35\0($Y?:OZ)/L%[CB4;DU4(R"L;AU_+:^PH@ MLP5F51@T68"U!P4`H#Q!0!05^T>CH56RM2\Z=.+=.#$8RX5:M1BL5JZU!W=- MS?BO7PU@_!+(`<:O8*#+^*]?NGRCW499H2G<0_WH>?3:?`-OMS)$+D#>-`\O M.N%3C$3!"3]"Q3XU%T*/=\P9CJMOT#\09^9VO4:^Y$TW%8!QY2V<>4O]Y@T! M;^G`PV]ZY&]J41W:C]"#O%>2XLMZ3F_7#SXBSB[^81D\H31.CNR$OB93\@[PC0GN96N#K/Y#P<<6.*>C!_US3X M2.8V^/0&2J"/^U:J]&9#\T]L-&?:>HZ"-W"`D^34;3T[(2'MF-C8;A_&1P@5 MP;!&*\/1K^8<6W:9-W!@425$K0>`)!1U:+,OVDNQHEI879%?T^4AV\:)XD&K M&<9R;YL_@%XS)-:QT:@+0<<#Y8`.)#D;H=^HM!E.OUB;?DX%6X;*[&2Y#7H" M>WI:[LE#(4GR>Q\GM+*(`677'O)D=5X']8R(;CXN?>&2COQ\9%C$D7.)LIP= M3T"BZ?_^`M.L*`*OO$\PV3"G([G=5)I!6ME!!A_)ZA/`IT8S\?6'D]!C$CF< M3'X`+>?I]`'[%53,@U2OP3IFV6()^`T58O+$?V MY]:RM3,",RKV!+Q@G7*^]$=B4666R]I,3L>K'DQKLZ_BMBZ^TR;4];1N"UU; M@PFMI+PR98\U.(F=P#B],^^+M#V5CFTMWUL9.Z,S>XC53`\Q3J%UNK`@#A7' MPJ\T=55@^\G5A#G=F/"I%RY#"@6#[O'PMAY_%&Z7^_9B.O^[)X[ME&K6`2AZ MJ.UB:[:']V)QGSH;NEVF=EYT-7/C1^.+]V8IW>[AW1[>E7'T]W%"<<1[1K:) M:VL3O`^DO=K>N0T3XT;&_7`9-GB+;ZB>ZMN!^7M_0]E77TJ=L.`&\+1OXX?) MX1@>-7@5AB=W/L#D"?FP>XZ?XN@)IL2#)SY^2OFN^OM%G&:?XNPGF-U#/]Y$ M)(.J^E:]1((-C6_^HHXAN@KSB_G`0O%:@&)TMG_&^^::^.&!P1%FH!QZ`>C@ M^3[;KN8Y20+3"=3)3*8PE-9&+VV95!2M.V#FM<0S4,$\EAXG_"O23I9#9GHB MST::ZV@C=^RCM/M1_%MI;JF.,J7$-!6,C7^6O M7D(#X972B2Q+>?),%C5G#!$S!YRB`24&+ M6L%4T%%6ECYU0],A4L'[-A-125)BUB4:-8O*&J#/O,DX?9P@."1$:5-C0`84M45?3 MJFREKAJCM(D19XQ\25>(#<(XGOZ8SZ)XI%RHDX=T95CE#L*V,WDEEW[63ZX0 MN:9@+0J]670VM7YXQW".Z'L)"A=[&M2[-6']`7L7E.$DV'[2UG*P($!%S_F' M)"%6U!%]-US2Z^ILK)C;=#'Y(]RY+IW-O6R-&_F)(EP0./ M1"T.849O$_E,"?OT;I$',ICL4.11"/A$>#'=0Q^M$;N"Y5?>K:O$,W#?&7_9 M+HOIN"SVP4(/-+AA7;O/I!FG]62E:M&1@+[.V]ASAOGU'\<^`3NB3U=#1P+B MA^#I1)[164%/>BL(HWJACIJM(`Y#+Z'ZDJGSYW.J,"LU.TX=C)'2^`'$4$IZ MG))[TA`0KV"+_"V/+V''`?L'P/-_.6`#PTRT^@2CM.2%O_$L;'E/:S;;`8.^ M*;-^[`";E]K,V'VML4_,YNO1<^YC"ORS'5MO[MRB-XV55JERHO',#-`P@@T] M[""VYFO3<.4Q0F[!GNF!B)XBG>&`I(\6M1N"Y%%1*P9'<_03,SFZ-)TUB)F? M`#QCLS.4SF*2[)GAJ1\@/3/;,YAJ.6^5ITO,='2:E^=G3WIIRJD#E;W5I$/' M6I8L2X\YG)Q]Z4-?DT=ES]O:C*&Z+DI](,?,W%L[U)',Y,>,XC-ZVSON*.8'*I&A)^S>G M;"NG601-:MV@=?T(ZZ2-Y<2DR_=C24&ZJO4BAH[MWW)NI9=ETNH-&'+)!?SK MK]Z^^_U=]%/T,;I\C/Z$_WF@7Q'@G9)6&02 MF\0SH28X@N`(O03W1%Z5W>%);M,%O9&3;1%N"K%;Y!V?U<6:OO;`U,F8IC%P MQ*I>XSFB*$7^/$7:-48\70O9HITA.UB,.VMQ6AMY+DJ*+C=XQT`R/YM$4.6T M/)ODE2Y67TV>77R(J-$,T'H-V;YU!;.OQ$:N:^7KB:FE6^7P2"@E M34(AIK9Q*(A[*!R#BD?PG&QPM_68S=+*3,<(>\I'8@?F(A/8:&36:C5G*#A= MX&?^%O<^3DQ42^EHSC2E(DY?FP![/)$M9E-2EQ2[V&Z\)-')O#4)E'#N>*$I M#E<>XSM.G@M*'7I[B%V/4(B47A=6!$X3.Q&7ER>ACS'(.P"L!WZOD/5A7V(G MPS038+J8%]4^,C\0U_(&86'6815ME]5#'S'M4A[]9=1@H>(H0P$*#QEZ@@_0 M/R0H0S#E3PT%[S$]B.=Q8*QQN[[R$K(Q2.]@PAR/8W<'RV](5AMUUE'-ET2> ME88M'[S2&)2MP1?2_K_M%V0SP%&M0L2FV,FV7'[R=O`R)B&RWL)5!75$0FK8 M:++Y`A`H$7!.&:E(C'X MPMH[P%O*M1"6H90OQ(B=RXWW9Y(AR48]_\4-A%D2X77=$MT5&1P_6]$-?6OBTWW_*\RAX,.5VW7G$:?5-KVDP MBXUBIOE\UTC4RD32C)9=_VO'\18M^1K1LS-2Y-5V_*N/X#4>Z>HK=>8L;_$V MY_FQ^/@G!!-,F.WQ!CYA^LJ#5[H=&+>=VIAU/CS.C[D+`&<"2OT6K&G*AJR6 M!6;\"+T4.Z4TG;L]3V7,IV<_]EA3$T\QAU89U)D@T*!E%')J_S6TP+#7$?;_ M4BI`KY4!(BF4/6;LQ$&F'!G``E`0\-J!_7&/=1'RFVI1['+7FT'<]<8I[GHS M@+O>.,Y=;_IS5^>BV.6NMX.XZZU3W/5V`'>]=9R[WO;GKLY%,<==ES!!3QZ) MF-P@;X5"&C*1$6@O7&.$LV[R4ME.Y`W/,ZT(<]@HGYZ;<"\0_F\3?*\E%N: MW*[!*N;X_#KRXQU\R+R,>JC+54HO:D@X70AAG-?% MA@;DC>TSO9*-FNROR4,&%3@,<9^;#S#"$PN74;`,=BA"9%+$1^'3E.EUS0[, MJWM=S%J7%1G@`G!0>J6I#IQ+DAM&8C2BFPJB7@W8OHCU8]"6N1G`G>:$[QZF MD,2!\;PNR:XWWA.?3BUS"CCCHJ;"H^VTL/:4X2H03HG5**2"$L*^"&FQ65-R M>O"81;>MC[OF@INFY9[-R_XT8Z&W8]8Q1RYQ>)M?A#PN8A9S7/XICN+Z M;+C<:>R^-6"-2X`./JW+DQ680B0XV`_.;,R'8':;;6%"GC*G*'%K("@Y:5)6 MM+FN*3D]6/$U=@JMEA;"],VYML/SK,7,WK_>>XD#ILTYW3ZC"]BB M?80@X0ES3/S!0Q$Q1K=1>21V'6'!HOF[Z2>8W24P\[Y)N%N_"^-LWP.[UOL< M&)1[222!N'+F6>F`GU&P3IS8+X_`^&)+:N"0`H'UND.!]G&O*;5PHDCV.8LW MRKGVE69?-=34IL-TD!4UB])]G")VS6>9IC"3[3$5<#85:B<>*EXL@8C0W27$ ML\N.M*0V]CQ^.2`:WUKP2V3$.;]%+"+^P4O+]N2+1T1O?^3?.2*L^E3!)`CJ MY(`Y_LYH5WULZ-Z\'SZ6](M8_B1*125\)G<=Y-HMH2K;#.5^I'3[(0*QL`\1 MSK[MV>=-^0:=)%RRUG9=K%XX\-T)VX_;EP,5][1W*3JL8X[[L;9?HTP1F*TV M,L[AM1FVPDXP:P9@\9_@*]2([FA?G0#Y!-0X`:2=UBYH`&O@3VY.![5*8!X7PY(Y6".;P79 MQ[&[)1G7E5_;LCE([NZ\A&Z%K5MY'50Z9>?C($/KS>'> M+-9AD'*25"ZL%9!K5E?T4N23C"!23Z:S1+@VI/EBGJ2;UE- MT=<2!M*`M5!<0XU/NV#%*@,ET`+D8*0P/E)._:KU@B$)Q^?/'=FNY2IE MF:Y7BV3\8M"+R*N6X'T7>=1@&X9%RH]706<^9K[ M"CQ:M?2+]H``G*$(#7MC5Z>[#@-5S*0',S&E4D9%AVW);M20!QB*9UE MZ;A8J+DF!ITS&O>7O\(A:6O>Z>J8;\O!HFT:S[V?0[R5HZ\XG,_ZXOL>)B@. ML-.39*H=N`XN?++J,YJ))GX5*=/U)YVV43=6Q.LMEU7.Z"-V_=0#9B]17QX2 MW/,=I3JM@YMOULJG-D3A@+Z]F(T3],:QO4$B3_FQ'@#K`K`^%GDEY&*C7GE` MQ^*C.:-1)K!48.)U[?EDL(Z3XI7EZM/+-J,IH[']2WX)DN'(7Y@/V$J3B`O3 M1>0I'0]@-`YAEL=BJK1@T*Y$9X:)=BUL,T:N3>Z9_WY@5S32QUBPW:(:=.6E M,""OC,$HI0QU3RYHI2B##S!Y0CYDZ-U#/]Y$M!>*J73;/??0%G;NLU.SO?DO MAB19DXU8`"AC`?S-^C,Z-*B.O0#%Z(`/SU4TJ$S`B20Y"P2F.GV?1A_U:DI+`>S&D)7$<_@+(Z7=F;.T6XIB``17Y-Q;):Q8Z\3UF`VY?2X=S=<6]B M%&M;#J9GVO(`A\P^\'2D&\0\O+Z43H-0G"6^D:I!/$^(R1&Y9!G"% M^?*0N""3$MY2%#]L,Y;1Q[<2Z)$YL'\K8LLWPGKO<6EW8N.)+GT,.U[MHD#@ M^QS\!VQ0*_:TR%-QQ)B.PI95!TR)W?-HE2=ZARLLGXAS0 MO-;QUY#Y/VY)"=!25P3TPP_HN??F$K[-&D\Q0W@^`0!3"A+3&) M=RGY>1-C'171"8<+;*83W(.784]DC<$";LL3K%*.(*95NCN271?6:NPRYZAJSAFD(\6_^^/'JM_[ MAX343N$VW&F;+:]`V9/M;,K2TJ<;E/3..Q(A)X]\^7YRP,NL]7;ST`X=D#I- MS#5%,>\-\.[8NW>L0U#IT8G#W,F(46"]KV#M<:P=][_[<+Y:P/NSO4VIOX1K MB'5MP-^2[27@+5@'9+F-C^:&.`<$TJ>`[<_'X M>))C8Z>/B[6.B5?Y(0X2'.*X41]O',HG<-[2GW&'GP@[)IRL!/9$N1W2SEP1 M5CG&/86VZ,S%D]=)"-#,[4`%QB<@P1K/!">+O. M7PNA#XY@W[IX.3=[-H1GG$OCJNRP+]C#+@N[&*J^S.+#S MG!)M=Y\M&<#`'679AW'OB..>9?!$;L^0(?GMB#_1*@.B4QYQ>[.'.Y)YMY-I M:%-`VN97G@!K;2=JVA>!\B&TRO$#.9W@B%')X)=YP'86Q/J<\O1?FOQK$GG_+\RAL'[JH9*=VUJ(G.-9=Z/QO]5&F^]M]!>5U@>@)>,@2YM7TC)6QC@.F=R3:1&WER4W$T_=S,M`/L.S1ON@.8>.F MT`[G8?,)^.2JK?2TM-K,6LH]GZ4P9YW\[D0X2#%A*O9[[OJDSXC:2)FO M[!0G5P7MW:]\A*RO'@- M*L#..($3(7F)4C^,4Q(G(5&33IQ_M"]6/=FU7;]]`*^:$\;;9.-%_&[011RE M<8A8`M0&Y&]A)22`@[54?'7?%Q0&3C/".1#@WQL M\(6,#NCPEM6-@Z2-9R:M2?UF1`,TM:)!\1]Q]'3)#Q/(N1:]1*'GIO2`-7LD MI8E/*YF/@X$E.;FE@+W\$F/''7W6JW;TT7^Q^EKH%/HO-O'3RP`B9ISQAZ9- MQE\5,ZE,X%%PITW>W!AG*68M9*8:!]'6%ME'A_0YQ^C3W4*MJ@3L7M$4GD=NZ0D+AN9C@,?%(K?R'XVX5MXC/<6BT,;KP MS?FU:C2PWP%K8'>M.VE9764)(6?V#6AU>EKA6.?M$%U`&UZ#'!.1"\&?42=@ MBX[7U%W0$3IKU.%>:"_0W(&-1]RM(IC!FE@)8/#9"8,6Y'D@=W5[:1E=7DEA)Q;7*$AOAE/(WE6?3RJM+7))==A`%>6MV.,9_`$`_$=X""JO_BS'7.]M:U263CE0I!O,&.]_E7)+J'QN:L79^+)O<>4>:)/O52X); MFH>=\I>+2>HCQBA!F"M\^FCG:XFAGW-0\QF,+(75,8C7FZU'1\3 MT$$7@`];/+-.!EZ`8FCV"+O-EXZ,$G19Z-`&!6KTL>]9S2^GK9Q50T)J,)'^ M!IN@ZPSN5.'G;A#;"?75V>LEU1,(0$'^BC M-8+!9;SS4,O-JTJM&,:\G9+,7Y1MOP"5UN`+:^]"\KUJ+5K*3&\A1NQ&R26V M0YAY4?81[E;BZH3M=F;WDAWS;!T1%$W`%]9HKE"_UG9)8\9^T<3R[D'$!;7- M@9P%#/O^=PGRNR(C78WL^-;Y##M]84!_M5P.03;+BS!.Z>5?\COSRQW0GZV5 M[_3^.I9]A(:D79ZK'K;2GS'25@`Y+W2WBN#!O3INTP1$/V`XEUQ9P63Q30=C!K3I&KF;3Y MYXF%S(S?#OV'?$7]\C,E7E03J6761_O`GI9YZ4'4NC94K+%K5@,\"/,;T MZVK6_^GKL1'$7I8A?"^DM;S3+225`.E;I#3F7RB_E%V80%$6@Z];Y&_!^A"& M1ZX,:3(-S.F,FY"O04JN)!1J,ZY0W?SRA$U>Q?97+ ME%IWF&9QQ@/$__>)W&R$![OSC7=2JE9&-X/>8#FNG>V:%5).=%;#B8ER8B[F MIZ8%_UI*SO)'8FI*C[O!;]BNT&>TV=D__XT^C?W2,.R18[I1Q3B&<01?!\G^;,S0D4_I"O#.GP0MBV=0KVEO!M0 M]%-)4BYZ`K@KD/=EXT#7%M[K^?'64XZ3H/ZX12F`K((H2.">%<9+`4G680YX MF?VSJ]%@7WN7"N7$(XXZ)2?SIW\I:%F4X;>N)X=KAKH*'*L6#,?B1VAKC,(: M(OKF4*ZR54']J4>SX23#G/H4&^G.U4D6STJRF6.9 M6C2K/@R0GY4!1AJ_2D*O3L)JNSTGH4>9+LXIF.44/.WS,+$NFRBNJ5)D]DZV M/GK?T.ZP(S.;Z2RK-L*I:.\.VLR6"\"'H>KH)!6W+K&FV(4O3)#+Q`&4G%[D MDN6.(TJ4;)X)P8Z53E?3BG3.E.='0H4S0LO>DTH"-'C9_>IC`,89)RMPE)*3_A>!\G,*]>]."%L"2=;1'6 M8^B:6/;AYG'76V%8.5',970!5A!O6,B1*]KM8("P MI(5'$!P@3?##SO].AP/<:&87>#>\!_X[_P M!Z+E*+K_'U!+`P04````"`#J:D]#!=2J)[TV``"ZO`,`%0`<`&UC970M,C`Q M,S`X,S%?<')E+GAM;%54"0`#!WI=4@=Z75)U>`L``00E#@``!#D!``#M?=MR MV\BRY?M$S#]X?)[=MGB1Q([=5695_^??OS]&;%Y9F81+_\O;HIP]O MW[`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`/61*%,[[Z^.A' M?`K_]L2881UU7F>AUM?IHQ^'_RKZ$W3]KSZ?#JX?KN=\]02_91_]+,RN'V`H MR\!4J^=N61#Y618^A.4B([N!*@:AX51D_^,'F,7N?/C)L+UIOK*U<;9.G:4O MLCWFUJW@;GG+XV^-:HF*MS46UZB>]#V$QI-SEOMAE-VQ[_G"CYR,*KM5L+R/ M:(!0]IJV]A@-JJOUO@.,W,M/6AVZU^\\R`KB!@:5.']B4%-S#LS>?3@^ZC0I MTUU7==:;4CKA;;7;;6-N_>"EFI6 MVY38>RRO,.L84%B^G7K5ZOR2U[2U$JYC1OF+VIK/O\&"L_Q4=4G:?"['WMN" MUM*D:RE>=0BK7_R^"/-7F(ZX9A`'KW9MO_]V%Y@L+Q0-/G4(M&=^]O0I2OZP MW&TJKSTHBA;)PKY!:*?O9&]?L<"\\N@5`-XR!8Q+#$P\6QF#5Z*Q1[+PF\*7 MHR38^EC$/;9)JC(\_\63?6!ZGW%?=;YZ4>3?LZAXO:==UAM-)ALCZ59V:9C" MAYRQX*?'Y.7]C(7O>?WY'PH@[SX<+3W(_P8_K6M3J42A1PEJ+WO<&W_XL%7A M*J_3=+OR?AJL7@]_W"-UVP>^?.+]O.A"[X*G,%JWAX:YEV65M$EU@BPRJ MF,SYK[S_)NF,I;^\/7K[9K[:*5Z5=D)A%!@*8S;C]<'/[HNW+K)WC[X_+\EE M49ZM?MEE>?FSMQZ8OL'NT$_#9/H]S`0T2Y_WQ@.G/*NIVJ96`XR8VT&WN%VB M^C7.YBR`@9;-SI-G/XQE_&)EP"Q'+CG6X`PA68Y(3/30`=$-!F>8(]DEF$74 M0STEQ_M5_QN9;T:,`>T*0QAU:]JG$ ML8@I').G\`PLD/K1):Q1O_\G>Y5RN/.L-SZB.)%JDB@$(V;QF#"+9XN4V^A3 MF,&V[)_,3R_BV3E,.@B1V.,`G^*XJN12CD=,YPEA.LNV^2F,6'H&,!Z35-XE MMYX$T(,NDHA"$?-W2IB_N]3GX>3?7I_ODPAA;NL9L,E)%SD3@!"S-2',UG(F M2)Z?D[CPV10NA^QZD?/`>8Y//A]*"H))3KO(JRXR1$[X0)CME3GNX+6*K0=_ M!'!V5J"@AF',6GR,54K/W/%C@N,MT(H`02BD+-=N( M^`Y)G]#UTX!^W'TZ=^`@9#:1;,`R[W>]@:UZ";=.!]KP"E9?J/("BI[UCFHX M_33JPN,[/D;%&3AU9=8/>VX]/7(K;3=7!0A+WKL7EMXG&;MRV&3%IT>-VJX= MAQ-\/3^'@2%*>.R6I+'+"WB#@2N7V542/]ZQ])E73-9!I,][`Z?K9@WCBCUE M.)C^]!7E$68;0[[J(ZII0+>\-QA;FQJ4Y^%4TX7V"[R!TX6LN84%TXH9V+YU M'\EY>GO=!_^(7O=1E_<&IY:[#_Y-S>ZC\0)OX-3/:VYAM/OH@NU/]]&YV<%& M#]K_CJ++H`6\X9&U/K+W$66GP$MX0Z=*LH;1!,U>`:<_[1RY%L3%EF2]`+Y^ MJ%;HED4\+OLLR?*L\,?PRY1F-_ZKJKO8>;$W'+G:XFA7_&.UXCJ;H89O]H9. M%3&+Q(JW5S;,T[,A8GU)CX.18?5M?A0A?'S*LZ])SHS4"\TW>,,3:U/H^@3D M^BO*.512Q!LZ=:C7L:-@5E4![$^?V;I-RD&7N?#3.(P?UW70Z"-8$6_TP=4$ MN%LEG:D-+>.-2$3%2\TLGH[DD/K3:<3WG3GH/>N*;`8JG86FK)@W&KKJ1:)J MZ?0D:3EOY#1D0=ODXAZEAM:?7K5W79^##K5;!XW.A!7Q1L>N.M)NE70Z$5K& M&SD-?=4RL[CSR"'UI^-HW"'IHBNM3M5=/WP*8ZA+Z$QR%9CRT/+^P][8J7M`CR4:P8-?&'/]RP5,&=0VAN3B*9! M:*D1&U"!Y?:4F,1&SY14+5ATSBU;F%VO)#<+X`][8Q*N'//Y M=!L!G;/+]9F<9AG3VAIO/^B-G09I*8@1LRA`8.FX\OZ^T<&*R,^>IO&,_X]? M]_;B1\7..C_ST_0UC!\+Y4FV2-(I[XU)Z`<")I'%DC8H2P>?*;2$SX6[ZY8% M#`##P+8\L2_A'BD!JU`2O5R;;BD.2X>E*3!\G3^QM+2*FMS]A[TQ";^N-JT( M`EL'HBDPJDOFCA65OGI/,D]R.G!-ZDR1Q6_J\\DJVX2Q"FFSE? MF7QE,CYEQ;QC$OJB-KU*++:.65/HL)4QZ6L2!R:C\.9Y[YB$KEAG(-X!8>OH M-05J2X#*0=@[)J$A&HZ^1:UMG:IV/^Q>A?Y]&(5YR'AX6"&U/"41P,G*.Z\U M-K:ZK_".20B-1EM>(VRVCF>3Z,-!D"QBGB'GE6\$`#S\DBX`P<8B&JLM_;=X MQR042R/"D7'"$#32;(QE,`K-YGS![I)EP/6-G^JU$KR0=TQ"Y[30*!08D39P M8"$-<5A,9R\\>N(3V&5]_OVO!7Z<6[V"WC$)?:0!OP8X$8X[*9%M7XF0J_NX MN(!W3$(.M="_)?@0WCLIG.T,UKUB=8Y M)(0V"WPCV!"N.ZC#50!N)`JS7>!^.>^$A!)GEW\$)M(4.BG2[@Y84) M;27E7EK2.R&A^]5O`6IT2#OHI/)GRCYB%6IJGA'G.":$:6.QCM1"3X]=[Z0O M8MPN*(148_7-/:G\%OPP7UU]!$N6/(P?61S(29:4\DY(*'1&3AL5'(3N3@IQ MM3QVDDYS0D*0,Z);@09ANY/RVW9,O"HB5?"T=T)">%-0AH7'B.$@)W>,=;8< M*N-ZN[W.8:*,-MYYU#LAH;#5(E:(!6'5PI%D!\[TV2PL@=SXX>PR/O/G8>Z+ MDBTI2GBG)'2T6BS+("%D=U(SNV6Y#[/6;'7_RS0(%L^+PO%;)I"7STADYJ:?MV,EJ7>:<3]=?PCA)BX3G4!>6 MR?KU[J/>*0E-K!:O0BP(JYU4P/:M=1H#78^X)V2T-@LC0VU+8"TO&XKWUG*7%;]E'/PNSZX>;*H/Q[)8%_*Q] M"*NH\K&;)`H+V<_!;4?+"-BB,Y>UT#D?C1;R3FM<\&H'R=+8.W5[+?^KY%NTC!)RS1[NWUN.ONO15;HSN MY9V2T'AJM9):6.U?M$0N'U)QB?GRM7NGW.4T6\Y`G MUS*X'U7Q"F_B/@&&$2/B?F<$MS^W0(H39-3I;):":XBFR9@X2Y/Q+7ABLT4$ MU=[D9*@"*!B\+MIB-@WR\`56^@5_6O>W-GZY-R&Q8;)`+[(!MV.AGHT8JU0' M[@:*PV7-F#C;5%7:WMYFGE=VA>`Z+0$8]GBS=WH3$ELO$]:4/;J&!?K3D:M) M/-SU8YNI/(X^.,OEL6E44]CQS<)HP0-AO[%@D1:"W,5WKMJR&3_ZR*>/14GF M]4.=)"#V/P:F(^$ME5.KZL]VK=&?GB[,/.*NR[>1?^3H@_L$)!7]?6GHV34L M0'E4-#2S0OXSVGB;O`\,0,+)I29)L?TV!]V??FK+I7'.PT>BPDX+,$D/'!M' M']RE1:F9L^'H`XD(8951,;?S/A8Z3HF,!3\])B_O9RPL>80_[-('/WE7[-&/ M+@!\_HHD9!`\!6!);'1$%&R3A5:>3MX%7:9*!&A^A=U'`*93#P]J^7V"]JM- M,H'"/UBAA()D;XLEH^7#X_ M+^*$WY7HSQEL>X),3IFR((!VN@_4)DX3R9\I$&!@.B(2&JN:SU08^I`%H909 MO[#\*9E=QB^L].=?_Q&S-'L*YSP2C]+XH"E<9,M'#)K5%^O"G$0/0OF'CL?`TTW86[S"BALJ;?WPE,* M="L@;(VK[.!E$MT:G3)TG?![, M06LOCG,FF\N$J-QN`ZTZX=%-A_`Y@$\B/%/"C9A,`0JWVT-;YS#7E^V^W@'` M#.:G0FQ^K?Z+8I#6?XEW-"!R-E=WQ#;%UH=-9Q69?Q@,0<*?;$J=N@%4 M\;G=D"++_"O_/Y(H\L^2%U;NGI)4H0KA)0`F">T`(T`@#*G`6-HNTEA)UU6$ M!K1D`?TU\PX&2[GT'(^T[5Z#<#0@$1B`48B-N'JXFJ;:FY0-(&:/_-46#K6N M'%YA,?:4K:#\\R[_Y:_>1N%:Q1U>?&=I$&;L)@T#D=2A5Q#L0R(P6X]W$TQ] MRL:WS/N\1+N,.+U>Y%GNQ_R,MZ3KJXJ"L:C>2"?I^'JHK&7SJ3=[;JW=!W MU$E*@8E(#+YZI&L#LN6.I M9MF"S;XN9/JGZ%F`2$+Y-%@%XC#:\^=:8&H[L&P9I.*7<0IA,L-(4Q0#X+34 M3#5_6H@0*HW%KE:H7$48K4'\.D_BRJ""C;+ZA<$(M&1,-:T&N!!R+1R9MW&W M21D9M*GY5?@XF9BXGD_,%O^.O'(>*RP"K[;>R M\]P($5*=K,%[O:,Q+4E-:W%E`3+2LHPE./>1U8@QBIM>LQ8:EN:+PL4;N=/;"W\>AK`-S_UK<^'^V M2+G=,&J5!<$$'1+E3#`AM![TR$8KIZMPRN4%P"P=E-ID6!"*.YA;>EM07&)F MLXWP7,Y,Y8QU)*'>[$5@Q@X)=TTP(DW%6-5KX0!7*3YN%ANWC`>1P)KDUY@M MYRU4V-,I"P;HFKJG#POA]<`2']&S\^,.R7\FF!#2#RS]M3*Y\\SGIO/[I@R8 MIT,RH28G5P M\JKF>8YC6K*#_AB\@Z$/YR+%:;^G?.G]6&#^^+IY9)E8?/J'G\Z62<$_E]%R M<>DG*_[&8V`OXSP-XRP,"N^\K'T9 M7[*]CP(_9$/1%,VV17M8.H-,IKW:ZN$K4YV'+^&,Q;-##KJB;P-;9&/G#C3H MXF;ITRGL5DSVMR2"UT1A_NJB'6]_'2@C&R)XX)8L,DQ[I\M=7!,*_;0P69PE M43CCUXU]]",>E??MB;$\NRF8>F)0VE+:Q^KKM]ZN\FDI"P(]W4L(>>(^(:2F M8?6\6"=]RPYIQXMU0E)!/5%GN!%#^=.+%8,A:$F48J;TO5@GSI-`.O5BG9#0 M^C!B&GBQ3ISGA93R>MF(5U5I[^B4A!1FS*L>L%XXM)IZ)T]IJ4;Z<^L.ACY< MZ+F5&`WJ'81ED@4VCUA!2#R;/B?0K/]5_'Z3)G-HY*\WL`+-X=_X+8SS9WG, MK*U/@-')"C:G>\DDVT'?(X_.]B`)^YCKM+!L>=S\AJ7%[E\:G*OS`K`;67$$ M;S4FV'KD(-F&71XFFB[RIR0-_R4\BJ-7$.Q$*RBQ1AL08^J1LT$$MSQ(9LA[ M60CL0RMHL3;G53Q]TN5%6/525RI*@JE(1#@VIWX/5)]N2JU)IM0-M8'VZ\+0"VF#6EY0"$]%2^TRY%P/JTYVG>V"5LSU2`DQ#0@MLR'45 M#(U+2UOB63,_M:28=S0AH1(V9'P/$8T;4-M8WEV%O_.K>4J)@_\#BP.F"EW7 M?048CY:D6&/!IT+7WHVJ5`_FULI[ZOQ\[F3H7)X2[,(W;]<`G[L)=P!BM.Q=PJ M?![,04N#4,ZK$AA]"&S8@_?W,'\J$C3S>/&G<'Z77,1YJ)$VW/!-'AB`0DN0 M\*O9('1P]B$?ZL>$'^E^.`]3%O`\W&=/?I@^^[%R;)<7!`.14"5J\2IN(CJ` M>Q2.<,N/HBAF@_4S@)Y6>))R!MBINMODJ1894_;;RE,`G41XT`X7$L*J];85 M#N"4LV6Z&B5K6\\!?A(A/7N4B)D3U-V6*Y^&-G55+Q9X\*&K:M0.!EO.>*=L MMA5^-_A`2Y_:X4['/2/&9,L=W\+=YCL1I,N$V\5E,:LP$LS]9E0>#$%"KM(C MMP8T&JYX+99W+@72HW:G$(`F(4_5YE.(AX9C'2'QELT6`=N]T@F:8L#M_HCR MJ"H'T&EI4FHJ]2"1SBZZW1K%@/1ZIKBL-S@BH2_5[J`R6*13BU;SU.T&;SR' M_!:@I"*35X)[U%W9PJO!@"3D)H-V80TUC7RF6@/"ZJZ=Y8TFR.TQ>@4!/"W) MR70H0#'92B-*04440^98I>."27$P&@D5J\D.2X;,5NI/]XE(5B@S:/)<:UAF M59O&,ZW\,SK%P60DI#&SQJ"/C$8R4&O'KY-%G*]`\\/`09`N`$'HW_-[K$*6 M&3:1NJ\$X]+2XK2:33.TMA*0MK)NV.T1=XDJS@9;2)B_R1L/.R39-0)I*ULI M.>76SEG*P5&'&H(1*`HY3#5VFFCSE?-;ZSU@F*Z)N?4@VDI*VLK`O[[@+YWLVFU6%+ET6)67!!%W3=/5AVT3=U>6"JT=!.+=[*'HPH"5[*&<(!90^',MK>BAZ,*`E?(B9$M.+P7%[,,_EM>"#`0G9 M`R-&('N8`.O#*;IBVN*9>M+\]2[UXPSV+'P6^_A:_1?5:2KMEWB#(2W90SEF MFV*S=)".3*-0#N+[#X,A2,2TF5*G;@!5?&X/WB&C.G>CLQD/PKN$`2SC2TKY M0(X6`)`DHM0P\PO&;@667AR[,SS<.J058*8>;;>KWHO3=C5.MPY)2%\[9$@8 MJ]:[%V?J:IYN'9(0JO8H$3,GJ+NMDW%NN0MC/>ZJSP%^$MJ2+G?[=;=UXJW; M)Y.'796$=C#8.OI&+K[-RLGD(2V1:(<[,=,ZF&P=D7,?2B%"VR0OR&!(0DEJ M3GD5CZUS,%:"(_8_ZHB'@(M MX`U&1\YG.],`B)'3K;F.0?4B'D;XMMRMCK*+#MEQH\\"-)([[]%>,(H"@MO( M!4UV4(U2\C3`NWOS`"N;5*X_5I\!*$[WSTHK"TC9KW\? MKLIMO`T;D=A,JT<_%0:W+GG%\!?/5K?@;%HKRX(T+.JK&@[EI0$^K9WT#C&2 M\5$'F"67/(68F@WL+S!0P2+>CP.V7'E+>JVL&-B([`9[GWQ]1"3R\"*=^C*& M+154-T@>X[#()\/2,!'MEF6/`TZR^V2DVTJ1].A:VIU-\?I_!6ZY'*8JZ@W& MM*(JM/JK'JH>YYS`ME2G" M(C_.EFJ8F0QFZQJ3+(B2;)$R?NIV4Z]EC,59DN59H5+>P^)I=;V/3%JS\V(@ MOG/IMP9C$BYZ&X;7D^K&I/)R92SXZ3%Y>3]C87K0A%V M8_U;0`-9M6*,^H9;,H,EP7)>[,$!49J[/3#6T$J?X<$\NUQJ"I_3)),.4_:_ M!JR0%63::YRH(7JDNQ:[NS*:XWR1EM?;\CY31'F4]Q>5QKCXSM(@S*0*C_G+ MO,$Q64[/-#FXOL\3,MCQY>X8'RP;P-7 M9!6I]@8[3;,TE;(G91..8=.1+Y_M:B-VO%P\)G&PR?ER\=A>]KARN7@1=[M9 M+N<.V#63K!&@' M1F^5Z5;6<=[(C2H"--**WSQ,.Z]A(PJI)&DL5)2[8$?+ET;U`I)I>:EH"!IJ MD]DZC-S]?M&E!?R/[493&\?6H>S>R26.6K9F#8"\']`'9V0<&KE9+;;K>[7A M[HV'A%O&8WC@][,D+@+H%GYTQ]+G@:J-'[8VWN"DBZY!5X:BD;V61MO'!PW, MB$[5.OP1+A7$6!D7^F\.LS+>_">3\V#Y*D3EL M91?NC'S>L1;[`[HO%>:PE0"9T'[1SB2U;:P#+2%V/@H4==5AV:(];*5I=I^S M2W;XKM955#T_@W=R["Z2MN89O!,2XKP-PV/1LOMXZ9S!:W`Y('3%K_ZSZA[K MZF,`GI8Z7:%$3-Y^[>D^+,'^] MC`,`'[XP7F_XU$A^Z9:TD#BBC8)DL7B]L3>B;$'7VH0=RJ$(`E(7TU M(6X;2Q\28A6+[SOXBF*RVWH.X-/2?Y2SG:#Z;M->N0X`VQ@DGFE/FFU\#L@@ MH5QM65F>EC0(^18(_F$Z>PFS M)'TMLD++5P'&+P*KD!#0+-#?Q`"VSJ90"/9990U7#@C;#X(A2&AQ%@<"$4#' MN=Y'B6O#,\'*'C*&TQ(*'*VNJX(G>/L90A;9X!K$>5^G,OYVGW.&P]( MZ#>V&!/CZT6.,L.$JA,2$JO^/FJGZK;BO-U39I90=4*B.^Z0(6&L6N\6LH1U M)BGGA(1TN4>)F#E!W6W%U[KEKEXRW`D).5*7N_VZVXHWI7_=\:0CXB!:>5N! MEI3O.Y[0N^]XHG'?\025X*G;]8)![VOJW M@`<2>AO60FIZX>N9`6F.QCH/!?W5EHE>_##BW?M3DA97+1V@<>Y^TAL/2.RT MW+11L360IMHM>:O[%Z@//Y#0;@[4,E6&0!JEL8#7@0.[O;L]<#R@M<^VTY)M M&PAIX=V2.VOW_^(_?V-9OKX;7WDZTM)GP/HD(H,.--"B%D#:7R=SCM:VSN;2 MMW-@HXT6N/T%F-Q(!"<=J/&)P"/M[L"93A&MS,IZALU6L\`G/TRQJPI:_1Z8 MND.#W`%,@1QJLY!NM4.CGU_;9)IEB^?2FK=A]MNGE/%;(1BTGORVI7E?]]M`UX^DFIJ9!6G%?;QAW<1@ ML*QB`8P!?TMXA%L4YJ^';,7BKWOC(8G@38?M6&88I"5WT#U5YU(>F;5:NUQ1 M^5%@AE:4HWZ3;=$>2$O]01+]RHQTSH.+63QS,=A6OPT\_4BN`C.S(,VW#]XL MXS8'%B$1FVBCH918$'8/%=>-'FV';5+F1].H*,5F8@B\T<89J@69O<4;=LF3 M71L@0G@G+ZVNW3S,7N`-CSK4,NI@0QI%)UT7JT-BWUCZ$@9,C/YK$K_`QIB5 MWISL+LG]J/KO_.Z]KTG^3Y;?LB!YC'D<4C7+M*1-'>3[0%L')Z(#F@9IT0=V MBA!OT4MA/TF7/_'G9#O'PU8$B.Q@V(,+&R'WU'77%Z,5?%.&?@R/.N27P^J/ M$'A@YT)++MR_%2U]Y6Y!$V2W]BUO/.A0B$#+9D!:VJ'.:+33Q$JX9M;:G6ZGP<&.N1M/;QED+;I^.(-NWT1_LOO+?4?6XM@P;X'V_\.^9,. M8`JDN1WX1`G6ZOB.YC++%GX1N>;N5'8=O6H3W%H>R!--@#^Q:LK^/2 M\!&FD2+[87;]P"\8MK]VV_\&F+1#<6PMP4=:U($=$^WL#)8WQW#,+>T%*E\` M<_Y@>\\]\$A;LN`2<).C[.]^6@0R+U.3N11U]C7)V2:ME4;R M,Q+RM9J9W8TQKWP(K4]6\6VMJJ!DLI6!KUS7"9N>+ M='T+0X$TV]H9K2X)$C;&FZ* MJQ0VWL'6AIJ=[X!EJ083MS;,"$W0-,<:Z<;E=LE$-33XH$LF-`C86/`KETP7 M,>%&9GB)V4&_#UQ0C>,]1(-4F\96LCGB2WMF>M7>P;X--)"0:@^^]-+1<<'LK7B=M4^OK0`,M"?H@*T9MP]!(S'>@78JC5JI=!Z"$JIOY4+L;M7EL M)1BDV6*[LRJEY70@M2K%TV`:.S.ZMWNZ9=P]![^?)7'A&U^4D4D#!VT6K8LW M'/W(GA$S,]E*.$E^Q+T$]&&W6,:_S@B(?L:65@O_G&$B[:$H^IJ MQC^.:$FC%0HTXA]'>%X&PDQ=F,8_CIQGD!1:7A7_.$+E.\=GOJ_\_TBBR#]+ M7MAE<5-+DF;R!)]X"8#I/#IUW^R"A8@*@MO@1B*1JB-:HA$Z&JHP6(HF=$KF MZASW)[#/&;]1*MN"2EO.&8K*8RVML]:`.B',RW7)V5T6G8X+KU M$&`B*S'LDX35OVEHG?6CW:NU25@,_64G+/^\V_W*7[URCN`&V'7:8?J^7D&P M#]DM_#Z_)IB:1KRUV0_/(C_+KA^6M5]6GD\N\NA(13'`33;8$>FK6H@L!9:U M(R>S8)&&>KH%P8CD!!I#&@UP$4Z=&E[A.%7HZV::>5ZC3)&7[$NTGD% M&(26CJ.]:M)'1R,2R/[>9L<0LBVKK!@8B6P+DJ/KAUW3?7P5OP#Q@QS@JT`-+16CTF#$ M3:MU8]#QT]ANIU_]9X9ZW7.[L%*BY29!V'M%`7@)")X#!C51D7#ET4D4.N$A(978\FT@\&6#XN@ M+**M&4R?DX7THG\K[P=[TY+D=EI"*[)<%;HM_UFEJ5'PH#@\'V+5D7(R=#X8 MFSI23DAH%7*3ZCE23O!8D4Z-Q+EW?AI_GJ7^G$&=@`\V*KJ..*T>NU$S,%UAT]^F!:7 M;GQA/K]6H,#J,(1S79_-30>9AOH@*P:4=4^!."6A0*C-JJ="G/9$A5C;X^/K M^H]_#5D*5GUZO6(O+%(H$'HO`(.15!].T;6O":X^*`_"87,?N5*4,'H/F(^$ M7F%"MJ*YZ,/N0X3D&N%E/(=E9V&J(V5,G:04F(:$]%T7#P+#V01D1@1S4 M:@:#M6E(:"6M-H,MK'W05$0@A[6:P7!M&A+J2JO-8`MK'P(R&^ND$UI:C'*M MB&%P&X5IA\QSEH8O/H]IN`K]^S`J@AHD?`J?!W.0U50F:$"'!(HEN21GJ5NQ MY"R!4G%QXVF<)5$XX_Z>M96RZX?K.8QMA>_.A79R&4--V;H^&K()4@)8ZYYB M,B&AF$@MJB>63$B))2W?TCDA*71,]B8OM/)TU(S6;NF<.%4=4,OO$[1?[3ZH M!LT7B"0T`G4?4V'HP][_FQ^Q[!8V,O&"?66RN7GG23`!B3T^1@Y"I0B$I02S2X0T@DHBTL!6)FC$N:@'@ M?]0M0EH.K$1"!ZC5$#20D;A7U-+0($R&(AL*A`7`+B3N2JG7]2602%P\VM*4 M;S+5@S5(7'=2BV`$C:WCFWF2^Q$-:DL5AY_)TB%W\S08A(0*U8S>73RVCG*Z M)_AK$B?;*)<&TEBV*\N"L6B)65K+=TU8?;JC]#+.&5"CL3S;>1),02(`1Y,S M,>%"3(WO(IV4],;LD?M$G-+[V0]C/GA=QQN75"60]RO+;U*6^]\EO.N^`HQ' M0EMKU"#,P-I*KTMA(*@@#[-YDH7E6?-IEK%<-O-+RWGCHUZU"0RAK=RTNUY= M%_/!*@E&::?5""F=&,1%P*8D5-J&,X0,G*V\L*TJ8=P&^R$8EH0";-9:FF!%&I$% M9?#@\;W?%O<9^WW!_90OE7/0#B]BVZV1ADZ-%0&VCIVY1VL&]8YH2"ERDR+> M4`$2.E&]UEKD'7Q/=3^\N`28A(14(B(*H50&A$X8T3)@%A*"B)0U M;:*KF'H15+P-47GL4/B\-QK04$#D?&F17$5$)]"XW=,7HP$MS0(=@='*TSD' MW-;IB_'(:1=#+;]/T'ZU25Z.]@\6)X\L#H/L+$GG27E>3W[WI*0(`'7:A\2& M%ZC[2@Q].'[;]*C,>$ACR:*_)$4PN,U\8NLL]7U>R8^=AH\A@.&_EI>_'TFX M59:%08RJ@EL0**9;$U:/HFVW$2\OZV.S37Q*F4C[,LL6;*;?(E0O`CM2%7VU MFX<>1AK)5VCDFA\-J&JW`M+KH7.ZJ`\A6<*S=T146`CRFJT!9WLSSJL>A MLB"@IJ7AJVG4Q&0KNK7")+WKBLI+KL_90QB$+`Y>G7@X5_59)A5\2B(P=596 M31ME3YYJ$J>]S0$N+4-M7SQ$ZP&-&.[6\L9LJ>S2DX4D1D*6@50RE M#^[0IJFR1T-:[A4Q4V)Z,3@DLTD=)%7V:$A",,2($2QU3("Y=7FZ3)4]&I)0 M^HQYU0-&QT':)/G46LI2QBGL/0MF("'JZ?&K@-&K^X[+)22_*R2)BZ@ZS;63 MJ!R8AY;\I[]^PN'TP2.[@TZYC!(^#^:@)?OAG(G)EJ#J@Z=V.IN%)8`;/YQ= MQF?^/,S]2#E82\N!>4A(A!+NQ&1KH++DH'5*^BT/CH_9;'721,FVN``8A(2$ M:$RS#(XMIZI3@L4G`)4TRXJ!=4B(6L9DJT$Y=JS2B)\:N0U6;+`*V\'0"P?L MOEZ[/LE_DZ0%)\U.2=OY`%B5*Q(TE0)3'RH:%/?6`!/*O+@ M-'HOF)J$A%=C`&D&V9:3FD*@)V*.LE^UT+0T7PR&)B$?6FE;1IAMW?/4Y'XO MS"\@Z3JKR*I-AG?4/V#T%C`*+851VA!J`[1UFU,KD6C29MV8>.PU8!A:ZF-M MYN4(K=T$Y?Q"O^GLOQ;E!7;978+(<84M[G=O*R^"_+(PA]$P?0D#5MKME@7) M8UR\I>@\4DFSW4\#52144;/YZ#!6Z=.U5,9WT8U(J*AFS6*W_M9NHW(^`G5' M>B&AQSJ27E#9UOP*K'*#?A&[O?JZH?`RIJ7>UA5>QGC\H;&`*^*5?B#W36'H M)P8O.D`NO/J.Z]`-LQ+?&H0I:"5C&4 M/Z.Z8S`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`'9:!9":$A[ M,!9=J=QC>JA60<*CTTZK0!TU`V,EEK,X*7\4.2/I>$:9S= MU'L#&*^#NJD1.*1E=%(L747I\=OJ-.(:^6-@!!)RIQ%GF%=N%Q;";2=%S)51 M^!5A\,>-[A;/!`OH\S`+HB1;I$QC,&CZ:C`V"<'3?/9HCAHY&6HLU7:>/?AS^JR0HGGWU! M^3\N,FC567;.LB`-YTM&]G'=09OX"'7^36*-5K\+!B6QH551+AX5#F`:2TMO M[6'D+^\Y4I[/H^#D_P-02P,$%`````@`ZFI/0SP^>,?-#@``*Z8``!$`'`!M M8V5T+3(P,3,P.#,Q+GAS9%54"0`#!WI=4@=Z75)U>`L``00E#@``!#D!``#M M75%SXC@2?M^J_0\^GN:JEA"2F=V9U&2W'#`9[@AD@KHJZBWE\&4'&Z4J(H3#P6(,]>@\B!CE5LOWOWKB7>)D5#UIPCM%P5GB%V M+XK&+T3'-4_;S5777=A^Z`7T.:LCP_;)W']LQ2^+Q$)*82C*Y.*W7/`L*^A@ M4BP#+PK:P4_V0W%Y_J9`@'B/F`7%(M&[`B$/$9L5RXA77*2=%6'$+A:`%P7% M@8#@>8E9(37B30$L%BRII!%X4]"*@Y<4V]P'2,?7NQ:B-O5=#`C`">"GI8L\ M%/CTN0??5QWB>UZX**[$"6B+(VY!H2:4PI38*[GM0K$`>!/#>(\\SP,E$//T1JC*BNHQ49>];FS5\^\UF]2'# MSLC[47P&%AG4)F2YZXCEXR)JV74CNTK:R+5#5]IH+-;*$)*JLCQ3'=]SL`?M MP`?FN\3A(_@*N=P+3AXP#EC$ET8Y-6MG0-4$NA7'M'5&PZXUG%A=_FDR&O2[ MYA2^7)D#<]BQC,D'RYI.:O+V).\6P600/&"01JXNDUDA-:WG96@U7F6:^&M- M\^XTKSJ=C6:C)8\^`9?*6"4":GI?Z]$[F<)_-]80J!WUC-&M-3:G?2A0$[L? ML=;G$*8SB->)37A0ITEO3DQ-\ILR)%L_W_6GOQJONE:OW^E;P\ZOM1D?F&U= MYZU?AWH:P:PS-Z=W8RL9Y MWT&`/^F+X7([MB8P=,3S[X3`V.H,S,FD#_-#'15JC)MKGWASL'L;TSA9DGFB MY*]]NLG?]:@_O.;VW;'&P[KGM[GL1TP# MYISB*-R$.*(;W`K&,[ M'6(^(4J1%Z3Y6#U2T_!],0V?S/'8'-;;)=O\FL_8+::3!UC%Q@XL_43=]3_D M/-5H,C%@!61,/ICCVB&IN[Z'"/V(W!#?8,3[3\P6$0?%K]1DO-TDHV?VQ\9' M6.8&P6LP=-2MJ;Q3>,_PY!(VMQS4AN:=J+G(9@\G=U<3Z^0[ZW^"3 M=YO,,1\D;&JP1,G7K<;\T\1?"(Z:VJ+G))SH!DLN@'"5.C2$9,:9ZE.GO>!:-%,5[-=NYI$UF-[3FZ1#[HT6$ MZ114,Y?+\!3OG=84'GAE&'>GWM(P*:RF,I\@TEH;QI77A!Z$T(QY[BBCI/<\ ME_G9B=[:;@^SF2ZG65M&3;,LPZ/<:*]I/OS6>Q'3NXNIRLI3DHT1Y>_5!.52 M,1*":MO98_LC8T3*$FJR5JX21'> M@N+J)T'V9C_%#2=5Q-?WJ"^$@DK\)<^W8-9*P#>,U@$5`T9V52Q+8C75=)<5[63_HJKW52`"L3BS_L"*;HR3P=)6B[YLC>6 MHFOXM,"D!5??FNMJ2L')W=BG`V4E)#[MVR/YV_QT,*REHH_-=06E4&Q>$:B# M(9'A'_9N?_/V0"T`B9#X5`)"_B9",=EX>,[OE=#S7"ZE&2GNOMYQM]G^?F\8 MFLXS!2$X2//J^QAU(:5KL=:5E$"HO)539Z0D,OQ#"8-5WQNIU2&;4OOR5'SE MY6Y(?&]8&HSZLM#R,Z^H2TY1?%VO`)0]`&7>,WXW,(S/*`P5=]I>P#,HT@_P M@J^B&@:*2UTV`LI_KAN5@K"0^,Y4R#EA=,RN87C$=?EIR*0L@^5L0(*0O[VF M?KA,&B%0?;3BY7'NOXM1::C`E[%7KO@)>*1#=.?I19`\+])CAESV`HJDL$DT MV79ZHCH$Z2,MJ6K5B-P!KU)C^9F)JI&K@[2DJM4D5PNO1./\,8G*L*F`IJM, MU?A2`93HM-K;6^5#JZ:4$F%)+WJ#%_>8;BCH^`M$O&K-%PG0D@ZE8GIN!RK1 MTW0>>?*J1_W%ZG3S!]]U,.V(Y?J&.UGXL%Q!]'FGD1IER(*\CE'1^^B^YLN& M#9A)H*^Z!G:)UK]@SY]C#];@'9]"L"PXJ`RE2G02C6Z2'9_^8A%Z?O"`*5IB M:,IFE=%+`Z-L?D!_\Z'-CO^(^R*]YM/JJ*4")]'GU@_@"T'N+?5MC!W&QW#L MCJTG3&W"^._']K8\N7(;IN?@^UTL3Q._1'LPUJ`//H&*OW60]EP@R;>LYCBY M_'==C-V@)[((%RO"@>UE5/XPSDA7]SW12^<;.Z2$[W/]&@YG_M:33CPUUW27%$_31QRF;'R/K6Y0=D M08+***>&)_,8/+J+QF\WY*`CIL69*);K+E8!H]L9L6SV3$TZ:[&-Z\BJ.W?J MH)=H'CFJ=1>-,0]WH"?O/!Q7Y>Q-]-XSI!Y*V;#F@*]@?G'2Y\U-7M-Y1<_B#R]]0=196\\MA2A3_-8Z]N#/E(M53=&0P4&]A9\$JW&V`EMO#FX MUU'TOI'^_GIM1ZA%6'$UE>--!E,6%:>"KVQ%(GK!SM0'-P=3KW@V"@-N14XT MZU>&X8,HH34(NN21.-A+_/HXMZC[*I&G!D;9(CXNRZ`P;WGJ;[_%E?A5)A[%>AM>HYF%H2ZCI/VFAL:?[VP M0P^E;%_`COH1.]5+N"JP:>XOFD]D%GR[:-4^K;96:WS2->'2 M1;9X,A(CM#JSCAR:1)?1;`9&2/G])5%)-II-^%^R#/A]?Z;S2)A/GZ]\1)W* M*%D"LVQ\+I:N_XQQ953;!'3H_&,\**YYRI-')I%76@5A+YF1WC4$/I[.4C/G M82AR3=?EQXVQ4XS`>N(?*]UUNVIRZ%&7Y-A3R[,#;;+NO?XXAD['ZK[K:#ICC2*PYL_>R]K*OI" M+O?/W]L[J/ORKGIUTJ/C>Z(W0^1.,5V<52)Q]'44?P$6^AY/,3)B'VJEJ;O7 MLN/1IV/JK#Y_&D6(%0C(-O"H4:]\Z]1/LKBIW>@HQJV.3GIH=SCAO_I11V5R M2%HHI3F/V$5L'H\[Y&;PWM&M'LHMA[VK-NU*<.VV$!9^9MNYVFHEIW;51+X9 M1#%8W[T9YAXT,"W#N-D+'QQPSB4P.!H@S]` MNKF$,O)S2BQT^611F=DU#^E(>S0?H7_6BZC"?/G7V+,_CEK'Z<.H+6Z0,,YL M<5"2/_HS;4/LJNB+#-8J'9X]GF;;(C/N/'^&)3:9$>STB`??@8@;XO*0W,,] MGR:_LJFR,R^ESL%'&25S:%%D*_@?*`1=_M"NL$B=XUAF_*L]WM(?.[U5H(YT M#?LYY/G'6)K=>1!CB-]$!_P-02P$"'@,4````"`#J:D]#HBYQ?3V9``!UM@@`$0`8```````! M````I($`````;6-E="TR,#$S,#@S,2YX;6Q55`4``P=Z75)U>`L``00E#@`` M!#D!``!02P$"'@,4````"`#J:D]#*J&19!D'``!<7@``%0`8```````!```` MI(&(F0``;6-E="TR,#$S,#@S,5]C86PN>&UL550%``,'>EU2=7@+``$$)0X` M``0Y`0``4$L!`AX#%`````@`ZFI/0R4;SM#=+P``@B(#`!4`&````````0`` M`*2!\*```&UC970M,C`Q,S`X,S%?9&5F+GAM;%54!0`#!WI=4G5X"P`!!"4. M```$.0$``%!+`0(>`Q0````(`.IJ3T-*],/*8T@``&T(!``5`!@```````$` M``"D@1S1``!M8V5T+3(P,3,P.#,Q7VQA8BYX;6Q55`4``P=Z75)U>`L``00E M#@``!#D!``!02P$"'@,4````"`#J:D]#!=2J)[TV``"ZO`,`%0`8```````! M````I('.&0$`;6-E="TR,#$S,#@S,5]P&UL550%``,'>EU2=7@+``$$ M)0X```0Y`0``4$L!`AX#%`````@`ZFI/0SP^>,?-#@``*Z8``!$`&``````` M`0```*2!VE`!`&UC970M,C`Q,S`X,S$N>'-D550%``,'>EU2=7@+``$$)0X` <``0Y`0``4$L%!@`````&``8`&@(``/)?`0`````` ` end XML 26 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (DEFICIENCY) (Parenthetical)
9 Months Ended

Aug. 31, 2013

Aug. 31, 2012

Debt Conversion, Original Debt, Interest Rate of Debt 4.75% 4.75%

X

- Definition

The rate of interest that was being paid on the original debt issue that is being converted in the noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionOriginalDebtInterestRateOfDebt

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 27 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)
9 Months Ended

Aug. 31, 2013

Aug. 31, 2012

Debt Conversion, Original Debt, Interest Rate of Debt 4.75% 4.75%

X

- Definition

The rate of interest that was being paid on the original debt issue that is being converted in the noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionOriginalDebtInterestRateOfDebt

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 28 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONVERTIBLE DEBENTURES
9 Months Ended

Aug. 31, 2013

Debt Disclosure [Abstract]

Long-term Debt [Text Block]

NOTE 3. CONVERTIBLE DEBENTURES

MultiCell entered into a Securities Purchase Agreement with LJCI on February 28, 2007 (the “LJCI Agreement”), pursuant to which MultiCell agreed to sell a convertible debenture to LJCI in the principal amount of $100,000 and originally scheduled to mature on February 28, 2012 (the “Debenture”). On August 16, 2011, MultiCell and LJCI amended the Debenture to extend the maturity date to February 28, 2014. The Debenture accrues interest at 4.75% per year, payable in cash or common stock at the option of LJCI. In connection with the Debenture, MultiCell issued LJCI a warrant to purchase up to 10 million shares of the Company’s common stock (the “LJCI Warrant”) at an exercise price of $1.09 per share, exercisable over the next five years according to a schedule described in a letter agreement dated February 28, 2007. On August 16, 2011, MultiCell and LJCI amended the LJCI Warrant to extend the expiration date to February 28, 2014. Pursuant to the terms of the LJCI Warrant, upon the conversion of any portion of the principal amount of the Debenture, LJCI is required to simultaneously exercise and purchase that same percentage of the warrant shares equal to the percentage of the dollar amount of the Debenture being converted. Therefore, as an example, for each $1,000 of the principal converted, LJCI would be required to simultaneously purchase 100,000 shares under the LJCI Warrant at $1.09 per share.

The Debenture is convertible at the option of LJCI at any time up to maturity into the number of shares determined by the dollar amount of the Debenture being converted multiplied by 110, minus the product of the Conversion Price (as defined below) multiplied by 100 times the dollar amount of the Debenture being converted, with the entire result divided by the Conversion Price. The “Conversion Price” is equal to the lesser of $1.00 or 80% of the average of the three lowest volume-weighted average prices during the twenty trading days prior to the election to convert. LJCI converted $9,430 and $7,290 of the Debenture into 1,040,493,584 and 323,936,571 shares, respectively, of the Company’s common stock during the nine months ended August 31, 2013 and 2012, respectively. Simultaneously with these conversions, LJCI exercised warrants to purchase 943,000 shares and 729,000 shares of the Company’s common stock during the nine months ended August 31, 2013 and 2012, respectively. Proceeds from the exercise of the warrants were $1,027,870 and $794,610 for the nine months ended August 31, 2013 and 2012, respectively. At times, LJCI makes advances to MultiCell prior to the exercise of warrants. At August 31, 2013 and November 30, 2012, LJCI had advanced $0 and $50,000, respectively, to MultiCell in advance of LJCI’s exercise of warrants. At August 31, 2013 MultiCell had a receivable from LJCI of $130,800 for proceeds from LJCI’s exercise of warrants in excess of advances previously received. This receivable was collected on September 5, 2013.

As of August 31, 2013, the remainder of the Debenture in the amount of $46,596 could have been converted by LJCI into approximately 5.8 billion shares of the Company’s common stock, which would require LJCI to simultaneously exercise and purchase all of the remaining 4,659,629 shares of the Company’s common stock under the LJCI Warrant at $1.09 per share. As of November 30, 2012, the balance of the Debenture was $56,026. For the Debenture, upon receipt of a conversion notice from the holder, MultiCell may elect to immediately redeem that portion of the Debenture that the holder elected to convert in such conversion notice, plus accrued and unpaid interest. MultiCell, at its sole discretion, has the right, without limitation or penalty, to redeem the outstanding principal amount of the Debenture not yet converted by the holder into common stock, plus accrued and unpaid interest thereon.

X

- Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for long-term debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

ORGANIZATION AND NATURE OF OPERATIONS, BASIS OF PRESENTATION, AND RECLASSIFICATIONS
9 Months Ended

Aug. 31, 2013

Accounting Policies [Abstract]

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]

NOTE 1. ORGANIZATION AND NATURE OF OPERATIONS, BASIS OF PRESENTATION, AND RECLASSIFICATIONS

ORGANIZATION AND NATURE OF OPERATIONS

MultiCell Technologies, Inc. (“MultiCell”), has two subsidiaries, Xenogenics Corporation (“Xenogenics”) and MultiCell Immunotherapeutics, Inc. (“MCTI”). MultiCell holds 95.3% of the outstanding shares (on an as-if-converted to common stock basis) of Xenogenics. MultiCell holds approximately 67% of the outstanding shares (on an as-if-converted to common stock basis) of MCTI. As used herein, the “Company” refers to MultiCell, together with Xenogenics and MCTI.

The Company’s therapeutic development platform includes several patented techniques used to: (i) isolate, characterize and differentiate stem cells from human liver; (ii) control the immune response at transcriptional and translational levels through double-stranded RNA (dsRNA)-sensing molecules such as the Toll-like Receptors (TLRs), RIG-I-like receptor (RLR), and Melanoma Differentiation-Associated protein 5 (MDA-5) signaling; (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology; and (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway. The Company’s medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent™, for interventional cardiology and peripheral vessel applications.

BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements and related notes of MultiCell and its subsidiaries have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial statements. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. In the opinion of management, all adjustments consisting of normal recurring adjustments considered necessary for a fair presentation have been included. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended November 30, 2012, previously filed with the SEC. The results of operations for the three-month and nine-month periods ended August 31, 2013, are not necessarily indicative of the operating results for the fiscal year ending November 30, 2013. The condensed consolidated balance sheet as of November 30, 2012, has been derived from the Company’s audited consolidated financial statements.

RECLASSIFICATIONS

Certain amounts of operating expenses from the condensed consolidated statement of operations for the three months and the nine months ended August 31, 2012, have been reclassified in the current presentation to conform to the presentation of operating expenses for the three months and nine months ended August 31, 2013. These reclassifications had no effect on the total amount of operating expenses, on the amount of net loss, or on the basic and diluted loss per common share for the three months and the nine months ended August 31, 2012.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.

+ References

No definition available.

+ Details

Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONVERTIBLE DEBENTURES (Details Textual) (USD $)
9 Months Ended 9 Months Ended 0 Months Ended 12 Months Ended

Aug. 31, 2013

Aug. 31, 2012

Nov. 30, 2012

Aug. 31, 2013

Common Stock [Member]

Aug. 31, 2012

Common Stock [Member]

Aug. 16, 2011

La Jolla Cove Investors [Member]

Nov. 30, 2007

La Jolla Cove Investors [Member]

Securities Purchase, Agreement Date Feb. 28, 2007

Proceeds from Convertible Debenture, Principal Amount $ 100,000

Debt Conversion, Original Debt, Due Date of Debt Feb. 28, 2012

Debt Instrument, Maturity Date Feb. 28, 2014

Debt Conversion, Original Debt, Interest Rate of Debt 4.75% 4.75%

Warrants Issued Number 10,000,000

Class of Warrant, Exercisable Period 5 years 5 years

Exercise of Warrant upon Conversion of Debt each $1,000 of the principal converted, LJCI would be required to simultaneously purchase 100,000 shares under the LJCI Warrant at $1.09 per share.

Maximum Conversion Limit of Debt The “Conversion Price” is equal to the lesser of $1.00 or 80% of the average of the three lowest volume-weighted average prices during the twenty trading days prior to the election to convert.

Stock Issued During Period, Value, Conversion of Convertible Securities 9,430 7,290

Stock Issued During Period, Shares, Conversion of Convertible Securities 1,040,493,584 323,936,571

Stock Issued During Period, Shares, Exercise of Warrants 943,000 729,000

Proceeds from Exercise of Stock Warrants 1,027,870 794,610

Advance from Warrant Holder 0 50,000

Convertible Debentures 46,596 0

Debt Conversion, Converted Instrument, Shares 5,800,000,000

Number of Warrants, Remaining Unexercised 4,659,629

Investment Warrants, Exercise Price $ 1.09

Convertible Debt, Noncurrent 0 56,026

Receivable from Warrant Holder $ 130,800

X

- Definition

Exercise price of the warrants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 12

-Section 13

-Sentence Column A

+ Details

Name: invest_InvestmentWarrantsExercisePrice

Namespace Prefix: invest_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying amount as of the balance sheet date of obligations due all debenture holder.

+ References

No definition available.

+ Details

Name: mcet_AdvanceFromDebentureHolderCurrent

Namespace Prefix: mcet_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Class of warrants exercisable during the period.

+ References

No definition available.

+ Details

Name: mcet_ClassOfWarrantExercisablePeriod

Namespace Prefix: mcet_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Description related to the exercise of the warrant is required upon the conversion of the debt.

+ References

No definition available.

+ Details

Name: mcet_ExerciseOfWarrantUponConversionOfDebt

Namespace Prefix: mcet_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The maximum conversion limit of the debt.

+ References

No definition available.

+ Details

Name: mcet_MaximumConversionLimitOfDebt

Namespace Prefix: mcet_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of warrants remaining unexercised.

+ References

No definition available.

+ Details

Name: mcet_NumberOfWarrantsRemainingUnexercised

Namespace Prefix: mcet_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The cash inflow from exercise of stock warrants to purchase common shares at predetermined price.

+ References

No definition available.

+ Details

Name: mcet_ProceedsFromExerciseOfStockWarrants

Namespace Prefix: mcet_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The company entered into a securities purchase agreement date.

+ References

No definition available.

+ Details

Name: mcet_SecuritiesPurchaseAgreementDate

Namespace Prefix: mcet_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of stock issued during the period as a result of the exercise of warrants.

+ References

No definition available.

+ Details

Name: mcet_StockIssuedDuringPeriodSharesExerciseOfWarrants

Namespace Prefix: mcet_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of warrants issued during the period.

+ References

No definition available.

+ Details

Name: mcet_WarrantsIssuedNumber

Namespace Prefix: mcet_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20

-Article 5

+ Details

Name: us-gaap_ConvertibleDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_ConvertibleDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Date the original debt was scheduled to mature, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The rate of interest that was being paid on the original debt issue that is being converted in the noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionOriginalDebtInterestRateOfDebt

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock warrants.

+ References

No definition available.

+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Number of shares issued during the period as a result of the conversion of convertible securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-30)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The gross value of stock issued during the period upon the conversion of convertible securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 31 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8

LICENSE AGREEMENTS AND DEFERRED REVENUE (Details Textual) (USD $)
3 Months Ended 9 Months Ended

Aug. 31, 2013

Aug. 31, 2012

Aug. 31, 2013

Aug. 31, 2012

License and Purchase Agreement Description On October 9, 2007, MultiCell executed an exclusive license and purchase agreement (the “Agreement”) with Corning Incorporated (“Corning”) of Corning, New York.

License and Maintenance Revenue $ 750,000

Income Recognition Period 17 years

Deferred Revenue, Revenue Recognized 11,029 11,029 33,088 33,088

Deferred Revenue, Description The balance of deferred revenue from this license is $488,971 at August 31, 2013 and will be amortized into revenue through October 2024.

Pfizer [Member]

Deferred Revenue, Revenue Recognized $ 1,300 $ 1,300 $ 3,900 $ 3,900

Deferred Revenue, Description The balance of deferred revenue from the agreement with Pfizer is $22,100 at August 31, 2013, which will be amortized into revenue through January 2018.

X

- Definition

Represents the period for recognizing the income.

+ References

No definition available.

+ Details

Name: mcet_IncomeRecognitionPeriod

Namespace Prefix: mcet_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents License And Purchase Agreement Description.

+ References

No definition available.

+ Details

Name: mcet_LicenseAndPurchaseAgreementDescription

Namespace Prefix: mcet_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Description of the transaction or nature of business giving rise to deferred revenue or unearned revenue, other than annual membership fees. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

+ Details

Name: us-gaap_DeferredRevenueDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Revenue from multiple-deliverable arrangements that include licensing fees and maintenance revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Maintenance revenue is derived from maintenance services provided under contracts or arrangements with clients. Services may include the maintenance of software, plant and equipment, and facilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d),(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_LicenseAndMaintenanceRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 32 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8

LOSS PER SHARE (Details)
9 Months Ended

Aug. 31, 2013

Aug. 31, 2012

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 5,906,056,606 6,138,986,953

Series B Convertible Preferred Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 27,806,452 47,049,793

Series I Convertible Preferred Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 0 2,293,600

LJCI Debenture [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 5,819,876,621 6,055,511,583

Warrant [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 7,974,030 9,963,030

Employee Stock Option [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 50,399,503 24,168,947

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

EXCEL 33 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\X.3)D.#=A9E]C8V%C7S0U8SA?83(T.5\T969C M-V-B.6%A-CDB#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5- M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5-130\+W@Z3F%M93X-"B`@ M("`\>#I7;W)K#I7;W)K#I%>&-E;%=O#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/E-%4DE%4U]"7T-/3E9%4E1) M0DQ%7U!2149%4E)%1#PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-%4DE%4U])7T-/3E9%4E1)0DQ%7U!2149%4E)%1#PO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DQ)0T5.4T5?04=2145- M14Y44U]!3D1?1$5&15)213PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-43T-+7T-/35!%3E-!5$E/3E]03$%.4SPO>#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/E-43T-+7U=!4E)!3E13/"]X M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-50E-%455%3E1?159%3E13/"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-%4DE%4U]"7T-/3E9%4E1)0DQ%7U!2149%4E)%1#$\+W@Z3F%M M93X-"B`@("`\>#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7 M;W)K#I%>&-E;%=O M'1U86P\+W@Z3F%M93X-"B`@("`\ M>#I7;W)K#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-%4DE%4U])7T-/3E9%4E1)0DQ%7U!2149%4E)%1#$\+W@Z3F%M M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-43T-+7U=!4E)!3E137T1E=&%I;',\+W@Z3F%M M93X-"B`@("`\>#I7;W)K'1U86P\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0 M#I%>&-E;%=O7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA2!& M:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M4VUA;&QE3QS<&%N/CPO6UB;VP\+W1D M/@T*("`@("`@("`\=&0@8VQA2!#;VUM M;VX@4W1O8VLL(%-H87)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^,3`M43QS<&%N/CPO'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^43,\ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\X.3)D.#=A9E]C8V%C7S0U8SA?83(T.5\T969C-V-B M.6%A-CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#DR9#@W869? M8V-A8U\T-6,X7V$R-#E?-&5F8S=C8CEA838Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M2!A;F0@ M97%U:7!M96YT+"!N970@;V8@86-C=6UU;&%T960@9&5P2!R96QA=&5D M('1O(%-E'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2`H1&5F:6-I96YC M>2D@375L=&E#96QL(%1E8VAN;VQO9VEE2`H9&5F:6-I96YC>2D\+W-T2`H M9&5F:6-I96YC>2D\+W1D/@T*("`@("`@("`\=&0@8VQA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAAF5D+V1E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S&5R M8VES92!O9B!W87)R86YT'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X.3)D.#=A9E]C8V%C7S0U8SA? M83(T.5\T969C-V-B.6%A-CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO.#DR9#@W869?8V-A8U\T-6,X7V$R-#E?-&5F8S=C8CEA838Y+U=O'0O:'1M;#L@ M8VAA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X.3)D.#=A9E]C M8V%C7S0U8SA?83(T.5\T969C-V-B.6%A-CD-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO.#DR9#@W869?8V-A8U\T-6,X7V$R-#E?-&5F8S=C8CEA M838Y+U=O'0O:'1M;#L@8VAA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M2!I;G9E'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!O9B!S=&]C:R!W87)R86YT'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`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`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@8F]L9"!I=&%L:6,@,3!P="!4:6UE M6QE/3-$)R!& M3TY4+5-)6D4Z(#$P<'0G/CDU+C,\+V9O;G0^)2!O9B!T:&4@(&]U='-T86YD M:6YG('-H87)E6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G M/C8W/"]F;VYT/B4@;V8@=&AE(&]U='-T86YD:6YG('-H87)E6QE/3-$)V-L96%R.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E' M3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E2!A9V%I;G-T(&ME>2!T=6UO3L@86YD("AI=BD@(&UO9'5L871E('1H92!N;W)A9')E;F%L M:6YE+6%D6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF M>3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E6QE M/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`@("`\9&EV('-T>6QE/3-$)V-L96%R M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!& M3TY4.B!B;VQD(&ET86QI8R`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B!B;VQD(&ET86QI8R`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E&-H86YG M92!#;VUM:7-S:6]N("AT:&4@)B,X,C(P.U-%0R8C.#(R,3LI(&9O28C.#(Q M-SMS(&%U9&ET960@8V]N#L@1D].5#H@,3!P="!4:6UE#L@ M1D].5#H@,3!P="!4:6UE#L@1D].5#H@ M,3!P="!4:6UE'!E;G-E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV M/B`@/"]D:78^("`@("`@("`\=&%B;&4@8F]R9&5R/3-$,"`@&5D.R<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0@0FQO8VM= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X@("`@("`@("`@("`@ M(#QD:78@6QE/3-$)R!& M3TY4+5-)6D4Z(#$P<'0G/C0S+#$U."PQ-S(\+V9O;G0^+B!4:&4@0V]M<&%N M>2!W:6QL(&AA=F4@=&\@(')A:7-E(&%D9&ET:6]N86P@8V%P:71A;"!I;B!O M2!L:79E M28C.#(Q-SMS(&9U='5R92!C87-H(')E<75I2!A28C.#(Q-SMS("!T:&5R87!E=71I8R!P6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G M/C$N,#D\+V9O;G0^('!E6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G M/C0L-C4Y+#8R.3PO9F]N=#X@6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C0V+#4Y-CPO9F]N=#X@&5R8VES92!A;&P@;V8@:71S(')E;6%I;FEN M9R`@=V%R&EM871E;'D@)#QF;VYT('-T>6QE/3-$)R!& M3TY4+5-)6D4Z(#$P<'0G/C4N,3PO9F]N=#X@(&UI;&QI;VX@;V8@8V%S:"!W M;W5L9"!B92!P2X@5&AE($Q*0TD@($%G M&-E960@/&9O M;G0@2!E>'!E8W1S('1H870@($Q*0TD@=VEL;"!C;VYT:6YU92!T;R!E M>&5R8VES92!T:&4@=V%R2`R."P@(#(P,30\+V9O;G0^+"!T:&4@9&%T92!T:&%T('1H92!D M96)E;G1U2!O9B!A=71H;W)I>F5D(&-O;6UO;B!S M=&]C:R!O9B!T:&4@0V]M<&%N>2XF(S$V,#L\+V1I=CX@("`@/&1I=B!S='EL M93TS1"=C;&5A#L@1D].5#H@,3!P="!4:6UE#L@1D]. M5#H@,3!P="!4:6UE2!A8F]U="!T:&4@($-O;7!A;GDF(S@R,3<[2!C87!I=&%L M('1O(&-O;G1I;G5E("!I=',@;VXM9V]I;F<@28C.#(Q-SMS('!R;W!R:65T87)Y M(&UE9&EA+"!I;6UO2X@061D:71I;VYA;&QY M+"!T:&4@($-O;7!A;GD@8V]N=&EN=65S('1O('!U2!A;F0@ M8VQA2!B92!U;F%B;&4@=&\@8V]N M=&EN=64@87,@82!G;VEN9R!C;VYC97)N+CPO9&EV/B`@/"]D:78^("`@("`@ M("`\=&%B;&4@8F]R9&5R/3-$,"`@&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG M/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0@0FQO8VM=/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X@("`@("`@("`@("`@(#QD M:78@#L@1D]. M5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE M2`R."P@,C`P-SPO9F]N=#X@*'1H92`@)B,X,C(P.TQ*0TD@06=R965M M96YT)B,X,C(Q.RDL('!U6QE/3-$)R!&3TY4 M+5-)6D4Z(#$P<'0G/D9E8G)U87)Y(#(X+"`@,C`Q,CPO9F]N=#X@*'1H92`F M(S@R,C`[1&5B96YT=7)E)B,X,C(Q.RDN($]N($%U9W5S="`Q-BP@,C`Q,2P@ M($UU;'1I0V5L;"!A;F0@3$I#22!A;65N9&5D('1H92!$96)E;G1U2`@9&%T92!T;R`\9F]N="!S='EL93TS1"<@ M1D].5"U325I%.B`Q,'!T)SY&96)R=6%R>2`R."P@,C`Q-#PO9F]N=#XN("!4 M:&4@1&5B96YT=7)E(&%C8W)U97,@:6YT97)E6%B;&4@:6X@8V%S:"!O6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/B`@,3`\ M+V9O;G0^(&UI;&QI;VX@&5R8VES86)L92!O=F5R('1H92!N97AT(&9I=F4@>65A&%M<&QE+"!F;W(@/&9O;G0@2!P=7)C M:&%S92`Q,#`L,#`P('-H87)E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E#L@1D].5#H@,3!P="!4:6UE2`Q,#`@=&EM97,@=&AE(&1O;&QA6QE/3-$)R!& M3TY4+5-)6D4Z(#$P<'0G/C28C.#(Q-SMS("!C;VUM;VX@6QE/3-$)R!&3TY4 M+5-)6D4Z(#$P<'0G/C6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G M/C4P+#`P,#PO9F]N=#XL(')E2P@=&\@375L=&E#96QL(&EN M("!A9'9A;F-E(&]F($Q*0TDF(S@R,3<[&5R8VES92!O9B!W87)R86YT M6QE/3-$)R!&3TY4+5-)6D4Z M(#$P<'0G/C$S,"PX,#`\+V9O;G0^(&9O#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE2!,2D-)(&EN=&\@87!P2`\ M9F]N="!S='EL93TS1"<@1D].5"U325I%.B`Q,'!T)SXU+C@\+V9O;G0^(&)I M;&QI;VX@28C.#(Q-SMS(&-O;6UO M;B!S=&]C:R!U;F1E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\X.3)D.#=A9E]C8V%C7S0U8SA?83(T.5\T969C-V-B.6%A-CD- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#DR9#@W869?8V-A8U\T M-6,X7V$R-#E?-&5F8S=C8CEA838Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R#L@1D].5#H@,3!P="!4 M:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)R!&3TY4+5-)6D4Z M(#$P<'0G/C$L,#`P+#`P,#PO9F]N=#X@2!D97-I9VYA=&5D(#QF;VYT M('-T>6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/B`@,36QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)V-L96%R M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!T:6UE M(&EN=&\@28C.#(Q-SMS(&-O;6UO;B!S M=&]C:R!A="!A(&-O;G9E2`@9&EV M:61I;F<@=&AE('!U2!T:&4@ M8V]N=F5R6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/B`@.#4\+V9O;G0^)2!O9B!T M:&4@=&AE;BUA<'!L:6-A8FQE(&-O;G9EF%T:6]N2!S96QL M&5R8VES86)L92`@9F]R(&-O;6UO;B!S=&]C:R!A="!A M('!E&5R8VES92!O9B!W87)R86YT2!N;W0@<&%Y:6YG('1H92!397)I97,@0B`@9&EV:61E;F1S(&]N M(&$@;6]N=&AL>2!B87-I6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C`N,#$R-#PO9F]N=#X@<&5R('-H M87)E(&%S(&]F("!!=6=U2!O;FQY M(&-O;G9E6QE M/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE2!W87,@6%B;&4@;6]N=&AL>2!I M;B!A2!O9B!T:&%T(&UO;G1H+B!);B`@=&AE(&5V96YT M('1H92!#;VUP86YY(&1I9"!N;W0@<&%Y('1H92!397)I97,@0B!C;VYV97)T M:6)L92`@<')E9F5R6EN9R`@8V]N9&5N6QE/3-$)R!&3TY4 M+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G M/C$R-2PU,38\+V9O;G0^/"]F;VYT/B!A6%B;&4@86YD(&%C8W)U960@97AP M96YS97,N/"]D:78^("`@(#QD:78@6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C,L-#0X/"]F;VYT/B!S:&%R97,@ M;V8@4V5R:65S($(@8V]N=F5R=&EB;&4@('!R969E6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G M/C$Y+#(T-3PO9F]N=#X@*"0\9F]N="!S='EL93TS1"<@1D].5"U325I%.B`Q M,'!T)SXP+C`P,3(\+V9O;G0^('!E6QE M/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$)V-L96%R.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0G/B`@/&1I=B!S='EL93TS1"=C;&5A6QE/3-$)V-L96%R.F)O=&@[0D]21$52+4)/5%1/33H@(SEE8C9C92`P<'@@ M"!S;VQI9#L@34%21TE. M.B`P:6X@,&EN(#!I;B`P+C5I;CL@5TE$5$@Z(#@P)3L@0D]21$52+4-/3$Q! M4%-%.B!C;VQL87!S93L@3U9%4D9,3U6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`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`@/&1I=CXF(S$V,#L\+V1I=CX@(#PO M=&0^("`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@("!W M:61T:#TS1#$P)3X@(#QD:78^)B,Q-C`[/"]D:78^("`\+W1D/B`@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C M8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R`@('=I9'1H/3-$,3`E/B`@/&1I=CXR+C$V/"]D M:78^("`\+W1D/B`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R`@('=I9'1H/3-$,3`E M/B`@/&1I=CXQ,"!996%R6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6EE;&0\+V1I=CX@ M(#PO=&0^("`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`@/"]D:78^("`\+V1I=CX@ M("`@/&1I=B!S='EL93TS1"=C;&5A#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE2`D.3`R(&%N9"!B>2`@)#$Q+#,T,B!D=7)I;F<@ M=&AE('1H6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C8P+#4V,CPO M9F]N=#X@86YD(&)Y("0\9F]N="!S='EL93TS1"<@1D].5"U325I%.B`Q,'!T M)SXQ,#0L-3(V/"]F;VYT/B!D=7)I;F<@=&AE('1H6QE/3-$)V-L96%R.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E' M3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E2P@ M('=H971H97(@=F]L=6YT87)Y(&]R(&EN=F]L=6YT87)Y+"!H;VQD97)S(&]F M(&5A8V@@;W5T&5D M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO M=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0@0FQO8VM=/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X@("`@("`@("`@("`@(#QD:78@ M6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CQB/CQF;VYT("!S:7IE/3-$,CY./"]F M;VYT/CPO8CX\8CX\9F]N="!S:7IE/3-$,CY/5$4@-2X@4T522453($D@0T]. M5D525$E"3$4@(%!2149%4E)%1"!35$]#2SPO9F]N=#X\+V(^/"]D:78^("`@ M(#QD:78@6QE M/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C$L,#`P+#`P,#PO9F]N=#X@2!D M97-I9VYA=&5D(#QF;VYT('-T>6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/B`@ M,C`L,#`P/"]F;VYT/B!S:&%R97,@87,@4V5R:65S($D@8V]N=F5R=&EB;&4@ M<')E9F5R2`Q,RP@,C`P-"P@=&AE($-O;7!A M;GD@8V]M<&QE=&5D(&$@<')I=F%T92!P;&%C96UE;G0@;V8@4V5R:65S("!) M(&-O;G9E2!A;F0@;F\@('-H87)E28C.#(Q-SMS(%-E&5D.R<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$&5C=71E9"`@86X@97AC;'5S:79E(&QI8V5N2!O"!A7,N($UU;'1I0V5L;"!A;'-O("!R971A:6YS(')I9VAT2`@9')U9R!T87)G971S(&%N M9"!F;W(@;W1H97(@87!P;&EC871I;VYS(')E;&%T960@=&\@=&AE("!#;VUP M86YY)B,X,C$W.W,@:6YT97)N86P@9')U9R!D979E;&]P;65N="!P6QE/3-$)R!& M3TY4+5-)6D4Z(#$P<'0G/C2!IFEN9R`@=&AE(&EN8V]M92!R871A8FQY(&]V97(@82`\9F]N="!S M='EL93TS1"<@1D].5"U325I%.B`Q,'!T)SXQ-SPO9F]N=#X@('EE87(@<&5R M:6]D+B!4:&4@0V]M<&%N>2!R96-O9VYI>F5D("0\9F]N="!S='EL93TS1"<@ M1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"<@1D].5"U325I%.B`Q M,'!T)SXQ,2PP,CD\+V9O;G0^/"]F;VYT/B!A;F0@)#QF;VYT('-T>6QE/3-$ M)R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)R!&3TY4+5-)6D4Z M(#$P<'0G/C,S+#`X.#PO9F]N=#X\+V9O;G0^+"!R97-P96-T:79E;'DL(&EN M(&EN8V]M92`@9F]R(&5A8V@@;V8@=&AE('1H#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE2!H87,@86YO=&AE2!R96-O9VYI>F5D(')E=F5N=64@9G)O;2!T:&4@ M(&%G2`R,#$X+CPO9&EV/B`@/"]D:78^("`@("`@("`\=&%B M;&4@8F]R9&5R/3-$,"`@&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\ M='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^("`@("`@("`@("`@("`\ M9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E#L@ M1D].5#H@:71A;&EC(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE2!B92!G M:79E;B!T:&4@(&]P<&]R='5N:71Y('1O(&)E;F5F:70@9G)O;2!I;F-R96%S M97,@:6X@=&AE('9A;'5E(&]F('1H92`@0V]M<&%N>28C.#(Q-SMS(&-O;6UO M;B!S=&]C:R!T:')O=6=H(&=R86YT:6YG(&]F(&EN8V5N=&EV92!S=&]C:R`@ M;W!T:6]N2!S=&]C:R!O<'1I;VYS+"!S M=&]C:R!P=7)C:&%S92!A=V%R9',L("!S=&]C:R!B;VYU6QE/3-$)V-L96%R.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E MF5D(&]V97(@=&AE('!E65E(&ES(')E<75I&-H86YG M92`@9F]R('1H92!A=V%R9"`H=&AE('9E'1E;G0@86-T=6%L(')E"!B96YE9FET(&AAF5D(&9O6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)V-L M96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0G/B`@/&1I=B!S='EL93TS1"=C;&5A6QE/3-$)V-L96%R.F)O=&@[0D]21$52+4)/5%1/33H@(SEE8C9C M92`P<'@@"!S;VQI9#L@ M34%21TE..B`P:6X@,&EN(#!I;B`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`@/&1I=CXF(S$V,#L\+V1I=CX@(#PO=&0^("`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@("!W:61T:#TS1#$P)3X@ M(#QD:78^)B,Q-C`[/"]D:78^("`\+W1D/B`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R`@('=I9'1H/3-$,3`E/B`@/&1I=CXS,"PP M,#`L,#`P/"]D:78^("`\+W1D/B`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO&5R8VES960\+V1I M=CX@(#PO=&0^("`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R`@('=I9'1H/3-$,3`E/B`@/&1I=CXM/"]D:78^("`\+W1D/B`@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T M,#`G("`@=VED=&@],T0Q,"4^("`\9&EV/B@U+#8V.2PT-#0I/"]D:78^("`\ M+W1D/B`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`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($9/3E0M5T5)1TA4.B`T,#`G("`@=VED=&@],T0Q)3X@(#QD:78^)B,Q M-C`[/"]D:78^("`\+W1D/B`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!D M;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G("`@=VED=&@],T0Q)3X@(#QD:78^ M)B,Q-C`[/"]D:78^("`\+W1D/B`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R`@('=I9'1H/3-$,3`E/B`@ M/&1I=CXQ.2PP,36QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R`@('=I9'1H/3-$,3`E/B`@/&1I M=CXP+C`P.#8\+V1I=CX@(#PO=&0^("`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M65A6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)V-L96%R.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G M/CPO9&EV/B`@("`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E' M3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$)R!& M3TY4+5-)6D4Z(#$P<'0G/C`N,#`Q,3PO9F]N=#X@<&5R('-H87)E+B!4:&4@ M;W!T:6]N65A65A65A M28C M.#(Q-SMS("!C;VUM;VX@6QE/3-$)R!&3TY4 M+5-)6D4Z(#$P<'0G/C`N,#`S,CPO9F]N=#X@<&5R("!S:&%R92P@=&AE(&-L M;W-I;F<@<')I8V4@;V8@=&AE($-O;7!A;GDF(S@R,3<[2!O=F5R(&]N92!Y96%R+"!S=6)J96-T('1O("!C;VYT:6YU:6YG M('-E2P@=&AE($)O87)D(&]F($1I6QE/3-$)R!&3TY4+5-)6D4Z M(#$P<'0G/C`N,#`S,CPO9F]N=#X@<&5R('-H87)E+B!4:&ES(&]P=&EO;B!V M97-T2!O=F5R('1H6EE;&0@;V8@/&9O;G0@ M('-T>6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/GIE6QE/3-$)R!&3TY4+5-) M6D4Z(#$P<'0G/C4N,#PO9F]N=#X@>65A6EE M;&0@;V8@/&9O;G0@'!E8W1E9"`@ M=F]L871I;&ET>2!I28C.#(Q-SMS(&-O;6UO;B!S=&]C M:SL@*&EI:2D@=&AE(')I#L@ M1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C$L.#DS/"]F;VYT M/B!A;F0@("0\9F]N="!S='EL93TS1"<@1D].5"U325I%.B`Q,'!T)SXY+#4R M,3PO9F]N=#XL(')E2X@1F]R('1H92`@;FEN92!M;VYT:',@ M96YD960@075G=7-T(#,Q+"`R,#$S(&%N9"`R,#$R+"!-=6QT:4-E;&P@'!E;G-E(&9O6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C,R+#2X@07,@;V8@075G=7-T("`S,2P@,C`Q,RP@=&AE M2`D/&9O;G0@6QE/3-$)R!& M3TY4+5-)6D4Z(#$P<'0G/C$N-#PO9F]N=#X@>65A#L@1D].5#H@,3!P="!4:6UE6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-EF5D('1H92!G65E2`S+"`R,#$Q+"!T:&4@,C`Q,"!0;&%N M('=A2!W:&EC:"!E;&EG:6)L92`@2!T;R!B96YE9FET("!F2!T;R!E;7!L;WEE97,N(%1H92!E>&5R8VES92!P6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/B`@,3`P/"]F;VYT/B4@;V8@ M=&AE(&UA6QE/3-$)R!& M3TY4+5-)6D4Z(#$P<'0G/C$P)2!S=&]C:VAO;&1E'!I65A65A&5C=71I=F4@;V9F:6-E'!I6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/B`@,BPP,#`L,#`P M/"]F;VYT/B!S:&%R97,@=F5S="!I;B!T:&4@9G5T=7)E('5P;VX@=&AE(&%C M:&EE=F5M96YT(&]F("!S<&5C:69I960@;6EL97-T;VYE6QE/3-$)R!&3TY4+5-)6D4Z M(#$P<'0G/F9I=F4\+V9O;G0^('EE87)S+"!A;F0@(&1I=FED96YD('EI96QD M(&]F(#QF;VYT('-T>6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/GIE6QE/3-$)V-L96%R.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U! M3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF M>3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E&EM871E;'D@/&9O;G0@2!A;F0@=&AE("!R96UA:6YI;F<@/&9O;G0@ M6QE/3-$)R!& M3TY4+5-)6D4Z(#$P<'0G/C4L,#`P+#`P,#PO9F]N=#XN(%1H92!F86ER('9A M;'5E(&]F("!T:&5S92!O<'1I;VYS('=A6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C8Y,BPW,#`\+V9O;G0^ M+"!O6QE/3-$)R!&3TY4 M+5-)6D4Z(#$P<'0G/C(N,C`\+V9O;G0^)2P@=F]L871I;&ET>2!O9B`\9F]N M="`@2!$ M96-E;6)E6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C$L M-3`P+#`P,#PO9F]N=#X@'!E;G-E(&EN('1H92!T:')E92!M;VYT:',@96YD M960@1F5B6QE/3-$ M)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L96%R.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/F9I=F4\ M+V9O;G0^('EE87)S+"!P2!&96)R=6%R>2`R."P@,C`Q,RX@0V]N M'!I6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C`N,C,S.#PO9F]N=#X@<&5R M('-H87)E+"!A6QE/3-$ M)R!&3TY4+5-)6D4Z(#$P<'0G/C$W,#PO9F]N=#XE+"!E>'!E8W1E9"!L:79E M2`R."P@,C`Q,RP@6&5N;V=E;FEC6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C4P,"PP,#`\+V9O;G0^('-H87)E M65A M6QE/3-$)R!&3TY4 M+5-)6D4Z(#$P<'0G/C$Q-RPP,#`\+V9O;G0^+"!O6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/F9I=F4\+V9O;G0^('EE M87)S+"!A;F0@9&EV:61E;F0@>6EE;&0@;V8@(#QF;VYT('-T>6QE/3-$)R!& M3TY4+5-)6D4Z(#$P<'0G/GIE6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)V-L96%R M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'!E;G-E(&9O6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C$Y,RPT M,#,\+V9O;G0^+B!!&EM871E;'D@(#QF;VYT('-T>6QE/3-$)R!&3TY4+5-) M6D4Z(#$P<'0G/C`N-3PO9F]N=#X@>65A3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X.3)D.#=A9E]C8V%C7S0U M8SA?83(T.5\T969C-V-B.6%A-CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO.#DR9#@W869?8V-A8U\T-6,X7V$R-#E?-&5F8S=C8CEA838Y+U=O M'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U! M3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B!B;VQD(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V-L96%R.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4 M.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE28C.#(Q-SMS(&-O;6UO;B!S=&]C M:RX\+V1I=CX@("`@/&1I=B!S='EL93TS1"=C;&5A#L@1D].5#H@,3!P="!4:6UE M#L@1D].5#H@,3!P="!4:6UE6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C$P,"PP M,#`\+V9O;G0^+B`@26X@8V]N;F5C=&EO;B!W:71H('1H92!$96)E;G1U6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C$P/"]F M;VYT/B!M:6QL:6]N("!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[2!P;W)T:6]N(&]F('1H92`@<')I;F-I<&%L(&%M;W5N M="!O9B!T:&4@1&5B96YT=7)E+"!,2D-)(&ES(')E<75I2!E>&5R8VES92!A;F0@<'5R8VAA#L@1D].5#H@ M,3!P="!4:6UE#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S M=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0G/B`@/&1I=B!S='EL93TS1"=C;&5A6QE/3-$)V-L96%R.F)O=&@[0D]21$52+4)/5%1/ M33H@(SEE8C9C92`P<'@@"!S;VQI9#L@34%21TE..B`P:6X@,&EN(#!I;B`P+C5I;CL@5TE$5$@Z(#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@("!W:61T:#TS1#$E/B`@/&1I=CXF M(S$V,#L\+V1I=CX@(#PO=&0^("`\=&0@"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@("!W:61T:#TS1#$P)3X@(#QD:78^)B,Q-C`[/"]D:78^ M("`\+W1D/B`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R`@('=I9'1H/3-$,3`E/B`@/&1I=CXM/"]D:78^ M("`\+W1D/B`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R`@('=I9'1H/3-$,S$E/B`@/&1I=CY)6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R`@('=I9'1H M/3-$,3`E/B`@/&1I=CXM/"]D:78^("`\+W1D/B`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`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R`@('=I9'1H M/3-$,S$E/B`@/&1I=CY%>'!I6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G("`@=VED M=&@],T0Q,"4^("`\9&EV/B@S-C`L,#`P*3PO9&EV/B`@/"]T9#X@(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R`@('=I M9'1H/3-$,3`E/B`@/&1I=CXP+C4P,#`\+V1I=CX@(#PO=&0^("`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R`@ M('=I9'1H/3-$,3`E/B`@/&1I=CXW+#DW-"PP,S`\+V1I=CX@(#PO=&0^("`\ M=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\X.3)D.#=A9E]C8V%C7S0U8SA?83(T.5\T969C M-V-B.6%A-CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#DR9#@W M869?8V-A8U\T-6,X7V$R-#E?-&5F8S=C8CEA838Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$ M)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L M96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@8V5N M=&5R.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!O=71S=&%N9&EN9R`@ M9'5R:6YG('1H92!Y96%R+B!3:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[ M2!T:&4@0V]M<&%N>2P@ M87,@;V8@075G=7-T(#,Q+"`R,#$S("!A;F0@,C`Q,BP@87)E(&%S(&9O;&QO M=W,Z/"]D:78^("`@(#QD:78@6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E. M1$5.5#H@,&EN.R!724142#H@,3`P)2<^("`\=&%B;&4@"!S;VQI9#L@0D]2 M1$52+4Q%1E0Z(",Y96(V8V4@,'!X('-O;&ED.R!-05)'24XZ(#!I;B`P:6X@ M,&EN(#`N-6EN.R!724142#H@-C4E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA M<'-E.R!/5D521DQ/5SH@=FES:6)L93L@0D]21$52+51/4#H@(SEE8C9C92`P M<'@@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R`@('=I9'1H/3-$,3`E M/B`@/&1I=CXW+#DW-"PP,S`\+V1I=CX@(#PO=&0^("`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R`@('=I9'1H/3-$,3`E/B`@/&1I=CXU,"PS.3DL-3`S/"]D M:78^("`\+W1D/B`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C M8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R`@('=I9'1H/3-$,3`E/B`@/&1I=CXT-RPP-#DL M-SDS/"]D:78^("`\+W1D/B`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4 M+5=%24=(5#H@-#`P)R`@('=I9'1H/3-$,3`E/B`@/&1I=CXU+#@Q.2PX-S8L M-C(Q/"]D:78^("`\+W1D/B`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M("!W:61T:#TS1#$E/B`@/&1I=CXF(S$V,#L\+V1I=CX@(#PO=&0^("`\=&0@ M"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@("!W:61T:#TS1#$P)3X@(#QD:78^)B,Q-C`[/"]D:78^("`\ M+W1D/B`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R`@('=I9'1H/3-$,3`E/B`@/&1I=CXU+#DP-BPP-38L-C`V/"]D:78^("`\ M+W1D/B`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R`@('=I9'1H/3-$,3`E M/B`@/&1I=CXV+#$S."PY.#8L.34S/"]D:78^("`\+W1D/B`@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5#H@,3!P="!4:6UE#L@ M1D].5#H@,3!P="!4:6UEF5D('-H87)E6QE M/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C0V+#4Y-CPO9F]N=#X@<')I;F-I<&%L M(&%M;W5N="!O9B!T:&4@($1E8F5N='5R92P@3$I#22!I2!E>&5R8VES92!A;F0@<'5R8VAA2X@1G5R=&AE2!E;&5C="!T M;R`@8V]N=F5R="!A;F0@86QS;R!H87,@=&AE(')I9VAT('1O(')E9&5E;2!T M:&4@;W5T6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D M/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA#L@1D].5#H@ M,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@ M:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`@/'1A8FQE('-T>6QE/3-$)V-L96%R M.F)O=&@[34%21TE.+51/4#H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)U1%6%0M04Q)1TXZ(&IU6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`@)B,Q-C`[/"]D:78^ M("`@(#QD:78@6QE/3-$ M)U=)1%1(.B`P+C(U:6XG/B`@/&1I=CX\2<^("`\9&EV/DQE=F5L('1W;R`F(S$U,3L@26YP=71S(&]T:&5R('1H M86X@;&5V96P@;VYE(&EN<'5T6QE/3-$)V-L96%R M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0G/B`@/'1A8FQE('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE.+51/ M4#H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$)U1%6%0M04Q)1TXZ(&IU6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)V-L96%R M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0G/CPO9&EV/B`@("`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF5D(&%S(&9O;&QO=W,Z/"]D:78^("`@(#QD:78@6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CIC96YT M97([(%1%6%0M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)R`@(&%L:6=N/3-$ M8V5N=&5R/B`@/'1A8FQE('-T>6QE/3-$)V-L96%R.F)O=&@[0D]21$52+4)/ M5%1/33H@(SEE8C9C92`P<'@@"!S;VQI9#L@34%21TE..B`P<'@Z875T;SL@5TE$5$@Z(#DP)3L@0D]2 M1$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@("!W:61T:#TS1#6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@("!W:61T:#TS1#$E/B`@/&1I=CXF(S$V,#L\+V1I=CX@ M(#PO=&0^("`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@("!W:61T:#TS1#$E/B`@ M/&1I=CXF(S$V,#L\+V1I=CX@(#PO=&0^("`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@("!W:61T:#TS M1#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@("!W:61T:#TS M1#$E/B`@/&1I=CXF(S$V,#L\+V1I=CX@(#PO=&0^("`\=&0@"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@("!W:61T:#TS1#8E/B`@/&1I=CXF M(S$V,#L\+V1I=CX@(#PO=&0^("`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@("!W:61T:#TS1#$E/B`@/&1I=CXF(S$V,#L\+V1I=CX@ M(#PO=&0^("`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M("!W:61T:#TS1#8E/B`@/&1I=CXF(S$V,#L\+V1I=CX@(#PO=&0^("`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@("!W:61T:#TS1#$E M/B`@/&1I=CXF(S$V,#L\+V1I=CX@(#PO=&0^("`\=&0@"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@("!W:61T:#TS1#8E/B`@/&1I=CXF(S$V M,#L\+V1I=CX@(#PO=&0^("`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@("!W:61T:#TS1#$E/B`@/&1I=CXF(S$V,#L\+V1I=CX@(#PO M=&0^("`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@("!W M:61T:#TS1#8E/B`@/&1I=CXF(S$V,#L\+V1I=CX@(#PO=&0^("`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@("!W:61T:#TS1#$E/B`@ M/&1I=CXF(S$V,#L\+V1I=CX@(#PO=&0^("`\=&0@"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@("!W:61T:#TS1#8E/B`@/&1I=CXF(S$V,#L\ M+V1I=CX@(#PO=&0^("`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@("!W:61T:#TS1#$E/B`@/&1I=CXF(S$V,#L\+V1I=CX@(#PO=&0^ M("`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@("!W:61T M:#TS1#8E/B`@/&1I=CXF(S$V,#L\+V1I=CX@(#PO=&0^("`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@("!W:61T:#TS1#$E/B`@/&1I M=CXF(S$V,#L\+V1I=CX@(#PO=&0^("`\=&0@"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@("!W:61T:#TS1#8E/B`@/&1I=CXF(S$V,#L\+V1I M=CX@(#PO=&0^("`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@("!W:61T:#TS1#$E/B`@/&1I=CXF(S$V,#L\+V1I=CX@(#PO=&0^("`\ M=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@("!W:61T:#TS M1#8E/B`@/&1I=CXF(S$V,#L\+V1I=CX@(#PO=&0^("`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO3PO9&EV/B`@/"]T9#X@(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R`@('=I9'1H/3-$-B4^("`\9&EV/C,P M+#4X-SPO9&EV/B`@/"]T9#X@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R`@('=I9'1H/3-$-B4^("`\9&EV/C,P+#4X-SPO9&EV/B`@/"]T9#X@(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R`@('=I9'1H/3-$-B4^("`\9&EV M/C$Y+#(T-3PO9&EV/B`@/"]T9#X@(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R`@('=I9'1H/3-$-B4^("`\9&EV/C$Y+#(T-3PO9&EV/B`@/"]T9#X@ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\X.3)D.#=A9E]C8V%C7S0U8SA?83(T.5\T969C-V-B.6%A-CD-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#DR9#@W869?8V-A8U\T-6,X M7V$R-#E?-&5F8S=C8CEA838Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P M="!4:6UE#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P M="!4:6UE#L@1D].5#H@,3!P="!4:6UE&5R8VES92!W87)R86YT6QE M/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C$P.2PP,#`\+V9O;G0^+CPO9&EV/B`@ M("`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CQB6QE/3-$)V-L M96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L96%R.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)T-/3$]2.B!B;&%C:R<^3VX@4V5P=&5M8F5R(#(W+"`R,#$S+"!-=6QT M:4-E;&P@96YT97)E9"`@:6YT;SPO9F]N=#X@82!N97<@2!(96%L=&@@3F5T=V]R:R`H)B,X,C(P.U5(3B8C.#(R,3LI M('1O("!E=F%L=6%T92!-0U0M-#@U(&EN(&%N:6UA;"!M;V1E;',@9F]R('1H M92!T2`@;&EV97(@8V%N8V5R("AT:&4@)B,X M,C(P.T=H86YE:V%R($%G2!H860@<')E=FEO=7-L>2!E;G1E28C.#(Q M-SMS('!R;V1U8W0@8V%N9&ED871E2`@ M6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)V-L96%R.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S M=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E2X@ M3VX@($]C=&]B97(@,3$L(#(P,3,L(%AE;F]G96YI8W,@96YT97)E9"!I;G1O M($%M96YD;65N="!.;RX@,R!T;R!T:&4@($9O2!O M9B!T:&5S92!M:6QE6QE/3-$)R!&3TY4 M+5-)6D4Z(#$P<'0G/C0N,SPO9F]N=#X@;6EL;&EO;BP@8F5C;VUI;F<@:6UM M961I871E;'D@9'5E(&%N9"`@<&%Y86)L92X\+V1I=CX@(#PO9&EV/B`@/"]D M:78^("`@("`@("`\=&%B;&4@8F]R9&5R/3-$,"`@&5D.R<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA2!;4&]L:6-Y M(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X@ M("`@("`@("`@("`@(#QD:78@6EN9R!U;F%U9&ET960@8V]N9&5N2P@=&AE>2!D;R!N;W0@:6YC;'5D92!A M;&P@(&]F('1H92!I;F9O28C.#(Q-SMS(&%N;G5A;"!R97!O M65A&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T#L@1D].5#H@,3!P M="!4:6UE#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE'!E M;G-E&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D M/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$2!"86QA;F-E(%-H965T($=R;W5P:6YG(%M486)L M92!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E#L@1D].5#H@,3!P="!4:6UE"!S;VQI9#L@0D]21$52+5))1TA4.B`C.65B M-F-E(#!P>"!S;VQI9"<@("!C96QL6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO28C M,38P.S,Q+#QB6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO28C,38P.S(X+#QB6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@("!W:61T:#TS1#$E/B`@/&1I=CXF(S$V,#L\+V1I M=CX@(#PO=&0^("`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@("!W:61T:#TS1#$P)3X@(#QD:78^)B,Q-C`[/"]D:78^("`\+W1D/B`@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@("!W:61T M:#TS1#$E/B`@/&1I=CXF(S$V,#L\+V1I=CX@(#PO=&0^("`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@("!W:61T:#TS1#$P)3X@(#QD M:78^)B,Q-C`[/"]D:78^("`\+W1D/B`@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R`@('=I9'1H/3-$ M,3`E/B`@/&1I=CXP+C`P,3(\+V1I=CX@(#PO=&0^("`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R`@('=I9'1H/3-$,3`E/B`@/&1I=CXP+C`P,30\+V1I=CX@(#PO=&0^ M("`\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C M9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R`@('=I9'1H/3-$,3`E/B`@/&1I=CXP+C`P M,S@\+V1I=CX@(#PO=&0^("`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R`@('=I9'1H/3-$ M,3`E/B`@/&1I=CXP+C`P,3,\+V1I=CX@(#PO=&0^("`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R`@('=I9'1H/3-$,3`E/B`@/&1I=CXR+C6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R`@('=I9'1H/3-$,3`E/B`@/&1I=CXQ+C8R/"]D:78^("`\+W1D/B`@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO'!E8W1E9"!L:69E/"]D:78^("`\+W1D/B`@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R`@('=I9'1H/3-$,3`E/B`@/&1I=CXQ,"!996%R M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO3PO9&EV/B`@/"]T M9#X@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R`@('=I9'1H/3-$,3`E/B`@/&1I=CXQ-#@\+V1I=CX@(#PO=&0^("`\ M=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R`@('=I9'1H/3-$,3`E/B`@/&1I=CXQ-#@\+V1I M=CX@(#PO=&0^("`\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R`@('=I9'1H/3-$,3`E/B`@ M/&1I=CXQ-#<\+V1I=CX@(#PO=&0^("`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R`@('=I M9'1H/3-$,3`E/B`@/&1I=CXQ-#$\+V1I=CX@(#PO=&0^("`\=&0@&5D.R<@8V5L;'-P M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)V-L96%R.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`@/&1I=B!S M='EL93TS1"=C;&5A6QE/3-$)V-L96%R M.F)O=&@[0D]21$52+4)/5%1/33H@(SEE8C9C92`P<'@@"!S;VQI9#L@34%21TE..B`P:6X@,&EN(#!I M;B`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`@/&1I=CXF M(S$V,#L\+V1I=CX@(#PO=&0^("`\=&0@"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@("!W:61T:#TS1#$P)3X@(#QD:78^)B,Q-C`[/"]D:78^ M("`\+W1D/B`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`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R`@('=I9'1H/3-$,3`E/B`@/&1I=CXS,"PP,#`L,#`P/"]D:78^("`\+W1D M/B`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R`@('=I9'1H M/3-$,S8E/B`@/&1I=CY%>&5R8VES960\+V1I=CX@(#PO=&0^("`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R`@('=I9'1H/3-$,3`E M/B`@/&1I=CXM/"]D:78^("`\+W1D/B`@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+ M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G("`@=VED=&@],T0Q,"4^ M("`\9&EV/B@U+#8V.2PT-#0I/"]D:78^("`\+W1D/B`@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T M,#`G("`@=VED=&@],T0Q)3X@(#QD:78^)B,Q-C`[/"]D:78^("`\+W1D/B`@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[($9/3E0M5T5)1TA4 M.B`T,#`G("`@=VED=&@],T0Q)3X@(#QD:78^)B,Q-C`[/"]D:78^("`\+W1D M/B`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R`@('=I9'1H/3-$,3`E/B`@/&1I=CXQ.2PP,36QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R`@('=I9'1H/3-$,3`E/B`@/&1I=CXP+C`P.#8\+V1I=CX@(#PO M=&0^("`\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO65A6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO&5D.R<@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`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`@/"]T9#X@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@("!W:61T:#TS1#$E/B`@/&1I=CXF(S$V,#L\ M+V1I=CX@(#PO=&0^("`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R`@ M('=I9'1H/3-$,3`E/B`@/&1I=CXY+#(W-RPP,S`\+V1I=CX@(#PO=&0^("`\ M=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C M8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R`@('=I9'1H/3-$,S$E/B`@/&1I=CY%>&5R8VES M960\+V1I=CX@(#PO=&0^("`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R`@ M('=I9'1H/3-$,3`E/B`@/&1I=CXQ+C`Y,#`\+V1I=CX@(#PO=&0^("`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@("!W:61T:#TS M1#$E/B`@/&1I=CXF(S$V,#L\+V1I=CX@(#PO=&0^("`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M("!W:61T:#TS1#$P)3X@(#QD:78^)B,Q-C`[/"]D:78^("`\+W1D/B`@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R`@('=I9'1H/3-$ M,3`E/B`@/&1I=CXP+C6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO65A6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\ M='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)V-L96%R M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L96%R.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`@/&1I=B!S='EL M93TS1"=C;&5A6QE/3-$)V-L96%R.F)O M=&@[0D]21$52+4)/5%1/33H@(SEE8C9C92`P<'@@"!S;VQI9#L@34%21TE..B`P:6X@,&EN(#!I;B`P M+C5I;CL@5TE$5$@Z(#8U)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@ M3U9%4D9,3U6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M("!W:61T:#TS1#$E/B`@/&1I=CXF(S$V,#L\+V1I=CX@(#PO=&0^("`\=&0@ M"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@("!W:61T:#TS1#$P M)3X@(#QD:78^)B,Q-C`[/"]D:78^("`\+W1D/B`@/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R`@('=I9'1H/3-$,3`E/B`@/&1I=CXR-"PQ-C@L.30W/"]D:78^ M("`\+W1D/B`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4 M+5=%24=(5#H@-#`P)R`@('=I9'1H/3-$,3`E/B`@/&1I=CXM/"]D:78^("`\ M+W1D/B`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M("!W:61T:#TS1#$E/B`@/&1I=CXF(S$V,#L\+V1I=CX@(#PO=&0^("`\=&0@ M"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@("!W:61T:#TS1#$P)3X@(#QD:78^)B,Q-C`[/"]D:78^("`\ M+W1D/B`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`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$)V-L96%R.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0G/B`@/&1I=B!S='EL93TS1"=C;&5A"!S;VQI9#L@0D]21$52+5))1TA4.B`C M.65B-F-E(#!P>"!S;VQI9"<@("!C96QL6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U19 M3$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@("!W M:61T:#TS1#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@("!W:61T:#TS1#$E/B`@ M/&1I=CXF(S$V,#L\+V1I=CX@(#PO=&0^("`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@("!W:61T:#TS M1#6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@("!W:61T:#TS1#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@("!W M:61T:#TS1#$E/B`@/&1I=CXF(S$V,#L\+V1I=CX@(#PO=&0^("`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`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'1U M86PI/&)R/CPO2!-971H;V0@26YV97-T;65N="P@3W=N97)S:&EP(%!E7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M1F5B(#(X+`T*"0DR,#`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S2!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES86)L92!097)I;V0\+W1D/@T* M("`@("`@("`\=&0@8VQA65A&5R M8VES92!O9B!787)R86YT('5P;VX@0V]N=F5R2!P=7)C:&%S92`Q,#`L,#`P('-H87)E&EM M=6T@0V]N=F5R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA M'1087)T7S@Y,F0X-V%F7V-C86-?-#5C.%]A,C0Y7S1E9F,W8V(Y86$V.0T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X.3)D.#=A9E]C8V%C7S0U M8SA?83(T.5\T969C-V-B.6%A-CDO5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'!E8W1E9"!L M:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ,"!Y96%R'0^,3`@>65A6EE;&0\+W1D/@T* M("`@("`@("`\=&0@8VQA3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X.3)D.#=A9E]C8V%C7S0U8SA?83(T M.5\T969C-V-B.6%A-CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M.#DR9#@W869?8V-A8U\T-6,X7V$R-#E?-&5F8S=C8CEA838Y+U=O'0O:'1M;#L@8VAA M&EM=6T@6TUE;6)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$6UE;G0@4F%T93PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^0V]M<&%N>2!W87,@'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$&EM=6T@4&5R8V5N=&%G93PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A&5C=71E9"!A;B!E>&-L=7-I=F4@;&EC96YS92!A;F0@<'5R8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$F5D M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,S`P/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^5&AE(&)A;&%N8V4@ M;V8@9&5F97)R960@'1087)T M7S@Y,F0X-V%F7V-C86-?-#5C.%]A,C0Y7S1E9F,W8V(Y86$V.0T*0V]N=&5N M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X.3)D.#=A9E]C8V%C7S0U8SA?83(T M.5\T969C-V-B.6%A-CDO5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&5R8VES86)L93PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S&5R8VES92!0&5R8VES92!0'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES960@*&EN(&1O;&QA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$&5R8VES92!P&5R8VES86)L92`H:6X@9&]L;&%R&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,B!Y96%R'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M&5C M=71I=F4@3V9F:6-E2!";V%R9"!;365M8F5R73QB2!";V%R9"!;365M8F5R73QB65E M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S2!);F-E;G1I=F4@4&QA;B`R,#`T(%M-96UB97)=/&)R M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%SF5D/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G0@07=A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^-2!Y96%R M65A'0^-2!Y96%R65A'0^-2!Y96%R6UE;G0@07=A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^3F]V(#,P+`T*"0DR,#$U/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!& M86ER(%9A;'5E($%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S2!3:&%R92U"87-E M9"!087EM96YT($%W87)D+"!&86ER(%9A;'5E($%S'!E M8W1E9"!6;VQA=&EL:71Y(%)A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S2!3:&%R92U"87-E9"!087EM M96YT($%W87)D+"!&86ER(%9A;'5E($%S'!E8W1E9"!4 M97)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^,3`@>65A65A'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^-2!Y96%R65A'0^-2!Y96%R6UE;G0@07=A'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@Y,SQS M<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S65E(%-E65T M(%)E8V]G;FEZ960L(%-T;V-K($]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@ M8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^,2!Y96%R(#0@;6]N=&AS(#(T(&1A>7,\6UE;G0@ M07=A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^-3`P+#`P,#QS<&%N/CPO6UE M;G0@07=A6UE;G0@07=A6UE;G0@07=A'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,3`E('-T M;V-K:&]L9&5R('-H86QL(&YO="!B92!G6UE;G0@07=A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!0&5R8VES92!P&5R8VES92!0&5R8VES92!065A3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X.3)D.#=A9E]C8V%C7S0U M8SA?83(T.5\T969C-V-B.6%A-CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO.#DR9#@W869?8V-A8U\T-6,X7V$R-#E?-&5F8S=C8CEA838Y+U=O M'0O:'1M M;#L@8VAA'0^-2!Y96%R'0^96%C:"`D,2PP,#`@;V8@=&AE('!R:6YC:7!A;"!C;VYV97)T M960L($Q*0TD@=V]U;&0@8F4@'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^9F]R(&5A8V@@)#$L,#`P(&]F('1H M92!P'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$&5R8VES M97,\+W1D/@T*("`@("`@("`\=&0@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\X.3)D.#=A9E]C8V%C7S0U8SA?83(T.5\T969C-V-B.6%A-CD-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#DR9#@W869?8V-A8U\T-6,X M7V$R-#E?-&5F8S=C8CEA838Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$&-L=61E9"!F3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\X.3)D.#=A9E]C8V%C7S0U8SA?83(T.5\T969C-V-B.6%A-CD- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#DR9#@W869?8V-A8U\T M-6,X7V$R-#E?-&5F8S=C8CEA838Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X M.3)D.#=A9E]C8V%C7S0U8SA?83(T.5\T969C-V-B.6%A-CD-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#DR9#@W869?8V-A8U\T-6,X7V$R-#E? M-&5F8S=C8CEA838Y+U=O'0O:'1M;#L@8VAA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X.3)D.#=A M9E]C8V%C7S0U8SA?83(T.5\T969C-V-B.6%A-CD-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO.#DR9#@W869?8V-A8U\T-6,X7V$R-#E?-&5F8S=C M8CEA838Y+U=O'0O:'1M;#L@8VAA'1087)T7S@Y,F0X-V%F7V-C86-?-#5C.%]A 4,C0Y7S1E9F,W8V(Y86$V.2TM#0H` ` end XML 34 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 103 196 1 false 29 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.multicelltech.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.multicelltech.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS false false R3.htm 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.multicelltech.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.multicelltech.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS false false R5.htm 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (DEFICIENCY) Sheet http://www.multicelltech.com/role/CondensedConsolidatedStatementsOfEquityDeficiency CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (DEFICIENCY) false false R6.htm 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (DEFICIENCY) (Parenthetical) Sheet http://www.multicelltech.com/role/CondensedConsolidatedStatementsOfEquityDeficiencyParenthetical CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (DEFICIENCY) (Parenthetical) false false R7.htm 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.multicelltech.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS false false R8.htm 108 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Sheet http://www.multicelltech.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) false false R9.htm 109 - Disclosure - ORGANIZATION AND NATURE OF OPERATIONS, BASIS OF PRESENTATION, AND RECLASSIFICATIONS Sheet http://www.multicelltech.com/role/OrganizationAndNatureOfOperationsBasisOfPresentationAndReclassifications ORGANIZATION AND NATURE OF OPERATIONS, BASIS OF PRESENTATION, AND RECLASSIFICATIONS false false R10.htm 110 - Disclosure - GOING CONCERN Sheet http://www.multicelltech.com/role/GoingConcern GOING CONCERN false false R11.htm 111 - Disclosure - CONVERTIBLE DEBENTURES Sheet http://www.multicelltech.com/role/ConvertibleDebentures CONVERTIBLE DEBENTURES false false R12.htm 112 - Disclosure - SERIES B CONVERTIBLE PREFERRED STOCK Sheet http://www.multicelltech.com/role/SeriesBConvertiblePreferredStock SERIES B CONVERTIBLE PREFERRED STOCK false false R13.htm 113 - Disclosure - SERIES I CONVERTIBLE PREFERRED STOCK Sheet http://www.multicelltech.com/role/SeriesIConvertiblePreferredStock SERIES I CONVERTIBLE PREFERRED STOCK false false R14.htm 114 - Disclosure - LICENSE AGREEMENTS AND DEFERRED REVENUE Sheet http://www.multicelltech.com/role/LicenseAgreementsAndDeferredRevenue LICENSE AGREEMENTS AND DEFERRED REVENUE false false R15.htm 115 - Disclosure - STOCK COMPENSATION PLANS Sheet http://www.multicelltech.com/role/StockCompensationPlans STOCK COMPENSATION PLANS false false R16.htm 116 - Disclosure - STOCK WARRANTS Sheet http://www.multicelltech.com/role/StockWarrants STOCK WARRANTS false false R17.htm 117 - Disclosure - LOSS PER SHARE Sheet http://www.multicelltech.com/role/LossPerShare LOSS PER SHARE false false R18.htm 118 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.multicelltech.com/role/FairValueMeasurements FAIR VALUE MEASUREMENTS false false R19.htm 119 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.multicelltech.com/role/SubsequentEvents SUBSEQUENT EVENTS false false R20.htm 120 - Disclosure - ORGANIZATION AND NATURE OF OPERATIONS, BASIS OF PRESENTATION, AND RECLASSIFICATIONS (Policies) Sheet http://www.multicelltech.com/role/OrganizationAndNatureOfOperationsBasisOfPresentationAndReclassificationsPolicies ORGANIZATION AND NATURE OF OPERATIONS, BASIS OF PRESENTATION, AND RECLASSIFICATIONS (Policies) false false R21.htm 121 - Disclosure - SERIES B CONVERTIBLE PREFERRED STOCK (Tables) Sheet http://www.multicelltech.com/role/SeriesBConvertiblePreferredStockTables SERIES B CONVERTIBLE PREFERRED STOCK (Tables) false false R22.htm 122 - Disclosure - STOCK COMPENSATION PLANS (Tables) Sheet http://www.multicelltech.com/role/StockCompensationPlansTables STOCK COMPENSATION PLANS (Tables) false false R23.htm 123 - Disclosure - STOCK WARRANTS (Tables) Sheet http://www.multicelltech.com/role/StockWarrantsTables STOCK WARRANTS (Tables) false false R24.htm 124 - Disclosure - LOSS PER SHARE (Tables) Sheet http://www.multicelltech.com/role/LossPerShareTables LOSS PER SHARE (Tables) false false R25.htm 125 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.multicelltech.com/role/FairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) false false R26.htm 126 - Disclosure - ORGANIZATION AND NATURE OF OPERATIONS, BASIS OF PRESENTATION, AND RECLASSIFICATIONS (Details Textual) Sheet http://www.multicelltech.com/role/OrganizationAndNatureOfOperationsBasisOfPresentationAndReclassificationsDetailsTextual ORGANIZATION AND NATURE OF OPERATIONS, BASIS OF PRESENTATION, AND RECLASSIFICATIONS (Details Textual) false false R27.htm 127 - Disclosure - GOING CONCERN (Details Textual) Sheet http://www.multicelltech.com/role/GoingConcernDetailsTextual GOING CONCERN (Details Textual) false false R28.htm 128 - Disclosure - CONVERTIBLE DEBENTURES (Details Textual) Sheet http://www.multicelltech.com/role/ConvertibleDebenturesDetailsTextual CONVERTIBLE DEBENTURES (Details Textual) false false R29.htm 129 - Disclosure - SERIES B CONVERTIBLE PREFERRED STOCK (Details) Sheet http://www.multicelltech.com/role/SeriesBConvertiblePreferredStockDetails SERIES B CONVERTIBLE PREFERRED STOCK (Details) false false R30.htm 130 - Disclosure - SERIES B CONVERTIBLE PREFERRED STOCK (Details Textual) Sheet http://www.multicelltech.com/role/SeriesBConvertiblePreferredStockDetailsTextual SERIES B CONVERTIBLE PREFERRED STOCK (Details Textual) false false R31.htm 131 - Disclosure - SERIES I CONVERTIBLE PREFERRED STOCK (Details Textual) Sheet http://www.multicelltech.com/role/SeriesIConvertiblePreferredStockDetailsTextual SERIES I CONVERTIBLE PREFERRED STOCK (Details Textual) false false R32.htm 132 - Disclosure - LICENSE AGREEMENTS AND DEFERRED REVENUE (Details Textual) Sheet http://www.multicelltech.com/role/LicenseAgreementsAndDeferredRevenueDetailsTextual LICENSE AGREEMENTS AND DEFERRED REVENUE (Details Textual) false false R33.htm 133 - Disclosure - STOCK COMPENSATION PLANS (Details) Sheet http://www.multicelltech.com/role/StockCompensationPlansDetails STOCK COMPENSATION PLANS (Details) false false R34.htm 134 - Disclosure - STOCK COMPENSATION PLANS (Details Textual) Sheet http://www.multicelltech.com/role/StockCompensationPlansDetailsTextual STOCK COMPENSATION PLANS (Details Textual) false false R35.htm 135 - Disclosure - STOCK WARRANTS (Details) Sheet http://www.multicelltech.com/role/StockWarrantsDetails STOCK WARRANTS (Details) false false R36.htm 136 - Disclosure - STOCK WARRANTS (Details Textual) Sheet http://www.multicelltech.com/role/StockWarrantsDetailsTextual STOCK WARRANTS (Details Textual) false false R37.htm 137 - Disclosure - LOSS PER SHARE (Details) Sheet http://www.multicelltech.com/role/LossPerShareDetails LOSS PER SHARE (Details) false false R38.htm 138 - Disclosure - LOSS PER SHARE (Details Textual) Sheet http://www.multicelltech.com/role/LossPerShareDetailsTextual LOSS PER SHARE (Details Textual) false false R39.htm 139 - Disclosure - FAIR VALUE MEASUREMENTS (Details) Sheet http://www.multicelltech.com/role/FairValueMeasurementsDetails FAIR VALUE MEASUREMENTS (Details) false false R40.htm 140 - Disclosure - SUBSEQUENT EVENTS (Details Textual) Sheet http://www.multicelltech.com/role/SubsequentEventsDetailsTextual SUBSEQUENT EVENTS (Details Textual) false false All Reports Book All Reports Element us-gaap_DebtConversionConvertedInstrumentSharesIssued1 had a mix of decimals attribute values: -8 0. Element us-gaap_EquityMethodInvestmentOwnershipPercentage had a mix of decimals attribute values: 2 3. Element us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice had a mix of decimals attribute values: 3 4. 'Shares' elements on report '128 - Disclosure - CONVERTIBLE DEBENTURES (Details Textual)' had a mix of different decimal attribute values. 'Shares' elements on report '136 - Disclosure - STOCK WARRANTS (Details Textual)' had a mix of different decimal attribute values. Process Flow-Through: 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Aug. 31, 2012' Process Flow-Through: Removing column 'Nov. 30, 2011' Process Flow-Through: 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (DEFICIENCY) (Parenthetical) Process Flow-Through: 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Process Flow-Through: Removing column '3 Months Ended Aug. 31, 2013' Process Flow-Through: Removing column '3 Months Ended Aug. 31, 2012' Process Flow-Through: 108 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) mcet-20130831.xml mcet-20130831.xsd mcet-20130831_cal.xml mcet-20130831_def.xml mcet-20130831_lab.xml mcet-20130831_pre.xml true true XML 35 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)

Aug. 31, 2013

Nov. 30, 2012

Accumulated depreciation, property and equipment (in dollars) $ 40,561 $ 40,561

Undesignated preferred stock, par value (in dollars per share) $ 0.01 $ 0.01

Preferred stock, shares authorized/designated 963,000 963,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

Common stock, par value (in dollars per share) $ 0.01 $ 0.01

Common stock, shares authorized 3,000,000,000 3,000,000,000

Common stock, shares issued 2,391,239,613 1,349,803,029

Common stock, shares outstanding 2,391,239,613 1,349,803,029

Series B Convertible Preferred Stock [Member]

Preferred stock, shares authorized/designated 17,000 17,000

Preferred stock, shares issued 3,448 3,448

Preferred stock, shares outstanding 3,448 3,448

Preferred stock, liquidation value (in dollars) $ 470,316 $ 470,316

Series I Convertible Preferred Stock [Member]

Preferred stock, shares authorized/designated 20,000 20,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

X

- Definition

Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Value of the difference between preference in liquidation and the par or stated values of the preferred shares.

+ References

No definition available.

+ Details

Name: us-gaap_PreferredStockLiquidationPreferenceValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 36 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

LICENSE AGREEMENTS AND DEFERRED REVENUE
9 Months Ended

Aug. 31, 2013

License Agreements [Abstract]

License Agreements [Text Block]

NOTE 6. LICENSE AGREEMENTS AND DEFERRED REVENUE

On October 9, 2007, MultiCell executed an exclusive license and purchase agreement (the “Agreement”) with Corning Incorporated (“Corning”) of Corning, New York. Under the terms of the Agreement, Corning has the right to develop, use, manufacture, and sell MultiCell’s Fa2N-4 cell lines and related cell culture media for use as a drug discovery assay tool, including biomarker identification for the development of drug development assay tools, and for the performance of absorption, distribution, metabolism, elimination and toxicity assays (ADME/Tox assays). MultiCell retained and will continue to support its existing licensee, Pfizer, Inc. (“Pfizer”). MultiCell retains the right to use the Fa2N-4 cells for use in applications not related to drug discovery or ADME/Tox assays. MultiCell also retains rights to use the Fa2N-4 cell lines and other cell lines to further develop its Sybiol® liver assist device, to identify drug targets and for other applications related to the Company’s internal drug development programs. Corning paid MultiCell $750,000 in consideration for the license granted. The Company is recognizing the income ratably over a 17 year period. The Company recognized $11,029 and $33,088, respectively, in income for each of the three months and nine months ended August 31, 2013 and 2012. The balance of deferred revenue from this license is $488,971 at August 31, 2013 and will be amortized into revenue through October 2024.

The Company has another license agreement with Pfizer, for which revenue is being deferred. The Company recognized revenue from the agreement with Pfizer in the amount of $1,300 and $3,900 for the three months and the nine months ended each of August 31, 2013 and 2012, respectively. The balance of deferred revenue from the agreement with Pfizer is $22,100 at August 31, 2013, which will be amortized into revenue through January 2018.

X

- Details

Name: mcet_LicenseAgreementsAbstract

Namespace Prefix: mcet_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for license agreements.

+ References

No definition available.

+ Details

Name: mcet_LicenseAgreementsTextBlock

Namespace Prefix: mcet_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (DEFICIENCY) (USD $)

Total

Additional Paid-in Capital [Member]

Retained Earnings [Member]

Noncontrolling Interest [Member]

Series B Convertible Preferred Stock [Member]

Series I Convertible Preferred Stock [Member]

Common Stock [Member]

Balance at Nov. 30, 2011 $ (1,753,599) $ 30,064,619 $ (40,998,344) $ (976,978) $ 1,349,844 $ 573,400 $ 8,233,860

Balance (in shares) at Nov. 30, 2011 11,339 5,734 823,385,986

Issuance of common stock for conversion of 4.75% debentures 7,290 (3,232,076) 0 0 0 0 3,239,366

Issuance of common stock for conversion of 4.75% debentures (in shares) 0 0 323,936,571

Issuance of common stock for exercise of warrants 794,610 787,320 0 0 0 0 7,290

Issuance of common stock for exercise of warrants (in shares) 0 0 729,000

Stock-based compensation 226,162 226,162 0 0 0 0 0

Net loss (1,015,757) 0 (943,916) (71,841) 0 0 0

Balance at Aug. 31, 2012 (1,741,294) 27,846,025 (41,942,260) (1,048,819) 1,349,844 573,400 11,480,516

Balance (in shares) at Aug. 31, 2012 11,339 5,734 1,148,051,557

Balance at Nov. 30, 2012 (1,618,462) 27,755,595 (42,254,594) (1,079,328) 461,835 0 13,498,030

Balance (in shares) at Nov. 30, 2012 3,448 0 1,349,803,029

Issuance of common stock for conversion of 4.75% debentures 9,430 (10,395,506) 0 0 0 0 10,404,936

Issuance of common stock for conversion of 4.75% debentures (in shares) 0 0 1,040,493,584

Issuance of common stock for exercise of warrants 1,027,870 1,018,440 0 0 0 0 9,430

Issuance of common stock for exercise of warrants (in shares) 0 0 943,000

Stock-based compensation 175,866 175,866 0 0 0 0 0

Net loss (994,789) 0 (903,578) (91,211) 0 0 0

Balance at Aug. 31, 2013 $ (1,400,085) $ 18,554,395 $ (43,158,172) $ (1,170,539) $ 461,835 $ 0 $ 23,912,396

Balance (in shares) at Aug. 31, 2013 3,448 0 2,391,239,613

X

- Definition

Number of stock issued during the period as a result of the exercise of warrants.

+ References

No definition available.

+ Details

Name: mcet_StockIssuedDuringPeriodSharesExerciseOfWarrants

Namespace Prefix: mcet_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Value of stock issued during the period as a result of the exercise of stock warrants.

+ References

No definition available.

+ Details

Name: mcet_StockIssuedDuringPeriodValueExerciseOfWarrants

Namespace Prefix: mcet_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415241&loc=d3e4534-113899

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11149-113907

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11178-113907

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares issued which are neither cancelled nor held in the treasury.

+ References

No definition available.

+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4568447-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4568740-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4I

-URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4590271-111686

+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Number of shares issued during the period as a result of the conversion of convertible securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-30)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The gross value of stock issued during the period upon the conversion of convertible securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 38 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)

Aug. 31, 2013

Nov. 30, 2012

ASSETS

Cash and cash equivalents $ 178,121 $ 199,472

Receivable from warrant holder 130,800 0

Other current assets 14,617 11,293

Total current assets 323,538 210,765

Property and equipment, net of accumulated depreciation of $40,561 0 0

Other assets 280 280

Total assets 323,818 211,045

LIABILITIES AND EQUITY (DEFICIENCY)

Accounts payable and accrued expenses 1,085,649 1,106,177

Payable to related party 50,000 50,000

Advance from warrant holder 0 50,000

Convertible debentures 46,596 0

Current portion of deferred revenue 49,318 49,318

Total current liabilities 1,231,563 1,255,495

Non-current liabilities

Convertible debentures 0 56,026

Deferred revenue, net of current portion 461,753 498,741

Derivative liability related to Series B convertible preferred stock 30,587 19,245

Total non-current liabilities 492,340 574,012

Total liabilities 1,723,903 1,829,507

Commitments and contingencies

Equity (Deficiency) MultiCell Technologies, Inc. equity (deficiency)

Preferred stock 0 0

Common stock, $0.01 par value; 3,000,000,000 shares authorized; 2,391,239,613 and 1,349,803,029 shares issued and outstanding at August 31, 2013 and November 30, 2012, respectively 23,912,396 13,498,030

Additional paid-in capital 18,554,395 27,755,595

Accumulated deficit (43,158,172) (42,254,594)

Total MultiCell Technologies, Inc. stockholders' equity (deficiency) (229,546) (539,134)

Noncontrolling interests (1,170,539) (1,079,328)

Total equity (deficiency) (1,400,085) (1,618,462)

Total liabilities and equity (deficiency) 323,818 211,045

Series B Convertible Preferred Stock [Member]

Equity (Deficiency) MultiCell Technologies, Inc. equity (deficiency)

Preferred stock 461,835 461,835

Total equity (deficiency) 461,835 461,835

Series I Convertible Preferred Stock [Member]

Equity (Deficiency) MultiCell Technologies, Inc. equity (deficiency)

Preferred stock 0 0

Total equity (deficiency) $ 0 $ 0

X

- Definition

Carrying amount as of the balance sheet date of obligations due all debenture holder.

+ References

No definition available.

+ Details

Name: mcet_AdvanceFromDebentureHolderCurrent

Namespace Prefix: mcet_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20

-Article 5

+ Details

Name: us-gaap_ConvertibleDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_ConvertibleDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13433-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13495-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=20225523&loc=SL20225862-175312

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

+ Details

Name: us-gaap_DerivativeLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_GrantsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesAndStockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of obligation due after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22, 23, 24, 25, 26, 27

-Article 5

+ Details

Name: us-gaap_LiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 27

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 7

+ Details

Name: us-gaap_MinorityInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4568447-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4568740-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4I

-URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4590271-111686

+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 39 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8

SERIES B CONVERTIBLE PREFERRED STOCK (Details) (USD $)
3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended

Feb. 28, 2013

May 31, 2013

Aug. 31, 2013

Nov. 30, 2012

Fair value of common stock $ 0.0038 $ 0.0014 $ 0.0012 $ 0.0013

Conversion price of preferred stock $ 0.0190 $ 0.0151 $ 0.0124 $ 0.0215

Risk free interest rate 1.89% 2.16% 2.78% 1.62%

Expected life 10 years 10 years 10 years 10 years

Dividend yield 0.00% 0.00% 0.00% 0.00%

Volatility 147.00% 148.00% 148.00% 141.00%

X

- Definition

Represents the conversion price of a share.

+ References

No definition available.

+ Details

Name: mcet_ShareBasedCompensationArrangementByShareBasedPaymentAwardConversionPriceOfPreferredStock

Namespace Prefix: mcet_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

XML 40 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCK WARRANTS (Tables)
9 Months Ended

Aug. 31, 2013

Warrants and Rights Note Disclosure [Abstract]

Schedule of Share-based Compensation Award, Shares Under Warrants [Table Text Block]

A summary of the status of warrants at August 31, 2013, and changes during the nine months then ended is presented in the following table:

Weighted

Weighted

Average

Shares

Average

Remaining

Aggregate

Under

Exercise

Contractual

Intrinsic

Warrants

Price

Life

Value

Outstanding at November 30, 2012

9,277,030

$

0.7535

2.2 years

$

-

Issued

-

-

Exercised

(943,000)

1.0900

Expired

(360,000)

0.5000

Outstanding at August 31, 2013

7,974,030

$

0.7251

1.7 years

$

-

X

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Article 5

+ Details

Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_WarrantsAndRightsNoteDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 41 R39.htm IDEA: XBRL DOCUMENT v2.4.0.8

FAIR VALUE MEASUREMENTS (Details) (USD $)

Aug. 31, 2013

Nov. 30, 2012

Derivative liability $ 30,587 $ 19,245

Fair Value, Inputs, Level 1 [Member]

Derivative liability 0 0

Fair Value, Inputs, Level 2 [Member]

Derivative liability 30,587 19,245

Fair Value, Inputs, Level 3 [Member]

Derivative liability $ 0 $ 0

X

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13433-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13495-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=20225523&loc=SL20225862-175312

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 55

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=28370219&loc=SL20226008-175313

+ Details

Name: us-gaap_DerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 42 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCK WARRANTS (Details) (USD $)
9 Months Ended 12 Months Ended

Aug. 31, 2013

Nov. 30, 2012

Shares Under Warrants, Outstanding , Beginning balance (in shares) 9,277,030

Shares Under Warrants, Issued (in shares) 0

Shares Under Warrants, Exercised (in shares) (943,000)

Shares Under Warrants, Expired (in shares) (360,000)

Shares Under Warrants, Outstanding, Ending balance (in shares) 7,974,030 9,277,030

Weighted Average Exercise Price, Outstanding, Beginning balance (in dollars per share) $ 0.7535

Weighted Average Exercise Price, Issued (in dollars per share) $ 0

Weighted Average Exercise price, Exercised (in dollars per share) $ 1.0900

Weighted Average Exercise Price, Expired (in dollars per share) $ 0.5000

Weighted Average Exercise Price, Outstanding, Ending balance (in dollars per share) $ 0.7251 $ 0.7535

Weighted Average Remaining Contractual Life, Outstanding 1 year 8 months 12 days 2 years 2 months 12 days

Aggregate Intrinsic Value, Outstanding, Beginning balance $ 0

Aggregate Intrinsic Value, Outstanding, Ending balance $ 0 $ 0

X

- Definition

Warrants exercised price for weighted average during the period.

+ References

No definition available.

+ Details

Name: mcet_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisedWeightedAverageExercisePrice

Namespace Prefix: mcet_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares under warrants that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.

+ References

No definition available.

+ Details

Name: mcet_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExpiredInPeriod

Namespace Prefix: mcet_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares under warrants that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the Warrants Plan.

+ References

No definition available.

+ Details

Name: mcet_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExpiredInPeriodWeightedAverageExercisePrice

Namespace Prefix: mcet_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross number of share warrants (or share units) granted for weighted average exercise price during the period.

+ References

No definition available.

+ Details

Name: mcet_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsGrantedWeightedAverageExercisePrice

Namespace Prefix: mcet_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross number of share warrants (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: mcet_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsGrantsInPeriodGross

Namespace Prefix: mcet_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of warrants outstanding.

+ References

No definition available.

+ Details

Name: mcet_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingIntrinsicValue

Namespace Prefix: mcet_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The number of shares reserved for issuance under stock warrants agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.

+ References

No definition available.

+ Details

Name: mcet_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber

Namespace Prefix: mcet_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance under the stock warrants plan.

+ References

No definition available.

+ Details

Name: mcet_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageExercisePrice

Namespace Prefix: mcet_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average remaining contractual term for warrants awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name: mcet_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: mcet_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share warrants (or share units) exercised during the current period.

+ References

No definition available.

+ Details

Name: mcet_StockIssuedDuringPeriodSharesStockWarrantsExercised

Namespace Prefix: mcet_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 43 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCK WARRANTS (Details Textual) (USD $)
9 Months Ended

Aug. 31, 2013

Aug. 31, 2012

Investment Warrants, Exercise Price $ 1.09

Class of Warrant, Exercisable Period 5 years

Exercise of Warrant upon Conversion of Debt each $1,000 of the principal converted, LJCI would be required to simultaneously purchase 100,000 shares under the LJCI Warrant at $1.09 per share.

Proceeds from Warrant Exercises $ 130,800

La Jolla Cove Investors [Member]

Proceeds from Convertible Debenture, Principal Amount 100,000

Warrant Issued 10,000,000

Securities Purchase, Agreement Date Feb. 28, 2007

Exercise of Warrant upon Conversion of Debt for each $1,000 of the principal of the Debenture converted, LJCI would be required to simultaneously purchase 100,000 shares under the warrant at $1.09 per share

Warrant Exercised to Purchase Common Stock, Shares 943,000 729,000

Proceeds from Warrant Exercises $ 1,027,870 $ 794,610

X

- Definition

Exercise price of the warrants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 12

-Section 13

-Sentence Column A

+ Details

Name: invest_InvestmentWarrantsExercisePrice

Namespace Prefix: invest_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Class of warrants exercisable during the period.

+ References

No definition available.

+ Details

Name: mcet_ClassOfWarrantExercisablePeriod

Namespace Prefix: mcet_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Description related to the exercise of the warrant is required upon the conversion of the debt.

+ References

No definition available.

+ Details

Name: mcet_ExerciseOfWarrantUponConversionOfDebt

Namespace Prefix: mcet_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The company entered into a securities purchase agreement date.

+ References

No definition available.

+ Details

Name: mcet_SecuritiesPurchaseAgreementDate

Namespace Prefix: mcet_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of warrants exercised to purchase common stock.

+ References

No definition available.

+ Details

Name: mcet_WarrantExercisedToPurchaseCommonStockShares

Namespace Prefix: mcet_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrants issued to purchase common stock.

+ References

No definition available.

+ Details

Name: mcet_WarrantIssued

Namespace Prefix: mcet_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock warrants.

+ References

No definition available.

+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 44 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

SERIES I CONVERTIBLE PREFERRED STOCK
9 Months Ended

Aug. 31, 2013

Series I Convertible Preferred Stock [Abstract]

Series I Convertible Preferred Stock [Text Block]

NOTE 5. SERIES I CONVERTIBLE PREFERRED STOCK

The Company’s Board of Directors has the authority, without further action by the stockholders, to issue up to 1,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions of these shares of preferred stock. The Board of Directors originally designated 20,000 shares as Series I convertible preferred stock. On July 13, 2004, the Company completed a private placement of Series I convertible preferred stock and a total of 20,000 shares were originally sold to accredited investors. As of August 31, 2013 and November 30, 2012, all of the shares of Series I convertible preferred stock have been converted into shares of the common stock of the Company and no shares of the Company’s Series I convertible preferred stock are outstanding.

X

- Details

Name: mcet_SeriesIConvertiblePreferredStockAbstract

Namespace Prefix: mcet_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure related to series I convertible preferred stock.

+ References

No definition available.

+ Details

Name: mcet_SeriesIConvertiblePreferredStockTextBlock

Namespace Prefix: mcet_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8

SERIES B CONVERTIBLE PREFERRED STOCK (Details Textual) (USD $)
3 Months Ended 9 Months Ended 9 Months Ended 12 Months Ended 9 Months Ended 12 Months Ended

Aug. 31, 2013

Aug. 31, 2012

Aug. 31, 2013

Aug. 31, 2012

Nov. 30, 2012

Aug. 31, 2013

Board of Directors Chairman [Member]

Aug. 31, 2013

Series B Convertible Preferred Stock [Member]

Nov. 30, 2012

Series B Convertible Preferred Stock [Member]

Aug. 31, 2013

Series B Convertible Preferred Stock [Member]

Maximum [Member]

Aug. 31, 2013

Common Stock [Member]

Nov. 30, 2012

Common Stock [Member]

Preferred Stock, Shares Designated 963,000 963,000 963,000 1,000,000 17,000 17,000

Preferred Stock, Purchase Price, Per Share, Value $ 100

Preferred Stock, Conversion Price $ 0.32

Reduced Conversion Price Percentage 85.00%

Preferred Stock Reduced Conversion Price $ 0.0124 $ 0.0215

Conversion of Preferred Stock Limited to Common Stock, Outstanding, Percentage 9.99%

Preferred Stock, Dividend Payment Rate Company was required to pay on each outstanding share of Series B convertible preferred stock a preferential cumulative dividend at an annual rate equal to the product of multiplying $100 per share by the higher of (i) the Wall Street Journal Prime Rate plus 1%, or (ii) 9%. In no event was the dividend rate to be greater than 12% per annum.

Preferred Stock, Dividend Rate, Maximum Percentage 12.00%

Dividends Payable $ 290,724 $ 290,724 $ 290,724

Accounts Payable and Accrued Liabilities 165,208 165,208 165,208

Dividends Payable to Series B Convertible Preferred Stock 125,516 125,516 125,516

Preferred Stock, Shares Outstanding 0 0 0 3,448 3,448

Conversion of Convertible Preferred Stock Outstanding 27,806,452 16,037,209

Fair Value Conversion Feature 30,587 30,587 19,245

Fair Value of Embedded Conversion Feature, per share $ 0.0011 $ 0.0011 $ 0.0012

Gain (Loss) on Derivative Instruments, Net, Pretax $ (902) $ 60,562 $ (11,342) $ 104,526

X

- Definition

The number preferred shares outstanding which are convertible into on the respective dates.

+ References

No definition available.

+ Details

Name: mcet_ConversionOfConvertiblePreferredStockOutstanding

Namespace Prefix: mcet_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The percentage of conversion of the Series I preferred stock is limited to common stock outstanding on the date of conversion.

+ References

No definition available.

+ Details

Name: mcet_ConversionOfPreferredStockLimitedToCommonStockOutstandingPercentage

Namespace Prefix: mcet_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of dividends declared but unpaid on permanent equity with the Series B convertible preferred stock.

+ References

No definition available.

+ Details

Name: mcet_DividendsPayableToSeriesBConvertiblePreferredStock

Namespace Prefix: mcet_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Fair value of conversion feature as on the date.

+ References

No definition available.

+ Details

Name: mcet_FairValueConversionFeature

Namespace Prefix: mcet_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Fair value of embedded conversion feature per share as on the reporting date.

+ References

No definition available.

+ Details

Name: mcet_FairValueOfEmbeddedConversionFeature

Namespace Prefix: mcet_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Conversion price of preferred stock.

+ References

No definition available.

+ Details

Name: mcet_PreferredStockConversionPrice

Namespace Prefix: mcet_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Description of the preferred stock dividend payment rate.

+ References

No definition available.

+ Details

Name: mcet_PreferredStockDividendPaymentRate

Namespace Prefix: mcet_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Preferred stock purchase price per share value.

+ References

No definition available.

+ Details

Name: mcet_PreferredStockPurchasePricePerShareValue

Namespace Prefix: mcet_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Reduced conversion price of preferred stock.

+ References

No definition available.

+ Details

Name: mcet_PreferredStockReducedConversionPrice

Namespace Prefix: mcet_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents the reduction in conversion price percentage.

+ References

No definition available.

+ Details

Name: mcet_ReducedConversionPricePercentage

Namespace Prefix: mcet_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(1),(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.15)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph 1, 5

-Article 9

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph a

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph 5

-Article 9

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(5))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_DividendsPayableCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5618551-113959

+ Details

Name: us-gaap_GainLossOnDerivativeInstrumentsNetPretax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The percentage rate used to calculate dividend payments on preferred stock.

+ References

No definition available.

+ Details

Name: us-gaap_PreferredStockDividendRatePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 46 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCK WARRANTS
9 Months Ended

Aug. 31, 2013

Warrants and Rights Note Disclosure [Abstract]

Warrants Disclosure [Text Block]

NOTE 8. STOCK WARRANTS

Since the Company’s inception, it has financed its operations primarily through the issuance of debt or equity instruments, which have often included the issuance of warrants to purchase shares of the Company’s common stock.

As further described in Note 3 to these condensed consolidated financial statements, MultiCell entered into the LJCI Agreement pursuant to which MultiCell agreed to sell the Debenture in the principal amount of $100,000. In connection with the Debenture, MultiCell issued LJCI a warrant to purchase up to 10 million shares of the Company’s common stock at an exercise price of $1.09 per share, exercisable over the next five years according to a schedule described in a letter agreement dated February 28, 2007. Pursuant to the terms of the LJCI Warrant, upon the conversion of any portion of the principal amount of the Debenture, LJCI is required to simultaneously exercise and purchase that same percentage of the warrant shares equal to the percentage of the dollar amount of the Debenture being converted. Therefore, as an example, for each $1,000 of the principal of the Debenture converted, LJCI would be required to simultaneously purchase 100,000 shares under the warrant at $1.09 per share. During the nine months ended August 31, 2013, LJCI exercised warrants to purchase 943,000 shares of the Company’s common stock, resulting in proceeds to the Company of $1,027,870. During the nine months ended August 31, 2012, LJCI exercised warrants to purchase 729,000 shares of the Company’s common stock, resulting in proceeds to the Company of $794,610.

A summary of the status of warrants at August 31, 2013, and changes during the nine months then ended is presented in the following table:

Weighted

Weighted

Average

Shares

Average

Remaining

Aggregate

Under

Exercise

Contractual

Intrinsic

Warrants

Price

Life

Value

Outstanding at November 30, 2012

9,277,030

$

0.7535

2.2 years

$

-

Issued

-

-

Exercised

(943,000)

1.0900

Expired

(360,000)

0.5000

Outstanding at August 31, 2013

7,974,030

$

0.7251

1.7 years

$

-

X

- Definition

The entire disclosure for warrants.

+ References

No definition available.

+ Details

Name: mcet_WarrantsDisclosureTextBlock

Namespace Prefix: mcet_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_WarrantsAndRightsNoteDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 47 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

SERIES B CONVERTIBLE PREFERRED STOCK
9 Months Ended

Aug. 31, 2013

Series B Convertible Preferred Stock [Abstract]

Series B Convertible Preferred Stock [Text Block]

NOTE 4. SERIES B CONVERTIBLE PREFERRED STOCK

The Company’s Board of Directors has the authority, without further action by the stockholders, to issue up to 1,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions of these shares of preferred stock. The Board of Directors originally designated 17,000 shares as Series B convertible preferred stock. The Series B convertible preferred stock does not have voting rights.

The Series B shares are convertible at any time into shares of the Company’s common stock at a conversion price determined by dividing the purchase price per share of $100 by the conversion price. The conversion price was originally $0.32 per share. Upon the occurrence of an event of default (as defined in the applicable Series B convertible preferred stock purchase agreement), the conversion price of the Series B shares shall be reduced to 85% of the then-applicable conversion price of such shares. The conversion price is subject to equitable adjustment in the event of any stock splits, stock dividends, recapitalizations and the like. In addition, the conversion price is subject to weighted average anti-dilution adjustments in the event the Company sells common stock or other securities convertible into or exercisable for common stock at a per share price, exercise price or conversion price lower than the conversion price then in effect in any transaction (other than in connection with an acquisition of the securities, assets or business of another company, a joint venture and/or the issuance of employee stock options). As a result of the Company issuing shares of its common stock upon conversion of convertible debentures and upon the exercise of warrants both at prices lower than the conversion price of the Series B convertible preferred stock, and due to the Company not paying the Series B dividends on a monthly basis (as discussed below), the conversion price of the Series B convertible preferred stock has been reduced to $0.0124 per share as of August 31, 2013 and to $0.0215 per share as of November 30, 2012. Pursuant to the applicable Series B convertible preferred stock purchase agreement, each investor may only convert that number of shares of Series B convertible preferred stock into that number of shares of the Company’s common stock that does not exceed 9.99% of the outstanding shares of common stock of the Company on the date of conversion.

Commencing on the date of issuance of the Series B convertible preferred stock until the date a registration statement registering the shares of the Company’s common stock underlying the preferred stock and warrants issued is declared effective by the SEC, the Company was required to pay on each outstanding share of Series B convertible preferred stock a preferential cumulative dividend at an annual rate equal to the product of multiplying $100 per share by the higher of (i) the Wall Street Journal Prime Rate plus 1%, or (ii) 9%. In no event was the dividend rate to be greater than 12% per annum. The dividend was payable monthly in arrears in cash on the last day of each month based on the number of shares of Series B convertible preferred stock outstanding as of the first day of that month. In the event the Company did not pay the Series B convertible preferred dividends when due, the conversion price of the Series B preferred shares was reduced to 85% of the otherwise applicable conversion price. The Company did not pay the required monthly Series B preferred dividends beginning on November 30, 2006, which, in part, caused the conversion price to be reduced. Subsequent to November 30, 2010, the Company received an opinion of outside counsel providing for the removal of the restrictive legend on the Series B convertible preferred stock, which in turn terminated the requirement to accrue the related dividends. Accordingly, no dividends have been accrued since November 30, 2010. Total accrued but unpaid preferred dividends recorded in the accompanying condensed consolidated balance sheets as of August 31, 2013, and as of November 30, 2012, are $290,724 of which $125,516 are recorded in permanent equity with the Series B convertible preferred stock, and $165,208 are recorded as a current liability in accounts payable and accrued expenses.

The conversion feature which gives the holders of the Series B convertible preferred stock the right to acquire shares of the Company’s common stock is an embedded derivative. As of August 31, 2013 and November 30, 2012, there were 3,448 shares of Series B convertible preferred stock that were convertible into 27,806,452 and 16,037,209 shares of common stock of the Company, respectively. The fair value of the conversion feature was estimated at $30,587 ($0.0011 per share of common stock) and $19,245 ($0.0012 per share of common stock) at August 31, 2013 and November 30, 2012, respectively, and has been estimated using the Black-Scholes option-pricing model using the following assumptions:

August 31,
2013

May 31,
2013

February 28,
2013

November 30,
2012

Fair value of common stock

$

0.0012

$

0.0014

$

0.0038

$

0.0013

Conversion price of preferred stock

$

0.0124

$

0.0151

$

0.0190

$

0.0215

Risk free interest rate

2.78

%

2.16

%

1.89

%

1.62

%

Expected life

10 Years

10 Years

10 Years

10 Years

Dividend yield

-

-

-

-

Volatility

148

%

148

%

147

%

141

%

The fair value of the conversion feature increased by $902 and by $11,342 during the three months and the nine months ended August 31, 2013, respectively, which has been recorded as a loss from the change in the fair value of the derivative liability. The fair value of the conversion feature decreased by $60,562 and by $104,526 during the three months and nine months ended August 31, 2012, respectively, which has been recorded as a gain from the change in the fair value of the derivative liability.

In the event of any dissolution or winding up of the Company, whether voluntary or involuntary, holders of each outstanding share of Series B convertible preferred stock shall be entitled to be paid first in priority out of the assets of the Company available for distribution to stockholders, an amount equal to $100 per share of Series B convertible preferred stock held plus any declared but unpaid dividends. After such payment has been made in full, such holders of Series B convertible preferred stock shall be entitled to no further participation in the distribution of the assets of the Company.

X

- Details

Name: mcet_SeriesBConvertiblePreferredStockAbstract

Namespace Prefix: mcet_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure related to series b redeemable convertible preferred stock.

+ References

No definition available.

+ Details

Name: mcet_SeriesBConvertiblePreferredStockTextBlock

Namespace Prefix: mcet_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
9 Months Ended

Aug. 31, 2013

Aug. 31, 2012

Cash flows from operating activities

Net loss $ (994,789) $ (1,015,757)

Adjustments to reconcile net loss to net cash used in operating activities

Stock-based compensation 175,866 226,162

Gain from disposition of equipment 0 (1,500)

Interest expense from amortization of discount on convertible debentures 0 5,000

Change in fair value of derivative liability 11,342 (104,526)

Changes in assets and liabilities

Grant receivable 0 303,102

Other current assets (3,324) 305

Accounts payable and accrued liabilities (20,528) 28,864

Deferred revenue (36,988) (36,988)

Net cash used in operating activities (868,421) (595,338)

Cash flows from investing activities

Proceeds from disposition of equipment 0 1,500

Net cash provided by investing activities 0 1,500

Cash flows from financing activities

Proceeds from the exercise of stock warrants 1,027,870 794,610

Change in receivable or advance from warrant holder (180,800) (301,930)

Net cash provided by financing activities 847,070 492,680

Net decrease in cash and cash equivalents (21,351) (101,158)

Cash and cash equivalents at beginning of period 199,472 405,327

Cash and cash equivalents at end of period 178,121 304,169

Supplemental Disclosures of Cash Flow Information:

Cash paid for interest 2,142 2,502

Noncash Investing and Financing Activities:

Issuance of common stock for conversion of 4.75% debentures $ 9,430 $ 7,290

X

- Definition

Advances received from warrant holders for issue of debentures.

+ References

No definition available.

+ Details

Name: mcet_AdvanceFromWarrantHolder

Namespace Prefix: mcet_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period of amounts due under the terms of governmental, corporate, foundation or any other grants receivable by the entity.

+ References

No definition available.

+ Details

Name: mcet_IncreaseDecreaseInGrantReceivable

Namespace Prefix: mcet_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from exercise of stock warrants to purchase common shares at predetermined price.

+ References

No definition available.

+ Details

Name: mcet_ProceedsFromExerciseOfStockWarrants

Namespace Prefix: mcet_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5618551-113959

+ Details

Name: us-gaap_GainLossOnDerivativeInstrumentsNetPretax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_GainLossOnDispositionOfAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of assets used to generate operating income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOperatingAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of the cost of borrowed funds accounted for as interest expense for debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_InterestExpenseDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The gross value of stock issued during the period upon the conversion of convertible securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCK COMPENSATION PLANS (Details) (USD $)
9 Months Ended 12 Months Ended

Aug. 31, 2013

Nov. 30, 2012

Shares Under Option, Outstanding, Beginning balance 26,068,947

Shares Under option, Granted 30,000,000

Shares Under Option, Exercised 0

Shares Under option, Expired or forfeited (5,669,444)

Shares Under Option,Outstanding, Ending balance 50,399,503 26,068,947

Shares Under Option,Exercisable 19,017,559

Weighted Average Exercise Price, Outstanding, Beginning balance $ 0.0084

Weighted Average Exercise Price,Granted (in dollars per share) $ 0.0011

Weighted Average Exercise Price, Exercised (in dollars per share) $ 0

Weighted Average Exercise Price, Expired or forfeited (in dollars per share) $ 0.0090

Weighted Average Exercise Price, Outstanding, Ending balance $ 0.0040 $ 0.0084

Weighted Average Exercise price,Exercisable (in dollars per share) $ 0.0086

Weighted Average Remaining Contractual Life, Outstanding 3 years 10 months 24 days 3 years 1 month 6 days

Weighted Average Remaining Contractual Life, Exercisable 2 years 2 months 12 days

Aggregate Intrinsic Value, Outstanding, Beginning balance $ 0

Aggregate Intrinsic Value, Outstanding, Ending balance 3,000 0

Aggregate Intrinsic Value, Exercisable $ 0

X

- Definition

Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price of options that were either forfeited or expired.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Number of options outstanding, including both vested and non-vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which option holders acquired shares when converting their stock options into shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 51 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

SUBSEQUENT EVENTS
9 Months Ended

Aug. 31, 2013

Subsequent Events [Abstract]

Subsequent Events [Text Block]

NOTE 11. SUBSEQUENT EVENTS

Stock Issued for Conversion of Debenture and Exercise of Warrants

As more fully discussed in Note 3 to these consolidated financial statements, MultiCell sold the Debenture to LJCI and issued LJCI a stock warrant in connection with the Debenture. During the period subsequent to August 31, 2013 through the date of issuance of the condensed consolidated financial statements, LJCI converted $1,000 of the Debenture into 122,122,222 shares of the Company’s common stock. Simultaneously with the conversions of the Debenture, LJCI was required to exercise warrants to purchase 100,000 shares of the Company’s common stock at $1.09 per share. The total proceeds from the exercise of the warrants were $109,000.

Sponsored Research Agreement

On September 27, 2013, MultiCell entered into a new sponsored research agreement with Anand Ghanekar, M.D., Ph.D, of the University Health Network’s Toronto General Hospital expanding the scope of the current research project with the University Health Network (“UHN”) to evaluate MCT-485 in animal models for the treatment of primary liver cancer (the “Ghanekar Agreement”). On July 5, 2011, the Company had previously entered into a sponsored research agreement with UHN pursuant to which UHN evaluated the Company’s product candidates, MCT-465 and MCT-485, in in vitro models for the treatment of primary liver cancer (the “UHN Agreement”). The mechanism of action of MCT-465 and MCT-485 and their potential selective effect on liver cancer stem cells were also evaluated. Under the terms of each of the Ghanekar Agreement and the UHN Agreement, the Company retains exclusive access to the research findings and intellectual property resulting from the research activities preformed by each of Dr. Ghanekar and UHN, respectively.

Ideal BioStent™ — Amendment of Foreclosure Sale Agreement

On September 30, 2010, Xenogenics entered into a Foreclosure Sale Agreement (“Foreclosure Sale Agreement”). Pursuant to the Foreclosure Sale Agreement, Xenogenics acquired all of the sellers’ interests in certain bioabsorbable stent assets (known as “Ideal BioStent™”) and related technologies. Under the Foreclosure Sale Agreement, Xenogenics is also required to make cash payments totaling $4.3 million to the sellers based on the achievement of certain milestones at certain dates. None of these milestones were achieved as of September 30, 2013. Xenogenics’ obligations under the Foreclosure Sale Agreement had been previously extended pursuant to Amendments No. 1 and No. 2, dated September 30, 2011 and October 23, 2012, respectively. On October 11, 2013, Xenogenics entered into Amendment No. 3 to the Foreclosure Sale Agreement which further extended the deadlines for the achievement of these milestones under the Foreclosure Sale Agreement by an additional twelve months. Xenogenics is required to use good faith reasonable efforts to achieve these milestones. Failure to achieve any of these milestones could result in all milestone payments, totaling $4.3 million, becoming immediately due and payable.

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCK COMPENSATION PLANS
9 Months Ended

Aug. 31, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

NOTE 7. STOCK COMPENSATION PLANS

On July 11, 2011, at the Company’s Annual Meeting of Stockholders, the stockholders approved an amendment to increase the number of shares reserved under the 2004 Equity Incentive Plan (the “2004 Plan”) to a total of 70,974,213 shares. Additionally, an annual increase in the number of shares reserved under the plan was approved and certain prior increases in the number of shares reserved for issuance under the plan were ratified. Furthermore, on each of December 1, 2011 and on December 1, 2012, the number of shares reserved under the 2004 Plan was increased by an additional 1,500,000 shares pursuant to the provisions of the 2004 Plan. The purpose of the 2004 Plan is to provide a means by which eligible recipients of stock awards may be given the opportunity to benefit from increases in the value of the Company’s common stock through granting of incentive stock options (ISO), non-statutory stock options, stock purchase awards, stock bonus awards, stock appreciation rights, stock unit awards and other stock awards. As amended, there are 22,074,710 shares of common stock available for future awards under the 2004 Plan at August 31, 2013.

GAAP treatment for stock options requires the recognition of the cost of employee services received in exchange for an award of equity instruments in the financial statements, which is measured based on the grant date fair value of the award, and requires the stock option compensation expense to be recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period), net of estimated forfeitures. The estimation of forfeitures requires significant judgment, and to the extent actual results or updated estimates differ from the current estimates, such resulting adjustment will be recorded in the period estimates are revised. No income tax benefit has been recognized for stock-based compensation arrangements and no compensation cost has been capitalized in the consolidated balance sheets.

A summary of the status of stock options granted by MultiCell at August 31, 2013, and changes during the nine months then ended is presented in the following table:

Weighted

Weighted

Average

Shares

Average

Remaining

Aggregate

Under

Exercise

Contractual

Intrinsic

Option

Price

Life

Value

Outstanding at November 30, 2012

26,068,947

$

0.0084

3.1 years

$

-

Granted

30,000,000

0.0011

Exercised

-

-

Expired or forfeited

(5,669,444)

0.0090

Outstanding at August 31, 2013

50,399,503

$

0.0040

3.9 years

$

3,000

Exercisable at August 31, 2013

19,017,559

$

0.0086

2.2 years

$

-

On August 16, 2013, the MultiCell Board of Directors granted an option to each of the five members of its Board of Directors to purchase 5,000,000 shares of the Company’s common stock at $0.0011 per share. The options vest quarterly over one year, subject to continuing service as a director on each such vesting date, and expire five years after grant. Additionally, the Board of Directors granted an option to an employee to purchase 5,000,000 shares of common stock at $0.0011 per share. This option vests monthly over three years, subject to continuing service as an employee on each such vesting date, and expires five years after grant. On June 1, 2012, the MultiCell Board of Directors granted an option to each of the five members of its Board of Directors to purchase 1,000,000 shares of the Company’s common stock at $0.0032 per share, the closing price of the Company’s common stock on the date of grant. The options vest quarterly over one year, subject to continuing service as a director on each such vesting date, and expire five years after grant. Additionally, the Board of Directors granted an option to an employee to purchase 1,000,000 shares of common stock at $0.0032 per share. This option vests monthly over three years, subject to continuing service as an employee on each such vesting date, and expires five years after grant. The fair value of stock option grants is estimated on the date of grant using the Black-Scholes option pricing model. The weighted-average fair value of stock options granted during the nine months ended August 31, 2013 was $0.0011 per share. The weighted-average assumptions used for options granted during the nine months ended August 31, 2013 were risk-free interest rate of 1.60%, volatility of 175%, expected life of 5.0 years, and dividend yield of zero. The weighted-average fair value of stock options granted during the nine months ended August 31, 2012 was $0.0030 per share. The weighted-average assumptions used for options granted during the nine months ended August 31, 2012 were risk-free interest rate of 0.62%, volatility of 170%, expected life of 5.0 years, and dividend yield of zero. The assumptions employed in the Black-Scholes option pricing model include the following: (i) the expected life of stock options represents the period of time that the stock options granted are expected to be outstanding prior to exercise; (ii) the expected volatility is based on the historical price volatility of the Company’s common stock; (iii) the risk-free interest rate represents the U.S. Treasury Department’s constant maturities rate for the expected life of the related stock options; and (iv) the dividend yield represents anticipated cash dividends to be paid over the expected life of the stock options.

For the three months ended August 31, 2013 and 2012, MultiCell reported stock-based compensation expense for services related to stock options of $1,893 and $9,521, respectively. For the nine months ended August 31, 2013 and 2012, MultiCell reported stock-based compensation expense for services related to stock options of $10,705 and $32,759, respectively. As of August 31, 2013, there is approximately $35,000 of unrecognized compensation cost related to stock-based payments that will be recognized over a weighted average period of approximately 1.4 years. The intrinsic values at August 31, 2013 are based on a closing price of $0.0012.

In October 2010, Xenogenics adopted the 2010 Stock Incentive Plan (the “2010 Plan”) which authorized the granting of stock awards to Xenogenics’ employees, directors, and consultants. As originally adopted, the 2010 Plan provided that the number of shares of Xenogenics’ common stock that could be issued pursuant to stock awards could not exceed 5,000,000 shares of common stock. On February 3, 2011, the 2010 Plan was amended such that the number of shares of Xenogenics’ common stock that could be issued pursuant to stock awards could not exceed 8,000,000 shares of common stock. The purpose of the 2010 Plan is to provide a means by which eligible recipients of stock awards may be given the opportunity to benefit from increases in the value of Xenogenics’ common stock through granting of incentive stock options (“ISO”), non-statutory stock options, stock bonus awards, stock appreciation rights, and rights to acquire restricted stock. ISO’s may be granted only to employees. The exercise price of each ISO granted under the plan must equal 100% of the market price of Xenogenics’ stock on the date of the grant. A 10% stockholder shall not be granted an ISO unless the exercise price of such option is at least 110% of the fair market value of Xenogenics’ common stock on the date of the grants and the option is not exercisable after the expiration of five years from the date of the grant. The Board of Directors of Xenogenics, in its discretion, shall determine the exercise price of each nonstatutory stock option. An option’s maximum term is 10 years.

In November 2010, Xenogenics granted an option to a prospective executive officer to purchase an aggregate of 2,500,000 shares of its common stock, exercisable at $0.246 per share of common stock and having an expiration date in November 2015. The option to acquire 500,000 of the shares vested on the grant date and the remaining 2,000,000 shares vest in the future upon the achievement of specified milestones. The fair value of these options was estimated to be $576,250, or $0.2305 per share, as estimated using the Black-Scholes option-pricing model, using a risk-free interest rate of 1.23%, volatility of 165%, expected life of five years, and dividend yield of zero.

In March 2011, Xenogenics granted options to other prospective officers and to the members of its scientific advisory board to purchase an aggregate of 3,000,000 shares of its common stock, exercisable at $0.246 per share of common stock and having a term of approximately five years. 50% of the options vested immediately and the remaining 50% were to vest upon the closing of a Qualified Financing by December 31, 2011. A “Qualified Financing” meant a single sale, or a related series of sales, by Xenogenics of its common stock (or common stock equivalents) in which the aggregate gross proceeds (before costs and commissions) received by Xenogenics was equal to or exceed $5,000,000. The fair value of these options was estimated to be $692,700, or $0.2309 per share, as estimated using the Black-Scholes option-pricing model, using a risk-free interest rate of 2.20%, volatility of 165%, expected lives of five years, and dividend yield of zero. A Qualified Financing was not closed by December 31, 2011, and accordingly, options to acquire 1,500,000 shares of Xenogenics common stock were forfeited. As described in the following paragraph, Xenogenics granted replacement options to four of five of these individuals whose options expired on December 31, 2011. The replacement of the options to the four individuals was treated as a modification under GAAP. The forfeiture of the option to the fifth individual resulted in the reversal of $57,725 of previously-recognized stock-based compensation expense in the three months ended February 29, 2012.

On February 28, 2012, Xenogenics granted replacement options to four of five of those individuals whose options expired on December 31, 2011, as described in the previous paragraph. The replacement options to purchase 1,250,000 shares of Xenogenics’ common stock are exercisable at $0.253 per share and vest monthly over one year. These replacement options have a term of five years, provided a Qualified Financing has closed by February 28, 2013. No Qualified Financing closed by February 28, 2013. Consequently, these replacement options expired on February 28, 2013. The fair value of these options was estimated to be $298,500, or $0.2338 per share, as estimated using the Black-Scholes option-pricing model, using a risk-free interest rate of 0.84%, volatility of 170%, expected lives of five years, and dividend yield of zero.

On July 28, 2013, Xenogenics granted an option to a consultant to purchase 500,000 shares of Xenogenics’ common stock at $0.246 per share. The option vests in equal increments of 125,000 on each of July 28, 2013, October 1, 2013, January 1, 2014, and April 1, 2014, subject to continuing service to Xenogenics on each such vesting date, and expires five years after grant. The fair value of these options was estimated to be $117,000, or $0.234 per share, as estimated using the Black-Scholes option-pricing model, using a risk-free interest rate of 1.37%, volatility of 175%, expected lives of five years, and dividend yield of zero.

For the three months and nine months ended August 31 2013, Xenogenics reported stock-based compensation of $51,052 and $165,161, respectively. For the three months ended August 31, 2012, Xenogenics reported stock-based compensation expense for options of $95,925. For the nine months ended August 31, 2012, Xenogenics reported stock-based compensation expense for options of $251,128, less the reversal of previously recognized stock-based compensation in the amount of $57,725, for net stock-based compensation of $193,403. As of August 31, 2013, there is approximately $83,000 of unrecognized compensation cost related to stock-based payments that will be recognized over a weighted average period of approximately 0.5 years.

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCK COMPENSATION PLANS (Tables)
9 Months Ended

Aug. 31, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of the status of stock options granted by MultiCell at August 31, 2013, and changes during the nine months then ended is presented in the following table:

Weighted

Weighted

Average

Shares

Average

Remaining

Aggregate

Under

Exercise

Contractual

Intrinsic

Option

Price

Life

Value

Outstanding at November 30, 2012

26,068,947

$

0.0084

3.1 years

$

-

Granted

30,000,000

0.0011

Exercised

-

-

Expired or forfeited

(5,669,444)

0.0090

Outstanding at August 31, 2013

50,399,503

$

0.0040

3.9 years

$

3,000

Exercisable at August 31, 2013

19,017,559

$

0.0086

2.2 years

$

-

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

ORGANIZATION AND NATURE OF OPERATIONS, BASIS OF PRESENTATION, AND RECLASSIFICATIONS (Policies)
9 Months Ended

Aug. 31, 2013

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements and related notes of MultiCell and its subsidiaries have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial statements. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. In the opinion of management, all adjustments consisting of normal recurring adjustments considered necessary for a fair presentation have been included. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended November 30, 2012, previously filed with the SEC. The results of operations for the three-month and nine-month periods ended August 31, 2013, are not necessarily indicative of the operating results for the fiscal year ending November 30, 2013. The condensed consolidated balance sheet as of November 30, 2012, has been derived from the Company’s audited consolidated financial statements.

Reclassification, Policy [Policy Text Block]

RECLASSIFICATIONS

Certain amounts of operating expenses from the condensed consolidated statement of operations for the three months and the nine months ended August 31, 2012, have been reclassified in the current presentation to conform to the presentation of operating expenses for the three months and nine months ended August 31, 2013. These reclassifications had no effect on the total amount of operating expenses, on the amount of net loss, or on the basic and diluted loss per common share for the three months and the nine months ended August 31, 2012.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).

+ References

No definition available.

+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document And Entity Information
9 Months Ended

Aug. 31, 2013

Oct. 08, 2013

Document Information [Line Items]

Entity Registrant Name MultiCell Technologies, Inc.

Entity Central Index Key 0000811779

Current Fiscal Year End Date --11-30

Entity Filer Category Smaller Reporting Company

Trading Symbol MCET

Entity Common Stock, Shares Outstanding 2,513,461,835

Document Type 10-Q

Amendment Flag false

Document Period End Date Aug. 31, 2013

Document Fiscal Period Focus Q3

Document Fiscal Year Focus 2013

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 56 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

SERIES B CONVERTIBLE PREFERRED STOCK (Tables)
9 Months Ended

Aug. 31, 2013

Series B Convertible Preferred Stock [Abstract]

Fair Value, by Balance Sheet Grouping [Table Text Block]
The fair value of the conversion feature was estimated at $30,587 ($0.0011 per share of common stock) and $19,245 ($0.0012 per share of common stock) at August 31, 2013 and November 30, 2012, respectively, and has been estimated using the Black-Scholes option-pricing model using the following assumptions:

August 31,
2013

May 31,
2013

February 28,
2013

November 30,
2012

Fair value of common stock

$

0.0012

$

0.0014

$

0.0038

$

0.0013

Conversion price of preferred stock

$

0.0124

$

0.0151

$

0.0190

$

0.0215

Risk free interest rate

2.78

%

2.16

%

1.89

%

1.62

%

Expected life

10 Years

10 Years

10 Years

10 Years

Dividend yield

-

-

-

-

Volatility

148

%

148

%

147

%

141

%

X

- Details

Name: mcet_SeriesBConvertiblePreferredStockAbstract

Namespace Prefix: mcet_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13467-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13476-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6447952&loc=d3e13220-108610

+ Details

Name: us-gaap_FairValueByBalanceSheetGroupingTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013	Aug. 31, 2012
Revenue	$ 12,329	$ 12,329	$ 36,988	$ 36,988
Operating expenses
Selling, general and administrative	207,753	231,953	626,092	649,454
Research and development	95,418	53,694	216,590	276,324
Stock-based compensation	52,945	105,446	175,866	226,162
Total operating expenses	356,116	391,093	1,018,548	1,151,940
Loss from operations	(343,787)	(378,764)	(981,560)	(1,114,952)
Other income (expense)
Interest expense	(707)	(762)	(2,058)	(7,424)
Change in fair value of derivative liability	(902)	60,562	(11,342)	104,526
Gain on disposition of equipment	0	1,500	0	1,500
Interest income	36	106	171	593
Total other income (expense)	(1,573)	61,406	(13,229)	99,195
Net loss	(345,360)	(317,358)	(994,789)	(1,015,757)
Less net loss attributable to the noncontrolling interests	(42,264)	(22,771)	(91,211)	(71,841)
Net loss attributable to MultiCell Technologies, Inc.	$ (303,096)	$ (294,587)	$ (903,578)	$ (943,916)
Basic and Diluted Loss Per Common Share (in dollars per share)	$ (0.00014)	$ (0.00028)	$ (0.00052)	$ (0.00099)
Basic and Diluted Weighted-Average Common Shares Outstanding (in shares)	2,105,332,608	1,065,058,664	1,730,465,999	957,413,780

LOSS PER SHARE (Details Textual) (USD $)	Aug. 31, 2013	Nov. 30, 2012
Convertible Debentures	$ 46,596	$ 0
La Jolla Cove Investors [Member]
Remaining Number of Warrants Outstanding	4,659,629
Debt Instrument, Convertible Percentage of Equity Instruments, Maximum	9.99%

GOING CONCERN (Details Textual) (USD $)	9 Months Ended
GOING CONCERN (Details Textual) (USD $)	Aug. 31, 2013	Nov. 30, 2012
Accumulated Deficit	$ 43,158,172	$ 42,254,594
Investment Warrants, Exercise Price	$ 1.09
La Jolla Cove Investors [Member]
Shares Remaining under Stock Warrant	4,659,629
Convertible Debt	46,596
Potential Proceeds from Warrant Exercises	$ 5,100,000
Debt Instrument, Convertible Percentage of Equity Instruments, Maximum	9.99%
Investment Warrants Expiration Date	Feb. 28, 2014

ORGANIZATION AND NATURE OF OPERATIONS, BASIS OF PRESENTATION, AND RECLASSIFICATIONS (Details Textual)	Aug. 31, 2013
Xenogenics Corporation [Member]
Equity Method Investment, Ownership Percentage	95.30%
Multicell Immunotherapeutics [Member]
Equity Method Investment, Ownership Percentage	67.00%

STOCK COMPENSATION PLANS (Details Textual) (USD $)	3 Months Ended			6 Months Ended	9 Months Ended		12 Months Ended	3 Months Ended		9 Months Ended				12 Months Ended	1 Months Ended	3 Months Ended	9 Months Ended				1 Months Ended	3 Months Ended
STOCK COMPENSATION PLANS (Details Textual) (USD $)	Aug. 31, 2013	Feb. 28, 2013	Aug. 31, 2012	May 31, 2013	Aug. 31, 2013	Aug. 31, 2012	Nov. 30, 2012	Aug. 31, 2013 Xenogenics Corporation [Member]	Aug. 31, 2012 Xenogenics Corporation [Member]	Aug. 31, 2013 Xenogenics Corporation [Member]	Aug. 31, 2012 Xenogenics Corporation [Member]	Feb. 03, 2011 Xenogenics Corporation [Member]	Oct. 31, 2010 Xenogenics Corporation [Member]	Nov. 30, 2010 Executive Officer [Member] Xenogenics Corporation [Member]	Mar. 31, 2011 Officers and Members of Scientific Advisory Board [Member] Xenogenics Corporation [Member]	Feb. 29, 2012 Officers and Members of Scientific Advisory Board [Member] Xenogenics Corporation [Member]	Aug. 31, 2013 Director [Member]	Aug. 31, 2012 Director [Member]	Aug. 31, 2013 Employee [Member]	Aug. 31, 2012 Employee [Member]	Jul. 28, 2013 Consultant [Member]	Feb. 29, 2012 Replacement Options [Member]	Aug. 31, 2013 Equity Incentive Plan 2004 [Member]	Dec. 02, 2012 Equity Incentive Plan 2004 [Member]	Dec. 02, 2011 Equity Incentive Plan 2004 [Member]	Jul. 11, 2011 Equity Incentive Plan 2004 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized												8,000,000	5,000,000											1,500,000	1,500,000	70,974,213
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant																							22,074,710
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					30,000,000									2,500,000	3,000,000		5,000,000	1,000,000	5,000,000	1,000,000	500,000	1,250,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price					$ 0.0011									$ 0.246	$ 0.246		$ 0.0011	$ 0.0032	$ 0.0011	$ 0.0032	$ 0.246	$ 0.253
Share-based Compensation Arrangement by Share-based Payment Award, Award Term															5 years		5 years	5 years	5 years	5 years	5 years	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date														Nov. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period Fair Value														$ 576,250	$ 692,700						$ 117,000	$ 298,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value					$ 0.0011	$ 0.0030								$ 0.2305	$ 0.2309						$ 0.234	$ 0.2338
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		1.89%		2.16%	2.78%		1.62%							1.23%	2.20%		1.60%	0.62%			1.37%	0.84%
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate		147.00%		148.00%	148.00%		141.00%							165.00%	165.00%		175.00%	170.00%			175.00%	170.00%
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Term		10 years		10 years	10 years		10 years							5 years	5 years		5 years	5 years			5 years	5 years
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%		0.00%	0.00%		0.00%							0.00%	0.00%		0.00%	0.00%			0.00%	0.00%
Share-based Compensation, Total	52,945		105,446		175,866	226,162					251,128
Reversal Allocated Share-based Compensation Expense											57,725					57,725
Allocated Share-based Compensation Expense	1,893		9,521		10,705	32,759		51,052	95,925	165,161	193,403
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options	35,000				35,000			83,000		83,000
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition					1 year 4 months 24 days					6 months
Closing Price Share	$ 0.0012				$ 0.0012
Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Number														500,000
Share Based Compensation Arrangement By Share Based Payment Award Option Vested And Expected To Vest Outstanding Number														2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Percentage															50.00%
Stock Issuance Qualified Financing Milestone for Proceeds															$ 5,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period															1,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent										100.00%
Share-based Compensation Arrangement by Share-based Payment Award, Original Terms of Plan										10% stockholder shall not be granted an ISO unless the exercise price of such option is at least 110% of the fair market value of Xenogenics’ common stock on the date of the grants and the option is not exercisable after the expiration of five years from the date of the grant.
Share-based Compensation Arrangement by Share-based Payment Award, Option, Maximum Term										10 years

SUBSEQUENT EVENTS (Details Textual) (USD $)	9 Months Ended
SUBSEQUENT EVENTS (Details Textual) (USD $)	Aug. 31, 2013
Proceeds from Warrant Exercises	$ 130,800
Subsequent Event [Member]
Debt Conversion, Original Debt, Amount	1,000
Debt Conversion, Converted Instrument, Shares Issued	122,122,222
Warrant Exercised To Purchase Common Stock Shares	100,000
Warrants Exercise Price	$ 1.09
Proceeds from Warrant Exercises	109,000
Subsequent Event [Member] \| Xenogenics Corporation [Member]
Required Payments Under Agreement	4,300,000
Contingent Liability Under Agreement	$ 4,300,000

SERIES I CONVERTIBLE PREFERRED STOCK (Details Textual)	Aug. 31, 2013	Nov. 30, 2012	Jul. 13, 2004 Accredited Investors [Member]	Aug. 31, 2013 Series I Convertible Preferred Stock [Member]	Nov. 30, 2012 Series I Convertible Preferred Stock [Member]	Aug. 31, 2013 Board of Directors Chairman [Member]
Preferred Stock, Shares Designated	963,000	963,000		20,000	20,000	1,000,000
Preferred Stock, Shares Issued	0	0	20,000	0	0

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (DEFICIENCY) (Parenthetical)	9 Months Ended
	Aug. 31, 2013	Aug. 31, 2012
Debt Conversion, Original Debt, Interest Rate of Debt	4.75%	4.75%

CONVERTIBLE DEBENTURES (Details Textual) (USD $)	9 Months Ended			9 Months Ended		0 Months Ended	12 Months Ended
CONVERTIBLE DEBENTURES (Details Textual) (USD $)	Aug. 31, 2013	Aug. 31, 2012	Nov. 30, 2012	Aug. 31, 2013 Common Stock [Member]	Aug. 31, 2012 Common Stock [Member]	Aug. 16, 2011 La Jolla Cove Investors [Member]	Nov. 30, 2007 La Jolla Cove Investors [Member]
Securities Purchase, Agreement Date							Feb. 28, 2007
Proceeds from Convertible Debenture, Principal Amount							$ 100,000
Debt Conversion, Original Debt, Due Date of Debt							Feb. 28, 2012
Debt Instrument, Maturity Date						Feb. 28, 2014
Debt Conversion, Original Debt, Interest Rate of Debt	4.75%	4.75%
Warrants Issued Number							10,000,000
Class of Warrant, Exercisable Period	5 years						5 years
Exercise of Warrant upon Conversion of Debt	each $1,000 of the principal converted, LJCI would be required to simultaneously purchase 100,000 shares under the LJCI Warrant at $1.09 per share.
Maximum Conversion Limit of Debt	The “Conversion Price” is equal to the lesser of $1.00 or 80% of the average of the three lowest volume-weighted average prices during the twenty trading days prior to the election to convert.
Stock Issued During Period, Value, Conversion of Convertible Securities	9,430	7,290
Stock Issued During Period, Shares, Conversion of Convertible Securities				1,040,493,584	323,936,571
Stock Issued During Period, Shares, Exercise of Warrants				943,000	729,000
Proceeds from Exercise of Stock Warrants	1,027,870	794,610
Advance from Warrant Holder	0		50,000
Convertible Debentures	46,596		0
Debt Conversion, Converted Instrument, Shares				5,800,000,000
Number of Warrants, Remaining Unexercised				4,659,629
Investment Warrants, Exercise Price	$ 1.09
Convertible Debt, Noncurrent	0		56,026
Receivable from Warrant Holder	$ 130,800

LOSS PER SHARE (Details)	9 Months Ended
LOSS PER SHARE (Details)	Aug. 31, 2013	Aug. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,906,056,606	6,138,986,953
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	27,806,452	47,049,793
Series I Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	2,293,600
LJCI Debenture [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,819,876,621	6,055,511,583
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,974,030	9,963,030
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	50,399,503	24,168,947

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Aug. 31, 2013	Nov. 30, 2012
Accumulated depreciation, property and equipment (in dollars)	$ 40,561	$ 40,561
Undesignated preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized/designated	963,000	963,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	3,000,000,000	3,000,000,000
Common stock, shares issued	2,391,239,613	1,349,803,029
Common stock, shares outstanding	2,391,239,613	1,349,803,029
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized/designated	17,000	17,000
Preferred stock, shares issued	3,448	3,448
Preferred stock, shares outstanding	3,448	3,448
Preferred stock, liquidation value (in dollars)	$ 470,316	$ 470,316
Series I Convertible Preferred Stock [Member]
Preferred stock, shares authorized/designated	20,000	20,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (DEFICIENCY) (USD $)	Total	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Series B Convertible Preferred Stock [Member]	Series I Convertible Preferred Stock [Member]	Common Stock [Member]
Balance at Nov. 30, 2011	$ (1,753,599)	$ 30,064,619	$ (40,998,344)	$ (976,978)	$ 1,349,844	$ 573,400	$ 8,233,860
Balance (in shares) at Nov. 30, 2011					11,339	5,734	823,385,986
Issuance of common stock for conversion of 4.75% debentures	7,290	(3,232,076)	0	0	0	0	3,239,366
Issuance of common stock for conversion of 4.75% debentures (in shares)					0	0	323,936,571
Issuance of common stock for exercise of warrants	794,610	787,320	0	0	0	0	7,290
Issuance of common stock for exercise of warrants (in shares)					0	0	729,000
Stock-based compensation	226,162	226,162	0	0	0	0	0
Net loss	(1,015,757)	0	(943,916)	(71,841)	0	0	0
Balance at Aug. 31, 2012	(1,741,294)	27,846,025	(41,942,260)	(1,048,819)	1,349,844	573,400	11,480,516
Balance (in shares) at Aug. 31, 2012					11,339	5,734	1,148,051,557
Balance at Nov. 30, 2012	(1,618,462)	27,755,595	(42,254,594)	(1,079,328)	461,835	0	13,498,030
Balance (in shares) at Nov. 30, 2012					3,448	0	1,349,803,029
Issuance of common stock for conversion of 4.75% debentures	9,430	(10,395,506)	0	0	0	0	10,404,936
Issuance of common stock for conversion of 4.75% debentures (in shares)					0	0	1,040,493,584
Issuance of common stock for exercise of warrants	1,027,870	1,018,440	0	0	0	0	9,430
Issuance of common stock for exercise of warrants (in shares)					0	0	943,000
Stock-based compensation	175,866	175,866	0	0	0	0	0
Net loss	(994,789)	0	(903,578)	(91,211)	0	0	0
Balance at Aug. 31, 2013	$ (1,400,085)	$ 18,554,395	$ (43,158,172)	$ (1,170,539)	$ 461,835	$ 0	$ 23,912,396
Balance (in shares) at Aug. 31, 2013					3,448	0	2,391,239,613

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Aug. 31, 2013	Nov. 30, 2012
ASSETS
Cash and cash equivalents	$ 178,121	$ 199,472
Receivable from warrant holder	130,800	0
Other current assets	14,617	11,293
Total current assets	323,538	210,765
Property and equipment, net of accumulated depreciation of $40,561	0	0
Other assets	280	280
Total assets	323,818	211,045
LIABILITIES AND EQUITY (DEFICIENCY)
Accounts payable and accrued expenses	1,085,649	1,106,177
Payable to related party	50,000	50,000
Advance from warrant holder	0	50,000
Convertible debentures	46,596	0
Current portion of deferred revenue	49,318	49,318
Total current liabilities	1,231,563	1,255,495
Non-current liabilities
Convertible debentures	0	56,026
Deferred revenue, net of current portion	461,753	498,741
Derivative liability related to Series B convertible preferred stock	30,587	19,245
Total non-current liabilities	492,340	574,012
Total liabilities	1,723,903	1,829,507
Commitments and contingencies
Equity (Deficiency) MultiCell Technologies, Inc. equity (deficiency)
Preferred stock	0	0
Common stock, $0.01 par value; 3,000,000,000 shares authorized; 2,391,239,613 and 1,349,803,029 shares issued and outstanding at August 31, 2013 and November 30, 2012, respectively	23,912,396	13,498,030
Additional paid-in capital	18,554,395	27,755,595
Accumulated deficit	(43,158,172)	(42,254,594)
Total MultiCell Technologies, Inc. stockholders' equity (deficiency)	(229,546)	(539,134)
Noncontrolling interests	(1,170,539)	(1,079,328)
Total equity (deficiency)	(1,400,085)	(1,618,462)
Total liabilities and equity (deficiency)	323,818	211,045
Series B Convertible Preferred Stock [Member]
Equity (Deficiency) MultiCell Technologies, Inc. equity (deficiency)
Preferred stock	461,835	461,835
Total equity (deficiency)	461,835	461,835
Series I Convertible Preferred Stock [Member]
Equity (Deficiency) MultiCell Technologies, Inc. equity (deficiency)
Preferred stock	0	0
Total equity (deficiency)	$ 0	$ 0

SERIES B CONVERTIBLE PREFERRED STOCK (Details) (USD $)	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
SERIES B CONVERTIBLE PREFERRED STOCK (Details) (USD $)	Feb. 28, 2013	May 31, 2013	Aug. 31, 2013	Nov. 30, 2012
Fair value of common stock	$ 0.0038	$ 0.0014	$ 0.0012	$ 0.0013
Conversion price of preferred stock	$ 0.0190	$ 0.0151	$ 0.0124	$ 0.0215
Risk free interest rate	1.89%	2.16%	2.78%	1.62%
Expected life	10 years	10 years	10 years	10 years
Dividend yield	0.00%	0.00%	0.00%	0.00%
Volatility	147.00%	148.00%	148.00%	141.00%

FAIR VALUE MEASUREMENTS (Details) (USD $)	Aug. 31, 2013	Nov. 30, 2012
Derivative liability	$ 30,587	$ 19,245
Fair Value, Inputs, Level 1 [Member]
Derivative liability	0	0
Fair Value, Inputs, Level 2 [Member]
Derivative liability	30,587	19,245
Fair Value, Inputs, Level 3 [Member]
Derivative liability	$ 0	$ 0

STOCK WARRANTS (Details) (USD $)	9 Months Ended	12 Months Ended
STOCK WARRANTS (Details) (USD $)	Aug. 31, 2013	Nov. 30, 2012
Shares Under Warrants, Outstanding , Beginning balance (in shares)	9,277,030
Shares Under Warrants, Issued (in shares)	0
Shares Under Warrants, Exercised (in shares)	(943,000)
Shares Under Warrants, Expired (in shares)	(360,000)
Shares Under Warrants, Outstanding, Ending balance (in shares)	7,974,030	9,277,030
Weighted Average Exercise Price, Outstanding, Beginning balance (in dollars per share)	$ 0.7535
Weighted Average Exercise Price, Issued (in dollars per share)	$ 0
Weighted Average Exercise price, Exercised (in dollars per share)	$ 1.0900
Weighted Average Exercise Price, Expired (in dollars per share)	$ 0.5000
Weighted Average Exercise Price, Outstanding, Ending balance (in dollars per share)	$ 0.7251	$ 0.7535
Weighted Average Remaining Contractual Life, Outstanding	1 year 8 months 12 days	2 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding, Beginning balance	$ 0
Aggregate Intrinsic Value, Outstanding, Ending balance	$ 0	$ 0

STOCK WARRANTS (Details Textual) (USD $)	9 Months Ended
STOCK WARRANTS (Details Textual) (USD $)	Aug. 31, 2013	Aug. 31, 2012
Investment Warrants, Exercise Price	$ 1.09
Class of Warrant, Exercisable Period	5 years
Exercise of Warrant upon Conversion of Debt	each $1,000 of the principal converted, LJCI would be required to simultaneously purchase 100,000 shares under the LJCI Warrant at $1.09 per share.
Proceeds from Warrant Exercises	$ 130,800
La Jolla Cove Investors [Member]
Proceeds from Convertible Debenture, Principal Amount	100,000
Warrant Issued	10,000,000
Securities Purchase, Agreement Date	Feb. 28, 2007
Exercise of Warrant upon Conversion of Debt	for each $1,000 of the principal of the Debenture converted, LJCI would be required to simultaneously purchase 100,000 shares under the warrant at $1.09 per share
Warrant Exercised to Purchase Common Stock, Shares	943,000	729,000
Proceeds from Warrant Exercises	$ 1,027,870	$ 794,610

STOCK COMPENSATION PLANS (Details) (USD $)	9 Months Ended	12 Months Ended
STOCK COMPENSATION PLANS (Details) (USD $)	Aug. 31, 2013	Nov. 30, 2012
Shares Under Option, Outstanding, Beginning balance	26,068,947
Shares Under option, Granted	30,000,000
Shares Under Option, Exercised	0
Shares Under option, Expired or forfeited	(5,669,444)
Shares Under Option,Outstanding, Ending balance	50,399,503	26,068,947
Shares Under Option,Exercisable	19,017,559
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 0.0084
Weighted Average Exercise Price,Granted (in dollars per share)	$ 0.0011
Weighted Average Exercise Price, Exercised (in dollars per share)	$ 0
Weighted Average Exercise Price, Expired or forfeited (in dollars per share)	$ 0.0090
Weighted Average Exercise Price, Outstanding, Ending balance	$ 0.0040	$ 0.0084
Weighted Average Exercise price,Exercisable (in dollars per share)	$ 0.0086
Weighted Average Remaining Contractual Life, Outstanding	3 years 10 months 24 days	3 years 1 month 6 days
Weighted Average Remaining Contractual Life, Exercisable	2 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding, Beginning balance	$ 0
Aggregate Intrinsic Value, Outstanding, Ending balance	3,000	0
Aggregate Intrinsic Value, Exercisable	$ 0

Document And Entity Information	9 Months Ended
Document And Entity Information	Aug. 31, 2013	Oct. 08, 2013
Document Information [Line Items]
Entity Registrant Name	MultiCell Technologies, Inc.
Entity Central Index Key	0000811779
Current Fiscal Year End Date	--11-30
Entity Filer Category	Smaller Reporting Company
Trading Symbol	MCET
Entity Common Stock, Shares Outstanding		2,513,461,835
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Aug. 31, 2013
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2013